Professional Documents
Culture Documents
Report 2015
a t l a s
p r o j e c t
m a l a r i a
Each icon on the cover page represents a technical area of WHOs global work on malaria.
For more information, visit: http://www.who.int/malaria/visual-refresh/en/
2015
ii
Contents
Foreword
Acknowledgements
Abbreviations
Key points
iv
vi
ix
x
SECTION 1 Introduction
1.1 Introduction to the World malaria report 2015
1.2 Introduction to malaria
1.3 Strategies to control and eliminate malaria
1.4 Global goals, targets and indicators 20002015
2
2
2
3
4
8
8
10
13
13
18
20
22
22
24
26
26
28
31
36
36
38
SECTION 5 Challenges
5.1 Continuing disease burden
5.2 Gaps in programme coverage
5.3 Weaknesses in health systems
5.4 Plasmodium vivax malaria
5.5 Resistance to insecticides
5.6 Antimalarial drug efficacy and resistance
5.7 Disease outbreaks
5.8 Other challenges
40
40
41
44
46
48
50
52
52
54
References
56
REGIONAL PROFILES
59
81
ANNEXES
34
181
iii
Foreword
Dr Margaret Chan
Director-General
World Health Organization
This World malaria report is released in a milestone year: 2015 marks the end
of the era of Millennium Development Goals and the dawn of a new global
agenda for human health and prosperity, the Sustainable Development
Goals. It is also the target year for malaria goals set by the World Health
Assembly and other global institutions.
Against this backdrop, our report tracks a dramatic decline in the global
malaria burden over 15 years. Target 6C of 2000 Millennium Development
Goals called for halting and beginning to reverse the global incidence of
malaria by 2015. The report shows unquestionably that this target has
been achieved. Fifty-seven countries have reduced their malaria cases by
75%, in line with the World Health Assemblys target for 2015.
For the rst time since WHO began keeping score, the European Region
is reporting zero indigenous cases of malaria. This is an extraordinary
achievement that can only be maintained through continued political
commitment and constant vigilance. The Region of the Americas and Western
Pacic Region have also achieved substantial reductions in malaria cases.
The African Region continues to shoulder the heaviest malaria burden.
However, here too we have seen impressive gains: since 2000, malaria
mortality rates have fallen by 66% among all age groups, and by 71% among
children under ve.
Progress was made possible through the massive rollout of effective
prevention and treatment tools. In sub-Saharan Africa, more than half of
the population is now sleeping under insecticide-treated mosquito nets,
compared to just 2% in 2000. A rapid expansion in diagnostic testing, and in
the availability of antimalarial medicines, has allowed many more people to
access timely and appropriate treatment.
Prevention and treatment efforts are saving millions of dollars in healthcare
costs. New estimates in our report show that reductions in malaria cases
in sub-Saharan Africa saved an estimated US $900 million over 14 years.
Mosquito nets contributed the largest savings, followed by artemisinin-based
combination therapies and indoor residual spraying.
iv
But our work is far from over. About 3.2 billion people remain at risk of
malaria. In 2015 alone, there were an estimated 214 million new cases of
malaria and 438 000 deaths. Millions of people are still not accessing the
services they need to prevent and treat malaria.
Approximately 80% of malaria deaths are concentrated in just 15 countries,
mainly in Africa. Taken together, these high-burden countries have achieved
slower-than-average declines in malaria incidence and mortality. In most of
these countries, weak health systems continue to impede progress.
To address these and other challenges, WHO has developed a Global
Technical Strategy for Malaria 2016-2030. The strategy sets ambitious but
achievable targets for 2030, including a reduction in global malaria incidence
and mortality of at least 90%. Achieving these targets will require country
leadership and a tripling of global investment for malaria.
We have arrived at a pivotal moment. Global progress in malaria control over
the last 15 years is nothing short of remarkable. Let us not lose momentum.
Together, we can transform the health, well-being and livelihood of millions
of people across the globe.
Acknowledgements
We are very grateful to the numerous people who contributed to the production of the World malaria
report 2015. The following people collected and reviewed data from malaria endemic countries:
Ahmad Murid Muradi, Mohamad Sami Nahzat and Ahmad Walid Sediqi (Afghanistan); Lammali Karima
(Algeria); Filomeno Fortes and Yava Luvundo Ricardo (Angola); Mario Zaidenberg (Argentina); Suleyman
Mammadov (Azerbaijan); Anjan Kumar Saha (Bangladesh); Kim Bautista (Belize); Mariam Oke Sopoh
(Benin); Rinzin Namgay (Bhutan); Omar Flores (Bolivia [Plurinational State of]); Tjantilili Mosweunyane,
N Mapuranga (Botswana); Cassio Roberto Leonel Peterka (Brazil); Sanon Harouna and Laurent Moyenga
(Burkina Faso); Moza Seleman, Dismas Baza (Burundi); Antnio Lima Moreira (Cabo Verde); Tol Bunkea
(Cambodia); Kouambeng Celestin (Cameroon); Aristide Dsir Komangoya-Nzonzo (Central African
Republic); Mahamat Idriss Djaskano (Chad); Li Zhang, Xiao Hong Li (China); Martha Lucia Ospina Martinez
(Colombia); Astaeva Marina (Comoros); Youndouka Jean Mermoz (Congo); Jose Luis F. Garces (Costa
Rica); Ehui Anicet, Parfait Katche and Genevive Saki-Nkouressi (Cte dIvoire); Kim Yun Chol (Democratic
Peoples Republic of Korea); Joris Losimba Likwela (Democratic Republic of the Congo); Abdoulkader Garad
(Djibouti); Juan Leonidas Castro Jimenez (Dominican Republic); Enrique Castro Saavedra (Ecuador); Jaime
Enrique Alemn Escobar (El Salvador); Ramona Mba Andeme (Equatorial Guinea); Selam Mihreteab,
Assefash Zehaie Kassahun (Eritrea); Hiwot Solomon Taffese (Ethiopia); Frdric Pags (France [Mayotte])
Abdou Razack Saou and Alain Mbongo (Gabon); Momodou Kalleh (Gambia); Merab Iosava (Georgia);
Keziah Malm (Ghana); Adolfo Miranda (Guatemala); Nouman Diakite (Guinea); Fernanda Alves and Paulo
Djata (Guinea-Bissau); Rawle Jadunath (Guyana); Darlie Antoine (Haiti); Engels Ilich Banegas and Alex
Rovelo (Honduras); G.S. Sonal (India); Dewi Novianti and Asik Surya (Indonesia); Leyla Faraji, Ftemeh
Nikpoor and Ahmad Raeisi (Iran [Islamic Republic of]); Mohammed Khider Ali (Iraq); Rebecca Kiptui
(Kenya); Nurbolot Usenbaev (Kyrgyzstan); Khamsouane Khamsy (Lao Peoples Democratic Republic); Oliver
J. Pratt (Liberia); Rakotorahalahy Andry Joeliarijaona (Madagascar); Misheck Luhanga (Malawi); Mohd
Hazi Bin Abdul Hamid, Ummi Kalthom Shamsudin and Wan Ming Keong (Malaysia); Oumar Coulibaly
and Diakalia Kone (Mali); Mohamed Lemine Khairy (Mauritania); Hector Olguin Bernal (Mexico); Baltazar
Candrinho (Mozambique); Thet Wai Nwe (Myanmar); Mwalenga H. Nghipumbwa (Namibia); Yuva Raj
Pokhrel (Nepal); Julio Csar Rosales Caballero (Nicaragua); Djermakoye Hadiza Jackou (Niger); Akubue
Augustine, Abdullahi Saddiq, Femi Ajumobi, Tolu Arowolo (Nigeria); Majed Al-Zadjali (Oman); Muhammad
Suleman Memon (Pakistan); Ral Medina and Lic Carlos Victoria (Panama); Steven Paniu (Papua New
Guinea); Cynthia Viveros (Paraguay); Victor Alberto Laguna Torres (Peru); Mario Baquilod (Philippines);
Park Kyeong-Eun (Republic of Korea); Corine Karema (Rwanda); Jessica Da Veiga Soares (Sao Tome and
Principe); Mohammed Hassan Al-Zahrani (Saudi Arabia); Medoune Ndiop (Senegal); Samuel J. Smith
(Sierra Leone); John Leaburi (Solomon Islands); Fahmi E. Yusuf, Abdi Adbilahi Ali, Abdikarim Hussein Hassan
and Abdiqani Sh. Omar (Somalia); Bridget Shandukani and Mary Anne Groepe (South Africa); Harriet Akello
Pasquale (South Sudan); Risintha Premaratne (Sri Lanka); Abd Alla Ahmed Ibrahim Mohd; (Sudan); Beatrix
Jubithana (Suriname); Zulisile Zulu (Swaziland); Atef Al Tawil (Syrian Arab Republic); Sharipov Azizullo
(Tajikistan); Nipon Chinanonwait, Deyer Gopinath (Thailand); Maria do Rosiro de Fatima Mota (TimorLeste); Kokou Davi and Tchadjobo Tchassama (Togo); Seher Topluoglu (Turkey); Mulyazaawo Mathias
Kasule (Uganda); Anna Mahendeka (United Republic of Tanzania [Mainland]); Abdul-wahid H. Al-mafazy
(United Republic of Tanzania [Zanzibar]); Inna Tyo, Natalya Lebedeva and SvetlanaTsay (Uzbekistan);
Wesley Donald (Vanuatu); Jesus Toro (Venezuela [Bolivarian Republic of]); Nguyen Quy Anh and Dai Tran
Cong (Viet Nam); Moamer Mohammed Badi (Yemen); Mercy Mwanza Ingwe (Zambia); Wonder Sithole
(Zimbabwe).
The following WHO staff in regional and subregional offices assisted in the design of data collection forms;
the collection and validation of data; and the review of epidemiological estimates, country proles, regional
proles and sections:
Birkinesh Amenshewa, Magaran Bagayoko, Steve Banza Kubenga and Issa Sanou (WHO Regional
Office for Africa [AFRO]); Spes Ntabangana (AFRO/Inter-country Support Team [IST] Central Africa);
Khoti Gausi (AFRO/IST East and Southern Africa); Abderrahmane Kharchi Tfeil (AFRO/IST West Africa);
Keith Carter, Eric Ndofor, Rainier Escalada, Maria Paz Ade and Prabhjot Singh (WHO Regional Office for
the Americas [AMRO]); Hoda Atta, Caroline Barwa and Ghasem Zamani (WHO Regional Office for the
Eastern Mediterranean [EMRO]); Elkhan Gasimov and Karen Taksoe-Vester (WHO Regional Office for
Europe [EURO]); Leonard Icutanim Ortega (WHO Regional Office for South-East Asia [SEARO]); Rabindra
Abeyasinghe, Eva-Maria Christophel, Steven Mellor, and Raymond Mendoza (WHO Regional Office for the
Western Pacic [WPRO]).
vi
Acknowledgements
Carol DSouza and Jurate Juskaite (Global Fund to Fight AIDS, Tuberculosis and Malaria [Global Fund]) supplied
information on nancial disbursements from the Global Fund. Adam Wexler (Kaiser Family Foundation) provided
information relating to nancial contributions for malaria control from the United States of America. On vector
control, Peter Gething, Samir Bhatt and the Malaria Atlas Project (www.map.ox.ac.uk) team at the University
of Oxford, with the support of the Bill & Melinda Gates Foundation and the Medical Research Council (United
Kingdom of Great Britain and Northern Ireland [UK]), produced estimates of insecticide-treated mosquito
net (ITN) coverage for African countries using data from household surveys, ITN deliveries by manufacturers,
ITNs distributed by national malaria control programmes (NMCPs) and ITN coverage indicators. They also
produced estimates of P. falciparum parasite prevalence in sub-Saharan Africa. Catherine Moyes and
Antoinette Wiebe (Malaria Atlas Project) and Christen Fornadel (United States Presidents Malaria Initiative)
provided data on insecticide resistance. Jamie Griffin from Imperial College, London, provided modelled data
to estimate the percentage of malaria cases moving to severe stage by country over the 20002015 period.
John Milliner (Milliner Global Associates) provided information on long-lasting insecticidal nets delivered by
manufacturers. On malaria diagnosis and treatment, Adam Bennett (Global Health Group), Donal Bisanzio
and Peter Gething (Malaria Atlas Project), and Thom Eisele (Tulane University) produced estimates of
malaria treatment from household surveys and antimalarials distributed by NMCPs. Li Liu (Johns Hopkins
Bloomberg School of Public Health), Dan Hogan and Colin Mathers (WHO Department of Health Statistics
and Information Systems) prepared malaria mortality estimates in children aged under 5 years on behalf
of the Child Health Epidemiology Reference Group.
Maps of ITN coverage and parasite prevalence for the WHO African Region were produced by the Malaria
Atlas Project (www.map.ox.ac.uk) under the leadership of Peter Gething. The maps for country and regional
proles were produced by the Malaria Atlas Projects ROAD-MAPII team led by Mike Thorn: Harry Gibson,
Joe Harris, Andy Henry and Zhi Huang. The Malaria Atlas Project is supported by the Bill & Melinda Gates
Foundation and the Medical Research Council (United Kingdom of Great Britain and Northern Ireland).
We are also grateful to:
Melanie Renshaw (African Leaders Malaria Alliance [ALMA]), Trenton Ruebush (independent consultant)
and Larry Slutsker (United States Centers for Disease Control and Prevention), who graciously reviewed all
sections and provided substantial comments for their formulation;
Claudia Nannini (WHO) for legal review;
Renata Cabrera and Amlie Latour for the translation into Spanish and French, respectively, of the foreword
and key points;
Samson Katikiti (ALMA) for reviewing data from Southern African countries;
Claude Cardot and the Designisgood team for the design and layout of the report;
Paprika (Annecy, France) for developing map layouts and generating country proles and annexes;
Blossom (Milan, Italy) for the design of the report cover; and
Hilary Cadman and the Cadman Editing Services team for technical editing of the report.
The production of the World malaria report 2015 was coordinated by Richard Cibulskis (WHO Global
Malaria Programme). Laurent Bergeron (WHO Global Malaria Programme) provided programmatic
support for overall management of the project. The World malaria report 2015 was written by John Aponte
(WHO consultant), Maru Aregawi, Richard Cibulskis, Cristin Fergus, Michael Lynch (United States Centers
for Disease Control and Prevention), Rossitza Mintcheva (WHO consultant), Edith Patouillard, Aafje Rietveld,
Saira Stewart and Ryan Williams on behalf of the WHO Global Malaria Programme. We are grateful to
our colleagues in the Global Malaria Programme who also contributed to the production of sections:
Pedro Alonso, Amy Barrette, Andrea Bosman, Jane Cunningham, Pearl Harlley, Tessa Knox, Abraham
Mnzava, Peter Olumese, Charlotte Rasmussen, Pascal Ringwald, Vasee Sathiyamoorthy, Silvia Schwarte
and Emmanuel Temu. We also thank Camille Pillon for her assistance with communications activities, and
Simone Colairo-Valerio and Eva Kakyomya for administrative support.
Funding for the production of this report was gratefully received from the United Kingdom Department for
International Development, the United States Agency for International Development and the Swiss Agency
for Development and Cooperation, through a grant to the Swiss Tropical and Public Health Institute. We also
thank the Government of Monaco for its programme, Accelerated Malaria Control towards Pre-elimination
in East and Southern Africa by 2015, which supported collection of malaria programme data.
vii
viii
Abbreviations
ACT
artemisinin-based combination
therapy
OECD
AL
artemether-lumefantrine
P.
Plasmodium
AMFm
PfPR
ANC
antenatal care
RBM
API
RDT
AQ
amodiaquine
SAGE
AS
artesunate
SMC
ASAQ
artesunate-amodiaquine
SP
sulfadoxine-pyrimethamine
ASMQ
artesunate-meoquine
UI
uncertainty interval
ASSP
artesunate-sulfadoxinepyrimethamine
U5MR
CCM
UN
United Nations
CFR
WHO
CI
condence interval
CRS
DDT
dichloro-diphenyl-trichloroethane
DHA-PPQ
dihydroartemisinin-piperaquine
G6PD
glucose-6-phosphate
dehydrogenase
GDP
AFRO
AMR
AMRO
GMAP
EMR
IPTi
EMRO
IPTp
EUR
EURO
IQR
interquartile range
SEAR
IRS
SEARO
ITN
K-13
Kelch 13
WPR
LLIN
WPRO
MDG
MPAC
MQ
meoquine
NMCP
ix
Key points
The World malaria report 2015 assesses global malaria disease trends and changes in the
coverage and nancing of malaria control programmes between 2000 and 2015. It also
summarizes progress towards international targets, and provides regional and country
proles that summarize trends in each WHO region and each country with malaria.
The report is produced with the help of WHO regional and country offices, ministries of
health in endemic countries, and a broad range of other partners. The data presented
were assembled from the 95 countries and territories with ongoing malaria transmission,
and a further six countries that have recently eliminated malaria. Most data are those
reported for 2014 and 2015, although in some cases projections have been made into
2015, to assess progress towards targets for 2015.
Key points
Cases and deaths averted. It is estimated that a cumulative 1.2 billion fewer malaria
cases and 6.2 million fewer malaria deaths occurred globally between 2001 and 2015
than would have been the case had incidence and mortality rates remained unchanged
since 2000. In sub-Saharan Africa, it is estimated that malaria control interventions
accounted for 70% of the 943 million fewer malaria cases occurring between 2001 and
2015, averting 663 million malaria cases (range: 542753 million). Of the 663 million cases
averted due to malaria control interventions, it is estimated that 69% were averted due
to use of insecticide-treated mosquito nets (ITNs) (UI: 6373%), 21% due to artemisininbased combination therapy (ACT) (UI: 1729%) and 10% due to indoor residual spraying
(IRS) (UI: 614%).
Progress to elimination. An increasing number of countries are moving towards
elimination of malaria. Whereas only 13 countries were estimated to have fewer than
1000 malaria cases in 2000, 33 countries are estimated to have achieved this milestone
in 2015. Also, in 2014, 16 countries reported zero indigenous cases (Argentina, Armenia,
Azerbaijan, Costa Rica, Iraq, Georgia, Kyrgyzstan, Morocco, Oman, Paraguay, Sri Lanka,
Tajikistan, Turkey, Turkmenistan, United Arab Emirates and Uzbekistan). Another three
countries and territories reported fewer than 10 indigenous cases (Algeria, El Salvador
and Mayotte [France]). The WHO European Region reported zero indigenous cases for
the rst time in 2015, in line with the goal of the Tashkent Declaration to eliminate malaria
from the region by 2015.
xi
one or more doses, and another nine countries reporting more than 80% receiving one
or more doses.
Chemoprevention in children. Adoption and implementation of chemoprevention in
children has been limited. As of 2014, six of the 15 countries for which WHO recommends
seasonal malaria chemoprevention (SMC) Chad, the Gambia, Guinea, Mali, the Niger
and Senegal had adopted the policy. Additionally, two countries outside the Sahel
subregion Congo and Togo reported that the policy had been adopted. Only one
country, Chad, reported adoption of an intermittent preventive treatment for infants
(IPTi) policy in 2014. The malaria vaccine, RTS,S/AS01, received a positive scientific
opinion from the European Medicines Agency under Article 58. Pilot implementation
of the first malaria vaccine was recommended by WHOs Strategic Advisory Group of
Experts on Immunization (SAGE) and the Malaria Policy Advisory Committee (MPAC).
Diagnostic testing. The proportion of suspected malaria cases presenting for care in the
public sector that receives a malaria diagnostic test has increased since 2005, from 74%
in 2005 to 78% in 2014. The global trend is dominated by countries in South-East Asia,
particularly India, which undertakes a high number of diagnostic tests, with more than
100 million performed in 2014. The WHO African Region has had the largest increase in
levels of malaria diagnostic testing, from 36% of suspected malaria cases tested in 2005,
to 41% in 2010 and 65% in 2014. This increase is primarily due to an increase in the use
of rapid diagnostic tests (RDTs). The level of malaria diagnostic testing is lower among
febrile children seeking care in the private sector than among those seeking care in the
public sector. Among 18 nationally representative surveys conducted in sub-Saharan
Africa from 2013 to 2015, the median proportion of febrile children who received a finger
or heel stick in public sector health facilities was 53% (interquartile range [IQR]: 3557%),
whereas it was 36% in the formal private sector (IQR: 2054%) and 6% in the informal
private sector (IQR: 39%).
Treatment. The proportion of children aged under 5 years with P. falciparum malaria
and who were treated with an ACT is estimated to have increased from less than 1% in
2005 to 16% in 2014 (range: 1222%). This proportion falls substantially short of the GMAP
target of universal access for malaria case management. A primary reason is that a high
proportion of children with fever are not taken for care or use the informal private sector,
where they are less likely to obtain ACTs for treatment. While the proportion of children
treated with an ACT has increased, the proportion treated with other antimalarial
medicines has decreased over time. Hence, an increasing proportion of children with
malaria who receive treatment are given an ACT (median 47% across 18 household
surveys, 20132015) The proportion of ACT antimalarial treatments was lowest when
care was sought from informal health-care providers, such as market stallholders or
itinerant vendors.
Ratio of treatments to tests. The total number of ACT treatments distributed in the public
sector is now fewer than the number of malaria diagnostic tests provided in sub-Saharan
Africa (ratio of treatments: tests = 0.88 in 2014). However, there is still scope for further
reductions, because the ratio of treatments to tests should approximate the test positivity
rate, which is less than 44% across all countries in sub-Saharan Africa.
Key points
control activities by NMCPs, and they exclude health system costs associated with
treating patients.
Spending on malaria control commodities. Spending on malaria control commodities
(ACTs, ITNs, insecticides and spraying equipment for IRS, and RDTs) is estimated to have
increased 40-fold over the past 11 years, from US$ 40 million in 2004 to US$ 1.6 billion
in 2014, and accounted for 82% of international malaria spending in 2014. In that year,
ITNs were responsible for 63% of total commodity spending, followed by ACT (25%), RDTs
(9%) and IRS (3%).
Health system cost savings due to malaria control. Of the cases averted since 2000, it is
estimated that 263 million cases would have sought care in the public sector, translating
into US$ 900 million saved on malaria case management costs in sub-Saharan Africa
between 2001 and 2014. Of the US$ 900 million saved, ITNs/LLINs contributed the
largest savings of US$ 610 million (68%), followed by ACTs (US$ 156 million, 17%) and
IRS (US$ 134 million, 15%). These estimates consider only savings to health services and
exclude savings to households.
xiii
P. vivax malaria occurred in the WHO South-East Asia Region (74%), followed by the
WHO Eastern Mediterranean Region (11%) and the WHO African Region (10%). More
than 80% of P. vivax malaria cases are estimated to occur in three countries (Ethiopia,
India and Pakistan). P. vivax predominates in countries that are prime candidates for
malaria elimination, and accounts for more than 70% of cases in countries with fewer
than 5000 reported cases each year.
Severe cases and deaths due to P. vivax malaria have been reported from all endemic
regions. Globally, in 2015 the total number of malaria deaths due to P. vivax was
estimated to be between 1400 and 14 900, and between 1400 and 12 900 outside
sub-Saharan Africa (i.e. 3.516% of all malaria deaths occurred outside sub-Saharan
Africa). However, information on the population-attributable risks of severe disease and
death from P. vivax malaria is sparse, and further research is required to rene mortality
estimates.
Insecticide resistance. The effectiveness of insecticide-based vector control is threatened
by malaria mosquitoes developing resistance to the insecticides used in ITNs and IRS.
Since 2010, of 78 countries reporting monitoring data, 60 reported resistance to at least
one insecticide in one vector population, and 49 reported resistance to insecticides from
two or more insecticide classes. Pyrethroid resistance was detected in all major malaria
vectors, with three quarters of countries that monitored this insecticide class in 2014
reporting resistance. However, long-lasting insecticidal nets remain effective despite
resistance.
Antimalarial drug resistance. P. falciparum resistance to artemisinins has now been
detected in ve countries in the Greater Mekong subregion: Cambodia, Lao Peoples
Democratic Republic, Myanmar, Thailand and Viet Nam. Despite the observed changes
in parasite sensitivity, which manifest in the form of delayed parasite clearance, patients
continue to respond to combination treatment, provided the partner drug remains
effective. The efficacy of artemether-lumefantrine (AL) in Africa and South America
remains high, with treatment failure rates generally below 10%. Failure rates of less than
10% have also been reported for artesunate-amodiaquine (ASAQ) in the 25 countries
in Africa in which ASAQ is the rst-line or second-line treatment. High treatment failure
rates with artesunate-SP (ASSP) have been reported in north-east India (1925.9%),
Somalia (22%) and the Sudan (9.4%). In Somalia, treatment failures are related to
resistance to SP, in the absence of artemisinin resistance. For P. vivax malaria, at least
one true case of chloroquine resistance (with whole blood concentrations of chloroquine
plus desethylchloroquine >100 ng/mL on the day of failure) has been conrmed in
10 countries: Bolivia, Brazil, Ethiopia, Indonesia, Malaysia, Myanmar, Papua New
Guinea, Peru, the Solomon Islands and Thailand.
Moving forward
To address remaining and emerging challenges, WHO developed the Global technical
strategy for malaria 20162030, which was adopted by the World Health Assembly
in May 2015. The strategy sets the most ambitious targets for reductions in malaria
cases and deaths since the malaria eradication era began. It was developed in
close alignment with the RBM Partnerships Action and investment to defeat malaria
20162030 for a malaria-free world, to ensure shared goals and complementarity.
The strategy has three main building blocks. Pillar 1 is to ensure universal access to
malaria prevention, diagnosis and treatment. Pillar 2 is to accelerate efforts towards
elimination of malaria and attainment of malaria-free status. Pillar 3 is to transform
malaria surveillance into a core intervention. It is estimated that annual investments in
malaria control and elimination will need to increase to US$ 6.4 billion per year by 2020
to meet the rst milestone of a 40% reduction in malaria incidence and mortality rates.
Annual investments should then further increase to US$ 7.7 billion by 2025 to meet the
second milestone of a 75% reduction. To achieve the 90% reduction goal, annual malaria
spending will need to reach an estimated US$ 8.7 billion by 2030.
xiv
MDG indicator
2000
2005
2010
2015
6.6. Incidence rate associated with malaria (per 1000 at risk) and
Death rate associated with malaria (per 100 000 at risk)
146
47
134
37
113
26
91
19
-37%
-60%
2%
7%
35%
68%
>100%
<1%
3%
12%
13%
>100%
2000
2005
2010
2015
6.8. Proportion of children under 5 with fever who are treated with
appropriate antimalarial drugsa,b
GMAP indicator
Inpatient malaria deaths per 1000 persons per year
% change
% change
76
63
52
43
ND
74%
71%
78%
% children aged under 5 years with fever in the last two weeks who
had a nger/heel stickd
ND
ND
ND
31%
NA
1%
7%
16%
NA
0%
41%
45%
-43%
>100%
32%
29%
22%
16%
-50%
2%
7%
36%
67%
>100%
2%
6%
29%
55%
>100%
c,f,g
2%
3%
6%
3%
50%
1%
4%
24%
46%
>100%
ND
ND
5%
17%
>100%
ND
ND
ND
ND
16
% households with at least one ITN for every two people and/or
sprayed by IRS within the last 12 monthsa,g
ANC, antenatal care; GMAP, Global Malaria Action Plan; IPTp, intermittent preventive treatment in pregnancy; IRS, indoor residual
spraying; ITN, insecticide-treated mosquito net; MDG, Millennium Development Goal; NA, not applicable; ND, no data; RDT, rapid
diagnostic test
a
Indicator calculated for sub-Saharan Africa only
b
Refers to artemisinin-based combination therapies
c
Estimate shown for 2015 is for 2014
d
Median estimate from most recent household surveys in sub-Saharan Africa for 20132015; interquartile range: 1940%
e
As data on the rst-line treatments adopted by countries are variable, the indicator shown considers P. falciparum cases treated
with artemisinin-based combination therapies
f
Estimate does not include countries in the WHO European Region
g
IRS coverage for 2015 was assumed to be the same as in 2014
h
Countries with zero indigenous cases for three consecutive years
WORLD MALARIA REPORT 2015
xv
xvi
Avant-propos
Dr Margaret Chan
Directeur gnral
de lOrganisation mondiale de la Sant (OMS)
xvii
xviii
Points essentiels
Le Rapport 2015 sur le paludisme dans le monde value les tendances au niveau
mondial relatives la maladie, ainsi que lvolution de la couverture et du nancement
des programmes de lutte contre le paludisme entre 2000 et 2015. Il rsume aussi les
progrs accomplis sur la voie des objectifs internationaux, et inclut des prols par rgion
et par pays qui dcrivent les changements observs la fois dans chacune des rgions
de lOMS et dans chaque pays touch par le paludisme.
Ce rapport est rdig en collaboration avec les bureaux nationaux et rgionaux de lOMS,
les ministres de la Sant des pays endmiques et un grand nombre de partenaires.
Les informations qui y sont prsentes proviennent des 95 pays et territoires o la
transmission du paludisme est active et des six autres pays ayant rcemment limin
le paludisme. La plupart de ces donnes ont t rapportes pour 2014 et 2015, avec
parfois des projections pour 2015 et ce, an dvaluer les progrs raliss par rapport
aux objectifs dnis pour cette date-butoir.
xix
tiers entre 1990 et 2015. Le paludisme reste nanmoins lune des principales causes de
mortalit infantile, surtout en Afrique subsaharienne, tuant un enfant toutes les deux
minutes.
Infections palustres chez les enfants gs de 2 10 ans. Depuis 2000, le pourcentage
dinfections palustres a diminu de moiti chez les enfants issus des rgions endmiques
dAfrique. La prvalence parasitaire dans cette tranche dge est passe de 33 % en
2000 (incertitude comprise entre 31 % et 35 %) 16 % en 2015 (incertitude: 14 %-19 %),
avec les trois-quarts de cette baisse observe aprs 2005.
Cas de paludisme et dcs vits. Au total, 1,2 milliard de cas de paludisme et 6,2 millions
de dcs associs ont t vits au niveau mondial entre 2001 et 2015, par rapport aux
chiffres que nous aurions enregistrs si les taux dincidence et de mortalit taient rests
inchangs depuis 2000. En Afrique subsaharienne, les interventions antipaludiques
expliquent 70 % des 943 millions de cas de paludisme en moins entre 2001 et 2015, soit
un total de 663 millions de cas vits (plage comprise entre 542 et 753 millions). Sur
ces 663 millions de cas vits par le biais des interventions antipaludiques, 69 % lont
t grce lutilisation de moustiquaires imprgnes dinsecticide (MII) (incertitude:
63 %-73 %), 21 % grce aux combinaisons thrapeutiques base dartmisinine (ACT)
(incertitude: 17 %-29 %) et 10 % grce aux pulvrisations intradomiciliaires dinsecticides
effet rmanent (PID) (incertitude: 6 %-14 %).
Progrs vers llimination. De plus en plus de pays progressent vers llimination du
paludisme. Alors que seuls 13 pays rapportaient moins de 1 000 cas de paludisme en
2000, ils sont 33 en 2015. Par ailleurs, en 2014, 16 pays ont rcens zro cas de paludisme
indigne (Argentine, Armnie, Azerbadjan, Costa Rica, mirats arabes unis, Gorgie,
Iraq, Kirghizistan, Maroc, Oman, Ouzbkistan, Paraguay, Sri Lanka, Tadjikistan, Turquie
et Turkmnistan). Trois autres pays et territoires ont rapport moins de dix cas de
paludisme indigne (Algrie, El Salvador et Mayotte [France]). La rgion Europe de
lOMS na signal aucun cas de paludisme indigne pour la premire fois en 2015,
conformment lobjectif de la Dclaration de Tachkent visant liminer le paludisme
dans toute la rgion dici 2015.
xx
Points essentiels
(100 %) dni dans les cibles actualises du Plan daction mondial contre le paludisme
(GMAP) en 2011.
Chimioprvention chez les femmes enceintes. Le pourcentage de femmes enceintes
ayant reu au moins trois doses de traitement prventif intermittent pendant la grossesse
(TPIp) a augment depuis que lOMS a mis jour ses recommandations en 2012. En 2014,
52 % des femmes enceintes pouvant bncier du TPIp ont reu au moins une dose,
40 % en ont reu deux ou plus, et 17 % au moins trois. La diffrence entre le pourcentage
de femmes se prsentant pour une consultation prnatale (CPN) dans un tablissement
de sant et le pourcentage recevant une ou plusieurs doses de TPIp laisse penser que
les possibilits dadministration du TPIp ne sont pas toutes exploites. Le pourcentage
de femmes enceintes bnciant du TPIp varie sur le continent africain : dans 10 pays,
plus de 60 % des femmes enceintes ont reu au moins une dose, alors que dans 9 autres
pays, elles sont plus de 80 %.
Chimioprvention chez les enfants. Ladoption et la mise en uvre de la chimioprvention
du paludisme saisonnier (CPS) chez les enfants sont limites. En 2014, sur les 15 pays
auxquels lOMS recommandait dadopter la CPS, six seulement lont fait: la Gambie,
la Guine, le Mali, le Niger, le Sngal et le Tchad. Deux autres pays en dehors de la
sous-rgion du Sahel, le Congo et le Togo, ont indiqu avoir galement dict cette
politique. Un seul pays, le Tchad, a indiqu avoir adopt une politique de traitement
prventif intermittent chez le nourrisson (TPIi) en 2014. Le vaccin contre le paludisme,
RTS,S/AS01, a reu un avis scientique positif de la part de lAgence europenne des
mdicaments au titre de larticle 58. Le Groupe stratgique consultatif dexperts (SAGE)
sur la vaccination et le Comit de pilotage de la politique de lutte antipaludique (MPAC)
de lOMS ont donc recommand la mise en uvre de projets pilotes autour de ce
premier vaccin antipaludique.
Tests de diagnostic. Le pourcentage de cas suspects de paludisme sollicitant un
traitement dans le secteur public et soumis un test de diagnostic du paludisme a
augment de faon constante, passant de 74 % en 2005 78 % en 2014. Cette tendance
mondiale est plus prononce dans les pays dAsie du Sud-Est, notamment lInde, o
un nombre trs important de tests de diagnostic rapide (TDR) sont utiliss (plus de
100 millions en 2014). La rgion Afrique de lOMS a connu la hausse la plus forte, avec
36 % de cas suspects ayant t soumis un test en 2005, 41 % en 2010, puis 65 % en
2014. Cette progression est principalement due une plus grande utilisation des TDR.
Lutilisation des TDR est plus faible chez les enfants vreux sollicitant des soins dans le
secteur priv que chez ceux visitant le secteur public. Sur 18 enqutes menes en Afrique
subsaharienne entre 2013 et 2015 et reprsentatives au niveau national, le pourcentage
mdian denfants vreux ayant subi un prlvement sanguin au doigt/talon des ns
de dpistage du paludisme dans le secteur public tait de 53 % (cart interquartile :
35 %-57 %), alors quil slevait 36 % dans le secteur priv formel (cart interquartile :
20 %-54 %) et 6 % dans le secteur priv informel (cart interquartile : 3 %-9 %).
Traitement. Le pourcentage denfants de moins de 5 ans atteints de paludisme
P. falciparum et traits par ACT a augment, passant de moins de 1 % en 2005
16 % en 2014 (plage comprise entre 12 % et 22 %), loin de lobjectif daccs universel
au traitement dni par le GMAP. Ceci sexplique notamment par le pourcentage
important denfants vreux qui ne sollicitent pas de soins ou qui font appel au service
priv informel, l ils sont moins susceptibles dobtenir un traitement par ACT. Alors que le
pourcentage denfants traits par ACT a augment, celui des enfants traits par dautres
mdicaments antipaludiques a diminu. Tout naturellement, le taux dutilisation des ACT
augmente parmi les enfants recevant un traitement antipaludique (valeur mdiane de
47 % sur la base de 18 enqutes ralises auprs des mnages entre 2013 et 2015). La
part des traitements par ACT est plus faible lorsque les soins ont t sollicits auprs des
prestataires de sant du secteur informel, tels que sur les tals de march ou auprs des
vendeurs itinrants.
Ratio entre traitements et tests. Le nombre total de traitements par ACT distribus
dans le secteur public est dsormais infrieur au nombre de tests de diagnostic fournis
en Afrique subsaharienne (le ratio entre traitements et tests slve 0,88 en 2014).
xxi
Nanmoins, ce ratio peut encore tre abaiss au niveau du taux de positivit des tests,
qui est infrieur 44 % en Afrique subsaharienne.
xxii
Points essentiels
Faiblesse des systmes de sant dans les pays o le paludisme svit le plus. La
capacit rpondre aux besoins de couverture des interventions est limite par
la faiblesse des systmes de sant dans les pays les plus durement touchs par le
paludisme. Le pourcentage de patients atteints de paludisme se prsentant dans des
tablissements de soins publics est plus faible dans les pays o les cas sont les plus
nombreux. En revanche, plus lincidence du paludisme est forte, plus le pourcentage de
patients suspects de paludisme et sollicitant des soins dans le secteur priv augmente.
La capacit des pays endmiques renforcer leurs systmes de sant est mise mal,
car les pays recensant le plus de cas de paludisme ont en effet un revenu national brut
et un niveau de dpenses publiques par habitant infrieurs aux autres. Les dpenses
internationales pour lutter contre le paludisme sont rparties de faon plus quitable
par rapport au poids du paludisme, mais une large part des nancements est consacre
aux produits antipaludiques et ne compense donc pas la faiblesse fondamentale des
systmes de sant. Par consquent, la prestation de services devra aussi se faire par des
mthodes novatrices, notamment via des approches communautaires ou lengagement
des prestataires privs, si lon veut rapidement tendre laccs aux interventions
antipaludiques.
Poids conomique du paludisme sur les systmes de sant. Depuis 2000, le seul cot
de la prise en charge des cas de paludisme en Afrique subsaharienne est estim
environ US$ 300 millions. Comme le paludisme se concentre dans des pays o le revenu
national est relativement faible, le cot des traitements antipaludiques apparat encore
plus difficile absorber dans les pays les plus pauvres.
Paludisme P. vivax. Le paludisme P. vivax est un problme de sant publique
important dans de nombreuses rgions du monde. En 2015, cette forme de paludisme est
responsable de 13,8 millions de cas dans le monde et de la moiti des cas de paludisme
hors Afrique. La plupart des cas de paludisme P. vivax ont t recenss dans la rgion
Asie du Sud-Est (74 %), loin devant la rgion Mditerrane orientale (11 %) et la rgion
Afrique (10 %) de lOMS. Plus de 80 % des cas de paludisme P. vivax sont enregistrs
dans trois pays (thiopie, Inde et Pakistan). P. vivax prdomine dans les pays engags
sur la voie de llimination du paludisme, et ce parasite est lorigine de plus de 70 % des
infections palustres dans les pays rapportant moins de 5 000 cas par an.
Des cas graves et des dcs dus au paludisme P. vivax ont t rapports dans toutes
les rgions endmiques. En 2015, le nombre de dcs dus au paludisme P. vivax est
estim entre 1 400 et 14 900 au niveau mondial, dont 1 400 12 900 en dehors de
lAfrique subsaharienne (i. e. entre 3,5 % et 16 % des dcs dus au paludisme ont t
enregistrs hors Afrique subsaharienne). Il existe nanmoins peu dinformations sur le
risque attribuable de paludisme P. vivax grave et de dcs associ pour une population
donne. Des travaux de recherche sont donc ncessaires pour affiner les estimations de
mortalit.
Rsistance aux insecticides. Lefficacit de la lutte antivectorielle base sur les
insecticides est menace par les moustiques porteurs du paludisme, qui dveloppent
une rsistance aux insecticides utiliss pour les MII et la PID. Depuis 2010, sur les
78 pays fournissant des donnes de suivi, 60 ont signal la rsistance dune population
de vecteurs au moins un insecticide, et 49 ont rapport une rsistance au moins
deux classes dinsecticides. La rsistance aux pyrthodes a t dtecte chez tous les
principaux vecteurs du paludisme, et les trois quarts des pays ayant effectu un suivi de
cette classe dinsecticides en 2014 ont fait tat dune rsistance. Nanmoins, et malgr
cette rsistance, les moustiquaires imprgnes dinsecticide longue dure (MILD)
restent efficaces.
Rsistance aux mdicaments antipaludiques. La rsistance du parasite P. falciparum
lartmisinine a t dtecte dans cinq pays de la sous-rgion du Grand Mkong : le
Cambodge, le Myanmar, la Rpublique dmocratique populaire lao, la Thalande et le
Viet Nam. Malgr les changements observs en termes de sensibilit des parasites, leur
processus dlimination est en effet plus long, les patients continuent de rpondre aux
combinaisons thrapeutiques, dans la mesure o le mdicament associ conserve son
efficacit. Lartmther-lumfantrine (AL) reste trs efficace en Afrique et en Amrique
xxiii
Prochaines tapes
Pour relever les ds daujourdhui et ceux venir, lOMS a dvelopp la
Stratgie technique mondiale de lutte contre le paludisme 2016-2030, qui
a t adopte par lAssemble mondiale de la Sant en mai 2015. Cette
stratgie dnit les objectifs les plus ambitieux depuis lre de lradication
du paludisme en termes de baisse du nombre de cas et de dcs associs.
Elle a t labore paralllement la rdaction par le Partenariat RBM du
plan Action et Investissement pour vaincre le paludisme 2016-2030 (AIM)
pour un monde sans paludisme et ce, an dassurer une complmentarit
des deux documents et de dnir des objectifs communs. Cette stratgie
sarticule autour de trois piliers : le pilier 1 vise garantir laccs universel
la prvention, au diagnostic et au traitement du paludisme ; le pilier 2 vise
acclrer les efforts vers llimination et vers lobtention du statut exempt
de paludisme ; et le pilier 3 consiste faire de la surveillance du paludisme
une intervention de base. Les investissements ncessaires pour le contrle et
llimination du paludisme sont estims US$ 6,4 milliards par an dici 2020
pour le premier objectif intermdiaire, savoir rduire de 40 % lincidence
du paludisme et la mortalit associe. Ces investissements devront ensuite
passer US$ 7,7 milliards par an dici 2025 pour atteindre le deuxime
objectif intermdiaire, savoir une baisse de 75 %. Enn, pour atteindre
lobjectif de diminution de 90 % de lincidence et du taux de mortalit
associe, les dpenses annuelles pour lutter contre le paludisme devront
atteindre US$ 8,7 milliards dici 2030.
xxiv
2000
2005
2010
2015
146
134
113
91
-37 %
47
37
26
19
-60 %
2%
7%
35 %
68 %
> 100 %
<1%
3%
12 %
13 %
> 100 %
Indicateurs du GMAP
2000
2005
2010
2015
Variation (%)
Variation (%)
76
63
52
43
ND
74 %
71 %
78 %
ND
ND
ND
31 %
NA
1%
7%
16 %
NA
0%
41 %
45 %
-43 %
> 100 %
32 %
29 %
22 %
16 %
-50 %
2%
7%
36 %
67 %
> 100 %
2%
6%
29 %
55 %
> 100 %
2%
3%
6%
3%
50 %
1%
4%
24 %
46 %
> 100 %
ND
ND
5%
17 %
> 100 %
ND
ND
ND
ND
16
MII, moustiquaire imprgne dinsecticide; NA, non applicable; ND, donnes non disponibles; OMD, Objectifs du Millnaire pour le
Dveloppement; PID, pulvrisation intradomiciliaire dinsecticides effet rmanent; TDR, test de diagnostic rapide; TPIp, traitement
prventif intermittent pendant la grossesse.
a
Indicateur calcul pour lAfrique subsaharienne uniquement.
b
Combinaisons thrapeutiques base dartmisinine.
c
Estimation de 2014 utilise pour 2015.
d
Estimation mdiane des enqutes les plus rcentes ralises auprs des mnages entre 2013 et 2015 en Afrique subsaharienne,
cart interquartile de 19 % 40 %.
e
Comme les donnes relatives aux traitements de premire intention adopts par les pays sont variables, cet indicateur ne concerne
que les cas de paludisme P. falciparum traits par combinaisons thrapeutiques base dartmisinine.
f
Estimation ne tenant pas compte des pays de la rgion Europe de lOMS.
g
Couverture en PID de 2014 utilise pour 2015.
h
Pays recensant zro cas indigne trois annes conscutives.
WORLD MALARIA REPORT 2015
xxv
xxvi
Prefacio
Dra. Margaret Chan
Directora General
Organizacin Mundial de la Salud
xxvii
xxviii
Puntos clave
El Informe Mundial sobre el Paludismo 2015 evala a nivel mundial las tendencias y los
cambios en la cobertura as como el financiamiento de los programas de control del
paludismo entre los aos 2000 y 2015. De esta manera, sintetiza los logros alcanzados
respecto a los objetivos internacionales, y proporciona los perfiles regionales y
nacionales que resumen las tendencias del paludismo en cada regin de la OMS y en
cada pas endmico.
El informe se ha elaborado con la ayuda de las oficinas regionales y nacionales de
la OMS, los ministerios de salud de los pases endmicos, y una amplia variedad de
colaboradores. Se presentan los datos recopilados de los 95 pases y territorios con
transmisin activa del paludismo, y de otros seis pases que han eliminado la enfermedad
recientemente. La mayora de los datos presentados son los datos reportados para el
ao 2014 y 2015, si bien en algunos casos se han realizado proyecciones para el 2015,
para poder evaluar el progreso hacia los objetivos del mismo ao.
xxix
xxx
Puntos clave
reportaron los tipos de insecticidas utilizados para el rociado en el ao 2014, 43 han
usado piretroides, aunque algunos pases tambin utilizaron insecticidas de una o dos
clases ms. Combinando los datos sobre la proporcin de la poblacin con acceso a
un MTI en la vivienda y la proporcin de personas protegidas por el RRI, la proporcin
estimada de personas que tuvieron alguna forma de control vectorial disponible en
frica subsahariana ha aumentado del 2% en el ao 2000 al 59% en el 2014. Estas cifras
estn an lejos de la meta de acceso universal marcada por la actualizacin del Plan
de Accin Global de Malaria (GMAP por sus siglas en ingles Global Malaria Action Plan)
en el 2011.
La quimioprevencin en mujeres embarazadas. La proporcin de mujeres
embarazadas que recibieron al menos tres dosis de tratamiento preventivo intermitente
durante el embarazo (TPIe) ha aumentado desde que la OMS revisara su recomendacin
en el ao 2012. En el 2014, se estima que 52% de las mujeres embarazadas elegibles
recibieron al menos una dosis de TPIe, el 40% recibi dos o ms dosis y slo el 17% recibi
tres o ms dosis. La diferencia entre la proporcin de mujeres que acuden a la clnica
de atencin prenatal y la proporcin que recibe la primera y siguientes dosis de TPIe
indica que se han perdido oportunidades de ofrecer el TPIe a estas mujeres. En el frica
subsahariana, la proporcin de mujeres que reciben TPIe vara en todo el continente,
con 10 pases que reportaron que ms del 60% de las mujeres embarazadas recibieron
una o ms dosis, y otros nueve pases que reportaron que ms del 80% recibieron una
o ms dosis.
La quimioprevencin en nios. La adopcin e implementacin de la quimioprevencin
en nios ha sido limitada. A partir del 2014, seis de los 15 pases para los que la OMS
recomienda la quimioprevencin del paludismo estacional (SMC, por sus siglas en ingls
Seasonal Malaria Chemoprevention) Chad, Gambia, Guinea, Mal, Nger y Senegal
han adoptado la poltica. Al mismo tiempo, dos pases de fuera de la subregin del
Sahel Congo y Togo reportaron la adopcin de esta poltica. Slo un pas, Chad,
report la adopcin de la poltica de tratamiento preventivo intermitente (TPI) para
los lactantes en el ao 2014. La vacuna contra el paludismo, RTS,S/AS01, recibi un
dictamen cientfico positivo de la Agencia Europea de Medicamentos en virtud del
artculo 58. Una implementacin piloto de la primera vacuna contra el paludismo
fue recomendada por el Grupo de Expertos de la OMS en Asesoramiento Estratgico
(SAGE por sus siglas en ingls Strategic Advisory Group of Experts on Immunization) y el
Comit Asesor de Polticas de la Malaria (MPAC por sus siglas en ingls Malaria Policy
Advisory Committee).
Pruebas de diagnstico. La proporcin de casos sospechosos de paludismo que
requieren atencin sanitaria en el sector pblico, a los que se les realiza una prueba de
diagnstico, ha aumentado del 74% en 2005 al 78% en 2014. La tendencia global est
dominada por pases en el Asia sudoriental, en particular la India, que lleva a cabo un
gran nmero de pruebas diagnsticas, con ms de 100 millones de pruebas realizadas
en 2014. La Regin de frica de la OMS ha tenido el mayor incremento en los niveles de
pruebas de diagnstico; de un 36% de casos de paludismo sospechosos en el ao 2005,
al 41% en el 2010 y al 65% en el 2014. Este aumento se debe principalmente al aumento
en el uso de pruebas de diagnstico rpido (PDR). El nivel de pruebas de diagnstico
realizadas es menor entre los nios febriles que buscan atencin en el sector privado
que en el sector pblico. En 18 encuestas representativas a nivel nacional, realizadas en
frica subsahariana entre los aos 2013 y 2015, la mediana de la proporcin de nios
febriles a los que se les practic una puncin en el dedo o en el taln en los centros
sanitarios del sector pblico fue del 53% (rango intercuartil [RIC]: 35 a 57%), mientras
que en el sector privado formal fue de 36% (RIC: 20-54%) y de 6% (RIC: 3-9%).
Tratamiento. Se estima que la proporcin de nios menores de 5 aos con paludismo
por P. falciparum que fueron tratados con TCA ha aumentado en menos de 1% en el
ao 2005 al 16% en el 2014 (rango 12-22%). Esta proporcin se reduce sustancialmente
por debajo del objetivo del acceso universal para el manejo de casos de paludismo
del GMAP. Una de las razones principal es que una alta proporcin de nios con
fiebre no toman nada para el cuidado o recurren al sector privado informal, dnde
son menos propensos a obtener un tratamiento con TCA. Mientras que la proporcin
xxxi
de nios tratados con TCA es cada vez mayor, la proporcin de nios tratados con
otros medicamentos antipaldicos ha disminuido. Por lo tanto, existe una proporcin
creciente de nios con paludismo que recibieron el tratamiento con TCA (mediana de
47% entre 18 encuestas nacionales representativas realizadas en hogares, entre 2013
y 2015). La proporcin de tratamientos antipaldicos TCA fue ms baja cuando se
solicit la atencin en salud con proveedores informales, tales como puestos de venta o
vendedores ambulantes.
Relacin entre tratamientos y pruebas diagnsticas. El nmero total de tratamientos
con TCA distribuidos en el sector pblico es hoy por hoy menor que el nmero de pruebas
de diagnstico para el paludismo suministradas en frica subsahariana (relacin de
tratamientos: pruebas = 0.88 en el ao 2014). No obstante, todava hay margen para
nuevas reducciones, ya que la proporcin de tratamientos de pruebas diagnsticas
debe aproximarse a la tasa de positividad de la prueba, que es menos de 44% en todos
los pases del frica subsahariana.
xxxii
Puntos clave
por paludismo en el ao 2000. Si se quiere obtener un mayor progreso a nivel mundial,
es necesario acelerar en gran medida las reducciones en la incidencia de casos.
Brechas en la cobertura de las intervenciones. Millones de personas todava no reciben
los servicios que necesitan. En frica subsahariana, se estima que 269 millones de los
834 millones de personas en riesgo de padecer el paludismo en el ao 2014 vivan en
viviendas sin ningn MTI o RRI; 15 millones de los 28 millones de mujeres embarazadas
en riesgo de sufrir la enfermedad no recibieron ninguna dosis de TPIe; y entre 68 y
80 millones de los 92 millones de nios con paludismo no recibieron TCA.
Deficiencias en los sistemas de salud en los pases con la carga de paludismo ms
elevada. La capacidad de cubrir las brechas en la cobertura de las intervenciones
est limitada por las deficiencias en los sistemas de salud en los pases con mayor
riesgo de transmisin. La proporcin de pacientes afectados por el paludismo que
buscan atencin en los centros sanitarios del sector pblico es menor en los pases
con un alto nmero estimado de casos de paludismo que en pases con menos casos.
Por el contrario, la proporcin de pacientes con sospecha de paludismo que buscan
atencin el sector privado aumenta con el nmero estimado de casos en un pas. La
capacidad de fortalecer los sistemas de salud en los pases dnde el paludismo es
endmico es limitada, ya que los pases con un alto nmero de casos tienen menos
ingresos nacionales brutos y menor gasto nacional total per cpita en comparacin
con los pases con menos casos. El gasto internacional para el control del paludismo
se distribuye de manera equitativamente segn la carga de la enfermedad, sin
embargo, una gran parte de este financiamiento se gasta en productos y no atiende
las debilidades fundamentales de los sistemas de salud. De este modo, para ampliar
rpidamente el acceso a las intervenciones contra el paludismo, se requieren formas
innovadoras de prestacin de servicios para expandir el acceso a las intervenciones y
tratamientos paldicos; tales medios incluyen enfoques basados en la comunidad y el
compromiso con los proveedores del sector privado.
La carga econmica del paludismo en los sistemas de salud. Desde el ao 2000, se
estima que el paludismo en frica subsahariana ha costado en promedio, slo por
el manejo de casos, cerca de US$ 300 millones. Dado que el paludismo se concentra
en los pases con ingresos nacionales relativamente bajos, el costo del tratamiento
del paludismo recae de manera desproporcionada en la mayora de los pases con
recursos limitados.
El paludismo por P. vivax. El paludismo por P. vivax es un problema importante de salud
pblica en muchas partes del mundo. Se estima que esta forma del paludismo caus
13.8 millones de casos en todo el mundo en el 2015 y contribuy con cerca de la mitad
de todos los casos de paludismo fuera de frica. La mayora de los casos de paludismo
por P. vivax ocurrieron en la Regin de Asia sudoriental de la OMS (74%), seguida de la
Regin del Mediterrneo Oriental (11%) y la Regin de frica (10%). Se estima que ms
del 80% de los casos de paludismo por P. vivax ocurren en tres pases (Etiopa, India y
Pakistn). P. vivax predomina en los pases que son los principales candidatos para la
eliminacin del paludismo y contribuye con ms del 70% de los casos en los pases con
menos de 5000 casos notificados cada ao.
En todas las regiones endmicas se han registrado casos graves y muertes debidas al
paludismo por P. vivax. A nivel mundial, se estima que en el ao 2015 el nmero total
de muertes por paludismo por P. vivax fue entre 1400 y 14 900, y entre 1400 y 12 900
fuera de frica subsahariana, es decir, de 3.5 a 16% de todas las muertes por paludismo
que ocurrieron fuera de frica subsahariana. Sin embargo, la informacin atribuibles
a la poblacin, sobre los riesgos de enfermedad severa y mortalidad debidos al
paludismo por P. vivax, es escasa y se requiere ms investigacin para perfeccionar las
estimaciones de mortalidad.
Resistencia a los insecticidas. La efectividad del control vectorial basado en el uso de
insecticidas se ve amenazada por el desarrollo de resistencia del parsito los insecticidas
utilizados en los MTI y el RRI. Desde el ao 2010, de los 78 pases que reportaron datos de
monitorizacin, 60 reportaron resistencia en una poblacin vectorial a por lo menos un
xxxiii
Prximos pasos
Para abordar los desafos pendientes y emergentes, la OMS ha desarrollado
la Estrategia Tcnica Mundial para la Malaria 2016-2030, que fue adoptada
por la Asamblea Mundial de la Salud en mayo del 2015. Dicha estrategia
establece los objetivos ms ambiciosos para la reduccin de casos y muertes
por paludismo desde que se inici la era de erradicacin del paludismo.
La estrategia est alineada con los objetivos de la Accin e Inversin
para vencer la Malaria 2016-2030 - por un mundo libre de malaria, de
la RBM para asegurar los objetivos compartidos y complementarios. La
estrategia tiene tres grandes pilares. El primero, lograr el acceso universal
a la prevencin, el diagnstico y el tratamiento del paludismo. El segundo,
acelerar los esfuerzos para lograr la eliminacin y alcanzar el estado
exento de paludismo. Y el tercero, transformar la vigilancia paldica en una
intervencin bsica. Se estima que las inversiones anuales para el control y
la eliminacin del paludismo tendrn que aumentar a US$ 6.4 mil millones
por ao para el 2020 para cumplir con el primer hito en una reduccin del
40% en las tasas de incidencia y mortalidad por paludismo. Posteriormente,
las inversiones anuales debern aumentar a US$ 7.7 mil millones para el ao
2025 para cumplir con el segundo de una reduccin del 75%. Finalmente,
para lograr el objetivo de una reduccin del 90%, se estima que el gasto
anual en paludismo tendr que alcanzar los US$ 8.7 mil millones para el
ao 2030.
xxxiv
2000
2005
2010
2015
146
134
113
91
-37%
47
37
26
19
-60%
2%
7%
35%
68%
>100%
<1%
3%
12%
13%
>100%
2000
2005
2010
2015
Tasa de mortalidad por todas las causas en menores de cinco aos (por
1000 nacidos vivos)
76
63
52
43
ND
74%
71%
78%
ND
ND
ND
31%
NA
1%
7%
16%
NA
0%
41%
45%
% de cambio
% de cambio
-43%
>100%
29%
22%
16%
-50%
2%
7%
36%
67%
>100%
2%
6%
29%
55%
>100%
2%
3%
6%
3%
50%
1%
4%
24%
46%
>100%
ND
ND
5%
17%
>100%
ND
ND
ND
ND
16
c,f,g
% viviendas con al menos un MTI para cada dos personas y/o rociadas
con RRI dentro de los ltimos 12 mesesa,g
MTI, mosquitero tratado con insecticida; NA, no aplicable; ND, datos no disponibles; ODM, Objetivo de Desarrollo del Milenio; PDR,
prueba de diagnstico rpido; RRI, rociado residual intradomiciliario; TPIe, tratamiento preventivo intermitente durante el embarazo
a
Indicador calculado solamente para el frica subsahariana
b
Se reere a terapias combinadas con artemisinas
c
El estimado mostrado para el 2015 corresponde al del 2014
d
Estimado de la mediana de las encuestas domiciliarias ms recientes en frica subsahariana para 20132015; rango intercuartil: 1940%
e
La informacion de tratamientos de primera linea adoptados por los pases son variables, el indicador mostrado considera casos
de P. falciparum tradados con terapias combinadas con artemisinas.
f
El estimado no incluye pases de la Regin Europea de la OMS
g
Se asume que la cobertura del RRI del 2015 es la misma que la del 2014
h
Pases con ningn caso autctonos por tres aos consecutivos
WORLD MALARIA REPORT 2015
xxxv
1. Introduction
2015 is the nal year for targets set by the World
Health Assembly and Roll Back Malaria to reduce
malaria incidence and mortality. It is also the year
that marks the end of the Millennium Development
Goals and the advent of the Sustainable
Development Goals.
1.1 Introduction to the World malaria report 2015
The World malaria report 2015 describes malaria disease trends and
changes in the coverage and financing of programmes between 2000 and
2015, summarizing progress towards international targets. It highlights the
key challenges that remain in 2015, the goals for malaria control between
2016 and 2030, and the strategies that will be used to achieve those goals.
It also contains regional proles that summarize trends in each WHO region,
and country proles for countries with ongoing malaria transmission and for
those that have recently achieved zero indigenous cases. Finally, annexes
provide details of the sources of data, the methods used in the analyses, and
tables containing country and regional data.
The world malaria report is produced every year by the WHO Global Malaria
Programme, with the help of WHO regional and country offices, ministries
of health in endemic countries, and a broad range of other partners. Data
are assembled from all 95 countries and territories with ongoing malaria
transmission, and a further six countries that have recently eliminated malaria
and are currently implementing measures to prevent re-establishment of
transmission. Most data presented are those reported for 2014 and 2015,
although in some cases projections have been made into 2015 to assess
progress against targets for 2015 (Annex 1 describes the methods used for
each chart and table).
1. Introduction
P. falciparum and P. vivax malaria pose the greatest public health challenge.
P. falciparum is most prevalent on the African continent, and is responsible
for most deaths from malaria. P. vivax has a wider geographical distribution
than P. falciparum because it can develop in the Anopheles mosquito vector
at lower temperatures, and can survive at higher altitudes and in cooler
climates. It also has a dormant liver stage (known as a hypnozoite) that can
activate months after an initial infection, causing a relapse of symptoms. The
dormant stage enables P. vivax to survive for long periods when Anopheles
mosquitoes are not present (e.g. during winter months). Although P. vivax
can occur throughout Africa, the risk of infection with this species is quite low
there because of the absence in many African populations of the Duffy gene,
which produces a protein necessary for P. vivax to invade red blood cells. In
many areas outside Africa, infections due to P. vivax are more common than
those due to P. falciparum, and cause substantial morbidity.
Mosquito vector
1. Vector control
2. Chemoprevention
3. Case management
Detect, diagnose,
treat and cure
infections
Human host
a variety of settings (2). When the nets are used by pregnant women, they
are also efficacious in reducing maternal anaemia, placental infection and
low birth weight. Historical and programme documentation has established
a similar impact for IRS, although randomized trial data are limited (3).
In a few specic settings and circumstances, the core interventions of ITNs
and IRS can be supplemented by larval source management (4) or other
environmental modications.
Chemoprevention is particularly effective in pregnant women and young
children. Intermittent preventive treatment in pregnancy (IPTp) involves
administration of sulfadoxine-pyrimethamine (SP) during antenatal clinic
visits in the second and third trimesters of pregnancy. It has been shown
to reduce severe maternal anaemia (5), low birth weight (6) and perinatal
mortality (7). By maintaining therapeutic antimalarial drug concentrations
in the blood during periods of greatest malaria risk, seasonal malaria
chemoprevention (SMC) with amodiaquine plus SP (AQ+SP) for children
aged 359 months has the potential to avert millions of cases and thousands
of deaths in children living in areas of highly seasonal malaria transmission in
the Sahel subregion (8). Intermittent preventive treatment in infants (IPTi) with
SP, delivered at routine childhood immunization clinics (at 2, 3 and 9 months
of age), provides protection in the rst year of life against clinical malaria
and anaemia; it reduces hospital admissions for infants with malaria and
admissions for all causes (9). A malaria vaccine, RTS,S/AS01, which requires
administration of four doses, has been found to reduce clinical malaria by 39%
(95% condence interval [CI]: 3443%) and severe malaria by 31.5% (95% CI:
9.348.3%) in children who received the vaccine at age 517 months (10).
However, the extent to which the protection observed in the Phase 3 trial
can be replicated in the context of the routine health system is uncertain;
WHOs Strategic Advisory Group of Experts on Immunization (SAGE) and the
Malaria Policy Advisory Committee (MPAC) recommended that these issues
be further assessed through large-scale implementation projects (11). WHO
has adopted these recommendations and supports the need to proceed with
these pilots as the next step for the worlds rst malaria vaccine.
Parasitological conrmation of malaria ensures treatment is given only to
those infected with malaria parasites; current medicines against malaria
are highly effective. In most malaria endemic areas, less than half of
patients with suspected malaria infection are truly infected with a malaria
parasite. Therefore, parasitological conrmation by light microscopy or rapid
diagnostic tests (RDTs) is recommended in all patients before antimalarial
treatment is started. Artemisinin-based combination therapy (ACT) of
uncomplicated P. falciparum malaria has been estimated to reduce malaria
mortality in children aged 123 months by 99% (range: 94100%), and in
children aged 2459 months by 97% (range: 8699%) (1).
1. Introduction
Table 1.1 Declarations and plans containing targets for malaria control and elimination 20002015
Year of publication
Declaration/Plan
2000
2015
2000
2005
2005
2015
2008
The Global Malaria Action Plan for a malaria-free world (GMAP) (15)
2015
2011
2015
Target
6C. Have halted by 2015 and begun to reverse the incidence of malaria and other major diseases
Indicators
as Goal 6 of the eight MDGs. Target 6C was to Have halted by 2015 and
begun to reverse the incidence of malaria and other major diseases, and
Indicators 6.66.8 were selected to track progress in reducing morbidity and
mortality and the implementation of malaria interventions (Table 1.2). Given
that, globally, malaria accounted for an estimated 7% of all deaths in children
aged 159 months in 2000, and 17% of all deaths in sub-Saharan Africa
(Section 2.2), malaria control was also central to MDG 4 (achieve a two thirds
reduction in the mortality rate among children aged under 5 years between
1990 and 2015). Malaria efforts were also expected to contribute to achieving
MDG 1 (eradicate extreme poverty and hunger), MDG 2 (achieve universal
primary education), MDG 3 (promote gender equality and empower women),
MDG 5 (improve maternal health) and MDG 8 (develop a global partnership
for development).
Malaria has been highlighted in World Health Assembly and RBM targets.
In 2005, the World Health Assembly set a target to reduce malaria cases
and deaths by 75% by 2015 (14). No baseline year was set, but it is assumed
to be 2000 (as for other targets), and that progress would be tracked using
incidence and death rates, as for MDG 6. In 2011, the RBM Partnership
updated the objectives and targets that had been set out in the Global
Malaria Action Plan (GMAP) in 2008 (15). The RBM update shared the World
Health Assemblys objective of reducing malaria cases by 75% by 2015, but
had a new and more ambitious objective to reduce malaria deaths to near
zero by 2015. A further RBM objective was to eliminate malaria by the end of
2015 in 810 new countries (since 2008) and in the WHO European Region.
The objectives of mortality and morbidity reduction are linked to targets for
universal access to malaria interventions which would mean that 100% of the
population in need of an intervention has access to it. A list of recommended
indicators against each objective and target is shown in Table 1.3.
The World malaria report 2015 aims to report on progress towards each
of the international targets, where possible. Some indicators of the RBM
updated objectives and targets were intended primarily for country-level
use rather than for international reporting and comparison (e.g. confirmed
malaria cases per 1000 persons per year and inpatient malaria deaths
per 1000 persons per year). In these cases, close equivalents are reported
(i.e. incidence and death rates associated with malaria which take into
account patients who use private-sector facilities, where reporting may be
absent or inconsistent, or those who do not seek care). In some cases, the
indicators do not measure a target directly (e.g. all-cause under-5 mortality
rate is not a direct measure of malaria mortality), but these indicators are in
widespread use and can inform progress on broader public health objectives.
Some indicators are reported only for sub-Saharan Africa because they are
most relevant there (e.g. all-cause under-5 mortality rate, pregnant women
who received intermittent preventive treatment for malaria) or because
of data availability (e.g. population who slept under an ITN the previous
night). Most of the data contained in the World malaria report 2015 cover
until the end 2014 or the first half of 2015. For some indicators, notably those
associated with MDG reporting, projections have been made to the end of
2015, as described in Annex 1.
1. Introduction
Table 1.3 Roll Back Malaria objectives, targets for 2015 and indicators for measuring progress (17)
GMAP objective or target
Key indicators
Objective 1.
Reduce global malaria deaths to near zero* by end
2015
Objective 2.
Reduce global malaria cases by 75% by end 2015
(from 2000 levels)
*
**
Objective 3.
Eliminate malaria by end 2015 in 10 new countries
(since 2008) and in the WHO European Region
In areas where public health facilities are able to provide a parasitological test to all suspected malaria cases, near zero malaria
deaths is defined as no more than 1 confirmed malaria death per 100 000 population at risk.
Universal access to and utilization is defined as every person at risk sleeping under a quality ITN or in a space protected by IRS
and every pregnant woman at risk receiving at least one dose of intermittent preventive treatment (IPTp) in settings where IPTp is
appropriate.
200
Incidence rate
Death rate
150
100
37% decrease
20002015
50
60% decrease
20002015
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Table 2.1 Estimated malaria cases and deaths, by WHO region, 20002015
Estimated number of malaria cases
(000's)
WHO region
2000
2005
2015
20002015
African
214 000
217 000
209 000
188 000
Americas
2 500
1 800
1 100
Eastern
Mediterranean
9 100
8 600
36
South-East Asia
Western Pacific
Change
2000
2005
2010
2015
-12%
764 000
670 000
499 000
395 000
-48%
660
-74%
1 600
1 200
1 100
500
-69%
4 000
3 900
-57%
15 000
15 000
7 000
7 000
-51%
5.6
0.2
-100%
33 000
34 000
28 000
20 000
-39%
51 000
48 000
44 000
32 000
-37%
3 700
2 300
1 700
1 500
-59%
8 100
4 200
3 500
3 200
-60%
World
262 000
264 000
243 000
214 000
-18%
839 000
738 000
554 000
438 000
-48%
Lower bound
205 000
203 000
190 000
149 000
653 000
522 000
362 000
236 000
Upper bound
316 000
313 000
285 000
303 000
1 099 000
961 000
741 000
635 000
European*
2010
Change
20002015
* There were no recorded deaths among indigenous cases in WHO European Region for the years shown.
Source: WHO estimates
Table 2.2 Estimated malaria incidence and death rates, by WHO region, 20002015
Estimated malaria incidence rate
per 1000 at risk of malaria
WHO region
2000
2005
2010
2015
427
378
315
246
Americas
40
26
16
Eastern
Mediterranean
59
49
European
28
South-East Asia
Western Pacific
Change
Change
2000
2005
2010
2015
-42%
153
117
75
52
-66%
-78%
2.6
1.9
1.5
0.7
-72%
20
18
-70%
9.3
8.3
3.6
3.3
-64%
0.1
-100%
-100%
44
42
33
23
-49%
6.9
6.0
5.1
3.5
-49%
11
-65%
2.4
1.2
1.0
0.9
-65%
World
146
134
113
91
-37%
47
37
26
19
-60%
Lower bound
114
103
88
63
36
27
17
10
Upper bound
176
159
132
129
61
49
34
27
African
20002015
20002015
European Region (100%), followed by the WHO Region of the Americas (78%),
the WHO Eastern Mediterranean Region (70%) and the WHO Western Pacific
Region (65%) (Figure 2.2). The malaria mortality rate is estimated to have
declined by 66% in the WHO African Region between 2000 and 2013.
The number of malaria deaths in children aged under 5 years is estimated to
have decreased from 723 000 globally in 2000 (range: 563 000948 000)
to 306 000 in 2015 (range: 219 000421 000). The bulk of this decrease
occurred in the WHO African Region, where the estimated number of deaths
fell from 694 000 in 2000 (range: 569 000901 000) to 292 000 in 2015
(range: 212 000384 000). While malaria remains a major killer of children,
taking the life of a child every 2 minutes, the progress made in reducing
deaths in children aged under 5 years has been substantial, particularly in
sub-Saharan Africa (Table 2.3).
Decrease
(a)
AMR
SEAR
EMR
WPR
0%
0%
20%
20%
40%
40%
60%
60%
80%
80%
100%
2000
2005
2010
2015
AFR
EUR*
(b)
100%
2000
2005
AMR
SEAR
2010
EMR
WPR
2015
AFR, African Region; AMR, Region of the Americas; EMR, Eastern Mediterranean Region; EUR,
European Region; SEAR, South-East Asia Region; WPR, Western Pacific Region
* There were no recorded deaths among indigenous cases in the WHO European Region for the
years shown.
Source: WHO estimates
10
2000
2005
2010
2005
2010
2015
African
694 000
591 000
410 000
292 000
-58%
7.84
5.82
3.55
2.26
-71%
400
300
300
100
-66%
0.06
0.05
0.04
0.02
-64%
5 300
5 200
2 000
2 200
-58%
0.44
0.33
0.15
0.14
-69%
South-East Asia
19 000
16 000
14 000
10 000
-49%
0.22
0.18
0.16
0.11
-48%
Western Pacific
4 700
2 000
1 600
1 500
-68%
0.18
0.08
0.06
0.06
-69%
World
723 000
614 000
428 000
306 000
-58%
3.12
2.49
1.63
1.10
-65%
Lower bound
563 000
434 000
279 000
219 000
2.43
1.76
1.06
0.79
Upper bound
948 000
800 000
572 000
421 000
4.09
3.24
2.17
1.51
Eastern
Mediterranean
European
20002015
Change
2000
Americas
2015
Change
20002015
Neonatal deaths
Malaria deaths
200
150
100
50
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
2011
Figure 2.4 Leading causes of death among children aged under 5 years in
sub-Saharan Africa, 20002015
Malaria
30
25
20
15
10
5
0
2000 2001
2011
2012
2013
2014
2015
Conditions that are responsible for more than 10 deaths per 1000 live births during any time
between 2000 and 2015 are shown.
Source: WHO estimates
11
The proportion of children infected with malaria parasites has been halved
in endemic areas of Africa since 2000. Infection prevalence among children
aged 210 years is estimated to have declined from 33% in 2000 (uncertainty
interval [UI]: 3135%); to 16% in 2015 (UI: 1419%), with three quarters of this
change occurring after 2005. Reductions were particularly pronounced in
central Africa. Whereas high transmission was common across much of central
and western Africa in 2000 (with P. falciparum infection prevalence in children
aged 210 years [PfPR210] exceeding 50%), it is geographically limited in 2015
(Figure 2.5). The proportion of the population living in areas where PfPR210
exceeds 50% has fallen from 33% (3037%) to 9% (513%). Even with a large
growth in underlying populations in stable transmission areas, this reduction
in PfPR210 has resulted in a 26% drop in the number of people infected, from
an average of 171 million people with malaria infections in 2000 to 127 million
in 2013. The population of areas experiencing very low transmission (PfPR210
<1%) has increased sixfold since 2000, to 121 million (range: 110133 million).
2000
PfPR210
100%
2015
0%
P. falciparum free
P. falciparum API <0.1
Not applicable
12
AMR
EMR
EUR
SEAR
WPR
60
Number of countries
50
40
30
20
10
0
Unable to assess
Increase
<50%
5075%
>75%
AFR, African Region; AMR, Region of the Americas; EMR, Eastern Mediterranean Region; EUR,
European Region; SEAR, South-East Asia Region; WPR, Western Pacic Region
Source: WHO estimates
13
Table 2.4 Summary of trends in reported malaria case incidence 20002015, by WHO region
WHO region
14
African
Algeria
Botswana
Cabo Verde
Eritrea
Namibia
Rwanda
Sao Tome and Principe
South Africa
Swaziland
Americas
Argentina
Belize
Bolivia
(Plurinational
State of)
Brazil
Colombia
Costa Rica
Ecuador
El Salvador
French Guiana,
France
Guatemala
Honduras
Mexico
Nicaragua
Paraguay
Suriname
Eastern
Mediterranean
Afghanistan
Iran (Islamic
Republic of)
Iraq
Morocco
Oman
Saudi Arabia
Syrian Arab
Republic
European
Armenia
Azerbaijan
Georgia
Kyrgyzstan
Tajikistan
Turkey
Turkmenistan
Uzbekistan
5075%
decrease in
incidence
projected
20002015
<50%
decrease in
incidence
projected
20002015
Ethiopia
Zambia
Zimbabwe
Madagascar
Dominican
Republic
Guyana
Panama
Peru
Increase in
incidence
20002015
Angola
Benin
Burkina Faso
Burundi
Cameroon
Central African
Republic
Chad
Comorosa
Congo
Cte dIvoire
Democratic
Republic of
the Congo
Equatorial
Guinea
Gabon
Gambia
Ghana
Venezuela
(Bolivarian
Republic of)
Haiti
Djibouti
Pakistan
Somalia
Sudan
Yemen
Guinea
Guinea-Bissau
Kenya
Liberia
Malawi
Mali
Mauritania
Mozambique
Niger
Nigeria
Senegal
Sierra Leone
South Sudan
Togo
Uganda
United Republic
of Tanzaniab
WHO region
South-East Asia
Bangladesh
Bhutan
Democratic
Peoples
Republic of
Korea
Nepal
Sri Lanka
Timor-Leste
Western Pacific
Cambodia
China
Lao Peoples
Democratic
Republic
Malaysia
Papua New
Guinea
Philippines
Republic of
Korea
Solomon
Islands
Vanuatu
Viet Nam
5075%
decrease in
incidence
projected
20002015
<50%
decrease in
incidence
projected
20002015
Increase in
incidence
20002015
India
Thailand
Indonesia
Myanmarc
Routinely reported data indicate a decrease of >75% in malaria case incidence between 2013 and 2014
Routinely reported data indicate a decrease of 5075% in malaria admissions rates in Zanzibar
c
Routinely reported data indicate a decrease of >75% in malaria case incidence since 2008
Source: National malaria control programme data
a
b
Table 2.5 Summary of trends in estimated malaria case incidence 20002015, for countries in which trends
could not be evaluated from reported data but can be assessed through modeling*
WHO region
African
Eastern
Mediterranean
>75% decrease in
incidence projected
20002015
Guinea-Bissau
Mauritania
50%75% decrease in
incidence projected
20002015
<50% decrease in
incidence projected
20002015
Angola
Burundi
Congo
Democratic Republic
of the Congo
Liberia
Malawi
Senegal
Uganda
United Republic of
Tanzania
Benin
Burkina Faso
Cameroon
Central African
Republic
Chad
Cte d'Ivoire
Equatorial Guinea
Gabon
Gambia
Ghana
Guinea
Kenya
Mali
Mozambique
Niger
Nigeria
Sierra Leone
South Sudan
Togo
Djibouti
Sudan
Somalia
Increase in incidence
20002015
* Trends could not be assessed by reported cases or modelling in 7 countries or areas: the Comoros, Haiti, Indonesia, Mayotte
(France), Myanmar, Pakistan and Yemen
15
AMR
EMR
EUR
SEAR
WPR
10 000 000
1 000 000
100 000
10 000
1000
100
10
1
2000 2015
2000 2015
2000 2015
2000 2015
2000 2015
2000 2015
AFR, African Region; AMR, Region of the Americas; EMR, Eastern Mediterranean Region; EUR,
European Region; SEAR, South-East Asia Region; WPR, Western Pacific Region
Diamonds represent countries within each WHO region
Source: National malaria control programme reports and WHO estimates
Figure 2.8 Number of countries with fewer than 1000, 100 and 10 cases,
20002015
Fewer than 1000 cases
Fewer than 10 cases
35
Number of countries
30
25
20
15
10
5
0
2000 2001
16
2011
2012
2013
2014
2015
Pre-elimination
Elimination
African
Cabo Verde
Swaziland
Algeria
Americas
Belize
Dominican Republic
Ecuador
El Salvador
Mexico
Argentina
Costa Rica
Paraguay
Prevention of
reintroduction
Malaria free
Eastern
Mediterranean
Egypt
Iraq
Oman
Syrian Arab Republic
Morocco 2010
United Arab Emirates
2007
European
Turkey
Tajikistan
Azerbaijan
Georgia
Kyrgyzstan
Uzbekistan
Turkmenistan 2010
Armenia 2012
South-East
Asia
Bhutan
Democratic People's
Republic of Korea
Western
Pacific
Malaysia
Sri Lanka
China
Republic of Korea
17
Figure 2.9 Indigenous malaria cases in the WHO European Region, by country, 19902015
Turkey
Tajikistan
Azerbaijan
Kyrgyzstan
Georgia
Armenia
Other countries
100 000
80 000
60 000
40 000
20 000
1990
1995
2000
18
2005
2010
2015
Figure 2.10 Indigenous malaria cases in the WHO European Region by parasite
species, 20002015
P. falciparum
P. vivax
40 000
30 000
20 000
10 000
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
2011
2012
2013
2014
2015
19
20
21
3. Coverage of key
interventions
3.1 Insecticide-treated mosquito nets
The proportion of the population sleeping under an ITN has increased
dramatically in sub-Saharan Africa since 2000. Most malaria endemic
countries have adopted policies promoting universal access to ITNs. However,
ITNs have been most widely deployed in Africa, which has the highest
proportion of the population at risk of malaria, and has malaria vectors
most amenable to control with ITNs. Based on data from household surveys
and reports from manufacturers and national malaria control programmes
(NMCPs), the proportion of the population sleeping under an ITN has
increased markedly in sub-Saharan Africa, from less than 2% in 2000 to an
estimated 46% in 2014 (95% CI: 4250%) and 55% in 2015 (95% CI: 5058%)
(Figure 3.1). The proportion of children aged under 5 years in sub-Saharan
Africa sleeping under an ITN increased to an estimated 68% (95% CI: 6172%)
in 2015. Although these results represent a substantial increase since 2000,
they fall short of universal (100%) coverage of this preventive measure.
The continent-wide estimates of those sleeping under an ITN obscure
variations in progress among and within countries. For example, in 2015,
the median proportion of the population sleeping under an ITN was 74%
among the five countries with the highest estimates and 20% among the five
countries with the lowest estimates (Figure 3.2).
Figure 3.1 Proportion of population at risk with access to an ITN and proportion
sleeping under an ITN, sub-Saharan Africa, 20002015
80%
60%
40%
20%
0%
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
2011
2012
2013
2014
2015
22
Figure 3.2 Proportion of population sleeping under an ITN, sub-Saharan Africa, 2015
100%
P. falciparum free
P. falciparum API <0.1
Not applicable
The rise in the proportion of the population sleeping under an ITN is driven by
increasing access to ITNs in the household. The proportion of the population
with access to an ITN in their household increased to 56% in 2014 (95% CI:
5161%) and 67% in 2015 (95% CI: 6171%) (Figure 3.1). This is a substantial
increase from the less than 2% with access to an ITN in 2000 but it is still lower
than the universal (100%) access called for in the updated GMAP targets. In
sub-Saharan Africa, estimates suggest that, overall, a high proportion (about
82%) of those with access to an ITN sleep under an ITN. Thus, while encouraging
consistent ITN use among those who have access remains important, ensuring
access to ITNs for those who do not have them is the highest priority activity to
increase the population protected by this intervention.
An increasing number of ITNs have been delivered to sub-Saharan African
countries, but those numbers are still insufficient to achieve universal access.
Most nets delivered by manufacturers to countries are subsequently distributed
by NMCPs to households. The number of nets delivered by manufacturers in a
given year usually does not exactly match the number distributed by NMCPs,
because of delays between delivery to the country and distribution through
campaigns. About 143 million LLINs were delivered to countries in sub-Saharan
Africa in 2013, over 189 million were delivered in 2014, and at least 154 million
WORLD MALARIA REPORT 2015
23
are projected to be delivered in 2015 (Figure 3.3). In recent years, most nets
delivered have been LLINs. The 189 million nets delivered in 2014 represent the
highest number delivered in a single year. This gure approaches the estimated
200 million nets required each year to achieve universal access to ITNs, if nets
were allocated to households with maximum efficiency (i.e. every household
received the exact number of nets required for 100% access within households)
and nets were retained in households for at least 3 years. However, this is the
best-case scenario; in reality, based on the current distribution patterns of nets
in households and the loss of nets estimated from distribution and survey data,
as many as 300 million new nets would be required each year to ensure that
all persons at risk of malaria had access to an LLIN in countries in which the use
of LLINs is the primary method of vector control.
Figure 3.3 Number of ITNs/LLINs delivered and distributed, and the estimated number of LLINs needed
annually to achieve universal access in sub-Saharan Africa, 20042015
ITNs/LLINs delivered by manufacturers
ITNs/LLINs distributed by NMCPs
Annual ITN/LLIN need, improved allocation and net retention
Annual ITN/LLIN need, current allocation and net retention
Number of ITNs/LLINs (million)
350
300
250
200
150
100
50
0
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
ITN, insecticide-treated mosquito net; LLIN, long-lasting insecticidal net; NMCP, national malaria control programme
Annual need for universal access was calculated under two scenarios: (1) current durability and net distribution patterns are
maintained and (2) every net lasts 3 years and each household receives the exact number of nets it needs.
Source: NMCP reports and Milliner Global Associates
24
2015
World
AFR
AMR
EMR
SEAR
WPR
15%
10%
5%
0%
2009
2010
2011
2012
2013
2014
AFR, African Region; AMR, Region of the Americas; EMR, Eastern Mediterranean Region; SEAR,
South-East Asia Region; WPR, Western Pacific Region
Source: National malaria control programme reports
Figure 3.5 Proportion of the population protected by IRS or with access to ITNs
in sub-Saharan Africa, 2014
>75%
5074%
2549%
<25%
Not malaria endemic
Not applicable
Source: National malaria control programme reports and insecticide-treated mosquito net
coverage model from Malaria Atlas Project (20), with further analysis by WHO
WORLD MALARIA REPORT 2015
25
100%
80%
60%
40%
20%
0%
2007
2008
2009
2010
2011
2012
2013
2014
26
>80%
6079%
4059%
2039%
<20%
No IPTp policy
Not applicable
The following country-years are shown in the map due to missing data for 2013 and 2014: Gabon
(2011), Somalia (2011), Sudan (2009).
Source: WHO estimates using national malaria control programme reports and United Nations
population estimates
27
AFR
AMR
EMR
EUR
SEAR
WPR
100%
80%
60%
40%
20%
0%
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
AFR, African Region; AMR, Region of the Americas; EMR, Eastern Mediterranean Region; EUR,
European Region; SEAR, South-East Asia Region; WPR, Western Pacic Region
Source: National malaria control programme reports
28
100%
80%
60%
40%
20%
0%
Public health
facility
Formal private
health care
Informal private
health care
Source: Nationally-representative household survey data from demographic and health surveys
and malaria indicator surveys
80%
60%
40%
20%
0%
Public health facility
Source: Nationally-representative household survey data from demographic and health surveys
and malaria indicator surveys
29
of a reduction in sales outside of Africa (Figure 3.11). About 62% of these RDTs
were P. falciparumspecic tests, and 38% were combination tests that can
detect more than one species of the malaria parasite. RDT sales reported by
manufacturers represent global totals delivered to both public and private
health sectors; the proportion delivered by manufacturers to each sector in
each WHO region is not known. RDTs distributed by NMCPs represent tests in the
public sector, and have followed a similar trend to total global sales. They rose
from fewer than 30 million distributed in 2008 to nearly 175 million in 2013, then
dipped slightly to 163 million in 2014. The sale and distribution of RDTs will need
to increase if universal access to malaria diagnostic testing is to be achieved.
Although the number of RDTs distributed fell slightly, the quality of RDTs has
improved and remained high following an RDT product-testing programme
conducted by WHO, the Foundation for Innovative New Diagnostics (FIND) and
the United States Centres for Disease Control and Prevention (CDC) (22).
EMR
EUR
SEAR
WPR
2011
2012
350
RDTs (million)
300
250
200
150
100
50
0
2008
2009
2010
2013
2014
AFR, African Region; AMR, Region of the Americas; EMR, Eastern Mediterranean Region; EUR,
European Region; NMCP, national malaria control programme; RDT, rapid diagnostic test;
SEAR, South-East Asia Region; WPR, Western Pacic Region
Source: NMCP reports and data from manufacturers eligible for the WHO Foundation for
Innovative new Diagnostics/US Centers for Disease Control and Prevention Malaria Rapid
Diagnostic Test Product Testing Program
0
2006
2007
2008
2009
2010
2011
2012
2013
30
2014
50%
40%
30%
20%
10%
0%
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
Source: Malaria treatment model from the Center for Applied Malaria Research and Evaluation
(Tulane University), the Global Health Group (University of California, San Francisco) and the
Malaria Atlas Project (University of Oxford).
31
less likely to obtain ACTs for treatment (Figure 3.16). Of those that seek care,
a signicant proportion of antimalarial treatments are not ACT medicines
(Figure 3.15). Although MDG Indicator 6.8 is much less relevant after the
change in the diagnostic testing recommendation by WHO, it is possible to
estimate that the proportion of children aged under 5 years, with fever and
who are treated with appropriate antimalarial drugs, rose from 0% in 2000
to 13% in 2014. This trend is, however, difficult to interpret; the indicator is not
expected to reach 100% because not all fevers are due to malaria, and the
proportion of fevers due to malaria in sub-Saharan Africa has decreased
over time through improved malaria control (23).
The proportion of children treated with an ACT among all children treated
for malaria is increasing. Nationally representative household surveys
conducted between 2004 and 2015 indicate that an increasing proportion
of febrile children who receive an antimalarial medicine are treated with an
ACT (Figure 3.14). After ACT (median 47%, IQR: 2977%), SP (median 5%, IQR:
118%), quinine (median 6%, IQR: 39%), chloroquine (median 2%, IQR: 010%)
Figure 3.14 Proportion of febrile children who receive an ACT among those
who receive any antimalarial, sub-Saharan Africa, 20042015
100%
80%
60%
40%
20%
0%
20042006
20072009
20102012
Household survey years
20132015
Only shows results for a subset of countries which have had household surveys in the stated years
Source: Nationally-representative household survey data from demographic and health surveys
and malaria indicator surveys
100%
80%
60%
40%
20%
0%
ACT
Mono
AQ
CQ
SP
QN
Other
32
100%
80%
60%
40%
20%
0%
Public health
facility
Formal private
health care
Informal private
health care
Only shows results for a subset of countries which have had household surveys in the stated years
Source: Nationally-representative household survey data from demographic and health surveys
and malaria indicator surveys
and AQ (median 1%, IQR: 05%) were the next most commonly used medicines
during 20132015 (Figure 3.15). The proportion of antimalarial treatments
that were ACTs was lowest when care was sought from informal health-care
providers, such as market stallholders or itinerant vendors (Figure 3.16).
The increasing proportion of malaria cases treated with ACT can be linked
to the increasing numbers of ACT treatments delivered by manufacturers
and distributed by NMCPs. The number of ACT treatment courses procured
from manufacturers increased from 11 million in 2005 to 337 million in 2014
(Figure 3.17). The WHO African Region accounted for 98% of all manufacturer
deliveries of ACT in 2014, with more than half of the total being doses for
children. The number of ACT treatments delivered by manufacturers to the
public sector in 2014 (223 million) was lower than the number delivered in
2013; likewise, NMCPs distributed 169 million treatments in 2014 through
Figure 3.17 Number of ACT treatment courses distributed by NMCPs, by WHO region, and ACT treatment
courses delivered by manufacturers to the public and private* sector, 20052014
Public sector ACT deliveries
AFR
AMR
EMR
EUR
SEAR
WPR
2010
2011
450
400
350
300
250
200
150
100
50
0
2005
2006
2007
2008
2009
2012
2013
2014
ACT, artemisinin-based combination therapy; AFR, African Region; AMR, Region of the Americas; EMR, Eastern Mediterranean
Region; EUR, European Region; NMCP, national malaria control programme; RDT, rapid diagnostic test; SEAR, South-East Asia
Region; WPR, Western Pacific Region
*2010-2013 includes AMFm public and private sectors, 2014 includes Global Fund co-payment mechanism, public and private sectors
Source: NMCP reports and companies eligible for procurement by WHO/UNICEF
33
Figure 3.18 Predicted time series of PfPR210 across endemic Africa with and
without interventions, 20002015
Actual PfPR
ITNs
ACTs
IRS
35%
30%
PfPR210
25%
20%
15%
10%
5%
0%
2000 2001
2010
2011
2012
2013
2014
2015
ACT, artemisinin-based combination therapy; IRS, indoor residual spraying; ITN, insecticidetreated mosquito net; PfPR, P. falciparum parasite rate
The red line shows the actual prediction and the dotted red line a counterfactual prediction
in a scenario without coverage by ITNs, ACT or IRS. The coloured regions indicate the relative
contribution of each intervention in reducing PfPR210 throughout the period.
Source: Malaria Atlas Project (18)
34
Figure 3.19 Predicted cumulative number of malaria cases averted by interventions, sub-Saharan Africa,
20002015
Cases averted due to ITNs
900
800
700
600
500
400
300
200
100
0
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
ACT, artemisinin-based combination therapy; IRS, indoor residual spraying; ITN, insecticide-treated mosquito net
Source: Malaria Atlas Project (18) estimates of cases averted attributable to ITNs, ACTs, and IRS and WHO estimates of total cases
averted
35
Global Fund
World Bank
USA
UK
AMFm
Others
US$ (million)
3000
2000
1000
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
AMFm, Affordable Medicine Facility-malaria; Global Fund, Global Fund to Fight AIDS, Tuberculosis and Malaria; NMCP, national
malaria control programme; UK, United Kingdom; USA, United States of America
Annual values have been converted to constant 2014 US$ using the gross domestic product (GDP) implicit price deator from the USA
in order to measure funding trends in real terms.
Source: ForeignAssistance.gov, Global Fund, NMCPs, Organisation for Economic Co-operation and Development (OECD) creditor
reporting system (CRS), the World Bank Data Bank
36
Figure 4.2 Investments in malaria control activities by WHO region and funding source,
20052014
International donors
2000
NMCPs
200
AMR
US$ (million)
US$ (million)
AFR
1500
1000
500
0
2005
150
100
50
0
2006
2007
2008
2009
2010
2011
2012
2013
2014
2005
200
2006
2007
2008
2009
2010
2011
2012
US$ (million)
US$ (million)
EUR
150
100
50
0
150
100
50
0
2006
2007
2008
2009
2010
2011
2012
2013
2014
2005
200
2006
2007
2008
2009
2010
2011
2012
2014
WPR
150
US$ (million)
US$ (million)
2013
200
SEAR
100
50
0
2005
2014
200
EMR
2005
2013
150
100
50
0
2006
2007
2008
2009
2010
2011
2012
2013
2014
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
AFR, African Region; AMFm, Affordable Medicine Facility-malaria; AMR, Region of the Americas; EMR, Eastern Mediterranean
Region; EUR, European Region; Global Fund, Global Fund to Fight AIDS, Tuberculosis and Malaria; NMCP, national malaria control
programme; SEAR, South-East Asia Region; UK, United Kingdom; USA, United States of America; WPR, Western Pacic Region
Annual values have been converted to constant 2014 US$ using the GDP implicit price deator from the USA in order to measure
funding trends in real terms.
Source: ForeignAssistance.gov, Global Fund, NMCPs, OECD CRS, the World Bank Data Bank
37
Most of the international funding in 2014 was spent in the WHO African
Region. Of the US$ 1.9 billion disbursed by international sources, 82% was
directed to the WHO African Region, 13% to other regions and 5% to malaria
endemic areas for which no information on country or region was available.
In 2014, international donors were the most important source of funding for
malaria control activities in the WHO African Region, representing 91% of the
total amount spent that year, with the balance coming from domestic funding.
In other regions, domestic governments generally finance a higher share of
malaria control expenditures, reflecting both the ability of those countries to
fund their own programmes and their limited access to international funding
for malaria.
Spending on commodities rose 40-fold between 2004 and 2014, and
accounted for about 82% of recorded international malaria spending
in 2014. Spending on commodities can be estimated by considering
manufacturers sales volumes data for ITNs/LLINs, ACTs and RDTs, and the
number of people covered by IRS (as reported by NMCPs), and applying
average procurement prices of those commodities (see Annex 1 for more
details). Over the past 11 years, variations in commodity spending, notably
for ITNs/LLINs, have closely followed variations in global international
funding (with a lag of about a year), highlighting the influence of funding
availability for operationalizing malaria control activities (Figure 4.3).
Spending on malaria control commodities is estimated to have increased
40-fold over the past 11 years, from about US$ 40 million in 2004 to about
US$ 1.6 billion in 2014. ITNs/LLINs, ACTs, RDTs and IRS represented 82% of the
total amount spent by international sources on malaria control activities in
2014. The remainder probably includes in-country supply-chain costs such
as personnel, training, transport and storage. Of the commodities, ITNs/
LLINs were responsible for 63% of total spending (US$ 1 billion), followed
by ACTs (25%, US$ 403 million), RDTs (9%, US$ 151 million) and IRS (3%,
US$ 46 million).
38
ACT
RDT
2009
2010
2011
IRS
International funding
2500
US$ (million)
2000
1500
1000
500
0
2004
2005
2006
2007
2008
2012
2013
2014
ACT, artemisinin-based combination therapy; IRS, indoor residual spraying; ITN, insecticide-treated mosquito net; LLIN, long-lasting
insecticidal net; RDT, rapid diagnostic test
Annual values have been converted to constant 2014 US$ using the GDP implicit price deflator from the USA in order to measure
funding/spending trends in real terms.
Source: Sales volumes of RDTs and ACTs reported to WHO by manufacturers as per Sections 3.5 and 3.6; net mapping project for
ITNs/LLINs; NMCP data for IRS as per Section 3.2; Management Science for Health International Price Indicator Guide, the United
States President's Malaria Initiative and the Global Fund Price and Quality Reporting Tool for commodity procurement prices. Total
international funding data sources as per Figure 4.1.
Figure 4.4 Provider savings in malaria case management costs attributable to expansion of malaria control
activities, 20012014
Savings in diagnostics and treatment
200
US$ (million)
150
100
50
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
Annual values have been converted to constant 2014 US$ using the GDP implicit price deflator from the USA in order to measure savings
trends in real terms.
Source: Data on malaria cases averted as per Section 2.3. Data on treatment-seeking behaviour, parasitological diagnosis and
treatment coverage as per Sections 3.5 and 3.6. WHO-CHOICE database on price estimates for outpatient care visit and inpatient bed
stay; Management Science for Health International Drug Price Indicator Guide and Global Fund Price and Quality Reporting Tool for
commodity prices.
39
5. Challenges
5.1 Continuing disease burden
Malaria remains a major public health problem in many countries of
the world. Despite the progress in reducing malaria cases and deaths, it
is estimated that 214 million cases of malaria occurred worldwide in 2015
(95% UI: 149303 million), leading to 438 000 malaria deaths (95% UI:
263 000635 000) (Section 2. 1).
More than 80% of estimated malaria cases and deaths occur in fewer than
20 countries. In 2015, it is estimated that 15 countries accounted for 80% of
cases, and 15 countries accounted for 78% of deaths (Figure 5.1). The global
burden of mortality is dominated by countries in sub-Saharan Africa, with the
Democratic Republic of the Congo and Nigeria together accounting for more
than 35% of the global total of estimated malaria deaths.
Rates of decline in malaria incidence and mortality are slower in highburden countries. The decreases in case incidence and mortality rates
have been most rapid in countries that had the smallest number of cases
in 2000, and slowest in countries that had the largest initial malaria burden
(Figure 5.2). The overall decrease in malaria incidence (32%) between 2000
and 2015 in the 15 countries that accounted for 80% of cases lags behind
that in the other countries (53%). Reductions in incidence need to be greatly
accelerated in these countries if global progress is to be improved.
Figure 5.1 Estimated proportion, and cumulative proportion, of the global number of (a) malaria cases and
(b) malaria deaths in 2015 for countries accounting for the highest share of the malaria disease burden
Proportion
(a)
0%
40
(b)
20%
40%
60%
80%
100%
0%
Nigeria
Nigeria
India
India
Uganda
Mali
Mozambique
Cte dIvoire
Mozambique
Mali
Burkina Faso
Ghana
Angola
Burkina Faso
Cte dIvoire
Kenya
Ghana
Cameroon
Uganda
Niger
Niger
Kenya
Indonesia
Guinea
Guinea
Cameroon
Cumulative proportion
20%
40%
60%
80%
100%
5. Challenges
Figure 5.2 Reduction in malaria incidence 20002015 versus estimated number
of cases in a country in 2000
Percentage reduction
100
80
60
40
20
0
<1000
100010 000
10 000100 000
Do not receive
IPTp: Pregnant
women receive
at least one dose
of IPTp
0%
20%
40%
60%
80%
100%
41
80%
100%
60%
40%
20%
80%
60%
40%
20%
0%
Total
population
Live in
household
with at least
one ITN or
protected by IRS
Have access to
an ITN
in household
or protected
by IRS
Slept under
an ITN
or protected
by IRS
42
0%
At least
one ANC visit
At least
1 dose of IPTp
At least
2 doses of IPTp
At least
3 doses of IPTp
5. Challenges
Multiple gaps exist in providing universal access to diagnostic testing and
treatment. In sub-Saharan Africa, the low proportion of children with malaria
who do not receive a diagnostic test or ACT is due to several factors. First,
a large proportion of febrile children are not brought for care (median 35%:
IQR 2441% among 18 household surveys conducted in sub-Saharan Africa
20132015) (Figure 5.6). This may be because of poor access to health-care
providers or because of a lack of awareness among caregivers regarding
necessary care for febrile children. Second, a signicant proportion of
febrile children seek care in the informal private sector (e.g. pharmacies
and shops). In these facilities, rates of malaria diagnostic testing are low
and ACT treatments are less likely to be available, or carers are less able
to afford them. Even if children are taken to a formal health-care provider
(e.g. a health facility or a community health worker), they may not receive
a diagnostic test or appropriate antimalarial treatment the provider may
have inadequate stocks or the patient may be unable to afford any charges
for medicines. Efforts are needed to close these gaps in access by (i) further
encouraging caregivers to bring febrile children to care, (ii) ensuring that
well trained and well equipped health-care providers are available, and (iii)
ensuring that children receive appropriate treatment when care is sought.
This can be accomplished by expanding the number of public health-care
providers, improving the quality of care in the public and private sector, and
expanding malaria diagnosis and treatment at the community level.
50%
Median proportion
40%
30%
20%
10%
0%
Public sector
Private sector
43
600
US$ (million)
500
400
300
200
100
0
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
Annual values have been converted to constant 2014 US$ using the GDP implicit price deflator
from the USA in order to measure spending/savings trends in real terms.
Source: Data on malaria cases as per section 2.1 and on malaria cases averted as per Section 2.3.
Data on treatment-seeking behaviour, parasitological diagnosis and treatment coverage as per
Sections 3.5 and 3.6. WHO-CHOICE database on price estimates for outpatient care visit and
inpatient bed stay; Management Science for Health International Drug Price Indicator Guide and
Global Fund Price and Quality Reporting Tool for commodity prices.
44
5. Challenges
Figure 5.7 Number of nurses per 1000 population in
malaria endemic countries versus estimated number
of malaria deaths*
AFR
AMR
EMR
SEAR
AFR
WPR
Gross national income per capita
10
Nurses
0
1
10
100
1000
10 000
100 000
AMR
EMR
SEAR
WPR
100 000
10 000
1000
0
1
10
100
1000
10 000
100 000
1 000 000
(a)
(b)
100%
100%
Figure 5.8 Proportion of malaria cases seeking care (a) in public sector and (b) private sector versus
estimated number of malaria cases, sub-Saharan Africa, 2015
80%
60%
40%
20%
0%
80%
60%
40%
20%
0%
100
1000
10 000
100 000
1 000 000
100
1000
10 000
100 000
1 000 000
Source: WHO estimates and nationally-representative household survey data from demographic and health surveys and malaria
indicator surveys
Figure 5.10 (a) Domestic government spending on malaria control per capita and (b) international
government spending on malaria control per capita versus estimated number of malaria deaths,
by WHO region, 2015
AFR
AMR
EMR
SEAR
WPR
100
10
1
0.10
0.01
10
100
1000
10 000
100 000
(b)
(a)
1000
AFR
AMR
EMR
SEAR
WPR
1000
100
10
1
0.10
0.01
10
100
1000
10 000
100 000
AFR, African Region; AMR, Region of the Americas; EMR, Eastern Mediterranean Region; SEAR, South-East Asia Region; WPR, Western
Pacific Region
Source: WHO estimates and the World Bank Data Bank
Source: ForeignAssistance.gov, Global Fund and OECD creditor
reporting system
45
Table 5.1 Estimated number of malaria cases and deaths due to P. vivax, by WHO region, 2015
Estimated P. vivax cases
WHO region
Estimate
Lower
Upper
1 400
300
3 000
1%
500
400
600
1 500
1 200
2 100
South-East Asia
10 000
7 000
15 000
Western Pacic
200
100
World
13 800
Outside sub-Saharan
Africa
12 300
African
Americas
Eastern Mediterranean
European
46
% of total cases
% of total deaths
Lower
Upper
500
50
1 900
0%
71%
140
50
500
25%
40%
450
110
1 800
6%
50%
3 500
1 200
10 300
11%
400
16%
80
20
240
3%
10 300
18 400
6%
4 700
1 400
14 900
1%
9 000
16 800
51%
4 100
1 400
12 900
11%
5. Challenges
Proportion of cases
80%
60%
40%
20%
0%
AFR
AMR
EMR
SEAR
WPR
Outside Africa
World
AFR, African Region; AMR, Region of the Americas; EMR, Eastern Mediterranean Region; SEAR,
South-East Asia Region; WPR, Western Pacific Region
Source: National malaria control programme reports and WHO estimates
Figure 5.13 Proportion of global P. vivax cases occurring in each WHO region
AFR
2%
AMR
EMR
SEAR
WPR
10%
3%
11%
74%
AFR, African Region; AMR, Region of the Americas; EMR, Eastern Mediterranean Region; SEAR,
South-East Asia Region; WPR, Western Pacific Region
Source: National malaria control programme reports and WHO estimates
Proportion of cases
80%
60%
40%
20%
0%
5 000 000 +
50 001500 000
500150 000
5015000
0500
47
Severe cases and deaths due to P. vivax malaria have been reported from
all endemic regions. The population-attributable risks of severe disease
or death from P. vivax malaria have rarely been estimated. Data from a
prospective, population-based study in Indonesia; routine case and death
reporting in Brazil, Colombia and Venezuela; and data on P. vivax morbidity
and mortality in travellers from non-endemic countries reveal case fatality
rates (CFRs) ranging from 0% to 0.089% (weighted average: 0.059%), with
a fourfold difference between Colombia (0.012%) and Indonesia (0.063%).
If CFRs lie between the values for Colombia and Indonesia, then, based on
the 13.8 million estimated P. vivax cases in 2015, the total number of malaria
deaths that could be attributed to P. vivax in 2015 is between 1400 and
14 900 globally. Similarly, the number of deaths from P. vivax malaria outside
sub-Saharan Africa in 2013 is estimated at between 1400 and 12 900 (i.e.
between 4% and 39% of the total number of deaths outside sub-Saharan
Africa). A clearer picture of severe P. vivax malaria is emerging, but further
research is required to rene existing knowledge of the spectrum of
syndromes and their risks of severe morbidity and mortality.
5. Challenges
Figure 5.15 Insecticide resistance and monitoring status, by insecticide class and WHO region, 20102014
Resistance reported
Not monitored
50
Number of countries
40
30
20
10
0
AFR AMR EMR EUR SEAR WPR AFR AMR EMR EUR SEAR WPR AFR AMR EMR EUR SEAR WPR AFR AMR EMR EUR SEAR WPR
Pyrethroids
Organochlorine (DDT)
Carbamates
Organophosphates
42
11
19
9
8
4
3
3
10
7
10
6
AFR, African Region; AMR, Region of the Americas; DDT, dichloro-diphenyl-trichloroethane; EMR, Eastern Mediterranean Region;
EUR, European Region; IRS, indoor residual spraying; ITN, insecticide-treated mosquito net; SEAR, South-East Asia Region; WPR,
Western Pacic Region
Source: National malaria control programme reports, African Network for Vector Resistance, Malaria Atlas Project, Presidents
Malaria Initiative (United States), scientific publications
Figure 5.16 Reported pyrethroid resistance status of malaria vectors, measured with insecticide bioassays
since 2010
Resistance status
O Conrmed resistance
O Possible resistance
Control
O Susceptible
Pre-elimination
Elimination
Prevention of reintroduction
Not applicable
Data shown are for standard bioassays. Where multiple insecticide classes or types, mosquito species or time points were tested, the
highest resistance status is shown.
Source: National malaria control programme reports, African Network for Vector Resistance, Malaria Atlas Project, Presidents
Malaria Initiative (United States), scientific publications.
New tools to address mosquito resistance to insecticides are mostly in the early
stages of development and evaluation. Tools include two LLINs and one IRS
formulation with new classes of insecticides. In certain settings, pyrethroid LLINs
that include a synergist to potentially improve efficacy against resistant vectors
are available. However, the operational conditions for deployment of these
new tools have not been established. Monitoring of LLIN durability and residual
transmission will further inform tool development and deployment. Mobilizing
resources is the key to adopting alternative tools for malaria vector control.
WORLD MALARIA REPORT 2015
49
50
5. Challenges
the median treatment failure rate was less than 2%. However, studies have
found elevated treatment failure rates in certain areas; for example, in
Somalia, a failure rate of 22.2% was observed during a therapeutic efficacy
study conducted in 2011. Similarly, the treatment failure rates in Sudan
have increased from 5.3% in 2005 to 9.4% in 2011. In north-east India near
the Myanmar border, treatment failure rates between 19% and 25.9% were
observed in three studies conducted in 2012, leading to a change in treatment
policy in this region to artemether-lumefantrine (AL). Molecular studies of
Pfdhfr and Pfdhps in Somalia indicate that treatment failures are related
to resistance to SP, in the absence of artemisinin resistance. It is well known
that resistance to antifolates emerges rapidly, and reductions in resistance
are rare. In India, Somalia and Sudan, treatment failures are associated with
Pfdhfr and Pfdhps quadruple and quintuple mutants. These mutations are still
rare in Afghanistan and Pakistan.
The efficacy of artemether-lumefantrine (AL) in Africa and South America
remains high. Currently, 40 countries in Africa and six countries in South
America are using AL as their rst- or second-line treatment. Isolated
studies conducted between 2006 and 2013 have shown treatment failure
rates above 10% in Angola, Burkina Faso, the Gambia, Ghana, Malawi,
the Niger, Nigeria and Zimbabwe; however, these rates are likely to be
outliers, because treatment failure rates have generally remained below 10%.
In South America, all studies conducted between 2005 and 2011 in Brazil,
Colombia, Ecuador and Suriname reported treatment failure rates of less
than 5% following treatment with AL. As with ASAQ, continued monitoring of
the treatment efficacy of AL in these countries is recommended.
The efficacy of dihydroartemisinin-piperaquine (DHA-PPQ) is vulnerable
in areas with existing piperaquine resistance. Currently, seven countries in
South-East Asia and the Western Pacic are recommending DHA-PPQ as
their rst- or second-line treatment (Cambodia, China, Indonesia, Myanmar,
Papua New Guinea, Thailand and Viet Nam). An increase in treatment failure
was observed in Cambodia in 2010, following a change in national policy to
treatment with DHA-PPQ. The median treatment failure rate in Cambodia
between 2005 and 2014 was 8.1%, with 11 studies observing treatment failure
rates exceeding 10%. In China and Viet Nam, no treatment failures were
observed, while Myanmar had a median treatment failure rate of 1.3%.
A molecular marker of artemisinin resistance was recently identied.
Mutations in the Kelch 13 (K13) propeller region are associated with delayed
parasite clearance, both in vitro and in vivo. The identication of the K13
marker for artemisinin resistance has allowed a more rened denition of
resistance that includes information on the genotype. However, as research
on mutations associated with artemisinin resistance is still evolving, the
denition of artemisinin resistance may require further modication. So
far, 186 K13 alleles, including 108 non-synonymous mutations, have been
reported.
Treatment or prophylactic failure with chloroquine for P. vivax malaria has
been observed in 24 countries. Treatment failure with chloroquine on or
before day 28, or prophylactic failure with chloroquine, has been observed
in 24 countries: Afghanistan, Brazil, Bolivia, Cambodia, China, Colombia,
Ethiopia, Guyana, India, Indonesia, Madagascar, Malaysia, Myanmar,
Pakistan, Papua New Guinea, Peru, Republic of Korea (after treatment
with hydroxychloroquine), the Solomon Islands, Sri Lanka, Thailand,
Timor-Leste, Turkey, Vanuatu and Viet Nam (28). At least one true case of
chloroquine resistance (with whole blood concentrations of chloroquine plus
desethylchloroquine >100 ng/mL on the day of failure) has been conrmed in
10 countries: Bolivia, Brazil, Ethiopia, Indonesia, Malaysia, Myanmar, Papua
New Guinea, Peru, the Solomon Islands and Thailand. ACT provides effective
treatment against P. vivax, with the exception of treatment with artesunate
51
plus SP; in this case, resistance to the partner drug may signicantly
compromise efficacy against P. vivax. Partner drugs may offer temporary
resolution of symptoms, but relapses commonly follow unless primaquine
is given. For example, relapses occur earlier following treatment with AL
than with DHA-PPQ or ASMQ, for parasites with short latency relapses,
because lumefantrine is eliminated more rapidly than is either meoquine
or piperaquine.
52
5. Challenges
Another important challenge is that many people who are infected with
malaria parasites remain asymptomatic or undiagnosed and are therefore
invisible to the health system. Further, in some settings the density of
parasitaemia is so low in a substantial proportion of individuals that it cannot
be detected with current routine diagnostic tools. These people unwittingly
contribute to the cycle of malaria transmission. If future disease control and
elimination strategies are to succeed, they will need to take into account this
large infectious parasite reservoir.
In some situations transmission of malaria parasites can continue even when
universal coverage with insecticidal nets or spraying has been achieved,
such as when mosquitoes bite in the early evening, or where they are outdoor
biting or resting. Consequently, they can evade the most frequently used
vector control interventions, and maintain transmission of malaria. Such
residual malaria transmission becomes increasingly important to tackle as
vector control coverage increases.
To overcome the range of challenges that malaria control programmes
face, it will be necessary to develop new tools and strategies for delivering
interventions. Malaria control programmes in 2015 are deploying tools such
as LLINs, RDTs and ACT that were not available in 2000. Similar innovation
and wide-scale deployment of new tools will be required in the next 15 years
for malaria programmes to advance further and overcome the challenges
they currently face.
53
6. Moving forward
To address remaining and emerging challenges, WHO developed a Global
technical strategy for malaria 20162030. The strategy was developed
under the guidance of a Steering Committee that comprised leading
malaria technical experts, scientists and country representatives. Oversight
was provided by the MPAC. During the strategy development process,
WHO consulted all affected countries through a series of seven regional
consultations and, in JulyAugust 2014, held a public web consultation. The
strategy was developed in close alignment with the RBM Partnerships Action
and investment to defeat malaria 20162030 for a malaria-free world
to ensure shared goals and complementarity. The WHO Global technical
strategy for malaria 20162030, was adopted by the World Health Assembly
in May 2015. WHO is now working on developing regional implementation
plans to roll out the technical strategy.
The Global technical strategy for malaria 20162030 sets the most
ambitious targets for reductions in malaria cases and deaths since
the malaria eradication era. The vision of WHO and the global malaria
community is a world free of malaria. As part of this vision, the strategy sets
ambitious yet feasible global targets for 2030 with milestones for 2020 and
2025 (Table 6.1). Countries will set their own national or subnational targets,
which may differ from the global targets.
Table 6.1 Goals, milestones and targets of the Global technical strategy for malaria 20162030 and Action
and investment to defeat malaria 20162030
VISION
Goals
Targets
2020
2025
2030
At least 40%
At least 75%
At least 90%
At least 40%
At least 75%
At least 90%
At least 10 countries
At least 20 countries
At least 35 countries
Re-establishment
prevented
Re-establishment
prevented
Re-establishment
prevented
54
Milestones
6. Moving forward
The Global technical strategy for malaria 20162030 provides a framework
for developing programmes that are tailored to local circumstances, with
the aim of accelerating progress towards malaria elimination. The strategy
has three main building blocks. Pillar 1 is to ensure universal access to
malaria prevention, diagnosis and treatment. All core malaria interventions
namely vector control, chemoprevention, diagnostic testing and treatment
should be expanded to cover all populations in need of them. Pillar 2 is to
accelerate efforts towards elimination and attainment of malaria-free
status. In addition to expanding interventions to all populations at risk, all
countries should intensify efforts to eliminate the disease, especially in areas
with low transmission. Pillar 3 is to transform malaria surveillance into a
core intervention. Strengthening malaria surveillance is a critical factor for
programme planning and implementation, and for accelerating progress
towards elimination. Maximal progress in these three areas will depend on
the development of new tools and innovations in service delivery. It will also
depend on strong political commitment, robust nancing and increased
multisectoral collaboration.
Malaria investments need to increase substantially to achieve the
milestones and goals set out in the Global technical strategy for malaria
20162030. It is estimated that annual investments in malaria control and
elimination will need to increase to a total of US$ 6.4 billion per year by 2020
to meet the rst milestone of at least a 40% reduction in malaria incidence
and mortality rates. This should then further increase to an annual investment
of US$ 7.7 billion by 2025 to meet the second milestone of at least a 75%
reduction. To achieve the 90% reduction goal, total annual malaria spending
will need to reach an estimated US$ 8.7 billion by 2030. If these resources
can be secured, and malaria interventions delivered with the resources, the
malaria landscape will change even more dramatically than it has over the
past 15 years, and a pathway will be set for the eventual eradication of this
ancient disease.
55
References
1. Thwing J., Eisele T.P., Steketee R.W. Protective efficacy of malaria case management
and intermittent preventive treatment for preventing malaria mortality in children:
a systematic review for the Lives Saved Tool. BMC Public Health, 2011 11 Suppl 3:S14
(http://www.ncbi.nlm.nih.gov/pubmed/21501431, accessed 19 November 2014).
2. Lengeler C. Insecticide-treated bed nets and curtains for preventing malaria.
Cochrane Database Syst Rev. 2004;(2):CD000363 (http://www.ncbi.nlm.nih.gov/
pubmed/15106149, accessed 30 November 2015).
3. Pluess B, Tanser FC, Lengeler C, Sharp BL. Indoor residual spraying for preventing
malaria. Cochrane Database Syst Rev. 2010;(4):CD006657 (http://www.ncbi.nlm.
nih.gov/pubmed/20393950, accessed 30 November 2015).
4. World Health Organization. Larval source management a supplementary
measure for malaria vector control. An operational manual. Geneva,
World Health Organization, 2013 (http://apps.who.int/iris/bitst
ream/10665/85379/1/9789241505604_eng.pdf?ua=1, accessed 16 November 2015).
5. Radeva-Petrova D., Kayentao K., ter Kuile F.O., Sinclair D., Garner P. Drugs for
preventing malaria in pregnant women in endemic areas: any drug regimen versus
placebo or no treatment. Cochrane Database Syst Rev, 2014 10:CD000169 (http://
www.ncbi.nlm.nih.gov/pubmed/25300703, accessed 17 November 2014).
6. Kayentao K., Garner P., van Eijk A.M., Naidoo I., Roper C., Mulokozi A. et al. Intermittent
preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of
sulfadoxine-pyrimethamine and risk of low birth weight in Africa: Systematic review
and meta-analysis. JAMA, 2013 309(6):594604 (http://www.ncbi.nlm.nih.gov/
pubmed/23403684, accessed 17 November 2014).
7. Garner P., Gulmezoglu A.M. Drugs for preventing malaria-related illness in
pregnant women and death in the newborn. Cochrane Database Syst Rev, 2003
(1):CD000169 (http://www.ncbi.nlm.nih.gov/pubmed/12535391, accessed 17
November 2014).
8. Roca-Feltrer A., Carneiro I., Smith L., Schellenberg J.R., Greenwood B., Schellenberg
D. The age patterns of severe malaria syndromes in sub-Saharan Africa across
a range of transmission intensities and seasonality settings. Malar J, 2010 9:282
(http://www.ncbi.nlm.nih.gov/pubmed/20939931, accessed 17 November 2014).
9. Aponte J.J., Schellenberg D., Egan A., Breckenridge A., Carneiro I., Critchley J. et al.
Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine
for malaria in African infants: a pooled analysis of six randomised, placebocontrolled trials. Lancet, 2009 374(9700):15331542 (http://www.ncbi.nlm.nih.gov/
pubmed/19765816, accessed 17 November 2014).
10. Joint Technical Expert Group on Vaccines (JTEG) and WHO Secretariat. Background
Paper on the RTS,S/AS01 Malaria Vaccine, September 2015 (www.who.int/
immunization/sage/meetings/2015/october/1_Final_malaria_vaccine_background_
paper_v2015_09_30.pdf, accessed 1 December 2015)
11. World Health Organization. Background brief: malaria vaccine RTS,S/AS01. Geneva,
World Health Organization, 2015 (http://www.who.int/malaria/news/2015/
background-brief-malaria-vaccine/en/, accessed 16 November 2015).
12. United Nations Millennium Declaration. United Nations General Assembly. 2000
(http://www.unmillenniumproject.org/documents/ares552e.pdf, accessed 23
August 2015).
13. World Health Organization. The Abuja declaration and the plan of action. An extract
from the African Summit on Roll Back Malaria, Abuja, 25 April 2000. Geneva, World
Health Organization, 2000 (WHO/CDS/RBM/2000.17) (http://apps.who.int/iris/
bitstream/10665/67816/1/WHO_CDS_RBM_2003.46.pdf, accessed 16 November
2015).
56
References
14. Resolution WHA58.2. Malaria control. Geneva, World Health Organization, 2005
(58th World Health Assembly, 23 May 2005) (http://www.who.int/malaria/
publications/WHO_malaria_resolution_2005.pdf, accessed 13 November 2015).
15. Roll Back Malaria. The global malaria action plan for a malaria free world.
Roll Back Malaria Partnership, 2008 (http://archiverbm.rollbackmalaria.org/gmap/
gmap.pdf, accessed 16 November 2015)
16. Rened/Updated GMAP Objectives, Targets, Milestones and Priorities Beyond
2011. Geneva, Roll Back Malaria, 2011 (http://www.rollbackmalaria.org/les/les/
gmap2011.pdf, accessed 16 November 2015).
17. Household survey indicators for malaria control. MEASURE Evaluation, MEASURE
DHS, Presidents Malaria Initiative, Roll Back Malaria Partnership, United Nations
Children's Fund, World Health Organization, 2013 (http://www.rollbackmalaria.
org/les/les/resources/tool_HouseholdSurveyIndicatorsForMalariaControl.pdf,
accessed 16 November 2015).
18. Bhatt, S., et al. The effect of malaria control on Plasmodium falciparum in Africa
between 2000 and 2015. Nature, 2015. 526(7572):p. 207-11.
19. Malaria 19621981. World Health Statistics Annual 1983. Geneva, World Health
Organization. 1983:791795.
20. Bhatt S, Weiss DJ, Mappin B, Dalrymple U, Cameron E et al. Coverage and system
efficiencies of insecticide-treated nets in Africa from 2000 to 2017s. eLife; in press.
21. Global plan for insecticide resistance management in malaria
vectors. Geneva, World Health Organization, 2012 (http://apps.who.int/iris/bitst
ream/10665/44846/1/9789241564472_eng.pdf?ua=1, accessed 16 November 2013).
22. World Health Organization, Global Malaria Programme. WHO product testing round
5 (2013): WHO-FIND Malaria RDT Evaluation Programme, April 2014 (http://www.
who.int/malaria/areas/diagnosis/rapid-diagnostic-tests, accessed 1 December
2015).
23. World Health Organization, United Nations Childrens Fund. Achieving
the malaria MDG target: reversing the incidence of malaria 20002015.
Geneva, World Health Organization, 2015 (http://apps.who.int/iris/bitst
ream/10665/184521/1/9789241509442_eng.pdf?ua=1, accessed 16 November 2015).
24. The Global Fund. The Global Fund 2014 annual nancial report. Geneva, The Global
Fund, 2015 (www.theglobalfund.org/documents/publications/annual_reports/
Corporate_2014AnnualFinancial_Report_en, accessed 27 November 2015).
25. Tanahashi T. Heath service coverage and its evaluation. Bulletin of the World Health
Organization, 56 (2): 295303 (1978) (http://www.ncbi.nlm.nih.gov/pmc/articles/
PMC2395571/pdf/bullwho00439-0136.pdf, accessed 26 November 2015).
26. World Health Organization. Global report on antimalarial efficacy and drug
resistance: 2000-2010. Geneva: World Health Organization; 2010 (http://whqlibdoc.
who.int/publications/2010/9789241500470_eng.pdf?ua=1, accessed 26 November
2015).
27. Word Health Organization Global Malaria Programme. Status report on artemisinin
resistance, September 2014 (http://www.who.int/malaria/publications/atoz/
status_rep_artemisinin_resistance_sep2014.pdf, accessed 16 November 2015).
28. Baird JK. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol
Rev 2009, 22:508-534 (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2708388/
pdf/0008-09.pdf, accessed 16 November 2015).
29. Cohen JM, Smith DL, Cotter C, Ward A, Yamey G, Sabot OJ, Moonen B. Malaria
resurgence: a systematic review and assessment of its causes. Malaria Journal,
2012, 11:122.
57
58
Regional profiles
African Region
Liberia
Mali
Mauritania
Niger
Nigeria
Senegal
Sierra Leone
Togo
Pakistan
Saudi Arabia
Somalia
Sudan
Yemen
European Region
Central Africa
Angola
Burundi
Cameroon
Central African
Republic
Chad
Afghanistan
Djibouti
Iran (Islamic
Republic of)
Iraq
Congo
Democratic Republic
of the Congo
Equatorial Guinea
Gabon
Sao Tome and
Principe
Azerbaijan
Georgia
Kyrgyzstan
Tajikistan
Turkey
Uzbekistan
Rwanda
South Sudan
Uganda
United Republic of
Tanzania
Zambia
Swaziland
Zimbabwe
Bangladesh
Bhutan
Democratic
Peoples Republic
of Korea
India
Indonesia
Myanmar
Nepal
Sri Lanka
Thailand
Timor-Leste
Guyana
Haiti
Honduras
Mexico
Nicaragua
Panama
Paraguay
Peru
Suriname
Venezuela (Bolivarian
Republic of)
Cambodia
China
Lao Peoples
Democratic
Republic
Malaysia
Papua New Guinea
Philippines
Republic of Korea
Solomon Islands
Vanuatu
Viet Nam
59
West Africa
Population at risk: About 342 million people in the 17 countries of
this subregion are at risk for malaria, with 289 million at high risk
(reported incidence >1 per 1000) (Figure A). Malaria cases are
almost exclusively due to P. falciparum. Among malaria endemic
countries, 15 are focused on malaria control, while Cabo Verde
is in the pre-elimination programme phase, and Algeria in the
elimination phase.
Financing: Funding for malaria control rose substantially from
US$ 104 million in 2005 to US$ 586 million in 2012, with a minimal
increase to US$ 637 million in 2014 (Figure B). In 20122014,
funding per capita per year exceeded US$ 4 in three countries
(Cabo Verde, the Gambia and Liberia) (Figure C), was US$ 13 in
12 countries, and was less than US$ 1 in two countries (Mauritania
and Niger).
Interventions: In 2014, the proportion of the at-risk population
estimated to have access to an insecticide-treated mosquito net
(ITN) in their household exceeded 50% in 11 countries (Burkina
Faso, Cte dIvoire, the Gambia, Ghana, Guinea, Guinea-Bissau,
Liberia, Mali, Senegal, Sierra Leone and Togo) (Figure D). Benin,
Cabo Verde, the Gambia, Ghana, Mali and Senegal used indoor
residual spraying (IRS), although this was limited to coverage of
between 5% and 20% of the at-risk population. Liberia, Benin and
Nigeria had implemented IRS on a limited scale and had stopped
spraying in 2014. Algeria did not report on vector control coverage
in 2014. All countries, except Guinea, Liberia, Mali and Togo
delivered sufficient antimalarial medicines to treat more than
80% of patients attending public health facilities (Figure E). Cte
dIvoire did not report on the delivery of antimalarial medicines.
Insecticide resistance: Countries in West Africa, particularly Benin,
Burkina Faso, Cte dIvoire and Ghana, have long been reporting
high prevalence of insecticide resistance in malaria vectors. Since
2010, reports of pyrethroid and dichlorodiphenyltrichloroethane
(DDT) resistance have been widespread, with increased reports
of carbamate resistance. Organophosphate resistance has been
reported in six of 11 countries, indicating the need to develop
alternative insecticides.
Conrmed cases
per 1000 population/
parasite prevalence (PP)
Insufficient data
0
00.1
0.11.0
1.010
PP
>85
0
Data are only shown for countries and areas that had ongoing malaria transmission in year 2000
60
West Africa
B. Financial contribution for malaria control
by source, 20052014
NMCPs
Global Fund
World Bank
PMI/US
UK
Australia
Others
600
500
400
300
200
100
0
2005
2006
2007
2008
2009
2010
2011
2012
2013
International donors
Cabo Verde
Liberia
Gambia
Benin
Ghana
Senegal
Mali
Guinea
Cte dIvoire
Sierra Leone
Guinea-Bissau
Burkina Faso
Nigeria
Togo
Niger
Mauritania
Algeria
700
US$ (million)
NMCPs
8
12
16
US$ per at-risk capita per year
2014
20
Global Fund, Global Fund to Fight AIDS, Tuberculosis and Malaria; NMCP,
national malaria control programme; PMI/US, President's Malaria
Initiative/United States; UK, United Kingdom of Great Britain and Northern Ireland
ACT
IRS
Burkina Faso
Guinea-Bissau
Gambia
Ghana
Senegal
Guinea
Togo
Mali
Sierra Leone
Liberia
Cte dIvoire
Nigeria
Benin
Niger
Mauritania
Cabo Verde
Algeria
Any antimalarial
Burkina Faso
Benin
Ghana
Gambia
Guinea-Bissau
Mauritania
Niger
Nigeria
Senegal
Cabo Verde
Sierra Leone
Togo
Mali
Guinea
Algeria
Liberia
Cte dIvoire
0%
20%
40%
60%
80%
100%
0%
20%
40%
60%
80%
100%
2000
2015
Admission
Death
Algeria*
Cabo Verde
Gambia
Mali
Liberia
Guinea-Bissau
Togo
Mauritania
Burkina Faso
Ghana
Senegal
Nigeria
Guinea
Niger
Benin
Cte dIvoire
Sierra Leone
Burkina Faso
Cte dIvoire
Togo
Liberia
Ghana
Sierra Leone
Guinea
Mali
Nigeria
Guinea-Bissau
Benin
Niger
Gambia
Senegal
Mauritania
Cabo Verde
Algeria
0
500
1000
Cases per 1000 population
1500
-100%
-50%
f Reduction
0%
Increase p
50%
100%
* Changes in case incidence due to all species (Q) and due to P. vivax (Q)
61
Central Africa
Population at risk: About 158 million people in the 10 countries of
this subregion are at some risk for malaria, with 145 million at high
risk (Figure A). Cases are almost exclusively due to P. falciparum.
All endemic countries in the subregion are in the control phase.
Financing: Funding for malaria control in the subregion rose from
US$ 81 million in 2005 to US$ 300 million in 2013, but declined to
US$ 237 million in 2014 (Figure B). Malaria funding per capita per
year during 20122014 was highest in Sao Tome and Principe at
US$ 13.8, was between US$ 1 and US$ 3 in six countries, and was
less than US$ 1 in the remaining three countries (Figure C).
Interventions: In 2014, the proportion of the at-risk population
estimated to have access to an ITN in their household exceeded
50% in four countries (Burundi, Central African Republic, Chad,
and Sao Tome and Principe) (Figure D). IRS was used to protect
the at-risk population in two countries (Sao Tome and Principe,
protecting >50%; and Equatorial Guinea, 20%). Five countries
(Burundi, Central African Republic, Chad, Democratic Republic of
the Congo and Gabon) reported distributing sufficient artemisininbased combination therapy (ACT) to treat more than 80% of
estimated malaria cases attending public health facilities in 2014.
Angola and Congo did not report on delivery of ACT (Figure E).
Insecticide resistance: Since 2010, there have been reports of
resistance to pyrethroids and DDT for the eight countries tested,
with no data reported for Gabon and Sao Tome and Principe.
Also, carbamate resistance has been reported for Angola,
Burundi and Cameroon. To date, no countries in the region have
reported organophosphate resistance.
Antimalarial drug efficacy: All countries in central Africa have
adopted either AS-AQ or AL as their rst-line treatment. The
therapeutic efficacy of both treatments remains high, with a
median treatment failure rate of less than 10% observed for both
medicines.
Trends in cases and deaths: Between 2000 and 2014, only Sao Tome
and Principe achieved at least 75% reduction in case incidence; it
also reported decreases of more than 90% in malaria admission
and death rates. Although the number of cases and admissions
during 20112013 increased compared to the number in the previous
4 years, the number of cases fell from 9234 in 2013 to 1754 in 2014.
Malaria admissions also fell from 1843 in 2013 to 417 in 2014, the
lowest number reported for the country since 2000.
In the remaining nine countries, it was not possible to assess
trends using routinely reported data, because of incomplete
reporting, or changes in health service access or diagnostic
testing. The number of conrmed malaria cases and admissions
has increased in several countries in recent years, possibly
reecting improved reporting or improved access to health
services (Figure G). Subnational decreases in malaria morbidity
and mortality have been reported in Equatorial Guinea on Bioko
Island (6), although high transmission persisted in some foci (7).
Similar decreases occurred in the Mbakong district of Cameroon
(8) between 2006 and 2012. However, no evidence of a decreased
malaria burden was reported in both urban and rural settings of
Gabon (9).
Estimates malaria case incidence inferred from surveys of
parasite prevalence suggest that, between 2000 and 2015, four
countries (Angola, Burundi, Congo and Democratic Republic of
the Congo) had decreases in case incidence of 5075% between
2000 and 2015, and the remaining ve countries had decreases
of less than 50% (Figure F).
62
Conrmed cases
per 1000 population/
parasite prevalence (PP)
Insufficient data
0
00.1
0.11.0
1.010
PP
>85
0
Data are only shown for countries and areas that had ongoing
malaria transmission in year 2000
Central Africa
B. Financial contribution for malaria control
by source, 20052014
NMCPs
Global Fund
World Bank
PMI/US
UK
Australia
Others
NMCPs
International donors
350
Equatorial Guinea
Democratic Republic
of the Congo
300
Angola
250
US$ (million)
Burundi
200
Chad
150
100
Cameroon
50
Gabon
0
0
2005
2006
2007
2008
2009
2010
2011
2012
2013
8
12
16
US$ per at-risk capita per year
2014
20
Global Fund, Global Fund to Fight AIDS, Tuberculosis and Malaria; NMCP,
national malaria control programme; PMI/US, Presidents Malaria
Initiative/United States; UK, United Kingdom of Great Britain and Northern Ireland
ACT
IRS
Burundi
Burundi
Democratic Republic
of the Congo
Chad
Gabon
Chad
Democratic Republic
of the Congo
Angola
Cameroon
Cameroon
Equatorial Guinea
Equatorial Guinea
Congo
Congo
Gabon
Angola
0%
20%
40%
60%
80%
100%
0%
20%
40%
60%
Any antimalarial
80%
100%
2000
2015
Admission
Democratic Republic
of the Congo
Gabon
Burundi
Equatorial Guinea
Cameroon
Angola
Equatorial Guinea
Congo
Chad
Death
Congo
Burundi
Gabon
Democratic Republic
of the Congo
Angola
Cameroon
Chad
0
500
1000
Cases per 1000 population
1500
-100%
-50%
0%
50%
f Reduction Increase p
WORLD MALARIA REPORT 2015
100%
63
64
Conrmed cases
per 1000 population/
parasite prevalence (PP)
Insufficient data
0
00.1
0.11.0
1.010
PP
>85
0
Data are only shown for countries and areas that had ongoing
malaria transmission in year 2000
Global Fund
World Bank
PMI/US
UK
Australia
Others
International donors
Zambia
900
Rwanda
800
Malawi
700
Comoros
Kenya
600
US$ (million)
NMCPs
Mozambique
500
South Sudan
400
Uganda
300
Ethiopia
Eritrea
200
100
Madagascar
0
0
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
8
12
16
US$ per at-risk capita per year
20
Global Fund, Global Fund to Fight AIDS, Tuberculosis and Malaria; NMCP,
national malaria control programme; PMI/US, Presidents Malaria
Initiative/United States; UK, United Kingdom of Great Britain and Northern Ireland
ACT
IRS
Any antimalarial
Eritrea
Ethiopia
Madagascar
Kenya
Comoros
Malawi
South Sudan
Mozambique
Uganda
Rwanda
Kenya
Mozambique
Malawi
Rwanda
Ethiopia
Comoros
Eritrea
South Sudan
Uganda
20%
40%
60%
80%
100%
0%
20%
40%
60%
80%
100%
2000
2015
Admission
Death
Uganda
Mozambique
Comoros
Malawi
Kenya
Rwanda
Eritrea
Zambia
Zambia
United Republic of Tanzania
Mozambique
South Sudan
Madagascar
Kenya
Malawi
Comoros
Ethiopia
Ethiopia
Uganda
United Republic of Tanzania
(Mainland)
South Sudan
Madagascar
Eritrea
0
500
1000
Cases per 1000 population
1500
2000
-100%
-50%
0%
50%
f Reduction Increase p
WORLD MALARIA REPORT 2015
100%
65
Conrmed cases
per 1000 population/
parasite prevalence (PP)
Insufficient data
0
00.1
0.11.0
1.010
PP
>85
0
Data are only shown for countries and areas that had ongoing malaria transmission in year 2000
66
Global Fund
World Bank
PMI/US
UK
Australia
Others
NMCPs
International donors
Swaziland
90
80
South Africa
70
US$ (million)
60
Namibia
50
40
Zimbabwe
30
20
Botswana
10
0
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
12
16
US$ per at-risk capita per year
20
Global Fund, Global Fund to Fight AIDS, Tuberculosis and Malaria; NMCP,
national malaria control programme; PMI/US, Presidents Malaria
Initiative/United States; UK, United Kingdom of Great Britain and Northern Ireland
ACT
IRS
Botswana
Zimbabwe
Zimbabwe
South Africa
Namibia
Swaziland
Swaziland
Botswana
South Africa
Namibia
20%
40%
60%
80%
100%
20%
40%
Any antimalarial
60%
80%
2000
2015
Zimbabwe
Namibia
Namibia
Swaziland*
Botswana
South Africa
South Africa
100%
Botswana*
Swaziland
Zimbabwe*
0
100
200
300
Cases per 1000 population
400
500
-100%
-50%
f Reduction
0%
Increase p
50%
100%
* Changes in case incidence due to all species (Q) and due to P. vivax (Q)
67
68
Confirmed cases
per 1000 population
Insufficient data
0
00.1
0.11.0
1.010
1050
50100
> 100
Data are only shown for countries and areas that had ongoing
malaria transmission in year 2000
Global Fund
World Bank
PMI/US
UK
Australia
Others
250
200
US$ (million)
NMCPs
150
100
50
(37)
0
2005
2006
2007
2008
2009
2010
2011
2012
2013
International donors
Paraguay
Suriname
Mexico
Argentina
Costa Rica
Panama
El Salvador
Colombia
Brazil
Guyana
Belize
Bolivia (Plurinational State of)
Nicaragua
Dominican Republic
Haiti
Honduras
Ecuador
Peru
Guatemala
Venezuela (Bolivarian Republic of)
French Guiana, France
2014
4
8
12
16
US$ per at-risk capita per year
20
Global Fund, Global Fund to Fight AIDS, Tuberculosis and Malaria; NMCP,
national malaria control programme; PMI/US, Presidents Malaria
Initiative/United States; UK, United Kingdom of Great Britain and Northern Ireland
Nicaragua
Guyana
Dominican Republic
Haiti
Honduras
Colombia
Bolivia (Plurinational State of)
Guatemala
Costa Rica
Mexico
Brazil
Ecuador
French Guiana, France
Suriname
Belize
Peru
El Salvador
Venezuela (Bolivarian Republic of)
Panama
Paraguay
Argentina
0%
20%
40%
60%
80%
ACT
IRS
100%
Brazil
Colombia
Costa Rica
Mexico
Paraguay
Venezuela (Bolivarian Republic of)
Guyana
Dominican Republic
Honduras
Belize
Haiti
Nicaragua
Panama
El Salvador
Argentina
Bolivia (Plurinational State of)
Ecuador
French Guiana, France
Guatemala
Peru
Suriname
0%
20%
40%
60%
Any antimalarial
80%
P. falciparum
Haiti
Dominican Republic
Guyana
French Guiana, France
Suriname
Colombia
Venezuela (Bolivarian Republic of)
Ecuador
Nicaragua
Brazil
Peru
Honduras
Bolivia (Plurinational State of)
El Salvador
Guatemala
Panama
Costa Rica
Belize
Argentina
Mexico
Paraguay
0%
P. vivax
Other
100%
Argentina
Costa Rica
Paraguay
Ecuador
El Salvador
Belize
Suriname
French Guiana, France
Nicaragua
Guatemala
Mexico
Honduras
Bolivia (Plurinational State of)
Brazil
Colombia
Dominican Republic
Guyana
Haiti
Panama
Peru
Venezuela (Bolivarian Republic of)
20%
40%
60%
80%
100%
-100%
-50%
0%
50%
f Reduction Increase p
WORLD MALARIA REPORT 2015
100%
69
Conrmed cases
per 1000 population/
parasite prevalence (PP)
Insufficient data
0
00.1
0.11.0
1.010
PP
>85
0
Data are only shown for countries and areas that had ongoing malaria transmission in year 2000
70
Global Fund
World Bank
PMI/US
UK
Australia
Others
International donors
NMCPs
Iran (Islamic Republic of)
(29)
Saudi Arabia
(25)
250
200
Djibouti
US$ (million)
Sudan
150
Somalia
100
Afghanistan
Yemen
50
Pakistan
0
0
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
8
12
16
US$ per at-risk capita per year
20
Global Fund, Global Fund to Fight AIDS, Tuberculosis and Malaria; NMCP,
national malaria control programme; PMI/US, Presidents Malaria
Initiative/United States; UK, United Kingdom of Great Britain and Northern Ireland
ACT
IRS
Saudi Arabia
Saudi Arabia
Afghanistan
Afghanistan
Yemen
Djibouti
Sudan
Pakistan
Somalia
Sudan
Djibouti
Somalia
Pakistan
Yemen
0%
20%
40%
60%
80%
IRS, indoor residual spraying; ITN, insecticide-treated mosquito net
100%
P. vivax
Other
0%
20%
40%
ACT, artemisinin-based combination therapy
80%
100%
Djibouti
Saudi Arabia
Saudi Arabia
Yemen
Somalia
Somalia
Yemen
Afghanistan
Sudan
Djibouti
Pakistan
Sudan
Pakistan
Afghanistan
0%
60%
Any antimalarial
20%
40%
60%
80%
100%
-100%
-50%
0%
50%
f Reduction Increase p
WORLD MALARIA REPORT 2015
100%
71
European Region
Population at risk: In 2000, eight countries in the WHO
European Region (Armenia, Azerbaijan, Georgia, Kyrgyzstan,
Tajikistan, Turkey, Turkmenistan and Uzbekistan) had indigenous
transmission of malaria; however, in 2014, indigenous transmission
was conned to Tajikistan, in which 3 million people were living
in areas with some risk for malaria. Turkey and Tajikistan are in
the elimination phase, with the other countries in the prevention
of reintroduction phase. In 2015, the WHO European Region
reported zero indigenous cases for the rst time.
Financing: Funding for malaria control in the region rose from
about US$ 42 million in 2005 to US$ 58 million in 2009, but fell to
US$ 29 million in 2014 (Figure B). Between 2012 and 2014, funding
per capita per year ranged from US$ 1.5 in Tajikistan to US$ 2566
in Turkey (Figure C).
Interventions: In all countries in the region, malaria is a notiable
disease. Each case and focus is epidemiologically investigated
and classied; there are national quality assurance programmes
for microscopy and for radical treatment of P. vivax cases, and
there is adequate access to antimalarial medicines. IRS and ITNs
are used in targeted focal areas.
Insecticide resistance: Since 2010, data from standard bioassays
have been reported for two countries only (Azerbaijan and
Tajikistan), with susceptibility to pyrethroids conrmed in both
countries, and susceptibility to organophosphates conrmed
in Tajikistan. Continuous monitoring is necessary in the areas in
which IRS and ITN use continues.
Trends in cases and deaths: All countries in the region achieved
a 100% decrease in case incidence between 2000 and 2015
Very low PP
2040
6080
No cases
020
4060
80100
Data are only shown for countries and areas that had ongoing malaria transmission in year 2000
72
European Region
B. Financial contribution for malaria control
by source, 20052014
NMCPs
Global Fund
World Bank
PMI/US
UK
Australia
Others
International donors
NMCPs
Turkey
(2566)
70
60
US$ (million)
50
Kyrgyzstan
(247)
Uzbekistan
(65)
Azerbaijan
(42)
40
30
Georgia
20
10
Tajikistan
0
0
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
12
16
US$ per at-risk capita per year
20
Global Fund, Global Fund to Fight AIDS, Tuberculosis and Malaria; NMCP,
national malaria control programme; PMI/US, Presidents Malaria
Initiative/United States; UK, United Kingdom of Great Britain and Northern Ireland
Year
Imported
Tajikistan
Indigenous
Turkey
Kyrgyzstan
Azerbaijan
Georgia
Uzbekistan
35 000
2006
2007
30 000
2008
25 000
2009
20 000
2010
15 000
2011
10 000
2012
2013
5000
2014
0
500
1000
1500
Cases
2000
2500
3000
0
2000
2002
2004
2006
2008
2010
2012
2014
P. vivax
40 000
Azerbaijan
Turkey
30 000
Tajikistan
20 000
Georgia
Kyrgyzstan
10 000
Uzbekistan
0
2000
2002
2004
2006
2008
2010
2012
2014
-100%
-50%
f Reduction
0%
Increase p
50%
100%
73
Conrmed cases
per 1000 population/
parasite prevalence (PP)
Insufficient data
0
00.1
0.11.0
1.010
PP
>85
0
Data are only shown for countries and areas that had ongoing malaria transmission in year 2000
74
Global Fund
World Bank
PMI/US
UK
Australia
Others
International donors
NMCPs
Timor-Leste
300
Myanmar
Bhutan
250
Sri Lanka
US$ (million)
200
Bangladesh
Thailand
150
Nepal
100
Democratic Peoples
Republic of Korea
Indonesia
50
India
0
0
2005
2006
2007
2008
2009
2010
2011
2012
2013
8
12
16
US$ per at-risk capita per year
2014
20
Global Fund, Global Fund to Fight AIDS, Tuberculosis and Malaria; NMCP,
national malaria control programme; PMI/US, Presidents Malaria
Initiative/United States; UK, United Kingdom of Great Britain and Northern Ireland
ACT
IRS
Bhutan
Bangladesh
Nepal
Sri Lanka
Timor-Leste
Myanmar
Myanmar
Timor-Leste
Bangladesh
Thailand
Indonesia
Bhutan
Thailand
Democratic Peoples
Republic of Korea
Sri Lanka
India
Democratic Peoples
Republic of Korea
Indonesia
India
Nepal
0%
20%
40%
60%
80%
100%
0%
20%
40%
60%
Any antimalarial
80%
P. falciparum
P. vivax
Other
100%
Sri Lanka
Bangladesh
Bhutan
Timor-Leste
Timor-Leste
Myanmar
Bangladesh
Indonesia
Democratic Peoples
Republic of Korea
India
Myanmar
Bhutan
Nepal
Thailand
India
Nepal
Thailand
Sri Lanka
Indonesia
Democratic Peoples
Republic of Korea
0%
20%
40%
60%
80%
100%
-100%
-50%
0%
50%
f Reduction Increase p
WORLD MALARIA REPORT 2015
100%
75
tive, and AS+MQ has since become the rst-line treatment in these
areas (see Section 5.6).
Trends in cases and deaths: Three countries accounted for 89% of
reported conrmed cases in 2014: Papua New Guinea (71%), Lao
Peoples Democratic Republic (12%) and Cambodia (6%). Eight of
the 10 countries in the region achieved more than 75% reduction
in the incidence of microscopically conrmed cases between 2000
and 2014 (Cambodia, China, Malaysia, Philippines, Republic of
Korea, Solomon Islands, Vanuatu, Viet Nam) (Figure G). Cambodia
is on track to achieve a 50-75% reduction in case incidence by 2015.
In Vanuatu, reported cases dropped sharply from 2381 in 2013 to
982 in 2014 (58% decrease). Although the Lao Peoples Democratic
Republic has reduced malaria incidence by 50% since 2000, case
incidence has increased since 2011, with more than 48 000 cases
reported in 2014. This increase is associated with an inux of migrant
workers in the south of the country. Papua New Guinea has reported
considerably more conrmed cases since 2012, due to an increase
in diagnostic testing with RDTs. However, the incidence of malaria
admissions to public health facilities decreased by more than 75%
between 2000 and 2014, and nationally representative household
surveys indicated a drop in parasite prevalence from 12.4% to 1.8%
between 2009 and 2014.
Reported malaria deaths in the region decreased from 2360 to 264
between 2000 and 2014. In 2014, two countries accounted for 86%
of all reported deaths: Papua New Guinea (77%) and the Solomon
Islands (9%). Vanuatu has reported no deaths from malaria since
2012.
Malaysia is in the pre-elimination phase, but the number of
indigenous cases increased from 2921 in 2013 to 3147 in 2014, and
the number of people living in active foci remains high (1.3 million).
Malaria transmission occurs primarily in the districts of Sabah and
Sarawak. In the Republic of Korea, which is in the elimination phase,
the number of indigenous cases between 2013 and 2014 increased
from 383 to 557. China reported only 56 locally acquired cases in
2014; six were caused by P. falciparum and 50 by P. vivax. China
is aiming to eliminate malaria nationally by 2020. The Philippines
is proceeding with a subnational elimination approach, with a
focus on the provinces most affected by malaria: Maguindanao
(Mindanao) and the islands of Palawan and Tawi-Tawi.
>85
0
Data are only shown for countries and areas that had ongoing malaria transmission in year 2000
76
Global Fund
World Bank
PMI/US
UK
Australia
Others
180
(47)
Vanuatu
160
140
Solomon Islands
120
US$ (million)
International donors
NMCPs
Malaysia
Cambodia
100
Lao Peoples
Democratic Republic
80
Republic of Korea
60
Philippines
40
Viet Nam
20
China
0
0
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
8
12
16
US$ per at-risk capita per year
20
Global Fund, Global Fund to Fight AIDS, Tuberculosis and Malaria; NMCP,
national malaria control programme; PMI/US, Presidents Malaria
Initiative/United States; UK, United Kingdom of Great Britain and Northern Ireland
ACT
IRS
Malaysia
Any antimalarial
China
Solomon Islands
Cambodia
Lao Peoples
Democratic Republic
Vanuatu
Malaysia
Philippines
Lao Peoples
Democratic Republic
Philippines
Cambodia
Solomon Islands
China
Viet Nam
Viet Nam
Vanuatu
Republic of Korea
Republic of Korea
0%
20%
40%
60%
80%
100%
0%
20%
40%
60%
80%
P. falciparum
P. vivax
Other
100%
China
Cambodia
Lao Peoples
Democratic Republic
Philippines
Philippines
Viet Nam
Vanuatu
Solomon Islands
Republic of Korea
Cambodia
Solomon Islands
Vanuatu
Lao Peoples
Democratic Republic
China
Viet Nam
Malaysia
Malaysia
Republic of Korea
20%
40%
60%
80%
100%
-100%
-50%
0%
50%
f Reduction Increase p
100%
77
References
1. Beiersmann C., Bountogo M., Tiendrebeogo J., De Allegri M., Louis V.R., Coulibaly B. et al.
Falciparum malaria in young children of rural Burkina Faso: comparison of survey data in 1999
with 2009. Malar J, 2011 10:296.
2. Giardina F., Kasasa S., Sie A., Utzinger J., Tanner M., Vounatsou P. Effects of vector-control
interventions on changes in risk of malaria parasitaemia in sub-Saharan Africa: a spatial and
temporal analysis. Lancet Glob Health, 2014 2(10):e601-615 (http://www.ncbi.nlm.nih.gov/
pubmed/25304636, accessed 20 November 2014).
3. Trape J.F., Tall A., Sokhna C., Ly A.B., Diagne N., Ndiath O. et al. The rise and fall of malaria in a
West African rural community, Dielmo, Senegal, from 1990 to 2012: a 22 year longitudinal study.
Lancet Infect Dis, 2014 14(6):476-488.
4. Landoh E.D., Tchamdja P., Saka B., Tint K.S., Gitta S.N., Wasswa P. et al. Morbidity and mortality
due to malaria in Est Mono district, Togo, from 2005 to 2010: A times series analysis. Malar J, 2012
11:389.
5. Terlouw D.J., Morgah K., Wolkon A., Dare A., Dorkenoo A., Eliades M.J. et al. Impact of mass
distribution of free long-lasting insecticidal nets on childhood malaria morbidity: the Togo
National Integrated Child Health Campaign. Malar J, 2010 9:199.
6. Bradley J., Matias A., Schwabe C., Vargas D., Monti F., Nseng G. et al. Increased risks of malaria
due to limited residual life of insecticide and outdoor biting versus protection by combined use of
nets and indoor residual spraying on Bioko Island, Equatorial Guinea. Malar J, 2012 11:242.
7. Overgaard H.J., Reddy V.P., Abaga S., Matias A., Reddy M.R., Kulkarni V. et al. Malaria
transmission after ve years of vector control on Bioko Island, Equatorial Guinea. Parasit Vectors,
2012 5:253.
8. Ndong I.C., van Reenen M., Boakye D.A., Mbacham W.F., Grobler A.F. Trends in malaria
admissions at the Mbakong Health Centre of the North West Region of Cameroon: a
retrospective study. Malar J, 2014 13(1):328 (http://www.malariajournal.com/content/pdf/14752875-13-328.pdf, accessed 20 November 2014).
9. Mawili-Mboumba D.P., Bouyou Akotet M.K., Kendjo E., Nzamba J., Medang M.O., Mbina J.R. et al.
Increase in malaria prevalence and age of at risk population in different areas of Gabon. Malar
J, 2013 12(1):3 (http://www.malariajournal.com/content/pdf/1475-2875-12-3.pdf, accessed 20
November 2014).
10. Aregawi MW, Ali AS, Al-mafazy AW, Molteni F, Katikiti S, Warsame M et al. Reductions in malaria
and anaemia case and death burden at hospitals following scale-up of malaria control in
Zanzibar, 1999-2008. Malar J. 2011;10(1):46 (http://www.malariajournal.com/content/pdf/14752875-10-46.pdf, accessed 24 November 2015).
11. Karema C., Aregawi M.W., Rukundo A., Kabayiza A., Mulindahabi M., Fall I.S. et al. Trends in
malaria cases, hospital admissions and deaths following scale-up of anti-malarial interventions,
20002010, Rwanda. Malar J, 2012 11:236.
12. Aregawi M., Lynch M., Bekele W., Kebede H., Jima D., Taffese H.S. et al. Time series
analysis of trends in malaria cases and deaths at hospitals and the effect of antimalarial
interventions, 2001-2011, Ethiopia. PLoS One, 2014 9(11):e106359 (http://www.ncbi.nlm.nih.gov/
pubmed/25406083, accessed 20 November 2014).
13. Ishengoma D.S., Mmbando B.P., Segeja M.D., Alifrangis M., Lemnge M.M., Bygbjerg I.C.
Declining burden of malaria over two decades in a rural community of Muheza district, northeastern Tanzania. Malar J, 2013 12(1):338 (http://www.malariajournal.com/content/pdf/14752875-12-338.pdf, accessed 20 November 2014).
14. Kalayjian B.C., Malhotra I., Mungai P., Holding P., King C.L. Marked decline in malaria prevalence
among pregnant women and their offspring from 1996 to 2010 on the south Kenyan coast. Am J
Trop Med Hyg, 2013 (http://www.ncbi.nlm.nih.gov/pubmed/24080635, accessed 20 November
2013).
78
References
15. Kigozi R., Baxi S.M., Gasasira A., Sserwanga A., Kakeeto S., Nasr S. et al. Indoor
residual spraying of insecticide and malaria morbidity in a high transmission
intensity area of Uganda. PLoS ONE, 2012 7(8):e42857.
16. Okiro E.A., Bitira D., Mbabazi G., Mpimbaza A., Alegana V.A., Talisuna A.O. et al.
Increasing malaria hospital admissions in Uganda between 1999 and 2009. BMC
Medicine, 2011 9:37.
17. Mharakurwa S., Mutambu S.L., Mberikunashe J., Thuma P.E., Moss W.J., Mason
P.R. et al. Changes in the burden of malaria following scale up of malaria control
interventions in Mutasa District, Zimbabwe. Malar J, 2013 12(1):223 (http://www.
malariajournal.com/content/pdf/1475-2875-12-223.pdf, accessed 20 November
2014).
79
80
Liberia131
Madagascar132
Malawi133
Malaysia134
Mali135
Mauritania136
Mayotte, France
137
Mexico138
Mozambique139
Myanmar140
Namibia141
Nepal142
Nicaragua143
Niger144
Nigeria145
Pakistan146
Panama147
Papua New Guinea
148
Paraguay149
Peru150
Philippines151
Republic of Korea
152
Rwanda153
Sao Tome and Principe
154
Saudi Arabia
155
Senegal156
Sierra Leone
157
Solomon Islands
158
Somalia159
South Africa
160
South Sudan
161
Sri Lanka
162
Sudan163
Suriname164
Swaziland165
Tajikistan166
Thailand167
Timor-Leste168
Togo169
Turkey170
Uganda171
United Republic of Tanzania (Mainland)172
United Republic of Tanzania (Zanzibar)173
Vanuatu174
Venezuela (Bolivarian Republic of )
175
Viet Nam
176
Yemen177
Zambia178
Zimbabwe179
AFGHANISTAN
Eastern
Mediterranean Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Insufficient data
Insufficient data
0
PF-RATIO
2014
8500000
15400000
7720000
31600000
27
49
24
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2010
ITNs/LLINs distributed to all age groups
Yes
2010
IRS
IRS is recommended
Yes
2012
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2000
Malaria diagnosis is free of charge in the public sector
Yes
2000
Treatment ACT is free for all ages in public sector
Yes
2003
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes 2014
Primaquine is used for radical treatment of P.vivax
Yes 2010
G6PD test is a requirement before treatment with primaquine
Yes
2010
Directly observed treatment with primaquine is undertaken
Yes
2010
System for monitoring of adverse reactions to antimalarials exists
No
Mass screening is undertaken
No
USAID/PMI
WHO/UNICEF
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
6000
4800
3600
2400
1200
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
30
24
18
12
6
0
Others
Tests (%)
Population (%)
(%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102014
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
82
(p.vivax)
WORLD MALARIACases
REPORT
2015
50
40
30
20
10
0
Deaths
World Bank
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AS+SP 20052013
0 0 1 28 days 8
P.falciparum
CQ
20072009
0
0
0
28 days
4
P.vivax
Sources of financing
Global Fund
Adopted
CQ
AS+SP+PQ
2014
AM; AS; QN
CQ+PQ(8w)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
20
16
12
8
4
0
ABER (%)
Contribution (US$m)
III. Financing
ALGERIA
Insufficient data
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
2014
0
38900000
38900000
0
100
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
Number of active foci
Number of people living within active foci
Number of people living in malaria free areas
Total
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
PP
Population
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
No
ITNs/LLINs distributed to all age groups
No
IRS
IRS is recommended
Yes
1980
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
-
Diagnosis
Patients of all ages should receive diagnostic test
Malaria diagnosis is free of charge in the public sector
Yes
1968
Treatment ACT is free for all ages in public sector
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes
Primaquine is used for radical treatment of P.vivax
Yes
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
Yes
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
Foci and case investigation undertaken
Yes
1968
Case reporting from private sector is mandatory
Yes
World Bank
Cases tracked
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Cases tested
100
80
60
40
20
0
Malaria
test positivity
and ABER
Antimalarials
distributedrate
vs reported
cases
Others
(%)
Cases (%)
WHO/UNICEF
USAID/PMI
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
10
8
6
4
2
0
Year
20102014
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Cases (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Sources of financing
Global Fund
Adopted
CQ
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Foci investigated
Cases
100
80
60
40
20
0
ABER (%)
Contribution (US$m)
III. Financing
1000
800
600
400
200
0
Reporting completeness
Foci investigated
Cases investigated points
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Total cases
Indigenous cases (P. falciparum)
Imported cases
Indigenous cases (P. vivax)
Imported WORLD
cases points MALARIA REPORT 2015
Imported cases
Indigenous (P.vivax) points
83
ANGOLA
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
24200000
0
0
24200000
100
0
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2001
ITNs/LLINs distributed to all age groups
No
IRS
IRS is recommended
Yes
2003
DDT is authorized for IRS
No
System for monitoring of adverse reactions to antimalarials exists
Yes
2006
Surveillance ACD for case investigation (reactive)
No
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000
1600
1200
800
400
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Tests (%)
Population (%)
(%)
Year
20102015
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
84
(p.vivax)
WORLD MALARIACases
REPORT
2015
250
200
150
100
50
0
Deaths
Global Fund
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20132013 2.7
7.2
11.7
28 days
2
P.falciparum
DHA-PPQ
20132013
0
0
0
28 days
2
P.falciparum
Government
100
80
60
40
20
0
Adopted
AL
2006
AL
2006
QN 2006
AS; QN
2006
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Admissions
120
96
72
48
24
0
ABER (%)
Contribution (US$m)
III. Financing
ARGENTINA
EURO / PAHO
Confirmed cases
API 1000 population
per
OTHERS
PF-RATIO
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
no cases
Insufficient data
0
Insufficient data
0
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
1050
4060
>85
4060
50100
6080
6080
>100
80100
PP
no cases
80100
I. Epidemiological profile
Population
Number of active foci
Number of people living within active foci
Number of people living in malaria free areas
Total
2014
43000000
43000000
100
0
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
No
ITNs/LLINs distributed to all age groups
No
IRS
IRS is recommended
Yes
2013
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
Malaria diagnosis is free of charge in the public sector
Yes
1980
Treatment ACT is free for all ages in public sector
Yes
Sale of oral artemisinin-based monotherapies
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes
Primaquine is used for radical treatment of P.vivax
Yes
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
Yes
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
Yes
Foci and case investigation undertaken
Yes
Case reporting from private sector is mandatory
Yes
Global Fund
World Bank
USAID/PMI
WHO/UNICEF
Cases tested
100
80
60
40
20
0
(%)
Cases tracked
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Malaria
test positivity
and ABER
Antimalarials
distributedrate
vs reported
cases
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Cases (%)
Population (%)
Cases (%)
Year
20102014
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
10
8
6
4
2
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Adopted
Sources of financing
IV. Coverage
100
80
60
40
20
0
AL+PQ
CQ+PQ
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
100
80
60
40
20
0
Medicine
Foci investigated
Cases
5
4
3
2
1
0
ABER (%)
Contribution (US$m)
III. Financing
500
400
300
200
100
0
Reporting completeness
Foci investigated
Cases investigated points
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Total cases
Indigenous cases (P. falciparum)
Imported cases
Indigenous cases (P. vivax)
Imported WORLD
cases points MALARIA REPORT 2015
Imported cases
Indigenous (P.vivax) points
85
AZERBAIJAN
EURO / PAHO
Confirmed cases
API 1000 population
per
European Region
OTHERS
PF-RATIO
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
no cases
Insufficient data
0
Insufficient data
0
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
1050
4060
>85
4060
50100
6080
6080
>100
80100
PP
no cases
80100
I. Epidemiological profile
Population
Number of active foci
Number of people living within active foci
Number of people living in malaria free areas
Total
2014
0
9630000
9630000
0
100
0
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2009
ITNs/LLINs distributed to all age groups
No
IRS
IRS is recommended
Yes
1930
DDT is authorized for IRS
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
Malaria diagnosis is free of charge in the public sector
Yes
1930
Treatment ACT is free for all ages in public sector
Yes
2009
Sale of oral artemisinin-based monotherapies
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
Yes 1956
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
Yes
1956
System for monitoring of adverse reactions to antimalarials exists
Yes
1956
Surveillance ACD for case investigation (reactive)
Yes
1930
ACD of febrile cases at community level (pro-active)
Yes
1930
Mass screening is undertaken
No
World Bank
Cases tracked
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Cases tested
100
80
60
40
20
0
Malaria
test positivity
and ABER
Antimalarials
distributedrate
vs reported
cases
Others
(%)
Cases (%)
WHO/UNICEF
USAID/PMI
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
0.5
0.4
0.3
0.2
0.1
0
Year
2010
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Cases (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Sources of financing
Global Fund
2000
1600
1200
800
400
0
Reporting completeness
Foci investigated
Cases investigated points
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Total cases
Indigenous cases (P. falciparum)
Aberpositivity
(microscopy
RDT)
RDT
rate&points
positivity rate
WORLD MALARIARDT
REPORT
2015
Slide positivity points
Slide positivity rate
Foci investigated
86
Adopted
AS+SP
2008
AS+SP
2008
QN+CL 2008
AS; QN
2008
CQ+PQ(14d)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Cases
10
8
6
4
2
0
ABER (%)
Contribution (US$m)
III. Financing
Imported cases
Indigenous cases (P. vivax)
BANGLADESH
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
4230000
12300000
142600000
159100000
3
8
90
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2008
ITNs/LLINs distributed to all age groups
Yes
2008
IRS
IRS is recommended
Yes
2008
DDT is authorized for IRS
No
1993
Larval control Use of larval control recommended
Yes
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2008
Malaria diagnosis is free of charge in the public sector
Yes
2008
Treatment ACT is free for all ages in public sector
Yes
2008
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes
Primaquine is used for radical treatment of P.vivax
Yes 2008
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
2008
Surveillance ACD for case investigation (reactive)
Yes
2008
ACD of febrile cases at community level (pro-active)
Yes
2008
Mass screening is undertaken
No
(%)
USAID/PMI
WHO/UNICEF
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
6000
4800
3600
2400
1200
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
10
8
6
4
2
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Year
20122014
Tests (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
600
480
360
240
120
0
Deaths
World Bank
2004
2004
2004
2004
0.25 mg/kg (14 d)
P.f + P.v, P.o, P.m (Combo).
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20062014
0
0
11.1
28 days
10
P.falciparum
QN+DX
20082009
0
0
0
28 days
1
P.falciparum
Sources of financing
Global Fund
Adopted
AL
QN+D; QN+T
AM; QN
CQ+PQ(14d)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
20
16
12
8
4
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
87
BELIZE
EURO / PAHO
Confirmed cases
API 1000 population
per
OTHERS
PF-RATIO
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
no cases
Insufficient data
0
Insufficient data
0
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
1050
4060
>85
4060
50100
6080
6080
>100
80100
PP
no cases
80100
I. Epidemiological profile
Population
Number of active foci
Number of people living within active foci
Number of people living in malaria free areas
Total
2014
8
8590
343000
351590
2
98
0
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2009
ITNs/LLINs distributed to all age groups
Yes
2009
IRS
IRS is recommended
Yes
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
Malaria diagnosis is free of charge in the public sector
Yes
Directly observed treatment with primaquine is undertaken
Yes
System for monitoring of adverse reactions to antimalarials exists
No
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
Yes
Foci and case investigation undertaken
Yes
Case reporting from private sector is mandatory
Yes
World Bank
Cases tracked
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Cases tested
100
80
60
40
20
0
Malaria
test positivity
and ABER
Antimalarials
distributedrate
vs reported
cases
Others
(%)
Cases (%)
WHO/UNICEF
USAID/PMI
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
10
8
6
4
2
0
Year
20102014
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Cases (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Sources of financing
Global Fund
2000
1600
1200
800
400
0
Reporting completeness
Foci investigated
Cases investigated points
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Total cases
Indigenous cases (P. falciparum)
Aberpositivity
(microscopy
RDT)
RDT
rate&points
positivity rate
WORLD MALARIARDT
REPORT
2015
Slide positivity points
Slide positivity rate
Foci investigated
88
Adopted
CQ+PQ (1d)
AL; QN
CQ+PQ(14d)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Cases
0.5
0.4
0.3
0.2
0.1
0
ABER (%)
Contribution (US$m)
III. Financing
Imported cases
Indigenous cases (P. vivax)
BENIN
Insufficient data
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
2014
10600000
0
0
10600000
100
0
0
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
PP
Population
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2007
ITNs/LLINs distributed to all age groups
No
IRS
IRS is recommended
Yes
2006
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
Yes
2005
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2011
Malaria diagnosis is free of charge in the public sector
Yes
2008
Treatment ACT is free for all ages in public sector
No
Sale of oral artemisinin-based monotherapies
Is banned
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
2005
Surveillance ACD for case investigation (reactive)
ACD of febrile cases at community level (pro-active)
Yes
Mass screening is undertaken
No
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases (%)
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
1000
800
600
400
200
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
Tests (%)
Population (%)
(%)
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
25
20
15
10
5
0
Deaths
Global Fund
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Cases per 1000
Year
20102014
120
96
72
48
24
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20052011
0
0.75
6.5
28 days
6
P.falciparum
Government
Adopted
AL
2004
AL
2004
QN 2004
AS; QN
2004
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Admissions
50
40
30
20
10
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
89
BHUTAN
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
Number of active foci
Number of people living within active foci
Number of people living in malaria free areas
Total
2014
121000
644000
765000
16
84
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2006
ITNs/LLINs distributed to all age groups
Yes
2006
IRS
IRS is recommended
Yes
1964
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
1964
Malaria diagnosis is free of charge in the public sector
Yes
1964
Treatment ACT is free for all ages in public sector
Yes
2006
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes 2012
Primaquine is used for radical treatment of P.vivax
Yes
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
2012
Surveillance ACD for case investigation (reactive)
Yes
2013
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
Yes
2011
Uncomplicated P.falciparum cases routinely admitted
Yes
2012
Uncomplicated P.vivax cases routinely admitted
Yes
2012
Foci and case investigation undertaken
Yes
2012
Case reporting from private sector is mandatory
No
Global Fund
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases tested
Cases (%)
Population (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Cases tracked
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
(%)
Cases (%)
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102012
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
10
8
6
4
2
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20052011
0
0
0
28 days
23
P.falciparum
CQ
20052011
0
0
0
28 days
22
P.vivax
Government
100
80
60
40
20
0
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
Cases investigated
Malaria
test positivity
and ABER
Antimalarials
distributedrate
vs reported
cases
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
8000
6400
4800
3200
1600
0
Reporting completeness
Foci investigated
Cases investigated points
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Total cases
Indigenous cases (P. falciparum)
Aberpositivity
(microscopy
RDT)
RDT
rate&points
positivity rate
WORLD MALARIARDT
REPORT
2015
Slide positivity points
Slide positivity rate
Foci investigated
90
Adopted
AL
2006
QN 2006
AM; QN
2006
CQ+PQ(14d)
2006
0.25 mg/kg (14 d)
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Cases
2.0
1.6
1.2
0.8
0.4
0
ABER (%)
Contribution (US$m)
III. Financing
Imported cases
Indigenous cases (P. vivax)
OTHERS
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
PP
Insufficient data
0
Insufficient data
00.1
Very low PP
0.11.0
020
1.010
2040
>85
4060
6080
no cases
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
265000
4540000
5790000
10600000
2
43
55
[780020000]
<10
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2008
ITNs/LLINs distributed to all age groups
Yes
2005
IRS
IRS is recommended
Yes
1959
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2000
Malaria diagnosis is free of charge in the public sector
Yes
1996
Treatment ACT is free for all ages in public sector
Yes
2003
Sale of oral artemisinin-based monotherapies
Is banned
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes
Primaquine is used for radical treatment of P.vivax
Yes 1998
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
No
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
Yes
1998
Uncomplicated P.falciparum cases routinely admitted
No
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases (%)
Population (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Tests (%)
(%)
300
240
180
120
60
0
15
12
9
6
3
0
Deaths
Global Fund
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
2013
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
10
8
6
4
2
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
CQ
20062011
0
8.1
10.4
28 days
4
P.vivax
Government
100
80
60
40
20
0
Adopted
AS+MQ+PQ
2001
QN+CL
QN
2001
CQ+PQ(7d)
2001
0.50 mg/kg (7 d)
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Admissions
5
4
3
2
1
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
91
BOTSWANA
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
93500
1380000
748000
2220000
4
62
34
[5302100]
<10
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2009
ITNs/LLINs distributed to all age groups
Yes
2009
IRS
IRS is recommended
Yes
1950
DDT is authorized for IRS
Yes
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2010
Malaria diagnosis is free of charge in the public sector
Yes
1974
Treatment ACT is free for all ages in public sector
Yes
2007
Sale of oral artemisinin-based monotherapies
Never allowed 2007
Single dose of primaquine is used as gametocidal medicine for P.falciparum
Primaquine is used for radical treatment of P.vivax
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
1200
960
720
480
240
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Tests (%)
Population (%)
(%)
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
92
(p.vivax)
WORLD MALARIACases
REPORT
2015
40
32
24
16
8
0
Deaths
Global Fund
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102013
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
10
8
6
4
2
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Government
100
80
60
40
20
0
Adopted
AL
2007
AL
2007
QN 2007
QN
2007
P.f only.
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Admissions
2.0
1.6
1.2
0.8
0.4
0
ABER (%)
Contribution (US$m)
III. Financing
BRAZIL
OTHERS
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
PP
Insufficient data
0
Insufficient data
00.1
Very low PP
0.11.0
020
1.010
2040
>85
4060
6080
no cases
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
4740000
37100000
164300000
206100000
2
18
80
[200000260000]
<50
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2007
ITNs/LLINs distributed to all age groups
Yes
2007
IRS
IRS is recommended
Yes
1945
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
1972
Malaria diagnosis is free of charge in the public sector
Yes
1972
Treatment ACT is free for all ages in public sector
Yes
2006
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes 2011
Primaquine is used for radical treatment of P.vivax
Yes 1972
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
No
ACD of febrile cases at community level (pro-active)
Yes
Mass screening is undertaken
Yes
Median
0
0
1.3
Max
0
0
5.2
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20112014
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases (%)
Population (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Tests (%)
(%)
Min
0
0
0
15 000
12 000
9000
6000
3000
0
250
200
150
100
50
0
Deaths
Global Fund
Year
20052007
20052007
20052014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
20
16
12
8
4
0
Medicine
AL
AS+MQ
CQ+PQ
Government
100
80
60
40
20
0
Adopted
AL+PQ(1d); AS+MQ+PQ(1d)
2012
QN+D+PQ
AM+CL; AS+CL; QN+CL
CQ+PQ(7d)
2006
0.50 mg/kg (7 d)
P.f + all species (Combo).
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Admissions
120
96
72
48
24
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
93
BURKINA FASO
Insufficient data
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
2014
17600000
0
0
17600000
100
0
0
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
PP
Population
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2007
ITNs/LLINs distributed to all age groups
Yes
1998
IRS
IRS is recommended
Yes
2006
DDT is authorized for IRS
No
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
2009
Surveillance ACD for case investigation (reactive)
No
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
(%)
100
80
60
40
20
0
World Bank
USAID/PMI
WHO/UNICEF
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
3000
2400
1800
1200
600
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
350
280
210
140
70
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
94
(p.vivax)
WORLD MALARIACases
REPORT
2015
60
48
36
24
12
0
Deaths
Global Fund
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102014
Tests (%)
Population (%)
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20052012
0
6.15
12.5
28 days
9
P.falciparum
AS+AQ
20062012
0
5.05
21.5
28 days
6
P.falciparum
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Adopted
AL; AS+AQ
2005
AL; AS+AQ
2005
QN
AS; QN
P.f only.
Sources of financing
IV. Coverage
Medicine
Admissions
120
96
72
48
24
0
ABER (%)
Contribution (US$m)
III. Financing
BURUNDI
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
10800000
0
0
10800000
100
0
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2004
ITNs/LLINs distributed to all age groups
No
IRS
IRS is recommended
Yes
2000
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2012
Malaria diagnosis is free of charge in the public sector
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
No
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
USAID/PMI
WHO/UNICEF
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
1500
1200
900
600
300
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
500
400
300
200
100
0
Year
2014
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
35
28
21
14
7
0
Deaths
(%)
100
80
60
40
20
0
World Bank
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Tests (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AS+AQ
20052006 2.9
5.2
7.5
28 days
2
P.falciparum
Sources of financing
Global Fund
Adopted
AS+AQ
2003
AS+AQ
2003
QN 2003
AS; QN
2003
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
35
28
21
14
7
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
95
CABO VERDE
Insufficient data
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
2014
10
483000
30900
513900
94
6
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
Number of active foci
Number of people living within active foci
Number of people living in malaria free areas
Total
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
PP
Population
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
2
2
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
No
ITNs/LLINs distributed to all age groups
No
IRS
IRS is recommended
Yes
1998
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
1998
Malaria diagnosis is free of charge in the public sector
Yes
1975
Treatment ACT is free for all ages in public sector
Yes
2008
Sale of oral artemisinin-based monotherapies
are allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
Yes
System for monitoring of adverse reactions to antimalarials exists
Yes
2007
Surveillance ACD for case investigation (reactive)
Yes
2001
ACD of febrile cases at community level (pro-active)
Yes
2001
Mass screening is undertaken
Yes
2001
Uncomplicated P.falciparum cases routinely admitted
Yes
2007
Uncomplicated P.vivax cases routinely admitted
No
Foci and case investigation undertaken
Yes
Case reporting from private sector is mandatory
Yes
World Bank
100
80
60
40
20
0
Cases tracked
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
Cases investigated
Malaria
test positivity
and ABER
Antimalarials
distributedrate
vs reported
cases
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Cases tested
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
WHO/UNICEF
(%)
Cases (%)
2.5
2.0
1.5
1.0
0.5
0
USAID/PMI
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102014
Cases (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Sources of financing
Global Fund
200
160
120
80
40
0
Reporting completeness
Foci investigated
Cases investigated points
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Total cases
Indigenous cases (P. falciparum)
Aberpositivity
(microscopy
RDT)
RDT
rate&points
positivity rate
WORLD MALARIARDT
REPORT
2015
Slide positivity points
Slide positivity rate
Foci investigated
96
Adopted
AL
2007
AL
2007
QN
QN
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Cases
25
20
15
10
5
0
ABER (%)
Contribution (US$m)
III. Financing
Imported cases
Indigenous cases (P. vivax)
CAMBODIA
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
7360000
3460000
4480000
15300000
48
23
29
[6200095000]
[10220]
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2000
ITNs/LLINs distributed to all age groups
Yes
2000
IRS
IRS is recommended
Yes
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2000
Malaria diagnosis is free of charge in the public sector
Yes
2000
Treatment ACT is free for all ages in public sector
Yes
2000
Sale of oral artemisinin-based monotherapies
Is banned 2008
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
Yes 2013
G6PD test is a requirement before treatment with primaquine
Yes
2012
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
2010
Surveillance ACD for case investigation (reactive)
No
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
Yes
2010
Uncomplicated P.falciparum cases routinely admitted
No
USAID/PMI
WHO/UNICEF
Others
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
20 000
16 000
12 000
8000
4000
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Max
19.4
62.5
3.3
10
8
6
4
2
0
Year
2014
Tests (%)
Population (%)
(%)
Median
3.15
8.1
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Min
0
0
0
100
80
60
40
20
0
Year
20052011
20082015
20102014
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
800
640
480
320
160
0
Deaths
World Bank
IV. Coverage
100
80
60
40
20
0
Medicine
AS+MQ
DHA-PPQ
DHA-PPQ
Sources of financing
Global Fund
Adopted
AS+MQ; DHA-PPQ+PQ
2000
QN+T 2000
AM; AS; QN
DHA-PPQ
2011
0.25 mg/kg (14 d)
P.f + P.v specific (Combo).
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
50
40
30
20
10
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
97
CAMEROON
Insufficient data
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
PP
Population
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
2014
16200000
6600000
0
22800000
71
29
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2004
ITNs/LLINs distributed to all age groups
No
IRS
IRS is recommended
Yes
2007
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
Yes
2004
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2011
Malaria diagnosis is free of charge in the public sector
No
Sale of oral artemisinin-based monotherapies
Is banned
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
Directly observed treatment with primaquine is undertaken
System for monitoring of adverse reactions to antimalarials exists
Yes
2004
Surveillance ACD for case investigation (reactive)
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases (%)
Population (%)
(%)
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
Suspected cases tested
<5 with fever with finger/heel stick (survey)
ACTs as % of all antimalarials received by <5
Primaquine distributed vs reported P.v cases points
Primaquine distributed vs reported P.v cases
data reported
2014
ACTsNo
distributed
vs reported P.ffor
cases
points
ACTs distributed vs reported P.f cases
Antimalarials distributed vs reported cases points
Antimalarials distributed vs reported cases
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2500
2000
1500
1000
500
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
98
(p.vivax)
WORLD MALARIACases
REPORT
2015
40
32
24
16
8
0
Deaths
Global Fund
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Cases per 1000
Year
20102014
1.5
1.2
0.9
0.6
0.3
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AS+AQ
20052013
0
3.7
8.7
28 days
15
P.falciparum
AL
20062013
0
1.9
5
28 days
12
P.falciparum
Government
Adopted
AS+AQ
2004
AS+AQ
2004
QN 2004
AS, AM; QN
2004
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Admissions
200
160
120
80
40
0
ABER (%)
Contribution (US$m)
III. Financing
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
4800000
0
0
4800000
100
0
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2006
ITNs/LLINs distributed to all age groups
Yes
2010
IRS
IRS is recommended
Yes
2012
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
Yes
2004
Diagnosis
Patients of all ages should receive diagnostic test
Yes
Malaria diagnosis is free of charge in the public sector
Yes
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
No
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000
1600
1200
800
400
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Tests (%)
Population (%)
(%)
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
35
28
21
14
7
0
Deaths
Global Fund
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
80
64
48
32
16
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20082010
0
3.8
7.6
28 days
2
P.falciparum
AS+AQ
20082010
0
3.4
6.8
28 days
2
P.falciparum
Government
100
80
60
40
20
0
Adopted
AL
2005
AL
QN
AS, AM; QN
2005
P.f only.
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Admissions
10
8
6
4
2
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
99
CHAD
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
9160000
4290000
149000
13600000
67
32
1
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2010
ITNs/LLINs distributed to all age groups
No
IRS
IRS is recommended
Yes
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
Yes
2004
Diagnosis
Patients of all ages should receive diagnostic test
Yes
Malaria diagnosis is free of charge in the public sector
Yes
Sale of oral artemisinin-based monotherapies
Is banned 2012
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
400
320
240
160
80
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Tests (%)
Population (%)
(%)
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
(p.vivax)
WORLD MALARIACases
REPORT
2015
15
12
9
6
3
0
Deaths
Global Fund
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20112014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
80
64
48
32
16
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AS+AQ
20092011
0
0
1.8
28 days
3
P.falciparum
Government
100
80
60
40
20
0
Adopted
AL; AS+AQ
AL; AS+AQ
QN
AS,QN
2014
P.f only.
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Admissions
50
40
30
20
10
0
ABER (%)
Contribution (US$m)
III. Financing
CHINA
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
Number of active foci
Number of people living within active foci
Number of people living in malaria free areas
Total
2014
56
47900
1377200000
1377247900
0
100
24
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2003
ITNs/LLINs distributed to all age groups
Yes
2000
IRS
IRS is recommended
Yes
2000
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2000
Malaria diagnosis is free of charge in the public sector
No
Directly observed treatment with primaquine is undertaken
Yes
1970
System for monitoring of adverse reactions to antimalarials exists
Yes
1970
Surveillance ACD for case investigation (reactive)
Yes
2010
ACD of febrile cases at community level (pro-active)
Yes
2010
Mass screening is undertaken
Yes
2010
Uncomplicated P.falciparum cases routinely admitted
No
Foci and case investigation undertaken
Yes
2010
Case reporting from private sector is mandatory
Yes
1956
World Bank
WHO/UNICEF
Cases tested
100
80
60
40
20
0
Cases tracked
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
Cases investigated
Malaria
test positivity
and ABER
Antimalarials
distributedrate
vs reported
cases
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Max
0
4.3
6
Others
USAID/PMI
Median
0
0
0
(%)
Cases (%)
1.0
0.8
0.6
0.4
0.2
0
Year
20102012
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Min
0
0
0
100
80
60
40
20
0
Year
20082010
20082013
20122014
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Cases (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
CQ+PQ
CQ
DHA-PPQ
Sources of financing
Global Fund
Adopted
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Foci investigated
Cases
60
48
36
24
12
0
ABER (%)
Contribution (US$m)
III. Financing
40 000
32 000
24 000
16 000
8000
0
Reporting completeness
Foci investigated
Cases investigated points
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Total cases
Indigenous cases (P. falciparum)
Imported cases
Indigenous cases (P. vivax)
Imported WORLD
cases points MALARIA REPORT 2015
Imported cases
Indigenous (P.vivax) points
101
COLOMBIA
OTHERS
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
PP
Insufficient data
0
Insufficient data
00.1
Very low PP
0.11.0
020
1.010
2040
>85
4060
6080
no cases
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
2150000
8470000
37200000
47800000
5
18
78
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2005
ITNs/LLINs distributed to all age groups
Yes
2005
IRS
IRS is recommended
Yes
1958
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
1984
Malaria diagnosis is free of charge in the public sector
Yes
1958
Treatment ACT is free for all ages in public sector
Yes
2008
Sale of oral artemisinin-based monotherapies
are allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
Yes
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
Mass screening is undertaken
No
World Bank
WHO/UNICEF
100
80
60
40
20
0
Tests (%)
Test positivity
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Cases (%)
Population (%)
(%)
USAID/PMI
30
24
18
12
6
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20112014
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
CQ+PQ
20062011
0
0
0
28 days
2
P.vivax
AL
20072009
0
0.6
1
28 days
3
P.falciparum
800
640
480
320
160
0
102
(p.vivax)
WORLD MALARIACases
REPORT
2015
200
160
120
80
40
0
Deaths
Global Fund
Adopted
Sources of financing
IV. Coverage
AL
2006
QN+CL 2004
AS; AL
CQ+PQ
1960s
0.25 mg/kg (14 d)
P.f + P.v specific (Combo).
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
100
80
60
40
20
0
Medicine
Admissions
35
28
21
14
7
0
ABER (%)
Contribution (US$m)
III. Financing
COMOROS
Insufficient data
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
PP
Population
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
2014
366000
404000
0
770000
48
52
0
[82000180000]
[10660]
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2005
ITNs/LLINs distributed to all age groups
Yes
2010
IRS
IRS is recommended
Yes
2010
DDT is authorized for IRS
Yes
IPT
IPT used to prevent malaria during pregnancy
Yes
2004
Diagnosis
Patients of all ages should receive diagnostic test
Yes
1997
Malaria diagnosis is free of charge in the public sector
Yes
2011
Treatment ACT is free for all ages in public sector
Yes
2010
Sale of oral artemisinin-based monotherapies
Is banned 2005
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
No
Mass screening is undertaken
Yes
2010
Uncomplicated P.falciparum cases routinely admitted
Yes
(%)
World Bank
USAID/PMI
WHO/UNICEF
Cases (%)
Test positivity
100
80
60
40
20
0
25 000
20 000
15 000
10 000
5000
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
2000
1600
1200
800
400
0
Year
20142015
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Deaths
Global Fund
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Tests (%)
Population (%)
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20062013
0
0
3.2
28 days
16
P.falciparum
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Adopted
AL
2003
AL
2003
QN 2003
QN
2003
Sources of financing
IV. Coverage
Medicine
Admissions
5
4
3
2
1
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
103
CONGO
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
4500000
0
0
4500000
100
0
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2011
ITNs/LLINs distributed to all age groups
Yes
2011
IRS
IRS is recommended
Yes
2007
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
Yes
2006
Diagnosis
Patients of all ages should receive diagnostic test
Yes
Malaria diagnosis is free of charge in the public sector
No
Sale of oral artemisinin-based monotherapies
Is banned 2006
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
No
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
1200
960
720
480
240
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Tests (%)
Population (%)
(%)
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
104
(p.vivax)
WORLD MALARIACases
REPORT
2015
80
64
48
32
16
0
Deaths
Global Fund
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20132014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
35
28
21
14
7
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AS+AQ
20052014
0
2.7
5.6
28 days
3
P.falciparum
AL
20062014
0
2.8
3.6
28 days
3
P.falciparum
Government
100
80
60
40
20
0
Adopted
AS+AQ
AS+AQ
AL
QN
P.f only.
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Admissions
15
12
9
6
3
0
ABER (%)
Contribution (US$m)
III. Financing
COSTA RICA
EURO / PAHO
Confirmed cases
API 1000 population
per
OTHERS
PF-RATIO
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
no cases
Insufficient data
0
Insufficient data
0
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
1050
4060
>85
4060
50100
6080
6080
>100
80100
PP
no cases
80100
I. Epidemiological profile
Population
Number of active foci
Number of people living within active foci
Number of people living in malaria free areas
Total
2014
0
4760000
4760000
0
100
0
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2009
ITNs/LLINs distributed to all age groups
Yes
2009
IRS
IRS is recommended
Yes
1957
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
Malaria diagnosis is free of charge in the public sector
Yes
1957
Treatment ACT is free for all ages in public sector
No
Sale of oral artemisinin-based monotherapies
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes
Primaquine is used for radical treatment of P.vivax
Yes
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
Yes
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
Yes
Mass screening is undertaken
No
Foci and case investigation undertaken
Yes
Case reporting from private sector is mandatory
Yes
Global Fund
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases tested
Cases (%)
Population (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Cases tracked
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
(%)
Cases (%)
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
30
24
18
12
6
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Government
100
80
60
40
20
0
Adopted
CQ+PQ(1d)
AL
QN
CQ+PQ(7d); CQ+PQ(14d)
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
Cases investigated
Malaria
test positivity
and ABER
Antimalarials
distributedrate
vs reported
cases
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Foci investigated
Cases
10
8
6
4
2
0
ABER (%)
Contribution (US$m)
III. Financing
4000
3200
2400
1600
800
0
Reporting completeness
Foci investigated
Cases investigated points
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Total cases
Indigenous cases (P. falciparum)
Imported cases
Indigenous cases (P. vivax)
Imported WORLD
cases points MALARIA REPORT 2015
Imported cases
Indigenous (P.vivax) points
105
CTE DIVOIRE
Insufficient data
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
2014
22200000
0
0
22200000
100
0
0
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
PP
Population
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2008
ITNs/LLINs distributed to all age groups
No
IRS
IRS is recommended
No
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
Yes
2005
Diagnosis
Patients of all ages should receive diagnostic test
Yes
Malaria diagnosis is free of charge in the public sector
Yes
2012
Treatment ACT is free for all ages in public sector
Yes
Sale of oral artemisinin-based monotherapies
Is banned
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
G6PD test is a requirement before treatment with primaquine
Directly observed treatment with primaquine is undertaken
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
Mass screening is undertaken
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
800
640
480
320
160
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Tests (%)
Population (%)
(%)
Year
20102013
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
106
(p.vivax)
WORLD MALARIACases
REPORT
2015
100
80
60
40
20
0
Deaths
Global Fund
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
200
160
120
80
40
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20052014
0
1.5
7.4
28 days
12
P.falciparum
AS+AQ
20072014
0
0
1.3
28 days
7
P.falciparum
Government
100
80
60
40
20
0
Adopted
AS+AQ
2003
AS+AQ
2003
AL 2003
QN
2003
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Admissions
250
200
150
100
50
0
ABER (%)
Contribution (US$m)
III. Financing
OTHERS
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
Number of active foci
Number of people living within active foci
Number of people living in malaria free areas
Total
2014
11700000
13300000
25000000
47
53
0
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2002
ITNs/LLINs distributed to all age groups
Yes
2002
IRS
IRS is recommended
Yes
2005
DDT is authorized for IRS
Diagnosis
Patients of all ages should receive diagnostic test
Yes
1953
Malaria diagnosis is free of charge in the public sector
Yes
1953
Treatment ACT is free for all ages in public sector
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
Yes 2000
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
Yes
2000
System for monitoring of adverse reactions to antimalarials exists
Yes
2002
Surveillance ACD for case investigation (reactive)
No
ACD of febrile cases at community level (pro-active)
Yes
2012
Mass screening is undertaken
No
Foci and case investigation undertaken
No
Case reporting from private sector is mandatory
No
World Bank
Cases tracked
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Cases tested
100
80
60
40
20
0
Malaria
test positivity
and ABER
Antimalarials
distributedrate
vs reported
cases
Others
(%)
Cases (%)
WHO/UNICEF
USAID/PMI
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Year
20112014
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Cases (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Sources of financing
Global Fund
Adopted
CQ+PQ(14d)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Foci investigated
150 000
120 000
90 000
60 000
30 000
0
Cases
15
12
9
6
3
0
ABER (%)
Contribution (US$m)
III. Financing
Reporting completeness
Foci investigated
Cases investigated points
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Total cases
Indigenous cases (P. falciparum)
Imported cases
Indigenous cases (P. vivax)
Imported WORLD
cases points MALARIA REPORT 2015
Imported cases
Indigenous (P.vivax) points
107
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
72700000
2200000
0
74900000
97
3
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2006
ITNs/LLINs distributed to all age groups
Yes
2008
IRS
IRS is recommended
Yes
2007
DDT is authorized for IRS
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
2010
Surveillance ACD for case investigation (reactive)
ACD of febrile cases at community level (pro-active)
Yes
2010
Mass screening is undertaken
No
World Bank
USAID/PMI
WHO/UNICEF
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
1500
1200
900
600
300
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
150
120
90
60
30
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
108
(p.vivax)
WORLD MALARIACases
REPORT
2015
50
40
30
20
10
0
Deaths
(%)
100
80
60
40
20
0
Year
20102015
Cases (%)
Global Fund
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Tests (%)
Population (%)
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AS+AQ
20052012
0
4.2
6.9
28 days
8
P.falciparum
AL
20052013
0
2.4
9.2
28 days
10
P.falciparum
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Adopted
AS+AQ
2005
AS+AQ
2005
QN 2005
AS, QN
2005
Sources of financing
IV. Coverage
Medicine
Admissions
200
160
120
80
40
0
ABER (%)
Contribution (US$m)
III. Financing
DJIBOUTI
Eastern
Mediterranean Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Insufficient data
Insufficient data
0
PP
Population
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
2014
0
438000
438000
876000
0
50
50
[100017000]
<50
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2008
ITNs/LLINs distributed to all age groups
Yes
IRS
IRS is recommended
Yes
2006
DDT is authorized for IRS
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2007
Malaria diagnosis is free of charge in the public sector
Yes
2007
Treatment ACT is free for all ages in public sector
Yes
2007
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes 2014
Primaquine is used for radical treatment of P.vivax
Yes 2014
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
No
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
1500
1200
900
600
300
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Tests (%)
Population (%)
(%)
Year
2011
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
30
24
18
12
6
0
Deaths
Global Fund
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
15
12
9
6
3
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Government
100
80
60
40
20
0
Adopted
AL
2014
AL+PQ
2014
AS+AQ 2014
QN
CQ+PQ (14 d)
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Admissions
1.5
1.2
0.9
0.6
0.3
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
AdmissionsWORLD
(P.vivax)
MALARIADeaths
REPORT
2015
(all species) points
Deaths (all species)
109
DOMINICAN REPUBLIC
OTHERS
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
PP
Insufficient data
0
Insufficient data
00.1
Very low PP
0.11.0
020
1.010
2040
>85
4060
6080
no cases
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
96200
4910000
5390000
10400000
1
47
52
[650980]
<10
Adopted
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2008
ITNs/LLINs distributed to all age groups
Yes
2008
IRS
IRS is recommended
Yes
1946
DDT is authorized for IRS
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
1964
Malaria diagnosis is free of charge in the public sector
Yes
1964
Treatment ACT is free for all ages in public sector
No
Sale of oral artemisinin-based monotherapies
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes 1964
Primaquine is used for radical treatment of P.vivax
Yes 1964
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
Yes
System for monitoring of adverse reactions to antimalarials exists
No
ACD of febrile cases at community level (pro-active)
Yes
1964
Mass screening is undertaken
Yes
1964
Uncomplicated P.falciparum cases routinely admitted
No
USAID/PMI
WHO/UNICEF
100
80
60
40
20
0
Tests (%)
100
80
60
40
20
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
1.0
0.8
0.6
0.4
0.2
0
Others
Cases (%)
Population (%)
(%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Year
20122014
200
160
120
80
40
0
110
(p.vivax)
WORLD MALARIACases
REPORT
2015
20
16
12
8
4
0
Deaths
World Bank
IV. Coverage
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Sources of financing
Global Fund
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
CQ+PQ(1d)
CQ; QN
CQ; QN
CQ+PQ(14d)
Admissions
10
8
6
4
2
0
ABER (%)
Contribution (US$m)
III. Financing
Medicine
ECUADOR
EURO / PAHO
Confirmed cases
API 1000 population
per
OTHERS
PF-RATIO
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
no cases
Insufficient data
0
Insufficient data
0
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
1050
4060
>85
4060
50100
6080
6080
>100
80100
PP
no cases
80100
I. Epidemiological profile
Population
Number of active foci
Number of people living within active foci
Number of people living in malaria free areas
Total
2014
15900000
15900000
100
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2004
ITNs/LLINs distributed to all age groups
Yes
IRS
IRS is recommended
Yes
2005
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
1956
Malaria diagnosis is free of charge in the public sector
Yes
1956
Treatment ACT is free for all ages in public sector
Yes
2005
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes
Primaquine is used for radical treatment of P.vivax
Yes
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
Yes
System for monitoring of adverse reactions to antimalarials exists
No
ACD of febrile cases at community level (pro-active)
Yes
Mass screening is undertaken
No
Foci and case investigation undertaken
Yes
Case reporting from private sector is mandatory
No
World Bank
WHO/UNICEF
100
80
60
40
20
0
Cases tracked
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
Cases investigated
Malaria
test positivity
and ABER
Antimalarials
distributedrate
vs reported
cases
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Cases tested
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
25
20
15
10
5
0
USAID/PMI
(%)
Cases (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20112012
Cases (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20052006
0
0
0
28 days
1
P.falciparum
Sources of financing
Global Fund
Adopted
AL+PQ
2012
QN+CL 2004
QN
2004
CQ+PQ(14d)
2004
0.50 mg/kg (7 d)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Foci investigated
120 000
96 000
72 000
48 000
24 000
0
Cases
10
8
6
4
2
0
ABER (%)
Contribution (US$m)
III. Financing
Reporting completeness
Foci investigated
Cases investigated points
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Total cases
Indigenous cases (P. falciparum)
Imported cases
Indigenous cases (P. vivax)
Imported WORLD
cases points MALARIA REPORT 2015
Imported cases
Indigenous (P.vivax) points
111
EL SALVADOR
EURO / PAHO
Confirmed cases
API 1000 population
per
OTHERS
PF-RATIO
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
no cases
Insufficient data
0
Insufficient data
0
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
1050
4060
>85
4060
50100
6080
6080
>100
80100
PP
no cases
80100
I. Epidemiological profile
Population
Number of active foci
Number of people living within active foci
Number of people living in malaria free areas
Total
2014
2
92700
6020000
6112700
2
98
0
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
ITNs/LLINs distributed to all age groups
No
IRS
IRS is recommended
Yes
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2010
Malaria diagnosis is free of charge in the public sector
Yes
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes
Primaquine is used for radical treatment of P.vivax
Yes
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
Yes
System for monitoring of adverse reactions to antimalarials exists
No
ACD of febrile cases at community level (pro-active)
Yes
Mass screening is undertaken
Yes
Foci and case investigation undertaken
Yes
Case reporting from private sector is mandatory
No
World Bank
Cases tracked
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Cases tested
100
80
60
40
20
0
Malaria
test positivity
and ABER
Antimalarials
distributedrate
vs reported
cases
Others
(%)
Cases (%)
WHO/UNICEF
USAID/PMI
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Year
20102014
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Cases (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Sources of financing
Global Fund
800
640
480
320
160
0
Reporting completeness
Foci investigated
Cases investigated points
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Total cases
Indigenous cases (P. falciparum)
Aberpositivity
(microscopy
RDT)
RDT
rate&points
positivity rate
WORLD MALARIARDT
REPORT
2015
Slide positivity points
Slide positivity rate
Foci investigated
112
Adopted
CQ+PQ(1d)
AL
QN
2012
CQ+PQ(14d)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Cases
5
4
3
2
1
0
ABER (%)
Contribution (US$m)
III. Financing
Imported cases
Indigenous cases (P. vivax)
EQUATORIAL GUINEA
Insufficient data
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
2014
821000
0
0
821000
100
0
0
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
PP
Population
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
[68000290000]
[160440]
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2008
ITNs/LLINs distributed to all age groups
No
IRS
IRS is recommended
Yes
2004
DDT is authorized for IRS
Yes
2015
Larval control Use of larval control recommended
Yes
2013
IPT
IPT used to prevent malaria during pregnancy
-
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2007
Malaria diagnosis is free of charge in the public sector
Yes
2007
Treatment ACT is free for all ages in public sector
Yes
2010
Sale of oral artemisinin-based monotherapies
Is banned 2014
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
No
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000
1600
1200
800
400
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Tests (%)
Population (%)
(%)
Year
20102014
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
10
8
6
4
2
0
Deaths
Global Fund
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
80
64
48
32
16
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AS+AQ
20062011
0
2.3
5
28 days
5
P.falciparum
Government
100
80
60
40
20
0
Adopted
AS+AQ
2004
AS+AQ
2004
QN 2004
AS
2004
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Admissions
10
8
6
4
2
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
113
ERITREA
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
3630000
1480000
0
5110000
71
29
0
[42000120000]
[10270]
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2002
ITNs/LLINs distributed to all age groups
Yes
2002
IRS
IRS is recommended
Yes
1995
DDT is authorized for IRS
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
1997
Malaria diagnosis is free of charge in the public sector
Yes
1997
Treatment ACT is free for all ages in public sector
Yes
2007
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
Yes 2002
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
2013
Surveillance ACD for case investigation (reactive)
Yes
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
USAID/PMI
WHO/UNICEF
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
800
640
480
320
160
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
10
8
6
4
2
0
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
114
(p.vivax)
WORLD MALARIACases
REPORT
2015
5
4
3
2
1
0
Deaths
(%)
World Bank
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102014
Tests (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AS+AQ
20062012
0
2.25
9.3
28 days
16
P.falciparum
Sources of financing
Global Fund
Adopted
AS+AQ
2007
AS+AQ
2007
QN 2002
QN
2002
AS+AQ+PQ
2007
0.25 mg/kg (14 d)
P.f + P.v specific (Combo).
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
20
16
12
8
4
0
ABER (%)
Contribution (US$m)
III. Financing
ETHIOPIA
Insufficient data
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
PP
Population
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
2014
26400000
39600000
31000000
97000000
27
41
32
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2004
ITNs/LLINs distributed to all age groups
Yes
2004
IRS
IRS is recommended
Yes
1960
DDT is authorized for IRS
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
1960
Malaria diagnosis is free of charge in the public sector
Yes
1960
Treatment ACT is free for all ages in public sector
Yes
2004
Sale of oral artemisinin-based monotherapies
Never allowed 2004
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
No
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Max
10
13.7
7.5
50
40
30
20
10
0
Year
20102014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Median
10
7.05
1.1
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
5
4
3
2
1
0
Deaths
(%)
100
80
60
40
20
0
Min
10
3.8
0
Year
20062006
20062010
20062013
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Tests (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
QN
CQ
AL
Sources of financing
Global Fund
Adopted
AL
2004
AL
2004
QN 2004
AS; AM; QN
2004
CQ
2004
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
200
160
120
80
40
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
115
OTHERS
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
PP
Insufficient data
0
Insufficient data
00.1
Very low PP
0.11.0
020
1.010
2040
>85
4060
6080
no cases
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
223000
37800
0
261000
86
14
0
[9403400]
<10
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2012
ITNs/LLINs distributed to all age groups
Yes
2012
IRS
IRS is recommended
Yes
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
Malaria diagnosis is free of charge in the public sector
No
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
Yes
G6PD test is a requirement before treatment with primaquine
Yes
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases (%)
Population (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Tests (%)
(%)
Year
20102014
120
96
72
48
24
0
116
(p.vivax)
WORLD MALARIACases
REPORT
2015
5
4
3
2
1
0
Deaths
Global Fund
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
25
20
15
10
5
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Government
100
80
60
40
20
0
Adopted
AL
AQ+PG
Artesunate IV + relais AL
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Admissions
1.0
0.8
0.6
0.4
0.2
0
ABER (%)
Contribution (US$m)
III. Financing
GABON
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
1690000
0
0
1690000
100
0
0
[110000630000]
[96510]
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
No
2005
ITNs/LLINs distributed to all age groups
Yes
2007
IRS
IRS is recommended
Yes
2013
DDT is authorized for IRS
No
Sale of oral artemisinin-based monotherapies
Is banned
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
No
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
(%)
World Bank
USAID/PMI
WHO/UNICEF
Cases (%)
Test positivity
100
80
60
40
20
0
4000
3200
2400
1600
800
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
60
48
36
24
12
0
Year
20102014
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
200
160
120
80
40
0
Deaths
Global Fund
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Tests (%)
Population (%)
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Adopted
AS+AQ
2003
AS+AQ
2003
AL 2003
AS; AM; QN
2003
PAN-only.
Sources of financing
IV. Coverage
Medicine
Admissions
10
8
6
4
2
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
117
GAMBIA
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
1930000
0
0
1930000
100
0
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2000
ITNs/LLINs distributed to all age groups
Yes
1998
IRS
IRS is recommended
Yes
2008
DDT is authorized for IRS
Yes
2007
Larval control Use of larval control recommended
IPT
IPT used to prevent malaria during pregnancy
Yes
2002
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2009
Malaria diagnosis is free of charge in the public sector
Yes
1998
Treatment ACT is free for all ages in public sector
Yes
2008
Sale of oral artemisinin-based monotherapies
are allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum
Primaquine is used for radical treatment of P.vivax
G6PD test is a requirement before treatment with primaquine
Directly observed treatment with primaquine is undertaken
System for monitoring of adverse reactions to antimalarials exists
ACD of febrile cases at community level (pro-active)
Mass screening is undertaken
USAID/PMI
WHO/UNICEF
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
1500
1200
900
600
300
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
200
160
120
80
40
0
Others
(%)
World Bank
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
118
(p.vivax)
WORLD MALARIACases
REPORT
2015
30
24
18
12
6
0
Deaths
Global Fund
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102014
Tests (%)
Population (%)
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20072013
0
1.6
11.9
28 days
7
P.falciparum
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Adopted
AL
2005
AL
2005
QN 2005
QN
2005
P.f only.
Sources of financing
IV. Coverage
Medicine
Admissions
10
8
6
4
2
0
ABER (%)
Contribution (US$m)
III. Financing
GHANA
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
26800000
0
0
26800000
100
0
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2004
ITNs/LLINs distributed to all age groups
Yes
2010
IRS
IRS is recommended
Yes
2005
DDT is authorized for IRS
No
Sale of oral artemisinin-based monotherapies
Is banned 2006
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
2001
Surveillance ACD for case investigation (reactive)
No
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
(%)
100
80
60
40
20
0
World Bank
USAID/PMI
WHO/UNICEF
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
2000
1600
1200
800
400
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
150
120
90
60
30
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
35
28
21
14
7
0
Deaths
Global Fund
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102014
Tests (%)
Population (%)
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20052011
0
0
13.8
28 days
11
P.falciparum
AS+AQ
20052011
0
3.15
14
28 days
12
P.falciparum
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Adopted
AS+AQ
2004
AL; AS+AQ
2004
QN 2004
AS; AM; QN
2004
P.f only.
Sources of financing
IV. Coverage
Medicine
Admissions
120
96
72
48
24
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
119
GUATEMALA
OTHERS
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
PP
Insufficient data
0
Insufficient data
00.1
Very low PP
0.11.0
020
1.010
2040
>85
4060
6080
no cases
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
3980000
8290000
3720000
16000000
25
52
23
[660023000]
<10
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2006
ITNs/LLINs distributed to all age groups
Yes
2006
IRS
IRS is recommended
Yes
DDT is authorized for IRS
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
Malaria diagnosis is free of charge in the public sector
Yes
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes
Primaquine is used for radical treatment of P.vivax
Yes
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
World Bank
USAID/PMI
WHO/UNICEF
Tests (%)
Test positivity
100
80
60
40
20
0
100
80
60
40
20
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
Cases (%)
Population (%)
(%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
5
4
3
2
1
0
120
(p.vivax)
WORLD MALARIACases
REPORT
2015
5
4
3
2
1
0
Deaths
Global Fund
10
8
6
4
2
0
Year
2011
Sources of financing
IV. Coverage
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Admissions
15
12
9
6
3
0
Adopted
CQ+PQ(3d)
QN
CQ+PQ(14d)
ABER (%)
Contribution (US$m)
III. Financing
Medicine
GUINEA
Insufficient data
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
2014
12300000
0
0
12300000
100
0
0
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
PP
Population
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2009
ITNs/LLINs distributed to all age groups
Yes
2009
IRS
IRS is recommended
Yes
2013
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
Yes
2005
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2012
Malaria diagnosis is free of charge in the public sector
Yes
2012
Treatment ACT is free for all ages in public sector
Yes
2010
Sale of oral artemisinin-based monotherapies
Is banned
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
2009
Surveillance ACD for case investigation (reactive)
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
1000
800
600
400
200
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Tests (%)
Population (%)
(%)
Year
20122014
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
10
8
6
4
2
0
Deaths
Global Fund
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
60
48
36
24
12
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Government
100
80
60
40
20
0
Adopted
AS+AQ
AS+AQ
QN
AS
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Admissions
30
24
18
12
6
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
121
GUINEA-BISSAU
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
1800000
0
0
1800000
100
0
0
[70000370000]
[160990]
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2005
ITNs/LLINs distributed to all age groups
No
IRS
IRS is recommended
No
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
Yes
2005
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2008
Malaria diagnosis is free of charge in the public sector
Yes
2008
Treatment ACT is free for all ages in public sector
No
Sale of oral artemisinin-based monotherapies
Is banned 2006
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
USAID/PMI
WHO/UNICEF
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
1500
1200
900
600
300
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
60
48
36
24
12
0
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
122
(p.vivax)
WORLD MALARIACases
REPORT
2015
100
80
60
40
20
0
Deaths
(%)
World Bank
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102014
Tests (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20062008 3.6
3.6
3.6
28 days
1
P.falciparum
Sources of financing
Global Fund
Adopted
AL
AL
QN
AS; QN
P.f only.
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
120
96
72
48
24
0
ABER (%)
Contribution (US$m)
III. Financing
GUYANA
OTHERS
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
PP
Insufficient data
0
Insufficient data
00.1
Very low PP
0.11.0
020
1.010
2040
>85
4060
6080
no cases
80100
Based on 2013 reported data
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
267000
443000
53500
764000
35
58
7
[4500090000]
[10190]
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2005
ITNs/LLINs distributed to all age groups
Yes
2005
IRS
IRS is recommended
Yes
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
1946
Malaria diagnosis is free of charge in the public sector
Yes
1946
Treatment ACT is free for all ages in public sector
Yes
2005
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes
Primaquine is used for radical treatment of P.vivax
Yes
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
Yes
System for monitoring of adverse reactions to antimalarials exists
No
ACD of febrile cases at community level (pro-active)
Yes
Mass screening is undertaken
Yes
USAID/PMI
WHO/UNICEF
100
80
60
40
20
0
Tests (%)
100
80
60
40
20
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
60
48
36
24
12
0
Others
Cases (%)
Population (%)
(%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102014
1200
960
720
480
240
0
50
40
30
20
10
0
Deaths
World Bank
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
CQ
20062006 32.4
32.4
32.4
28 days
1
P.vivax
Sources of financing
Global Fund
Adopted
AL+PQ(1d)
2004
QN+T 2004
AM
CQ+PQ(14d)
2004
0.25 mg/kg (14 d)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
2.5
2.0
1.5
1.0
0.5
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
123
HAITI
OTHERS
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
PP
Insufficient data
0
Insufficient data
00.1
Very low PP
0.11.0
020
1.010
2040
>85
4060
6080
no cases
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
5620000
4980000
0
10600000
53
47
0
[62000170000]
[10600]
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2012
ITNs/LLINs distributed to all age groups
Yes
2012
IRS
IRS is recommended
No
DDT is authorized for IRS
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
1988
Malaria diagnosis is free of charge in the public sector
Yes
2011
Treatment ACT is free for all ages in public sector
Yes
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
100
80
60
40
20
0
WHO/UNICEF
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
Tests (%)
(%)
USAID/PMI
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
10
8
6
4
2
0
Year
20132014
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Cases (%)
Population (%)
IV. Coverage
1200
960
720
480
240
0
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
124
(p.vivax)
WORLD MALARIACases
REPORT
2015
120
96
72
48
24
0
Deaths
World Bank
Adopted
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Sources of financing
Global Fund
CQ+PQ(1d)
MQ; SP
QN
CQ+PQ(14d)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
25
20
15
10
5
0
ABER (%)
Contribution (US$m)
III. Financing
HONDURAS
OTHERS
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
PP
Insufficient data
0
Insufficient data
00.1
Very low PP
0.11.0
020
1.010
2040
>85
4060
6080
no cases
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
371000
4670000
2920000
7960000
5
59
37
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2009
ITNs/LLINs distributed to all age groups
Yes
2009
IRS
IRS is recommended
Yes
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
Malaria diagnosis is free of charge in the public sector
Yes
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes
Primaquine is used for radical treatment of P.vivax
Yes
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
No
ACD of febrile cases at community level (pro-active)
Yes
Mass screening is undertaken
Yes
World Bank
WHO/UNICEF
Test positivity
Source: DHS 2006, DHS 2012
100
80
60
40
20
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
Tests (%)
(%)
USAID/PMI
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
10
8
6
4
2
0
Year
20132014
5
4
3
2
1
0
5
4
3
2
1
0
Deaths
Global Fund
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Cases (%)
Population (%)
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
CQ
20082009
0
0
0
28 days
1
P.falciparum
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Adopted
CQ+PQ(1d)
SP 2011
QN
CQ+PQ(14d)
Sources of financing
IV. Coverage
Medicine
Admissions
5
4
3
2
1
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
125
INDIA
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
PP
no cases
80100
Based on 2011 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Insufficient data
Insufficient data
0
PP
Population
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
2014
181300000
997400000
116600000
1295300000
14
77
9
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2001
ITNs/LLINs distributed to all age groups
Yes
2001
IRS
IRS is recommended
Yes
1953
DDT is authorized for IRS
Yes
1953
Larval control Use of larval control recommended
Yes
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
1958
Malaria diagnosis is free of charge in the public sector
Yes
1953
Treatment ACT is free for all ages in public sector
Yes
2006
Sale of oral artemisinin-based monotherapies
Is banned 2009
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes 1982
Primaquine is used for radical treatment of P.vivax
Yes 1982
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
Yes
Mass screening is undertaken
Yes
(%)
USAID/PMI
WHO/UNICEF
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
5
4
3
2
1
0
2.5
2.0
1.5
1.0
0.5
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Tests (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102015
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
126
(p.vivax)
WORLD MALARIACases
REPORT
2015
2000
1600
1200
800
400
0
Deaths
World Bank
2007
2007
2007
2007
0.25 mg/kg (14 d)
P.f + P.v specific (Combo).
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AS+SP
20052012
0
0
25.9
28 days
36
P.falciparum
Sources of financing
Global Fund
Adopted
CQ
AS+SP+PQ
QN+D; QN+T
AM; AS; QN
CQ+PQ(14d)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
150
120
90
60
30
0
ABER (%)
Contribution (US$m)
III. Financing
INDONESIA
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
PP
no cases
80100
Based on 2012 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Insufficient data
Insufficient data
0
PP
Population
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
2014
30000000
36500000
188000000
254500000
12
14
74
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2004
ITNs/LLINs distributed to all age groups
Yes
2004
IRS
IRS is recommended
Yes
1959
DDT is authorized for IRS
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2007
Malaria diagnosis is free of charge in the public sector
Yes
1959
Treatment ACT is free for all ages in public sector
Yes
2004
Sale of oral artemisinin-based monotherapies
Never allowed 2010
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes 2004
Primaquine is used for radical treatment of P.vivax
Yes 2004
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
No
USAID/PMI
WHO/UNICEF
100
80
60
40
20
0
Test positivity
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
10
8
6
4
2
0
Others
Cases (%)
Population (%)
(%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20112014
500 000
400 000
300 000
200 000
100 000
0
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
1000
800
600
400
200
0
Deaths
World Bank
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Sources of financing
Global Fund
Adopted
DHA-PP+PQ
2008
QN+D+PQ 2004
AM; AS; QN
2004
AS+AQ; DHA-PP+PQ(14d)
2008
0.25 mg/kg (14 d)
P.f + all species (Combo).
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
60
48
36
24
12
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species) points
Deaths (all species)
127
Eastern
Mediterranean Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
2014
319
606000
77500000
78106000
1
99
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
Number of active foci
Number of people living within active foci
Number of people living in malaria free areas
Total
Insufficient data
Insufficient data
0
PP
Population
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2005
ITNs/LLINs distributed to all age groups
Yes
2005
IRS
IRS is recommended
Yes
1949
DDT is authorized for IRS
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
Malaria diagnosis is free of charge in the public sector
Yes
1949
Treatment ACT is free for all ages in public sector
Yes
2005
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes 1949
Primaquine is used for radical treatment of P.vivax
Yes 1949
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
Yes
1949
System for monitoring of adverse reactions to antimalarials exists
Yes
1949
Surveillance ACD for case investigation (reactive)
Yes
1949
ACD of febrile cases at community level (pro-active)
Yes
1949
Mass screening is undertaken
No
Foci and case investigation undertaken
Yes
2010
Case reporting from private sector is mandatory
Yes
1949
World Bank
100
80
60
40
20
0
Cases tracked
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
Cases investigated
Malaria
test positivity
and ABER
Antimalarials
distributedrate
vs reported
cases
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Cases tested
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
WHO/UNICEF
(%)
Cases (%)
2.0
1.6
1.2
0.8
0.4
0
USAID/PMI
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102012
Cases (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AS+SP 20052012
0 0 1 28 days 15
P.falciparum
CQ+PQ
20082011
0
0
0
28 days
4
P.vivax
Sources of financing
Global Fund
25 000
20 000
15 000
10 000
5000
0
Reporting completeness
Foci investigated
Cases investigated points
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Total cases
Indigenous cases (P. falciparum)
Aberpositivity
(microscopy
RDT)
RDT
rate&points
positivity rate
WORLD MALARIARDT
REPORT
2015
Slide positivity points
Slide positivity rate
Foci investigated
128
Adopted
AS+SP; AS+SP+PQ
2010
AL; AL+PQ
2010
AS; QN+D
0.75 mg/kg (8 w)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Cases
15
12
9
6
3
0
ABER (%)
Contribution (US$m)
III. Financing
Imported cases
Indigenous cases (P. vivax)
KENYA
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
31500000
13400000
0
44900000
70
30
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2006
ITNs/LLINs distributed to all age groups
Yes
2010
IRS
IRS is recommended
Yes
2003
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
Yes
2001
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2009
Malaria diagnosis is free of charge in the public sector
Yes
Directly observed treatment with primaquine is undertaken
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
USAID/PMI
WHO/UNICEF
(%)
World Bank
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
600
480
360
240
120
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
80
64
48
32
16
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
200
160
120
80
40
0
Deaths
Global Fund
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102015
Tests (%)
Population (%)
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20052011
0
1.65
6.6
28 days
16
P.falciparum
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Adopted
AL
2004
AL
2004
QN 2004
AS; AM; QN
2004
P.f only.
Sources of financing
IV. Coverage
Medicine
Admissions
120
96
72
48
24
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
129
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
2090000
4110000
494000
6690000
31
61
7
[72000120000]
[10340]
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2003
ITNs/LLINs distributed to all age groups
Yes
2000
IRS
IRS is recommended
Yes
2010
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2003
Malaria diagnosis is free of charge in the public sector
Yes
2005
Treatment ACT is free for all ages in public sector
Yes
2005
Sale of oral artemisinin-based monotherapies
Is banned 2005
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
Yes
G6PD test is a requirement before treatment with primaquine
Yes
2010
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
No
World Bank
(%)
USAID/PMI
WHO/UNICEF
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
25 000
20 000
15 000
10 000
5000
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
10
8
6
4
2
0
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
130
(p.vivax)
WORLD MALARIACases
REPORT
2015
350
280
210
140
70
0
Deaths
Global Fund
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20132014
Tests (%)
Population (%)
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20052015
0
2.4
18.1
28 days
13
P.falciparum
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Adopted
AL
2001
QN+D 2001
AS+AL
2001
CQ+PQ(14d)
2001
0.25 mg/kg (14 d)
P.f + P.v specific (Combo).
Sources of financing
IV. Coverage
Medicine
Admissions
10
8
6
4
2
0
ABER (%)
Contribution (US$m)
III. Financing
LIBERIA
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
4400000
0
0
4400000
100
0
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2005
ITNs/LLINs distributed to all age groups
Yes
2008
IRS
IRS is recommended
Yes
2009
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
Yes
2005
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2005
Malaria diagnosis is free of charge in the public sector
Yes
2005
Treatment ACT is free for all ages in public sector
Yes
2005
Sale of oral artemisinin-based monotherapies
Is banned 2011
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
USAID/PMI
WHO/UNICEF
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
6000
4800
3600
2400
1200
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
500
400
300
200
100
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
60
48
36
24
12
0
Deaths
(%)
100
80
60
40
20
0
World Bank
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102014
Tests (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AS+AQ
20072011
0
0
1
28 days
4
P.falciparum
Sources of financing
Global Fund
Adopted
AS+AQ
2004
AS+AQ
2004
QN 2004
AS; AM; QN
2004
P.f only.
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
35
28
21
14
7
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
131
MADAGASCAR
Insufficient data
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
PP
Population
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
2014
20700000
2890000
0
23600000
88
12
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2004
ITNs/LLINs distributed to all age groups
Yes
2009
IRS
IRS is recommended
Yes
1993
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
Yes
2006
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2006
Malaria diagnosis is free of charge in the public sector
Yes
2006
Treatment ACT is free for all ages in public sector
Yes
2006
Sale of oral artemisinin-based monotherapies
Is banned 2006
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes 2015
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
Yes
System for monitoring of adverse reactions to antimalarials exists
Yes
2008
Surveillance ACD for case investigation (reactive)
Yes
2003
ACD of febrile cases at community level (pro-active)
Yes
1993
Mass screening is undertaken
Yes
2003
Uncomplicated P.falciparum cases routinely admitted
Yes
2006
Uncomplicated P.vivax cases routinely admitted
No
World Bank
USAID/PMI
WHO/UNICEF
Others
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
80
64
48
32
16
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
20
16
12
8
4
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
132
(p.vivax)
WORLD MALARIACases
REPORT
2015
5
4
3
2
1
0
Deaths
(%)
100
80
60
40
20
0
Year
20102015
Cases (%)
Global Fund
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Tests (%)
Population (%)
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20062006 1.7
1.7
1.7
28 days
1
P.falciparum
AS+AQ
20062013
0
0
8.7
28 days
18
P.falciparum
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Adopted
AS+AQ
2006
AS+AQ
2006
QN 2006
QN
2006
Sources of financing
IV. Coverage
Medicine
Admissions
80
64
48
32
16
0
ABER (%)
Contribution (US$m)
III. Financing
MALAWI
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
16700000
0
0
16700000
100
0
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2006
ITNs/LLINs distributed to all age groups
Yes
2010
IRS
IRS is recommended
Yes
2007
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
Yes
1993
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2011
Malaria diagnosis is free of charge in the public sector
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
2007
Surveillance ACD for case investigation (reactive)
No
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
USAID/PMI
WHO/UNICEF
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
1500
1200
900
600
300
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
80
64
48
32
16
0
Deaths
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Test positivity
Tests (%)
Population (%)
(%)
World Bank
Cases (%)
Global Fund
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Cases per 1000
200
160
120
80
40
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20052012
0
4.45
19.5
28 days
8
P.falciparum
AS+AQ
20052012
0
1.7
3.6
28 days
3
P.falciparum
Government
Adopted
AL
2007
AL
2007
AS+AQ 2007
AS; QN
2007
P.f only.
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Admissions
60
48
36
24
12
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
133
MALAYSIA
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
Number of active foci
Number of people living within active foci
Number of people living in malaria free areas
Total
2014
1300000
28600000
29900000
4
96
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
1995
ITNs/LLINs distributed to all age groups
Yes
1995
IRS
IRS is recommended
DDT is authorized for IRS
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
Malaria diagnosis is free of charge in the public sector
Yes
1967
Treatment ACT is free for all ages in public sector
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes 2013
Primaquine is used for radical treatment of P.vivax
Yes 1993
G6PD test is a requirement before treatment with primaquine
Yes
1993
Directly observed treatment with primaquine is undertaken
Yes
System for monitoring of adverse reactions to antimalarials exists
Yes
2003
Surveillance ACD for case investigation (reactive)
Yes
1965
ACD of febrile cases at community level (pro-active)
Yes
1965
Mass screening is undertaken
Yes
1965
Uncomplicated P.falciparum cases routinely admitted
Yes
2013
Uncomplicated P.vivax cases routinely admitted
Yes
2013
Foci and case investigation undertaken
Yes
1995
Case reporting from private sector is mandatory
Yes
1988
World Bank
Cases tested
100
80
60
40
20
0
Cases tracked
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Malaria
test positivity
and ABER
Antimalarials
distributedrate
vs reported
cases
Others
(%)
Cases (%)
WHO/UNICEF
USAID/PMI
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
1.0
0.8
0.6
0.4
0.2
0
Year
20102014
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Cases (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Sources of financing
Global Fund
15 000
12 000
9000
6000
3000
0
Reporting completeness
Foci investigated
Cases investigated points
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Total cases
Indigenous cases (P. falciparum)
Aberpositivity
(microscopy
RDT)
RDT
rate&points
positivity rate
WORLD MALARIARDT
REPORT
2015
Slide positivity points
Slide positivity rate
Foci investigated
134
Adopted
AS+MQ
QN+T
QN+T
CQ+PQ(14d)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Cases
60
48
36
24
12
0
ABER (%)
Contribution (US$m)
III. Financing
Imported cases
Indigenous cases (P. vivax)
MALI
Insufficient data
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
PP
Population
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
2014
15400000
1710000
0
17100000
90
10
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2005
ITNs/LLINs distributed to all age groups
No
IRS
IRS is recommended
Yes
2007
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
Yes
2003
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2008
Malaria diagnosis is free of charge in the public sector
Yes
2008
Treatment ACT is free for all ages in public sector
No
Sale of oral artemisinin-based monotherapies
Is banned
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
2010
Surveillance ACD for case investigation (reactive)
No
ACD of febrile cases at community level (pro-active)
Yes
2008
Mass screening is undertaken
No
USAID/PMI
WHO/UNICEF
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
4000
3200
2400
1600
800
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
120
96
72
48
24
0
Year
20102014
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
20
16
12
8
4
0
Deaths
(%)
100
80
60
40
20
0
World Bank
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Tests (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AS+AQ
20052007
0
2.25
7.6
28 days
4
P.falciparum
AL
20052014
0
1.75
3.8
28 days
10
P.falciparum
Sources of financing
Global Fund
Adopted
AS+AQ
2007
AL; AS+AQ
2007
AL 2007
QN
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
60
48
36
24
12
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
135
MAURITANIA
Insufficient data
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
PP
Population
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
2014
2780000
1190000
0
3970000
70
30
0
[40000120000]
[2401500]
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
1998
ITNs/LLINs distributed to all age groups
No
IRS
IRS is recommended
No
DDT is authorized for IRS
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
Mass screening is undertaken
Yes
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
800
640
480
320
160
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Tests (%)
Population (%)
(%)
Year
20102014
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
136
(p.vivax)
WORLD MALARIACases
REPORT
2015
10
8
6
4
2
0
Deaths
Global Fund
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
5
4
3
2
1
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AS+AQ
20122012 1.8
1.8
1.8
28 days
2
P.falciparum
Government
100
80
60
40
20
0
Adopted
AS+AQ
AL; AS+AQ
QN
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Admissions
15
12
9
6
3
0
ABER (%)
Contribution (US$m)
III. Financing
MAYOTTE, FRANCE
Insufficient data
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
2014
1
59100
169000
228100
26
74
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
Number of active foci
Number of people living within active foci
Number of people living in malaria free areas
Total
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
PP
Population
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
0
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2010
ITNs/LLINs distributed to all age groups
Yes
2010
IRS
IRS is recommended
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
No
Diagnosis
Patients of all ages should receive diagnostic test
No
Malaria diagnosis is free of charge in the public sector
Yes
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
Yes
G6PD test is a requirement before treatment with primaquine
Yes
Directly observed treatment with primaquine is undertaken
Yes
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
Foci and case investigation undertaken
Yes
Case reporting from private sector is mandatory
Yes
III. Financing
Medicine
AL
QN
CQ+PQ
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102011
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Cases tracked
(%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
Cases investigated
Malaria
test positivity
and ABER
Antimalarials
distributedrate
vs reported
cases
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Foci investigated
Cases
Cases (%)
20
16
12
8
4
0
Cases tested
Cases (%)
100
80
60
40
20
0
ABER (%)
Population (%)
100
80
60
40
20
0
Sources of financing
IV. Coverage
Adopted
800
640
480
320
160
0
Reporting completeness
Foci investigated
Cases investigated points
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Total cases
Indigenous cases (P. falciparum)
Imported cases
Indigenous cases (P. vivax)
Imported WORLD
cases points MALARIA REPORT 2015
Imported cases
Indigenous (P.vivax) points
137
MEXICO
EURO / PAHO
Confirmed cases
API 1000 population
per
OTHERS
PF-RATIO
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
no cases
Insufficient data
0
Insufficient data
0
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
1050
4060
>85
4060
50100
6080
6080
>100
80100
PP
no cases
80100
I. Epidemiological profile
Population
Number of active foci
Number of people living within active foci
Number of people living in malaria free areas
Total
2014
56
3450000
121900000
125350000
3
97
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2012
ITNs/LLINs distributed to all age groups
Yes
2012
IRS
IRS is recommended
No
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
Malaria diagnosis is free of charge in the public sector
Yes
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes
Primaquine is used for radical treatment of P.vivax
Yes
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
Yes
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
Yes
Mass screening is undertaken
Yes
Foci and case investigation undertaken
Yes
Case reporting from private sector is mandatory
Yes
Global Fund
World Bank
USAID/PMI
WHO/UNICEF
Cases tested
100
80
60
40
20
0
(%)
Cases tracked
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Malaria
test positivity
and ABER
Antimalarials
distributedrate
vs reported
cases
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Cases (%)
Population (%)
Cases (%)
Year
20102014
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
0.5
0.4
0.3
0.2
0.1
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
8000
6400
4800
3200
1600
0
Reporting completeness
Foci investigated
Cases investigated points
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Total cases
Indigenous cases (P. falciparum)
Aberpositivity
(microscopy
RDT)
RDT
rate&points
positivity rate
WORLD MALARIARDT
REPORT
2015
Slide positivity points
Slide positivity rate
Foci investigated
138
Adopted
Sources of financing
IV. Coverage
100
80
60
40
20
0
CQ+PQ
AL+QN
AL
CQ+PQ
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
100
80
60
40
20
0
Medicine
Cases
30
24
18
12
6
0
ABER (%)
Contribution (US$m)
III. Financing
Imported cases
Indigenous cases (P. vivax)
MOZAMBIQUE
Insufficient data
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
2014
27200000
0
0
27200000
100
0
0
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
PP
Population
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2006
ITNs/LLINs distributed to all age groups
Yes
2008
IRS
IRS is recommended
Yes
1992
DDT is authorized for IRS
Yes
2006
Larval control Use of larval control recommended
No
IPT
IPT used to prevent malaria during pregnancy
Yes
2006
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2006
Malaria diagnosis is free of charge in the public sector
Yes
2006
Treatment ACT is free for all ages in public sector
Yes
2009
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
(%)
100
80
60
40
20
0
World Bank
USAID/PMI
WHO/UNICEF
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
800
640
480
320
160
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
300
240
180
120
60
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
30
24
18
12
6
0
Deaths
Global Fund
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102014
Tests (%)
Population (%)
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20052012
0
3.1
5.8
28 days
9
P.falciparum
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Adopted
AL
2004
AL
2004
AS, QN
2004
P.f only.
Sources of financing
IV. Coverage
Medicine
Admissions
120
96
72
48
24
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
139
MYANMAR
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
8440000
23300000
21600000
53400000
16
44
40
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2000
ITNs/LLINs distributed to all age groups
Yes
2000
IRS
IRS is recommended
Yes
1957
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
1962
Malaria diagnosis is free of charge in the public sector
Yes
1962
Treatment ACT is free for all ages in public sector
Yes
2003
Sale of oral artemisinin-based monotherapies
Is banned 2012
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes 2002
Primaquine is used for radical treatment of P.vivax
Yes 1951
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
Yes
2014
System for monitoring of adverse reactions to antimalarials exists
Yes
World Bank
WHO/UNICEF
Test positivity
Others
Tests (%)
(%)
USAID/PMI
100
80
60
40
20
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Max
11.9
6
2.2
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Median
0
0
0
20
16
12
8
4
0
Year
20112014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Min
0
0
0
100 000
80 000
60 000
40 000
20 000
0
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
140
(p.vivax)
WORLD MALARIACases
REPORT
2015
3000
2400
1800
1200
600
0
Deaths
Global Fund
100
80
60
40
20
0
Year
20062015
20072014
20112013
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Cases (%)
Population (%)
100
80
60
40
20
0
Medicine
CQ
AL
AS+MQ
Sources of financing
IV. Coverage
Adopted
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
60
48
36
24
12
0
ABER (%)
Contribution (US$m)
III. Financing
NAMIBIA
Insufficient data
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
PP
Population
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
2014
1110000
797000
495000
2400000
46
33
21
[680011000]
<50
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
1998
ITNs/LLINs distributed to all age groups
Yes
2014
IRS
IRS is recommended
Yes
1965
DDT is authorized for IRS
Yes
1965
Larval control Use of larval control recommended
Yes
IPT
IPT used to prevent malaria during pregnancy
Yes
2005
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2005
Malaria diagnosis is free of charge in the public sector
Yes
1990
Treatment ACT is free for all ages in public sector
Yes
2005
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes 2015
Primaquine is used for radical treatment of P.vivax
Yes 2015
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
Yes
System for monitoring of adverse reactions to antimalarials exists
Yes
Mass screening is undertaken
Yes
USAID/PMI
WHO/UNICEF
Others
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
50 000
40 000
30 000
20 000
10 000
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000
1600
1200
800
400
0
Deaths
(%)
World Bank
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
30
24
18
12
6
0
Year
20102014
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Tests (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Sources of financing
Global Fund
Adopted
AL
2006
AL
2006
QN 2006
QN
2006
AL
2006
0.75 mg/kg (8 w)
P.f + P.v, P.o, P.m (Combo).
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
20
16
12
8
4
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
141
NEPAL
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Insufficient data
Insufficient data
0
PP
Population
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
2014
1020000
12500000
14700000
28200000
4
44
52
[1000022000]
<10
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2007
ITNs/LLINs distributed to all age groups
Yes
2007
IRS
IRS is recommended
Yes
1962
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2009
Malaria diagnosis is free of charge in the public sector
Yes
1962
Treatment ACT is free for all ages in public sector
Yes
2005
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum
Primaquine is used for radical treatment of P.vivax
Yes
G6PD test is a requirement before treatment with primaquine
Yes
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
USAID/PMI
WHO/UNICEF
Cases (%)
Test positivity
100
80
60
40
20
0
3000
2400
1800
1200
600
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
1.5
1.2
0.9
0.6
0.3
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Tests (%)
Population (%)
(%)
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
2014
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
142
(p.vivax)
WORLD MALARIACases
REPORT
2015
50
40
30
20
10
0
Deaths
World Bank
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20052014
0
0
6.3
28 days
10
P.falciparum
CQ
20082011
0
0
0
28 days
8
P.vivax
Sources of financing
Global Fund
Adopted
CQ
AL+PQ
2004
AS; QN
AS; QN
CQ+PQ(14d)
2004
0.25 mg/kg (14 d), 3.75 - 15mg/day (14 d)
P.f + P.v specific (Combo).
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
10
8
6
4
2
0
ABER (%)
Contribution (US$m)
III. Financing
NICARAGUA
OTHERS
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
PP
Insufficient data
0
Insufficient data
00.1
Very low PP
0.11.0
020
1.010
2040
>85
4060
6080
no cases
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
78100
2940000
2990000
6010000
1
49
50
[19003000]
<10
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2005
ITNs/LLINs distributed to all age groups
Yes
2005
IRS
IRS is recommended
Yes
1959
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
Malaria diagnosis is free of charge in the public sector
Yes
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes 2013
Primaquine is used for radical treatment of P.vivax
Yes
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
Yes
System for monitoring of adverse reactions to antimalarials exists
No
ACD of febrile cases at community level (pro-active)
Yes
Mass screening is undertaken
Yes
USAID/PMI
WHO/UNICEF
100
80
60
40
20
0
100
80
60
40
20
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
10
8
6
4
2
0
Others
Tests (%)
(%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Year
20102014
Cases (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
250
200
150
100
50
0
10
8
6
4
2
0
Deaths
World Bank
0.50 mg/kg (7 d)
P.f + P.v specific (Combo).
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
CQ
20052006
0
0
0
28 days
1
P.falciparum
Sources of financing
Global Fund
Adopted
CQ+PQ(1d)
AS+MQ; AS+SP
QN
CQ+PQ(7d)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
5
4
3
2
1
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
143
NIGER
Insufficient data
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
PP
Population
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
2014
10100000
7830000
1150000
19100000
53
41
6
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2005
ITNs/LLINs distributed to all age groups
No
IRS
IRS is recommended
Yes
2003
DDT is authorized for IRS
Yes
Sale of oral artemisinin-based monotherapies
Is banned 2007
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
USAID/PMI
WHO/UNICEF
(%)
World Bank
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
2000
1600
1200
800
400
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
150
120
90
60
30
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
144
(p.vivax)
WORLD MALARIACases
REPORT
2015
25
20
15
10
5
0
Deaths
Global Fund
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
2013
Tests (%)
Population (%)
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20052011 3.7
5.55
10.4
28 days
6
P.falciparum
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Adopted
AL
2005
AL
2005
QN 2005
AS; QN
2005
P.f only.
Sources of financing
IV. Coverage
Medicine
Admissions
3000
2400
1800
1200
600
0
ABER (%)
Contribution (US$m)
III. Financing
NIGERIA
Insufficient data
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
PP
Population
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
2014
135600000
41900000
0
177500000
76
24
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2001
ITNs/LLINs distributed to all age groups
Yes
2009
IRS
IRS is recommended
Yes
2007
DDT is authorized for IRS
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
WHO/UNICEF
50
40
30
20
10
0
Test positivity
100
80
60
40
20
0
600
480
360
240
120
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
10
8
6
4
2
0
Deaths
USAID/PMI
(%)
World Bank
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Cases (%)
Global Fund
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102014
Tests (%)
Population (%)
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20052011
0
2.3
12.7
28 days
17
P.falciparum
AS+AQ
20052011
0
0.8
13.7
28 days
20
P.falciparum
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Adopted
AL; AS+AQ
2004
AL; AS+AQ
2004
QN 2004
AS; AM; QN
2004
P.f only.
Sources of financing
IV. Coverage
Medicine
Admissions
300
240
180
120
60
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
145
PAKISTAN
Eastern
Mediterranean Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Insufficient data
Insufficient data
0
PF-RATIO
2014
53500000
128400000
3120000
185000000
29
69
2
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2008
ITNs/LLINs distributed to all age groups
No
IRS
IRS is recommended
Yes
1961
DDT is authorized for IRS
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2011
Malaria diagnosis is free of charge in the public sector
Yes
1961
Treatment ACT is free for all ages in public sector
Yes
2009
Sale of oral artemisinin-based monotherapies
Is banned 2008
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes 2012
Primaquine is used for radical treatment of P.vivax
Yes 2009
G6PD test is a requirement before treatment with primaquine
Yes
2009
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
No
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
(%)
USAID/PMI
WHO/UNICEF
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
80 000
64 000
48 000
32 000
16 000
0
2.0
1.6
1.2
0.8
0.4
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Tests (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20112013
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
146
(p.vivax)
WORLD MALARIACases
REPORT
2015
300
240
180
120
60
0
Deaths
World Bank
2013
2013
2007
2007
0.25 mg/kg (14 d)
P.f + all species (Combo).
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AS+SP
20072012
0
0
1.5
28 days
9
P.falciparum
AL
20122013
0
0.6
1.2
28 days
2
P.falciparum
Sources of financing
Global Fund
Adopted
CQ
AS+SP+PQ
AL; QN
AS; QN
CQ+PQ(14d)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
20
16
12
8
4
0
ABER (%)
Contribution (US$m)
III. Financing
PANAMA
OTHERS
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
PP
Insufficient data
0
Insufficient data
00.1
Very low PP
0.11.0
020
1.010
2040
>85
4060
6080
no cases
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
170000
11100
3690000
3870000
4
0
95
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2012
ITNs/LLINs distributed to all age groups
No
IRS
IRS is recommended
Yes
1957
DDT is authorized for IRS
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
1957
Malaria diagnosis is free of charge in the public sector
Yes
1957
Treatment ACT is free for all ages in public sector
Yes
Sale of oral artemisinin-based monotherapies
Is banned
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes
Primaquine is used for radical treatment of P.vivax
Yes
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
No
ACD of febrile cases at community level (pro-active)
Yes
Mass screening is undertaken
Yes
WHO/UNICEF
100
80
60
40
20
0
Tests (%)
Test positivity
100
80
60
40
20
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
Cases (%)
Population (%)
(%)
USAID/PMI
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
35
28
21
14
7
0
Year
2011
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
120
96
72
48
24
0
5
4
3
2
1
0
Deaths
World Bank
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Sources of financing
Global Fund
Adopted
AL+PQ(1d)
2012
QN
CQ+PQ(7d); CQ+PQ(14d)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
15
12
9
6
3
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
147
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
7010000
448000
0
7460000
94
6
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2004
ITNs/LLINs distributed to all age groups
Yes
2005
IRS
IRS is recommended
Yes
2000
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
Yes
2010
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2010
Malaria diagnosis is free of charge in the public sector
Yes
2004
Treatment ACT is free for all ages in public sector
Yes
2010
Sale of oral artemisinin-based monotherapies
Is banned
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
Yes 2009
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
2000
Surveillance ACD for case investigation (reactive)
No
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102014
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
30 000
24 000
18 000
12 000
6000
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Tests (%)
Population (%)
(%)
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
DHA-PPQ
20052007
12
12
12
42 days
1
P.falciparum
AL
20052013
1
1.85
2.7
28 days
2
P.falciparum
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
148
(p.vivax)
WORLD MALARIACases
REPORT
2015
800
640
480
320
160
0
Deaths
Global Fund
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
40
32
24
16
8
0
Adopted
Government
100
80
60
40
20
0
AL
2008
DHA-PPQ 2008
AM; AS
2008
AL+PQ
2009
7.5 mg - adult (14 d)
P.f + P.v, P.o, P.m (Combo).
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Admissions
35
28
21
14
7
0
ABER (%)
Contribution (US$m)
III. Financing
PARAGUAY
EURO / PAHO
Confirmed cases
API 1000 population
per
OTHERS
PF-RATIO
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
no cases
Insufficient data
0
Insufficient data
0
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
1050
4060
>85
4060
50100
6080
6080
>100
80100
PP
no cases
80100
I. Epidemiological profile
Population
Number of active foci
Number of people living within active foci
Number of people living in malaria free areas
Total
2014
8
497000
6060000
6557000
8
92
0
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
No
ITNs/LLINs distributed to all age groups
No
IRS
IRS is recommended
Yes
1957
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
1957
Malaria diagnosis is free of charge in the public sector
Yes
1957
Treatment ACT is free for all ages in public sector
Yes
2005
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes
Primaquine is used for radical treatment of P.vivax
Yes 1957
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
Yes
System for monitoring of adverse reactions to antimalarials exists
Yes
Global Fund
World Bank
USAID/PMI
WHO/UNICEF
Cases tested
100
80
60
40
20
0
(%)
Cases tracked
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Malaria
test positivity
and ABER
Antimalarials
distributedrate
vs reported
cases
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Cases (%)
Population (%)
Cases (%)
Year
20102014
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
10
8
6
4
2
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Adopted
Sources of financing
IV. Coverage
100
80
60
40
20
0
AL+PQ
AS
CQ + PQ
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
100
80
60
40
20
0
Medicine
Foci investigated
Cases
10
8
6
4
2
0
ABER (%)
Contribution (US$m)
III. Financing
8000
6400
4800
3200
1600
0
Reporting completeness
Foci investigated
Cases investigated points
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Total cases
Indigenous cases (P. falciparum)
Imported cases
Indigenous cases (P. vivax)
Imported WORLD
cases points MALARIA REPORT 2015
Imported cases
Indigenous (P.vivax) points
149
PERU
OTHERS
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
PP
Insufficient data
0
Insufficient data
00.1
Very low PP
0.11.0
020
1.010
2040
>85
4060
6080
no cases
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
1550000
10600000
18800000
31000000
5
34
61
[75000120000]
<10
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
ITNs/LLINs distributed to all age groups
Yes
IRS
IRS is recommended
Yes
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
Malaria diagnosis is free of charge in the public sector
Yes
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes
Primaquine is used for radical treatment of P.vivax
Yes
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
Yes
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
Yes
Mass screening is undertaken
Yes
World Bank
WHO/UNICEF
Tests (%)
Test positivity
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Cases per 1000
Year
2013
Cases (%)
Population (%)
(%)
USAID/PMI
10
8
6
4
2
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AS+MQ
20052006 1.1
1.1
1.1
28 days
1
P.falciparum
CQ+PQ
20062008 0.5
0.6
1.1
28 days
3
P.vivax
1 000 000
800 000
600 000
400 000
200 000
0
150
(p.vivax)
WORLD MALARIACases
REPORT
2015
25
20
15
10
5
0
Deaths
Global Fund
Adopted
Sources of financing
IV. Coverage
AS+MQ
2001
AS+MQ
CQ+PQ
0.50 mg/kg (7 d)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
100
80
60
40
20
0
Medicine
Admissions
150
120
90
60
30
0
ABER (%)
Contribution (US$m)
III. Financing
PHILIPPINES
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
6530000
53900000
38700000
99100000
7
54
39
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2006
ITNs/LLINs distributed to all age groups
Yes
2000
IRS
IRS is recommended
Yes
2002
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2004
Malaria diagnosis is free of charge in the public sector
Yes
2003
Treatment ACT is free for all ages in public sector
Yes
2003
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes 2006
Primaquine is used for radical treatment of P.vivax
Yes 2007
G6PD test is a requirement before treatment with primaquine
Yes
2011
Directly observed treatment with primaquine is undertaken
Yes
2010
System for monitoring of adverse reactions to antimalarials exists
Yes
2009
Surveillance ACD for case investigation (reactive)
Yes
2009
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
Yes
2009
Uncomplicated P.falciparum cases routinely admitted
No
USAID/PMI
WHO/UNICEF
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
5000
4000
3000
2000
1000
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
1.0
0.8
0.6
0.4
0.2
0
Others
Tests (%)
Population (%)
(%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20112015
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
600
480
360
240
120
0
Deaths
World Bank
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
CQ
20052010
0
0
0
28 days
2
P.vivax
Sources of financing
Global Fund
Adopted
AL
2009
AL+PQ
2009
QN+CL; QN+D; QN+T
2002
QN+T; QN+D; QN+CL
2002
CQ+PQ(14d)
2002
0.5 mg/kg (14 d)
P.f + all species (Combo).
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
40
32
24
16
8
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
151
REPUBLIC OF KOREA
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
Number of active foci
Number of people living within active foci
Number of people living in malaria free areas
Total
2014
27
6900000
43200000
50100000
14
86
0
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2001
ITNs/LLINs distributed to all age groups
Yes
2001
IRS
IRS is recommended
DDT is authorized for IRS
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
Malaria diagnosis is free of charge in the public sector
Yes
2001
Treatment ACT is free for all ages in public sector
Sale of oral artemisinin-based monotherapies
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
Yes 2001
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
2011
Surveillance ACD for case investigation (reactive)
No
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
Contribution (US$m)
III. Financing
5
4
3
2
1
0
Population (%)
IV. Coverage
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102014
USAID/PMI
WHO/UNICEF
Others
Cases tested
Management and other costs
Human Resources & technical Assistance
Monitoring and evaluation
Antimalarial medicines
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
ITNs
Cases tracked
(%)
Cases (%)
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
100
80
60
40
20
0
World Bank
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
Cases investigated
Malaria
test positivity
and ABER
Antimalarials
distributedrate
vs reported
cases
Cases
No data reported for 2014
5000
4000
3000
2000
1000
0
Reporting completeness
Foci investigated
Cases investigated points
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Total cases
Indigenous cases (P. falciparum)
Impact: On track for >75% decrease in incidence 20002015
Foci investigated
152
Adopted
CQ
CQ+PQ(14d)
Sources of financing
Global Fund
Medicine
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
100
80
60
40
20
0
Imported cases
Indigenous cases (P. vivax)
RWANDA
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
11300000
0
0
11300000
100
0
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2004
ITNs/LLINs distributed to all age groups
Yes
2009
IRS
IRS is recommended
Yes
2009
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2009
Malaria diagnosis is free of charge in the public sector
No
Sale of oral artemisinin-based monotherapies
Never allowed 0
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
No
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
USAID/PMI
WHO/UNICEF
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Tests (%)
Test positivity
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
200 000
160 000
120 000
80 000
40 000
0
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
5000
4000
3000
2000
1000
0
Deaths
Population (%)
(%)
World Bank
Cases (%)
Global Fund
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Cases per 1000
Year
20102015
150
120
90
60
30
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20062009
0
1.3
4.5
28 days
3
P.falciparum
Government
Adopted
AL
2005
AL
2005
QN 2005
AS; QN
2012
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Admissions
50
40
30
20
10
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
153
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
186000
0
0
186000
100
0
0
[1200025000]
<100
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2005
ITNs/LLINs distributed to all age groups
Yes
2008
IRS
IRS is recommended
Yes
2003
DDT is authorized for IRS
No
Directly observed treatment with primaquine is undertaken
Yes
2013
System for monitoring of adverse reactions to antimalarials exists
Yes
2004
Surveillance ACD for case investigation (reactive)
Yes
2008
ACD of febrile cases at community level (pro-active)
Yes
2013
Mass screening is undertaken
Yes
2014
Uncomplicated P.falciparum cases routinely admitted
No
(%)
World Bank
USAID/PMI
WHO/UNICEF
Test positivity
100
80
60
40
20
0
100
80
60
40
20
0
12 000
9600
7200
4800
2400
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Cases (%)
V. Impact
400
320
240
160
80
0
Year
20142015
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
154
(p.vivax)
WORLD MALARIACases
REPORT
2015
250
200
150
100
50
0
Deaths
Global Fund
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Tests (%)
Population (%)
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Adopted
AS+AQ
2004
AS+AQ
2004
AL 2004
QN
2004
Sources of financing
IV. Coverage
Medicine
Admissions
5
4
3
2
1
0
ABER (%)
Contribution (US$m)
III. Financing
SAUDI ARABIA
Eastern
Mediterranean Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
2014
20
41400
30800000
30841400
0
100
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
Number of active foci
Number of people living within active foci
Number of people living in malaria free areas
Total
Insufficient data
Insufficient data
0
PP
Population
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
1980
ITNs/LLINs distributed to all age groups
Yes
1980
IRS
IRS is recommended
Yes
1963
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
Malaria diagnosis is free of charge in the public sector
Yes
1963
Treatment ACT is free for all ages in public sector
Yes
1963
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes 1985
Primaquine is used for radical treatment of P.vivax
Yes
G6PD test is a requirement before treatment with primaquine
Yes
1985
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
1990
Surveillance ACD for case investigation (reactive)
Yes
1980
ACD of febrile cases at community level (pro-active)
Yes
1980
Mass screening is undertaken
Yes
Foci and case investigation undertaken
Yes
1990
Case reporting from private sector is mandatory
Yes
Global Fund
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases tested
Cases (%)
Population (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Cases tracked
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
(%)
Cases (%)
Year
20102014
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
0.5
0.4
0.3
0.2
0.1
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Government
100
80
60
40
20
0
Adopted
AS+SP+PQ
2012
AL 2007
AS; AM; QN
2007
CQ+PQ(14d)
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
Cases investigated
Malaria
test positivity
and ABER
Antimalarials
distributedrate
vs reported
cases
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Foci investigated
Cases
30
24
18
12
6
0
ABER (%)
Contribution (US$m)
III. Financing
8000
6400
4800
3200
1600
0
Reporting completeness
Foci investigated
Cases investigated points
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Total cases
Indigenous cases (P. falciparum)
Imported cases
Indigenous cases (P. vivax)
Imported WORLD
cases points MALARIA REPORT 2015
Imported cases
Indigenous (P.vivax) points
155
SENEGAL
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
14100000
600000
0
14700000
96
4
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
1998
ITNs/LLINs distributed to all age groups
Yes
1998
IRS
IRS is recommended
Yes
2005
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
Yes
2003
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2007
Malaria diagnosis is free of charge in the public sector
Yes
2007
Treatment ACT is free for all ages in public sector
Yes
2010
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
2007
Surveillance ACD for case investigation (reactive)
Yes
2012
ACD of febrile cases at community level (pro-active)
Yes
2012
Mass screening is undertaken
No
USAID/PMI
WHO/UNICEF
Test positivity
100
80
60
40
20
0
250
200
150
100
50
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
30
24
18
12
6
0
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Cases (%)
World Bank
20
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
15
10
5
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
156
(p.vivax)
WORLD MALARIACases
REPORT
2015
Deaths
(%)
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102014
Tests (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20042014
0
0.9
3.9
28 days
16
P.falciparum
AS+AQ
20042014
0
0.25
1.7
28 days
12
P.falciparum
Sources of financing
Global Fund
Adopted
AS+AQ
2005
AL; AS+AQ
2005
AS; QN
2005
P.f only.
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
40
32
24
16
8
0
ABER (%)
Contribution (US$m)
III. Financing
SIERRA LEONE
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
6320000
0
0
6320000
100
0
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2002
ITNs/LLINs distributed to all age groups
Yes
2010
IRS
IRS is recommended
Yes
2010
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
Yes
2005
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2010
Malaria diagnosis is free of charge in the public sector
Yes
2010
Treatment ACT is free for all ages in public sector
Yes
2010
Sale of oral artemisinin-based monotherapies
Is banned 2004
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
2005
Surveillance ACD for case investigation (reactive)
No
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
(%)
100
80
60
40
20
0
World Bank
USAID/PMI
WHO/UNICEF
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
1500
1200
900
600
300
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
300
240
180
120
60
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
150
120
90
60
30
0
Deaths
Global Fund
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
2010
Tests (%)
Population (%)
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20112011
0
0
0
28 days
2
P.falciparum
AS+AQ
20112011
0
0
0
28 days
2
P.falciparum
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Adopted
AS+AQ
2004
AL; AS+AQ
2004
QN 2004
AS; AM; QN
2004
P.f only.
Sources of financing
IV. Coverage
Medicine
Admissions
1000
800
600
400
200
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
157
SOLOMON ISLANDS
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Insufficient data
Insufficient data
0
PP
Population
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
2014
566000
0
5720
572000
99
0
1
[3500049000]
<50
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2009
ITNs/LLINs distributed to all age groups
Yes
1996
IRS
IRS is recommended
Yes
DDT is authorized for IRS
No
1969
Larval control Use of larval control recommended
Yes
2014
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
1968
Malaria diagnosis is free of charge in the public sector
Yes
2007
Treatment ACT is free for all ages in public sector
Yes
2008
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
Yes 2009
G6PD test is a requirement before treatment with primaquine
Yes
2009
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
No
World Bank
(%)
USAID/PMI
WHO/UNICEF
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
2000
1600
1200
800
400
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
250
200
150
100
50
0
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
158
(p.vivax)
WORLD MALARIACases
REPORT
2015
80
64
48
32
16
0
Deaths
Global Fund
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
2013
Tests (%)
Population (%)
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20082013
0
0
6.3
28 days
3
P.falciparum
AL
20082013
4
5.1
31.6
28 days
3
P.vivax
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Adopted
AL
2009
AL
2009
QN 2009
AL; AS
2009
AL+PQ(14d)
2009
0.25 mg/kg (14 d)
P.f + P.v specific (Combo).
Sources of financing
IV. Coverage
Medicine
Admissions
10
8
6
4
2
0
ABER (%)
Contribution (US$m)
III. Financing
SOMALIA
Eastern
Mediterranean Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
5340000
5160000
0
10500000
51
49
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2005
ITNs/LLINs distributed to all age groups
Yes
2005
IRS
IRS is recommended
Yes
2004
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2006
Malaria diagnosis is free of charge in the public sector
Yes
2006
Treatment ACT is free for all ages in public sector
Yes
2006
Sale of oral artemisinin-based monotherapies
are allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
No
Mass screening is undertaken
No
USAID/PMI
WHO/UNICEF
Others
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
10000
8000
6000
4000
2000
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
80
64
48
32
16
0
Deaths
(%)
World Bank
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
5
4
3
2
1
0
Year
20102013
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Tests (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AS+SP
20052011
0
1
22.2
28 days
5
P.falciparum
AL
20132013
0
0.5
1
28 days
2
P.falciparum
Sources of financing
Global Fund
Adopted
AS+SP
2011
AS+SP
2011
AL 2011
AS; QN
2006
2006
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
20
16
12
8
4
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
159
SOUTH AFRICA
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
2160000
3240000
48600000
54000000
4
6
90
[1400024000]
[120120]
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
No
ITNs/LLINs distributed to all age groups
No
IRS
IRS is recommended
Yes
1930
DDT is authorized for IRS
Yes
IPT
IPT used to prevent malaria during pregnancy
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
Malaria diagnosis is free of charge in the public sector
Yes
1997
Treatment ACT is free for all ages in public sector
Yes
2001
Sale of oral artemisinin-based monotherapies
Never allowed 2001
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
Yes
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
Yes
Mass screening is undertaken
No
WHO/UNICEF
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
6000
4800
3600
2400
1200
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
10
8
6
4
2
0
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
160
(p.vivax)
WORLD MALARIACases
REPORT
2015
500
400
300
200
100
0
Deaths
(%)
USAID/PMI
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
2001
2001
2001
P.f only.
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102014
Tests (%)
Population (%)
IV. Coverage
World Bank
Adopted
AL; QN+CL; QN+D
AS; QN
QN
AL+PQ; CQ+PQ
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Sources of financing
Global Fund
Medicine
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
100
80
60
40
20
0
Admissions
50
40
30
20
10
0
ABER (%)
Contribution (US$m)
III. Financing
SOUTH SUDAN
Insufficient data
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
2014
11900000
0
0
11900000
100
0
0
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
PP
Population
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2008
ITNs/LLINs distributed to all age groups
Yes
2008
IRS
IRS is recommended
Yes
2006
DDT is authorized for IRS
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
No
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Tests (%)
Population (%)
(%)
Year
20102014
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
15
12
9
6
3
0
Deaths
Global Fund
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Government
100
80
60
40
20
0
Adopted
AS+AQ
2006
AS+AQ
2006
AL 2006
AM; AS; QN
2004
AS+AQ+PQ
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Admissions
10 000
8000
6000
4000
2000
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
161
SRI LANKA
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
Number of active foci
Number of people living within active foci
Number of people living in malaria free areas
Total
2014
0
20600000
20600000
0
100
0
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
1992
ITNs/LLINs distributed to all age groups
Yes
2004
IRS
IRS is recommended
Yes
1945
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
Malaria diagnosis is free of charge in the public sector
Yes
1911
Treatment ACT is free for all ages in public sector
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes
Primaquine is used for radical treatment of P.vivax
Yes
G6PD test is a requirement before treatment with primaquine
Yes
Directly observed treatment with primaquine is undertaken
Yes
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
Yes
Mass screening is undertaken
Yes
World Bank
100
80
60
40
20
0
Cases tracked
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
Cases investigated
Malaria
test positivity
and ABER
Antimalarials
distributedrate
vs reported
cases
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Cases tested
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
WHO/UNICEF
(%)
Cases (%)
15
12
9
6
3
0
USAID/PMI
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102013
Cases (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Sources of financing
Global Fund
250 000
200 000
150 000
100 000
50 000
0
Reporting completeness
Foci investigated
Cases investigated points
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Total cases
Indigenous cases (P. falciparum)
Aberpositivity
(microscopy
RDT)
RDT
rate&points
positivity rate
WORLD MALARIARDT
REPORT
2015
Slide positivity points
Slide positivity rate
Foci investigated
162
Adopted
AL+PQ
2008
AS
2014
CQ+PQ(14d)
2008
0.25 mg/kg (14 d)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Cases
15
12
9
6
3
0
ABER (%)
Contribution (US$m)
III. Financing
Imported cases
Indigenous cases (P. vivax)
SUDAN
Eastern
Mediterranean Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
34200000
5200000
0
39400000
87
13
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2005
ITNs/LLINs distributed to all age groups
Yes
2010
IRS
IRS is recommended
Yes
1956
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2009
Malaria diagnosis is free of charge in the public sector
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
No
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
USAID/PMI
WHO/UNICEF
Test positivity
Source: DHS2012; Other Nat.
100
80
60
40
20
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Max
4.5
18.1
0
200 000
160 000
120 000
80 000
40 000
0
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2500
2000
1500
1000
500
0
Deaths
World Bank
Median
0
2
0
Tests (%)
(%)
35
28
21
14
7
0
Year
20102014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Min
0
0
0
100
80
60
40
20
0
Year
20052015
20052015
20112011
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Cases (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
AL
AS+SP
AL
Sources of financing
Global Fund
Adopted
AS+SP
2005
AS+SP
2005
AL 2005
AM; QN
2011
AL+PQ(14d)
2011
0.25 mg/kg (14 d)
P.f + P.v specific (Combo).
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
80
64
48
32
16
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
163
SURINAME
OTHERS
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
PP
Insufficient data
0
Insufficient data
00.1
Very low PP
0.11.0
020
1.010
2040
>85
4060
6080
no cases
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
84500
0
454000
538000
16
0
84
[7802000]
<10
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2006
ITNs/LLINs distributed to all age groups
Yes
2006
IRS
IRS is recommended
No
2006
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
1955
Malaria diagnosis is free of charge in the public sector
Yes
1955
Treatment ACT is free for all ages in public sector
Yes
2004
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes 2004
Primaquine is used for radical treatment of P.vivax
Yes 2004
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
No
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases (%)
Population (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Tests (%)
(%)
400
320
240
160
80
0
164
(p.vivax)
WORLD MALARIACases
REPORT
2015
25
20
15
10
5
0
Deaths
Global Fund
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
2013
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
250
200
150
100
50
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20052011
0
2.35
4.7
28 days
2
P.falciparum
Government
100
80
60
40
20
0
Adopted
AL+PQ
2004
AS+MQ 2004
AS
CQ+PQ(14d)
2004
0.25 mg/kg (14 d)
P.f + all species (Combo).
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Admissions
5
4
3
2
1
0
ABER (%)
Contribution (US$m)
III. Financing
SWAZILAND
Insufficient data
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
PP
Population
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
2014
77
356000
914000
1270000
0
28
72
[450890]
<10
Adopted
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2002
ITNs/LLINs distributed to all age groups
Yes
2002
IRS
IRS is recommended
Yes
1946
DDT is authorized for IRS
Yes
IPT
IPT used to prevent malaria during pregnancy
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2010
Malaria diagnosis is free of charge in the public sector
Yes
2009
Treatment ACT is free for all ages in public sector
Yes
2010
Sale of oral artemisinin-based monotherapies
are allowed 2010
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes 2014
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
Yes
2014
System for monitoring of adverse reactions to antimalarials exists
Yes
2010
Surveillance ACD for case investigation (reactive)
Yes
2010
ACD of febrile cases at community level (pro-active)
Yes
2010
Mass screening is undertaken
Yes
2010
Uncomplicated P.falciparum cases routinely admitted
USAID/PMI
WHO/UNICEF
Cases (%)
Test positivity
100
80
60
40
20
0
100
80
60
40
20
0
2000
1600
1200
800
400
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
Tests (%)
Population (%)
(%)
World Bank
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
5
4
3
2
1
0
Year
2011
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
80
64
48
32
16
0
Deaths
Global Fund
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
AL
2009
QN 2009
AS
Admissions
5
4
3
2
1
0
ABER (%)
Contribution (US$m)
III. Financing
Medicine
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
165
TAJIKISTAN
EURO / PAHO
Confirmed cases
API 1000 population
per
European Region
OTHERS
PF-RATIO
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
no cases
Insufficient data
0
Insufficient data
0
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
1050
4060
>85
4060
50100
6080
6080
>100
80100
PP
no cases
80100
I. Epidemiological profile
Population
Number of active foci
Number of people living within active foci
Number of people living in malaria free areas
Total
2014
130
613000
7680000
8293000
7
93
0
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2006
ITNs/LLINs distributed to all age groups
Yes
2006
IRS
IRS is recommended
Yes
1997
DDT is authorized for IRS
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
Malaria diagnosis is free of charge in the public sector
Yes
1997
Treatment ACT is free for all ages in public sector
Yes
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes 2004
Primaquine is used for radical treatment of P.vivax
Yes 1997
G6PD test is a requirement before treatment with primaquine
Yes
2014
Directly observed treatment with primaquine is undertaken
Yes
2004
System for monitoring of adverse reactions to antimalarials exists
Yes
1997
Surveillance ACD for case investigation (reactive)
Yes
2004
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
Foci and case investigation undertaken
Yes
2009
Case reporting from private sector is mandatory
Yes
2000
World Bank
100
80
60
40
20
0
Cases tracked
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
Cases investigated
Malaria
test positivity
and ABER
Antimalarials
distributedrate
vs reported
cases
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Cases tested
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
WHO/UNICEF
(%)
Cases (%)
10
8
6
4
2
0
USAID/PMI
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20112012
Cases (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Sources of financing
Global Fund
20 000
16 000
12 000
8000
4000
0
Reporting completeness
Foci investigated
Cases investigated points
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Total cases
Indigenous cases (P. falciparum)
Aberpositivity
(microscopy
RDT)
RDT
rate&points
positivity rate
WORLD MALARIARDT
REPORT
2015
Slide positivity points
Slide positivity rate
Foci investigated
166
Adopted
AL
2008
QN 2004
QN
2004
CQ+PQ(14d)
2004
0.25 mg/kg (14 d)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Cases
5
4
3
2
1
0
ABER (%)
Contribution (US$m)
III. Financing
Imported cases
Indigenous cases (P. vivax)
THAILAND
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
5420000
28400000
33900000
67700000
8
42
50
[37000390000]
<50
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
1992
ITNs/LLINs distributed to all age groups
Yes
1992
IRS
IRS is recommended
Yes
1953
DDT is authorized for IRS
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
1991
Malaria diagnosis is free of charge in the public sector
Yes
1953
Treatment ACT is free for all ages in public sector
Yes
1995
Sale of oral artemisinin-based monotherapies
Never allowed 1995
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes 1995
Primaquine is used for radical treatment of P.vivax
Yes 1965
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
Yes
2008
System for monitoring of adverse reactions to antimalarials exists
No
USAID/PMI
WHO/UNICEF
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
20 000
16 000
12 000
8000
4000
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
5
4
3
2
1
0
Others
Tests (%)
Population (%)
(%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102014
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
800
640
480
320
160
0
Deaths
World Bank
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Sources of financing
Global Fund
Adopted
AS+MQ
2007
QN+D 2007
QN+D
2007
CQ+PQ(14d)
2007
0.25 mg/kg (14 d)
P.f + all species (Combo).
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
30
24
18
12
6
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
167
TIMOR-LESTE
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Insufficient data
Insufficient data
0
PP
Population
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
2014
391000
650000
119000
1160000
34
56
10
[37000120000]
[10270]
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2005
ITNs/LLINs distributed to all age groups
Yes
2010
IRS
IRS is recommended
Yes
2006
DDT is authorized for IRS
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2007
Malaria diagnosis is free of charge in the public sector
Yes
2000
Treatment ACT is free for all ages in public sector
Yes
2007
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
Yes 2006
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
No
(%)
USAID/PMI
WHO/UNICEF
Cases (%)
Test positivity
100
80
60
40
20
0
2000
1600
1200
800
400
0
100
80
60
40
20
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Tests (%)
Population (%)
60
48
36
24
12
0
Year
20102014
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
168
(p.vivax)
WORLD MALARIACases
REPORT
2015
80
64
48
32
16
0
Deaths
World Bank
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
CQ
20112013 17.5
17.5
17.5
28 days
1
P.vivax
AL
20122013
0
0
0
28 days
1
P.falciparum
Sources of financing
Global Fund
Adopted
AL
QN+D
AM; AS; QN
CQ+PQ(14d)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
10
8
6
4
2
0
ABER (%)
Contribution (US$m)
III. Financing
TOGO
Insufficient data
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
2014
7120000
0
0
7120000
100
0
0
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
PP
Population
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2004
ITNs/LLINs distributed to all age groups
Yes
2011
IRS
IRS is recommended
No
DDT is authorized for IRS
IPT
IPT used to prevent malaria during pregnancy
Yes
2003
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2010
Malaria diagnosis is free of charge in the public sector
Yes
2012
Treatment ACT is free for all ages in public sector
Yes
2013
Sale of oral artemisinin-based monotherapies
Is banned 2011
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
Directly observed treatment with primaquine is undertaken
System for monitoring of adverse reactions to antimalarials exists
Yes
2009
Surveillance ACD for case investigation (reactive)
No
ACD of febrile cases at community level (pro-active)
Yes
2013
Mass screening is undertaken
No
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
1000
800
600
400
200
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Tests (%)
Population (%)
(%)
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
50
40
30
20
10
0
Deaths
Global Fund
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20112013
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
200
160
120
80
40
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20052013
0
1.4
4.4
28 days
11
P.falciparum
AS+AQ
20052013
0
0
6
28 days
11
P.falciparum
Government
100
80
60
40
20
0
Adopted
AL; AS+AQ
AL; AS+AQ
AS; AM; QN
P.f only.
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Admissions
20
16
12
8
4
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
169
TURKEY
EURO / PAHO
Confirmed cases
API 1000 population
per
European Region
OTHERS
PF-RATIO
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
no cases
Insufficient data
0
Insufficient data
0
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
1050
4060
>85
4060
50100
6080
6080
>100
80100
PP
no cases
80100
I. Epidemiological profile
Population
Number of active foci
Number of people living within active foci
Number of people living in malaria free areas
Total
2014
0
77500000
77500000
0
100
1
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
No
ITNs/LLINs distributed to all age groups
No
IRS
IRS is recommended
Yes
1926
DDT is authorized for IRS
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
Malaria diagnosis is free of charge in the public sector
Yes
1926
Treatment ACT is free for all ages in public sector
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
Yes 1926
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
Yes
2007
System for monitoring of adverse reactions to antimalarials exists
No
Foci and case investigation undertaken
Yes
1926
Case reporting from private sector is mandatory
Yes
1930
Global Fund
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases tested
Cases (%)
Population (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Cases tracked
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
(%)
Cases (%)
Year
20102014
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
1.0
0.8
0.6
0.4
0.2
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Government
100
80
60
40
20
0
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
Cases investigated
Malaria
test positivity
and ABER
Antimalarials
distributedrate
vs reported
cases
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
12 000
9600
7200
4800
2400
0
Reporting completeness
Foci investigated
Cases investigated points
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Total cases
Indigenous cases (P. falciparum)
Aberpositivity
(microscopy
RDT)
RDT
rate&points
positivity rate
WORLD MALARIARDT
REPORT
2015
Slide positivity points
Slide positivity rate
Foci investigated
170
Adopted
CQ+PQ(14d)
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Cases
50
40
30
20
10
0
ABER (%)
Contribution (US$m)
III. Financing
Imported cases
Indigenous cases (P. vivax)
UGANDA
Insufficient data
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
2014
37800000
0
0
37800000
100
0
0
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
PP
Population
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2006
ITNs/LLINs distributed to all age groups
Yes
2013
IRS
IRS is recommended
Yes
2005
DDT is authorized for IRS
Yes
2008
Larval control Use of larval control recommended
Yes
2011
IPT
IPT used to prevent malaria during pregnancy
Yes
1998
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2012
Malaria diagnosis is free of charge in the public sector
Yes
2001
Treatment ACT is free for all ages in public sector
Yes
2005
Sale of oral artemisinin-based monotherapies
Is banned 2009
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
USAID/PMI
WHO/UNICEF
Others
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
2500
2000
1500
1000
500
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
30
24
18
12
6
0
Deaths
(%)
100
80
60
40
20
0
World Bank
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20112014
Tests (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Sources of financing
Global Fund
Adopted
AL
2004
AL
2004
QN 2004
AS, QN
2004
P.f only.
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
200
160
120
80
40
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
171
African Region
OTHERS
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
50400000
0
0
50400000
100
0
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2014
ITNs/LLINs distributed to all age groups
No
IRS
IRS is recommended
Yes
2006
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
Yes
2001
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2009
Malaria diagnosis is free of charge in the public sector
Yes
Sale of oral artemisinin-based monotherapies
Is banned 2006
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
USAID/PMI
WHO/UNICEF
Test positivity
100
80
60
40
20
0
2000
1600
1200
800
400
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
80
64
48
32
16
0
Others
Cases (%)
World Bank
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
172
(p.vivax)
WORLD MALARIACases
REPORT
2015
60
48
36
24
12
0
Deaths
(%)
100
80
60
40
20
0
Year
20102015
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Tests (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
Sources of financing
Global Fund
Adopted
AL
2004
AL
2004
QN 2004
AS, AM; QN
2004
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
250
200
150
100
50
0
ABER (%)
Contribution (US$m)
III. Financing
African Region
OTHERS
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
901000
569000
0
1470000
61
39
0
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2005
ITNs/LLINs distributed to all age groups
Yes
2008
IRS
IRS is recommended
Yes
2006
DDT is authorized for IRS
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
2003
Surveillance ACD for case investigation (reactive)
Yes
2008
ACD of febrile cases at community level (pro-active)
Yes
2011
Mass screening is undertaken
Yes
2011
Uncomplicated P.falciparum cases routinely admitted
No
USAID/PMI
WHO/UNICEF
Others
Cases (%)
100
80
60
40
20
0
Test positivity
100
80
60
40
20
0
1200
960
720
480
240
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
40
32
24
16
8
0
Deaths
(%)
World Bank
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
20
16
12
8
4
0
Year
20102015
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Tests (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20062007
0
0
0
28 days
2
P.falciparum
Sources of financing
Global Fund
Adopted
AS+AQ
2004
AS+AQ
2004
QN 2004
AS; QN
2004
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
10
8
6
4
2
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
173
VANUATU
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
225000
33900
0
259000
87
13
0
[580010000]
<10
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2008
ITNs/LLINs distributed to all age groups
Yes
1990
IRS
IRS is recommended
Yes
2008
DDT is authorized for IRS
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2009
Malaria diagnosis is free of charge in the public sector
No
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
1200
960
720
480
240
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Tests (%)
Population (%)
(%)
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
174
(p.vivax)
WORLD MALARIACases
REPORT
2015
15
12
9
6
3
0
Deaths
Global Fund
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
2013
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
80
64
48
32
16
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20112012 2.8
2.8
2.8
28 days
1
P.vivax
Government
100
80
60
40
20
0
Adopted
AL
2007
QN 2007
AS
2014
AL+PQ(14d)
2007
0.25 mg/kg (14 d)
P.f + P.v specific (Combo).
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Admissions
10
8
6
4
2
0
ABER (%)
Contribution (US$m)
III. Financing
OTHERS
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
PP
Insufficient data
0
Insufficient data
00.1
Very low PP
0.11.0
020
1.010
2040
>85
4060
6080
no cases
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
798000
4970000
24900000
30700000
3
16
81
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2005
ITNs/LLINs distributed to all age groups
Yes
2005
IRS
IRS is recommended
Yes
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
1936
Malaria diagnosis is free of charge in the public sector
Yes
1936
Treatment ACT is free for all ages in public sector
Yes
2004
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes
Primaquine is used for radical treatment of P.vivax
Yes
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
Yes
System for monitoring of adverse reactions to antimalarials exists
No
ACD of febrile cases at community level (pro-active)
Yes
Mass screening is undertaken
Yes
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases (%)
Population (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
Tests (%)
(%)
5
4
3
2
1
0
40
32
24
16
8
0
Deaths
Global Fund
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
20
16
12
8
4
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AS+MQ
20052006
0
0
0
28 days
2
P.falciparum
Government
100
80
60
40
20
0
Adopted
AS+MQ+PQ
2004
2004
AM; QN
2004
CQ+PQ(14d)
2004
0.25 mg/kg (14 d)
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Admissions
15
12
9
6
3
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
175
VIET NAM
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
Insufficient data
0
Insufficient data
Insufficient data
0
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PP
PF-RATIO
PP
no cases
80100
80100
I. Epidemiological profile
Population
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
2014
6280000
61800000
24300000
92400000
7
67
26
[2000027000]
<50
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
1992
ITNs/LLINs distributed to all age groups
Yes
1992
IRS
IRS is recommended
Yes
1958
DDT is authorized for IRS
No
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Yes
1958
Malaria diagnosis is free of charge in the public sector
Yes
1958
Treatment ACT is free for all ages in public sector
Yes
2003
Sale of oral artemisinin-based monotherapies
Never allowed 2013
Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes 2003
Primaquine is used for radical treatment of P.vivax
Yes 1960
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
1980
Surveillance ACD for case investigation (reactive)
Yes
1958
ACD of febrile cases at community level (pro-active)
Yes
1958
Mass screening is undertaken
No
(%)
USAID/PMI
WHO/UNICEF
Cases (%)
Test positivity
100
80
60
40
20
0
80 000
64 000
48 000
32 000
16 000
0
100
80
60
40
20
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Tests (%)
Population (%)
1.5
1.2
0.9
0.6
0.3
0
Year
20102013
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
176
(p.vivax)
WORLD MALARIACases
REPORT
2015
150
120
90
60
30
0
Deaths
World Bank
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
DHA-PPQ
20062010
0
0
2.1
28 days
13
P.falciparum
DHA-PPQ
20062014
0
0
3.4
42 days
16
P.falciparum
Sources of financing
Global Fund
Adopted
DHA-PPQ
DHA-PPQ
QN+CL; QN+D
2013
AS; QN
2013
CQ+PQ(14d)
2013
0.25 mg/kg (14 d), 15mg (14 d)
P.f + P.v specific (Combo).
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
20
16
12
8
4
0
ABER (%)
Contribution (US$m)
III. Financing
YEMEN
Eastern
Mediterranean Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Insufficient data
Insufficient data
0
PP
Population
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
2014
6570000
13800000
5790000
26200000
25
53
22
[290000710000]
[352500]
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2002
ITNs/LLINs distributed to all age groups
Yes
2009
IRS
IRS is recommended
Yes
2001
DDT is authorized for IRS
No
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2001
Malaria diagnosis is free of charge in the public sector
Yes
2002
Treatment ACT is free for all ages in public sector
Yes
2009
Sale of oral artemisinin-based monotherapies
Is banned
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
Yes 2001
G6PD test is a requirement before treatment with primaquine
Yes
2009
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
No
Mass screening is undertaken
Yes
2001
Uncomplicated P.falciparum cases routinely admitted
No
World Bank
(%)
USAID/PMI
WHO/UNICEF
Cases (%)
Test positivity
100
80
60
40
20
0
3500
2800
2100
1400
700
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
150
120
90
60
30
0
Year
20102014
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Deaths
Global Fund
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Tests (%)
Population (%)
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20072013
0
0
1.1
28 days
4
P.falciparum
AS+SP 20072013
0 0 3 28 days 7
P.falciparum
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Adopted
AS+SP
2009
AS+SP
2009
AL 2009
AM; QN
2009
CQ+PQ(14d)
Sources of financing
IV. Coverage
Medicine
Admissions
15
12
9
6
3
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
177
ZAMBIA
Insufficient data
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
2014
15700000
0
0
15700000
100
0
0
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
PP
Population
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2005
ITNs/LLINs distributed to all age groups
Yes
1998
IRS
IRS is recommended
Yes
DDT is authorized for IRS
Yes
IPT
IPT used to prevent malaria during pregnancy
Yes
Diagnosis
Patients of all ages should receive diagnostic test
Yes
Malaria diagnosis is free of charge in the public sector
Yes
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
ACD of febrile cases at community level (pro-active)
No
Mass screening is undertaken
No
USAID/PMI
WHO/UNICEF
100
80
60
40
20
0
Test positivity
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
300
240
180
120
60
0
Others
Tests (%)
(%)
World Bank
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
350 000
280 000
210 000
140 000
70 000
0
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
178
(p.vivax)
WORLD MALARIACases
REPORT
2015
10 000
8000
6000
4000
2000
0
Deaths
100
80
60
40
20
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20102014
Cases (%)
Population (%)
IV. Coverage
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20052012
0
0
6.7
28 days
12
P.falciparum
Sources of financing
Global Fund
Adopted
AL
2002
AL
2002
QN 2002
AS; AM; QN
2002
P.f only.
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Government
Medicine
Admissions
80
64
48
32
16
0
ABER (%)
Contribution (US$m)
III. Financing
ZIMBABWE
Insufficient data
Insufficient data
0
Insufficient data
no cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
1.010
2040
1.010
2040
>85
4060
>85
4060
6080
6080
PF-RATIO
PP
no cases
80100
Based on 2013 reported data
80100
I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total
Proportion of cases
PF-RATIO
due
to P.falciparum
PR
Insufficient data
0
PP
Population
African Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
2014
4350000
7620000
3230000
15200000
29
50
21
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
2009
ITNs/LLINs distributed to all age groups
Yes
2009
IRS
IRS is recommended
Yes
1947
DDT is authorized for IRS
Yes
2004
Larval control Use of larval control recommended
Yes
IPT
IPT used to prevent malaria during pregnancy
Yes
2004
Diagnosis
Patients of all ages should receive diagnostic test
Yes
2009
Malaria diagnosis is free of charge in the public sector
Yes
2009
Treatment ACT is free for all ages in public sector
Yes
2009
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P.falciparum No
Primaquine is used for radical treatment of P.vivax
No
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
Mass screening is undertaken
No
World Bank
USAID/PMI
WHO/UNICEF
Others
Cases (%)
100
80
60
40
20
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
50 000
40 000
30 000
20 000
10 000
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Test positivity
Tests (%)
Population (%)
(%)
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2000
1600
1200
800
400
0
Deaths
Global Fund
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
Cases per 1000
50
40
30
20
10
0
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20112015
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
100
80
60
40
20
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
AL
20062014
0
2.15
14.3
28 days
34
P.falciparum
Government
Adopted
AL
2004
AL
2004
QN 2004
QN
2004
P.f only.
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
Admissions
35
28
21
14
7
0
ABER (%)
Contribution (US$m)
III. Financing
Cases (p.vivax)
Admissions (P.vivax)
WORLD MALARIADeaths
REPORT
2015
(all species)
points
Deaths (all species)
179
Annexes
Annex 1
182
Annex 2A
Annex 2B
202
Annex 3
204
Annex 4
210
Annex 5
216
Annex 6A
218
Annex 6B
Annex 6C
234
Annex 6D
242
183
184
Elimination
Prevention of reintroduction
(1) R
ecently endemic country with
zero local transmission for at least
3 years; or
(2) c ountry on the register or
supplementary list that has ongoing
local transmissiona
Case management
All cases detected in the private sector are microscopically
confirmed
All cases detected in the public sector are microscopically
confirmed
Nationwide microscopy quality assurance system covers public
and private sector
Radical treatment with primaquine for P.vivax
Treatment with ACT plus single-dose primaquine for
P.falciparum
Yes
Yes
Yes
Yes
Initiated
Yes
Yes
Yes
Yes
Vigilance by the general health
services
Surveillance
Malaria is a notifiable disease nationwide
(<2448hours)
Centralized register on cases, foci and vectors
Malaria elimination database
Active case detection in groups at high risk or with poor access
to services (proactive case detection)
Case and foci investigation and classification (including
reactive case detection and entomological investigation)
Yes
Yes
Initiated
Initiated
Yes
Yes
Initiated
Yes
Yes
Certification process (optional)
In residual and cleared-up foci,
among high-risk population groups
Initiated
Yes
Yes
ABER: annual blood examination rate; ACD: active case detection; API: annual parasite index; PCD: passive case detection.
a
Ongoing local transmission = 2 consecutive years of local P.falciparum malaria transmission, or 3 consecutive years of local P.vivax malaria transmission, in the same locality or otherwise
epidemiologically linked.
b
The API has to be evaluated against the diagnostic activity in the risk area (measured as the ABER). Low values of ABER in a district raise the possibility that more cases would be found with improved
diagnostic efforts.
185
187
188
189
Section 5: Challenges
Figure5.1 Estimated proportion, and cumulative proportion,
of the global number of (a) malaria cases and (b) malaria
deaths in 2015 for countries accounting for the highest
share of the malaria disease burden
See the methods notes for Table 2.1 for the estimation of
malaria cases and deaths.
Figure5.2 Reduction in malaria incidence, 20002015
versus estimated number of cases in a country in 2000
See the methods notes for Table 2.1 and Table 2.2 for
the estimation of malaria cases and incidence rates.
190
Regional profiles
Figure A. Incidence was derived from reports of confirmed
malaria cases in 2014 (by microscopy or RDT) from ministries
of health to WHO, and from the number of people living at
risk for malaria in each geographical unit, as reported by
NMCPs. Values were corrected for reporting completeness
by dividing the proportion of health-facility reports received
in 2014 by the number expected. If subnational data on
population or malaria cases were lacking, an administrative
unit was labelled insufficient data on the map. In some
cases, the subnational data provided by the NMCP did not
correspond to a subnational administrative area known to
WHO, because of either modifications to administrative
boundaries, or the use of names not verifiable by WHO.
The maps for countries outside of the WHO Region of the
Americas and WHO European Region display a combination
of cases per 1000 per year, and parasite prevalence in areas
with >10 cases per 1000population per year. The parasite
prevalence used in regions with >10 cases per 1000 is the
sum of the rates for P.falciparum and P.vivax calculated at
each location (~1 km2). The parasite rate for P.falciparum
was from two sources, one global (34) and one for Africa(7),
with the African source taking precedence over the global
source. The parasite rate for P.vivax was taken from one
global source (35). Data on environmental suitability for
malaria transmission were used to identify areas that would
be free of malaria or have unstable malaria transmission.
WORLD MALARIA REPORT 2015
191
192
Country profiles
I. Epidemiological profile
Maps: The procedures used to create the map of confirmed
cases were the same as those used for Figure A for the
regional profiles; that is, for countries outside the WHO
Region of the Americas and the WHO European Region,
if an area has >10 cases per 1000, the parasite prevalence
is used instead. For countries in the WHO Region of the
Americas and WHO European Region, only the cases per
1000 data are used. For the map showing the proportion
of cases due to P.falciparum, the proportion is only shown
III. Financing
Sources of financing: The data shown are those reported
by NMCPs. The government contribution is usually the
declared government expenditure for the year. In cases
where government expenditure was not reported by the
programme, the government budget was used. External
contributions are those allocated to the programme by
external agencies; however, such contributions may or may
not be disbursed. Additional information about contributions
from specific donor agencies, as reported by these agencies,
is given in Annex 3. All countries were asked to convert their
local currencies to US$ for reporting on sources of financing.
Expenditure by intervention in 2014: The pie chart shows
the proportion of malaria funding from all sources that
was spent on ITNs, insecticides and spraying materials,
IRS, diagnosis, antimalarial medicines, monitoring and
evaluation, human resources, technical assistance and
management. There are differences in the completeness
of data between countries, and the activities for which
expenditures are reported do not necessarily include all
items of expenditure. For example, government expenditures
usually only include expenditures specific to malaria control,
and do not take into account costs related to health-facility
staff, infrastructure and so on.
193
IV. Coverage
V. Impact
195
References
1. United Nations. Millennium Development Goals
indicators. United Nations; 2008 (http://mdgs.un.org/
unsd/mdg/Host.aspx?Content=indicators/officiallist.
htm, accessed 10 November 2015).
2. World Health Organization. World malaria report.
Geneva: World Health Organization; 2012 (http://
www.who.int/malaria/publications/world_malaria_
report_2012/en/, accessed 15 October 2013).
3. M
EASURE DHS, Presidents Malaria Initiative,
Roll Back Malaria Partnership, United Nations,
World Health Organization. Household survey
indicators for malaria control. 2013 (http://www.
rollbackmalaria.org/files/files/resources/tool_
HouseholdSurveyIndicatorsForMalariaControl.pdf,
accessed 1 November 2015).
4. World Health Organization. World malaria report.
Geneva: World Health Organization; 2008 (http://www.
who.int/malaria/publications/atoz/9789241563697/
en/, accessed 15 October 2013).
5. C
ibulskis RE, Aregawi M, Williams R, Otten M, Dye C.
Worldwide incidence of malaria in 2009: estimates,
time trends, and a critique of methods. PLoS Med.
2011 Dec;8(12):e1001142.
6. K
im HJ, Fay MP, Feuer EJ, Midthune DN. Permutation
tests for joinpoint regression with applications to
cancer rates. Stat Med. 2000; 19: 335-51.
7. B
hatt S, et al. The effect of malaria control on
Plasmodium falciparum in Africa between 2000
and 2015. Nature 2015; 526: 207211.
8. L iu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE,
et al. Global, regional, and national causes of child
mortality in 2000-13, with projections to inform
post-2015 priorities: an updated systematic analysis.
Lancet. 2014;385(9966):43040.
9. Ross A, Maire N, Molineaux L, Smith T. An epidemiologic
model of severe morbidity and mortality caused
by Plasmodium falciparum. Am J Trop Med
Hyg. 2006;75(2):6373.
10. United Nations. Revision of world population prospects.
United Nations. (http://esa.un.org/unpd/wpp/,
accessed 1 August 2015).
11. Cibulskis RE, Bell D, Christophel EM, Hii J, Delacollette
C, Bakyaita N, et al. Estimating trends in the burden
of malaria at country level. Am J Trop Med Hyg.
2007;77(6 Suppl):1337.
196
197
198
Algeria
Angola
Benin
Botswana
Burkina Faso
Burundi
African
Togo
Swaziland
Cameroon
Central African
Republic
Chad
Comoros
Congo
Cte dIvoire
Democratic Republic
of the Congo
Equatorial Guinea
Eritrea
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Kenya
Liberia
Madagascar
Malawi
Mali
Mauritania
Mayotte, France
Mozambique
Namibia
Niger
Nigeria
Rwanda
Sao Tome and
Principe
Senegal
Sierra Leone
South Africa
South Sudan2
Cabo Verde
Country/area
WHO region
N
Y
Y
N
Y
Y
Y
Y
Y
Control
Control
Control
Control
Control
Y
Y
N
Y
Control
Control
Control
Control
Preelimination
Control
Y
Y
N
Y
Control
N
Y
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
N
N
Y
Y
Y
N
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Elimination
Control
Control
Control
Control
Control
N
N
N
Y
Y
N
ITNs/
LLINs are
distributed
to all age
groups
N
Y
Y
Y
Y
Y
ITNs/
LLINs are
distributed
for free
Y
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
N
Y
Y
Y
Y
Y
Y
ITNs/ LLINs
distributed
through
mass
campaigns
to all age
groups
Elimination
Control
Control
Control
Control
Control
Preelimination
Control
Programme
phase
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
Y
Y
IRS is
recommended
by malaria
control
programme
N
N
Y
N
N
N
N
N
Y
N
N
N
N
N
N
N
N
N
N
Y
Y
N
N
N
N
N
N
N
N
N
N
Y
N
N
DDT is
used for
IRS
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
NA
Y
Y
Y
Y
Y
ACT policy
adopted
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Patients
of all ages
should get
diagnostic
test
Y
Y
Y
Y
Y
Y
Y
N
Y
N
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
N
Y
Y
Y
Y
Y
Y
N
Malaria
diagnosis
is free of
charge in
the public
sector
Y
Y
Y
N
N
Y
Y
Y
N
Y
Y
N
N
Y
Y
N
Y
Y
Y
N
N
N
Y
N
N
N
Y
N
Y
N
N
Y
RDTs
used at
community
level
Y
Y
Y
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
N
N
N
N
N
N
N
N
N
N
N
N
Y
N
N
N
N
N
Y
N
N
N
N
N
N
N
Y
N
N
N
N
N
N
N
N
N
N
Y
N
N
N
N
N
N
N
N
N
Y
Y
Y
N
N
N
N
N
N
-
Y
Y
N
N
-
N
N
Y
N
N
N
N
N
N
N
N
N
N
N
Y
Y
N
N
N
N
N
N
N
-
N
Y
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
Y
N
N
N
Y
N
Y
N
N
N
N
N
N
-
Y
N
N
N
N
N
Y
Y
N
Y
N
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
Y
Y
Y
N
Y
N
N
N
N
N
N
N
Y
N
Y
N
N
N
N
N
Y
N
N
N
Y
N
N
Y
N
Y
-
N
N
N
N
Seasonal
malaria
chemoprevention
(SMC or
IPTc) is
used
Malaria in pregnancy
Primaquine
G6PD
Directly
IPTp used
PreSingle
is used for
test is
observed
to prevent
referral
dose of
radical
recomtreatment
malaria
treatment primaquine
is used as treatment
mended
with
during
with
gameof P. vivax
before
primaquine pregnancy
quinine or
tocidal
cases
treatment
is
artemether
medicine
with
undertaken
IM or
for
primaquine
artesunate
supposito- P.falciparum1
ries
Treatment
Country/area
Region of the
Americas
African
Y
Y
Y
Y
Y
Y
Elimination
Control
Elimination
Control
Control
Control
Elimination
Prevention
of reintroduction
Elimination
Elimination
Prevention
of reintroduction
Elimination
Preelimination
Y
Y
Y
N
Y
N
N
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Control
Control
Control
Control
Control
Preelimination
Control
Control
Elimination
Control
Control
Y
Y
Y
Y
Y
Y
Control
Control
Control
Elimination
Preelimination
Preelimination
Preelimination
Y
N
N
Y
Y
Y
Y
N
Y
N
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Control
Control
Control
Control
Control
Control
ITNs/
LLINs are
distributed
to all age
groups
Control
ITNs/
LLINs are
distributed
for free
Y
N
N
Y
N
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
Y
-
N
Y
Y
Y
Y
Y
ITNs/ LLINs
distributed
through
mass
campaigns
to all age
groups
Control
Programme
phase
Nicaragua
Panama
Paraguay
Peru
Suriname
Venezuela (Bolivarian
Control
Republic of)
Mexico
French Guiana,
France
Guatemala
Guyana
Haiti
Honduras
El Salvador
Ecuador
Dominican Republic
Bolivia (Plurinational
State of)
Brazil
Colombia
Costa Rica
Belize
Argentina
Uzbekistan
Tajikistan
Turkey
Kyrgyzstan
Uganda
United Republic of
Tanzania
Mainland
Zanzibar
Zambia
Zimbabwe
Eastern
Afghanistan
Mediterranean Djibouti
Iran (Islamic
Republic of)
Pakistan
Saudi Arabia
Somalia
Sudan
Yemen
European
Azerbaijan
WHO region
Y
Y
Y
Y
N
Y
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
IRS is
recommended
by malaria
control
programme
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
Y
Y
N
N
DDT is
used for
IRS
NA
NA
Y
Y
Y
NA
NA
Y
NA
NA
NA
NA
NA
Y
Y
NA
NA
NA
Y
NA
Y
Y
Y
Y
Y
NA
Y
Y
Y
Y
Y
Y
ACT policy
adopted
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Patients
of all ages
should get
diagnostic
test
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
Malaria
diagnosis
is free of
charge in
the public
sector
Y
N
N
Y
Y
Y
N
N
N
Y
Y
N
N
N
Y
Y
-
N
N
Y
Y
Y
N
RDTs
used at
community
level
N
N
N
Y
Y
N
N
N
N
Y
Y
N
Y
Y
Y
Y
-
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
N
Y
Y
N
N
N
N
N
N
N
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
Y
N
N
N
N
Y
Y
N
N
N
N
N
N
N
N
N
N
N
N
Y
N
Y
Y
N
N
Y
N
N
N
N
N
Y
N
Y
N
Y
Y
N
N
Y
N
N
N
N
Y
Y
Y
N
N
N
N
N
Y
N
N
N
N
Y
N
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
N
N
NA
NA
NA
Y
Y
Y
Y
NA
N
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
N
N
NA
NA
NA
N
N
N
N
NA
N
Seasonal
malaria
chemoprevention
(SMC or
IPTc) is
used
Malaria in pregnancy
Primaquine
G6PD
Directly
IPTp used
PreSingle
is used for
test is
observed
to prevent
referral
dose of
radical
recomtreatment
malaria
treatment primaquine
is used as treatment
mended
with
during
with
gameof P. vivax
before
primaquine pregnancy
quinine or
tocidal
cases
treatment
is
artemether
medicine
with
undertaken
IM or
for
primaquine
artesunate
supposito- P.falciparum1
ries
Treatment
199
200
Programme
phase
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
ITNs/ LLINs
distributed
through
mass
campaigns
to all age
groups
ITNs/
LLINs are
distributed
to all age
groups
ITNs/
LLINs are
distributed
for free
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
IRS is
recommended
by malaria
control
programme
N
N
N
N
N
N
N
N
N
N
Y
N
N
N
DDT is
used for
IRS
Y
Y
NA
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
NA
ACT policy
adopted
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Patients
of all ages
should get
diagnostic
test
Y
Y
Y
Y
N
Y
Y
Y
Y
N
Y
Y
Y
Y
Malaria
diagnosis
is free of
charge in
the public
sector
N
Y
N
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
RDTs
used at
community
level
Y
Y
Y
Y
Y
N
Y
N
N
Y
Y
Y
-
N
Y
N
N
Y
Y
Y
N
N
Y
Y
Y
Y
-
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
Y
N
Y
Y
N
N
N
Y
N
N
N
N
Y
N
Y
N
N
Y
N
Y
N
N
Y
N
N
Y
N
NA
Y
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
N
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
Seasonal
malaria
chemoprevention
(SMC or
IPTc) is
used
Malaria in pregnancy
Primaquine
G6PD
Directly
IPTp used
PreSingle
is used for
test is
observed
to prevent
referral
dose of
radical
recomtreatment
malaria
treatment primaquine
is used as treatment
mended
with
during
with
gameof P. vivax
before
primaquine pregnancy
quinine or
tocidal
cases
treatment
is
artemether
medicine
with
undertaken
IM or
for
primaquine
artesunate
supposito- P.falciparum1
ries
Treatment
ACT, artemisinin-based combination therapy; DDT, dichloro-diphenyl-trichloroethane; G6PD, glucose-6-phosphate dehydrogenase; IM, intramuscular; IPTp, intermittent preventive treatment in pregnancy; IRS, indoor residual spraying; ITN, insecticide-treated mosquito net;
LLIN, long-lasting insecticidal net; NMCP, National malaria control programme; RDT, rapid diagnostic test; SMC, seasonal malaria chemoprevention
(Y) = Actually implemented.
(N) = Not implemented.
(-) = Question not answered or not applicable.
1 Single dose of primaquine (0.75mg base/kg) for countries in the Region of the Americas
2 In May 2013 South Sudan was reassigned to the WHO African Region (WHA resolution 66.21, http://apps.who.int/gb/ebwha/pdf_files/WHA66/A66_R21-en.pdf)
Bhutan
Bangladesh
Country/area
Control
Preelimination
Democratic Peoples PreRepublic of Korea
elimination
India
Control
Indonesia
Control
Myanmar
Control
Nepal
Control
Prevention
Sri Lanka
of reintroduction
Thailand
Control
Timor-Leste
Control
Western Pacific Cambodia
Control
China
Elimination
Lao Peoples
Control
Democratic Republic
PreMalaysia
elimination
Papua New Guinea Control
Philippines
Control
Republic of Korea
Elimination
Solomon Islands
Control
Vanuatu
Control
Viet Nam
Control
South-East
Asia
WHO region
Annex 2A Recommended policies and strategies for malaria control, 2014 (continued)
201
202
Country/area
Algeria
Angola
Benin
Botswana
Burkina Faso
Burundi
Cabo Verde
Cameroon
Central African Republic
Chad
Comoros
Congo
Cte dIvoire
Democratic Republic of the Congo
Equatorial Guinea
Eritrea
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Kenya
Liberia
Madagascar
Malawi
Mali
Mauritania
Mayotte, France
Mozambique
Namibia
Niger
Nigeria
Rwanda
Sao Tome and Principe
Senegal
Sierra Leone
South Africa
South Sudan1
Swaziland
Togo
Uganda
United Republic of Tanzania
Mainland
Zanzibar
Zambia
Zimbabwe
Eastern Mediterranean Afghanistan
Djibouti
Iran (Islamic Republic of)
Pakistan
Saudi Arabia
Somalia
Sudan
Yemen
African
WHO region
AL
AL
AL
AL; AS+AQ
AS+AQ
AL
AS+AQ
AL
AL; AS+AQ
AL
AS+AQ
AS+AQ
AS+AQ
AS+AQ
AS+AQ
AL
AS+AQ
AL
AS+AQ
AS+AQ
AL
AL
AS+AQ
AS+AQ
AL
AS+AQ
AS+AQ
AL
AL
AL
AL; AS+AQ
AL
AS+AQ
AS+AQ
AS+AQ
AS+AQ
AL; AS+AQ
AL
AL; AS+AQ
AL
AS+AQ
AL
AL
CQ
AL
CQ
AS+SP
AS+SP
AS+SP
Uncomplicated
unconfirmed
AL
AL
AL
AL; AS+AQ
AS+AQ
AL
AS+AQ
AL
AL; AS+AQ
AL
AS+AQ
AS+AQ
AS+AQ
AS+AQ
AS+AQ
AL
AS+AQ
AL
AL; AS+AQ
AS+AQ
AL
AL
AS+AQ
AS+AQ
AL
AL; AS+AQ
AL; AS+AQ
AL
AL
AL
AL
AL; AS+AQ
AL
AS+AQ
AL; AS+AQ
AL; AS+AQ
AL; QN+CL; QN+D
AS+AQ
AL
AL; AS+AQ
AL
AL; AS+AQ
AL
AS+AQ
AL
AL
AS+SP+PQ
AL+PQ
AS+SP; AS+SP+PQ
AS+SP+PQ
AS+SP+PQ
AS+SP
AS+SP
AS+SP
Uncomplicated
confirmed
P.falciparum
SP(IPT)
SP(IPT)
CQ+PG
SP(IPT)
CQ
SP(IPT)
SP(IPT)
SP(IPT)
SP(IPT)
SP(IPT)
SP(IPT)
SP(IPT)
SP(IPT)
SP(IPT)
SP(IPT)
SP(IPT)
SP(IPT)
SP(IPT)
SP(IPT)
SP(IPT)
SP(IPT)
SP(IPT)
SP(IPT)
SP(IPT)
SP(IPT)
CQ+PG
SP(IPT)
CQ+PG
SP(IPT)
SP(IPT)
SP(IPT)
SP(IPT)
-
CQ
AS+AQ+PQ
CQ
CQ+PQ
AL
AL+PQ; CQ+PQ
AS+AQ+PQ
CQ+PQ(8w)
CQ+PQ (14 d)
CQ+PQ(14d & 8w)
CQ+PQ(14d)
CQ+PQ(14d)
AL+PQ(14d)
CQ+PQ(14d)
Treatment
P.vivax
Country/area
1 In May 2013 South Sudan was reassigned to the WHO African Region (WHA resolution 66.21, http://apps.who.int/gb/ebwha/pdf_files/WHA66/A66_R21-en.pdf)
AM; AS; QN
AM; AS; QN
AM; AS; QN
AS; QN
AS
QN+D
AM; AS; QN
AM; AS; QN
AM; AS; PYR
AS+AL
QN+T
AM; AS
QN+T; QN+D; QN+CL
AL; AS
AS
AS; QN
AS+SP+PQ
AS+AQ; DHA-PP+PQ
AL; AM; AS+MQ; DHA-PPQ; PQ
AL+PQ
AL+PQ
AS+MQ
AL
AS+MQ; DHA-PPQ+PQ
ART+NQ; ART-PPQ; AS+AQ; DHA-PPQ
AL
AS+MQ
AL
AL+PQ
AL
AL
DHA-PPQ
Severe
CQ
CQ
AL
CQ
AL
DHA-PPQ
P.falciparum
AS; QN
QN
AL; QN
QN
AM+CL; AS+CL; QN+CL
AS+AL
QN
CQ; QN
QN
QN
AS; AL
QN
AM
QN
QN
AL
QN
QN
AS
AS+MQ
AS
AM; QN
AM; QN
AM; QN
Uncomplicated
confirmed
AS+SP
AL
AL+PQ
CQ+PQ (1d)
AS+MQ+PQ
AL+PQ(1d); AS+MQ+PQ(1d)
AL
CQ+PQ(1d)
CQ+PQ(1d)
AL+PQ
CQ+PQ(1d)
AL
CQ+PQ(3d)
AL+PQ(1d)
CQ+PQ(1d)
CQ+PQ(1d)
CQ+PQ
CQ+PQ(1d)
AL+PQ(1d)
AL+PQ
AS+MQ
AL+PQ
AS+MQ+PQ
AL
AL
AS+SP
-
Uncomplicated
unconfirmed
Azerbaijan
Kyrgyzstan
Tajikistan
Turkey
Uzbekistan
Region of the Americas Argentina
Belize
Bolivia (Plurinational State of)
Brazil
Colombia
Costa Rica
Dominican Republic
Ecuador
El Salvador
French Guiana, France
Guatemala
Guyana
Haiti
Honduras
Mexico
Nicaragua
Panama
Paraguay
Peru
Suriname
Venezuela (Bolivarian Republic of)
South-East Asia
Bangladesh
Bhutan
Democratic Peoples Republic of
Korea
India
Indonesia
Myanmar
Nepal
Sri Lanka
Thailand
Timor-Leste
Western Pacific
Cambodia
China
Lao Peoples Democratic Republic
Malaysia
Papua New Guinea
Philippines
Republic of Korea
Solomon Islands
Vanuatu
Viet Nam
European
WHO region
SP(IPT)
SP(IPT)
SP(IPT)
CQ
CQ(weekly)
-
P.vivax
CQ+PQ(14d)
AS+AQ; DHA-PP+PQ(14d)
CQ+PQ(14d)
CQ+PQ(14d)
CQ+PQ(14d)
CQ+PQ(14d)
CQ+PQ(14d)
DHA-PPQ
CQ+PQ(8d)
CQ+PQ(14d)
CQ+PQ(14d)
AL+PQ
CQ+PQ(14d)
CQ+PQ(14d)
AL+PQ(14d)
AL+PQ(14d)
CQ+PQ(14d)
CQ+PQ(14d)
CQ+PQ(14d)
CQ+PQ(14d)
CQ+PQ(14d)
CQ+PQ(14d)
CQ+PQ(14d)
CQ+PQ
CQ+PQ(14d)
CQ+PQ(7d)
CQ+PQ(7d)
CQ+PQ(14d)
CQ+PQ(7d);CQ+PQ(14d)
CQ+PQ(14d)
CQ+PQ(14d)
CQ+PQ(14d)
CQ+PQ
CQ+PQ(14d)
CQ+PQ(14d)
CQ+PQ(14d)
CQ+PQ(14d)
CQ+PQ
CQ+PQ(7d)
CQ+PQ(7d); CQ+PQ(14d)
CQ+PQ
CQ+PQ
CQ+PQ(14d)
CQ+PQ(14d)
CQ+PQ(14d)
CQ+PQ(14d)
Treatment
203
204
African
WHO Region
Gabon
Ethiopia
Eritrea
Equatorial Guinea
Cte dIvoire
Congo
Comoros
Chad
Cameroon
Cabo Verde
Burundi
Burkina Faso
Botswana
Benin
Angola
Algeria
Country/area
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
Year
7070600
25215799
-249158*
5848553
27645452
13105187
40321989
9399940
5963608
1018766
22752851
4774243
373386
892644
1632342
10878702
8613320
3836072
12276042
1991913
34674177
12587947
137122
3541013
1107319
1142527
735866
18895269
45346542
27496568
105080153
58206877
78117103
-307864*
-138121*
8229050
14460101
6797703
23762673
113143096
9890472
-275821*
-118*
-154828*
Global Fund
1
30750000
28548000
29000000
18500000
16653000
16500000
9000000
9421000
9500000
8000000
9229000
9500000
38000000
41869000
50000000
43000000
43773000
45000000
-
PMI/
USAID2
3
33200
0
1981243
4254781
0
8457772
11238171
-
281893
4751190
13731500
-
UK
4
98151555
05
1705134
574158195
640473485
27851717
1072280
980000
1082000
1921908
1947775
2142552
11380472
58920267
3126963
1279206
1134923
2001113
4812645
397920
253251
31786265
52468835
437090215
3714635
160000
5300005
74934005
91224005
2256215
137147
94797
69568155
0
72400005
2069259865
54723090
53942249
303835
7812690
8104841
26597915
25827475
0
19705028
226596
123200
Government
0
0
2135717
19286339
9011888
40580540
0
0
4834000
40645351
2433376
4382754
19481377
6027330
555169
64285
11655745
15293706
147856497
5342710
2852385
30125205
499000
1074877
4740367
0
74853096
33611939
64140129
86281277
102540781
0
11157713
15871769
4906745
42424919
85723876
93201479
0
-
Global Fund
The World
Bank
30750000
27200000
27000000
16100000
0
0
2698000
8552723
8571017
8000000
9260000
9229345
0
1123490
0
0
0
0
0
0
19678710
9839355
9839355
34930000
37001000
34000000
0
0
29370000
0
-
PMI/
USAID
0
0
0
16600
0
70804
1031803
2602730
0
0
5415537
74535
239735
0
0
0
0
336278
244000
45000
0
24838023
0
-
Other
bilaterals
33000
12000
660000
29500
37800
19048
94294
65000
79050
130448
19638
449000
904218
460000
20500
54574
20000
40000
104000
45000
45000
14466750
36338
6245966
520000
0
2100000
0
58832
0
111677
11276
34855
WHO
3555239
123571
0
0
14000
521760
136540
150502
453631
475936
1196800
118341
14718
219747
2000000
5596000
2667358
5576
51630
10000
24975817
29250235
5584965
1790452
7196262
0
0
0
-
UNICEF
0
0
0
1000000
250000
0
0
0
942955
379610
2602730
1277376
1324385
0
5415537
669000
0
673440
0
0
58500
0
3827
244000
12575325
35020370
0
5319581
4490030
0
0
15000000
-
Other
contributions6
African
WHO Region
Sierra Leone
Senegal
Rwanda
Nigeria
Niger
Namibia
Mozambique
Mayotte, France
Mauritania
Mali
Malawi
Madagascar
Liberia
Kenya
Guinea-Bissau
Guinea
Ghana
Gambia
Country/area
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
Year
5393233
9288845
4134951
24589072
67802357
14840935
20112537
4603535
9144353
268512
7320497
2340811
10881645
33311280
49541177
12187274
5882949
10405293
25540902
22647300
499317
2473270
9084196
7129260
13845815
10803020
-534600*
29682980
12626612
34642279
1243974
3608532
556809
490866
9305823
24009643
123123384
45365287
144939061
26012739
22881569
15427182
3699517
3306066
22520214
3662132
21674466
2991631
6214513
13788079
Global Fund1
32000000
28547000
28000000
10000000
12371000
12500000
36450000
34256000
35000000
12000000
12370000
12000000
27000000
26026000
26000000
24600000
24075000
22000000
27000000
25007000
25000000
30000000
29023000
29000000
60100000
73272000
75000000
18100000
18003000
17500000
0
0
0
24500000
24124000
24000000
-
PMI/
USAID2
3484590
1903200
1880060
2031197
25335000
27963280
62361
9455
-
2982020
2006310
145948
17515900
22345400
264584
7739210
12752900
30852400
6097560
-
UK4
597812
726578
799091
7700154
8736726
8855177
50880
3015335
956833
0
1000005
2635294
1372093
1178804
05
2843065
11341797
95000
15286
23658
720000
1259872
1871915
1756941
170000
1130593
2328000
65800000
65800000
4186129
4500000
14811934
2996923
21159265
2668014
2859000
1740000
5541401
0
128502
107238
1108444
2139865
24800
12313955
26898
3074
Government
4107095
4919685
5934320
34668998
67804357
64952156
1705505
15603972
18177
701363
2952761
9353875
29089771
48916476
14243081
14026642
10399555
31371350
29994536
2524013
9720000
880267
8023075
0
18180392
26392018
0
2497243
37646902
926804
882630
2910095
225901
19000000
2494013
83083666
100362906
137920815
0
926494
1002778
1715622
21567732
4675836
11304875
11763088
13216219
13525631
Global Fund
0
27010000
27000000
4730000
10000000
10000000
12052476
0
0
0
35604651
32400000
32400000
12000000
12000000
12000000
28742000
27000000
2592000
21600000
23000000
19118000
5298930
25500000
25500000
0
29000000
29023096
0
0
38000
0
0
48502012
60462012
73771000
0
0
0
0
24500000
25302960
0
PMI/
USAID
119149
0
581
38817
825000
0
0
232558
23457627
25635413
500000
0
51000
369500
0
3240000
0
0
0
0
0
0
36736654
20157565
0
2000
1050830
1020102
6156320
Other
bilaterals
0
0
0
0
0
0
8790698
1127907
0
0
0
0
0
600000
0
0
0
10500000
11000000
3500000
0
0
0
60000
0
0
5492349
7040569
52220588
0
459294
0
0
1952807
-
The World
Bank
134306
16000
132833
200000
47050
32514
41060
105114
124135
73734
16869
832402
73333
44890
111315
299000
3369341
120000
150000
150000
52584
92000
11767
46000
250000
100000
0
100000
100000
16000
27000
70248
285968
934980
861615
0
47962
32512
125209
30117
12490
12491
430000
64000
50000
WHO
26229
150000
79490
0
7519
15736
36639
436945
218811
7231
337209
0
0
340647
0
875717
737588
254170
3092000
1437552
42583
42000
2668555
268993
0
0
816535
4000000
1249000
1000000
3000000
1000000
0
3000
0
0
443356
200000
9780
2812
7874921
17912
UNICEF
119149
100000
120814
7911545
6429
6773166
16581
0
0
13111111
23457627
500000
0
0
0
0
720000
0
0
0
0
0
0
44000
18908794
0
1022740
2000
1600
112855
2200067
Other
contributions6
205
206
Region of the
Americas
African
WHO Region
El Salvador
Ecuador
Dominican Republic
Costa Rica
Colombia
Brazil
Belize
Argentina
Zimbabwe
Zambia
Zanzibar
Mainland
United Republic of
Tanzania8
Uganda
Togo
Swaziland
South Sudan7
South Africa
Country/area
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
Year
26978048
8716372
14253512
1116084
1336085
1654211
276521
20510821
7413283
83091440
19511505
14223217
14721341
56328793
28943792
15167601
52221547
28943792
-446260*
4107246
9069648
29335147
21665148
9985457
10695816
3423745
2112710
1318174
-253838*
-228780*
3369591
6737839
2894197
1475716
1149536
514691
1690157
1110598
1002244
-
Global Fund1
6300000
6947000
6000000
33000000
33782000
34000000
49000000
46056000
46000000
25700000
24028000
24000000
14000000
15035000
15000000
-
PMI/
USAID2
0
10454000
4903770
0
0
0
0
-
8955920
27083000
680702
8164570
7354400
4833820
19235700
-
UK4
24291216
13511860
17096911
05
685739
556245
678718
225535
5139088
80359635
553167
937500
6022000
1250
15152
407082
402975
185325
15462950
906000
706200
520000
1082700
10827005
10827005
2500005
2615005
2700005
11100975
11100975
613781945
732915095
722482865
228989875
231004985
114937085
53500005
48300005
20681415
19668125
18835035
20036205
18527405
36886505
28548445
-
Government
38496269
46437577
1458149
1715525
1203444
884398
4897544
83701649
20146401
24195015
18031872
140356602
145506422
0
2128631
2126000
12105399
19361732
24362218
19069239
7460006
7626664
0
0
0
0
0
10121
1909295
369153
0
0
5959287
4832745
3257687
0
0
129000
2323120
1158508
852947
150820
735047
983835
0
0
0
Global Fund
9600000
6900000
0
0
0
33000000
33781000
33000000
165480
37117700
450000
4123200
3485000
1525000
24000000
24000000
24000000
12000000
13000000
12000000
8832
14223
72000
0
56126
18700
47495
120000
120000
84974
0
0
0
0
3595
50000
0
-
PMI/
USAID
152277
68180
192057566
0
132445
0
0
39623353
0
0
0
138140
50000
1850000
3500000
0
0
0
0
0
0
0
0
0
0
0
0
-
Other
bilaterals
0
0
17304
3418520
0
0
0
2281500
0
0
3612027
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-
The World
Bank
2934000
2934000
0
20250
0
88490
1779
360000
500
500
130000
350
350
130000
204466
0
90060
0
0
0
0
0
0
0
0
0
45000
0
0
0
0
0
0
21930
0
0
0
0
56948
54340
WHO
842791
1000000
0
0
222460
1359595
0
0
0
138140
41153
0
50000
27318
20000
42000
42500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-
UNICEF
254869
1300000
4108159
0
0
0
8747
0
4896045
0
2487550
0
138140
41153
7161185
0
6000000
2000
0
0
8833
14222
6761
0
0
0
0
0
0
0
0
20776
23382
106598
0
98057
0
0
Other
contributions6
Eastern
Mediterranean
Region of the
Americas
Somalia
Saudi Arabia
Pakistan
Djibouti
Afghanistan
Venezuela (Bolivarian
Republic of)
Suriname
Peru
Paraguay
Panama
Nicaragua
Mexico
Honduras
Haiti
Guyana
Guatemala
Country/area
WHO Region
12526779
17626010
8403364
44923
8256054
3180088
2665232
19030225
5849945
9003535
22059494
2266628
9672384
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
PMI/
USAID2
3154876
52000
0
-
1729231
0
0
0
0
0
-
2821516
-2089393*
4388420
425717
379266
4516089
3902655
4531760
1288990
954631
967393
803339
2431682
1010094
355313
549463
158751
-
Global Fund1
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
Year
UK4
10500005
9222400
5000000
6300000
25000005
29440000
29440000
30000000
63250
64515
67740
56376455
13859195
5426635
10759525
9048585
8004395
24332415
5926315
9717425
5433125
242853545
252567685
238270545
4392585
9803265
6319075
79195055
72204105
111171485
21154365
51456625
55745805
1251555145
4292855
14280005
1528055
16504985
7902925
8000005
10000005
Government
16651753
9083870
48527
5238195
0
2979260
15231843
8057177
10718906
0
11904217
15062018
9604810
10613985
0
0
0
2780074
3498024
3278171
799527
809474
451597
19317275
4011797
5257474
970940
1106404
792634
0
0
0
1747908
2075252
1214811
0
0
200000
0
0
0
0
0
0
355000
550000
479600
0
0
0
Global Fund
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10561
105373
92461
150000
297569
115708
64222
102864
58936
99330
113187
0
43163
37630
52976
27065
32136
77562
0
0
77438
56073
102871
0
156965
0
0
0
0
PMI/
USAID
200000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6000
0
0
0
0
0
0
0
0
0
0
0
0
0
400000
400541
-
Other
bilaterals
8413
0
0
0
The World
Bank
109068
113341
55782
121616
73000
60500
34000
154000
0
103400
138400
85000
116291
0
0
0
5260
0
0
20000
15899
130882
205000
169000
24413
16437
0
0
0
0
0
6001
0
0
17186
0
0
5635
0
5740
0
0
0
100000
100000
-
WHO
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
142000
200563
0
UNICEF
9200
0
0
0
0
0
0
0
0
0
0
0
745000
820000
0
6000
6046
0
0
0
5333
0
0
0
0
0
0
0
0
0
0
0
0
400000
0
-
Other
contributions6
207
208
South-East Asia
European
Eastern
Mediterranean
WHO Region
China
Cambodia
Timor-Leste
Thailand
Sri Lanka
Nepal
Myanmar
Indonesia
India
Democratic Peoples
Republic of Korea
Bhutan
Bangladesh
Uzbekistan
Turkey
Tajikistan
Kyrgyzstan
Azerbaijan
Yemen
Sudan
Country/area
51832249
35680104
16053353
9824756
5973123
2017535
587129
554196
-35242*
496411
580063
376878
2240695
1308106
1032277
0
442231
544742
2346342
16404817
4395406
440259
405271
239889
3228671
2706329
6704605
11457066
7174057
4481942
18763721
31045276
11488128
19766042
15032712
18254744
6182591
4922108
1813110
2618112
3877889
2318045
7152654
11325529
16524453
5040394
2604409
1527841
1441288
12111758
17983122
12839868
1856499
-1738247*
2012
Global Fund1
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
Year
0
0
0
0
6566000
8000000
0
0
0
0
3997000
4500000
-
PMI/
USAID2
15798300
5377070
-
297389
2344460
11283400
-
UK4
26724830
27316109
1136850
22935535
8480
5000968
4827461
2446419
70000
65000
72300
4167535
633740
773000
22927000
1208161
1480992
1872954
4761717
4134615
5586290
213595
1882000
1895000
1957000
47240020
51336600
43802468
143603365
152884025
161081945
1000000
1028807
726465
1910485
572945
601528
708377
7098780
5893255
7546409
2687572
2981432
3427795
3484029
714343
16812725
20843118
26709969
Government
34938594
35883294
8908540
6256730
2110776
462920
432570
0
850061
434351
511055
2068376
1714393
1057879
0
0
0
448627
288060
265139
7505444
8033087
8912484
292324
6568434
2706329
1571206
7863868
4811540
16129032
11072851
34580791
15913410
10513382
14863117
42620577
2960440
3110685
1442758
1382732
1433109
16246556
9937671
20175612
5375143
4372545
3482955
22685407
13240888
2917174
33697258
0
0
38398132
Global Fund
-
0
0
0
0
0
0
5500000
5400000
6565881
278311
345667
0
456796
3996624
4500000
0
-
PMI/
USAID
258495
0
0
0
0
0
0
0
0
0
0
1757475
451400
0
80000
640741
0
0
0
-
Other
bilaterals
439490
0
0
0
16696978
4299233
0
0
0
0
0
0
0
0
0
0
-
The World
Bank
475893
446160
200000
465713
35000
35000
35000
0
25000
25000
20000
35000
75000
0
0
0
0
0
20000
98000
399189
27898
5000
25000
98000
51141
400000
400000
142500
142500
25000
46500
46500
46500
7400
10000
104979
139166
0
25000
65012
201718
431792
334029
0
0
641921
WHO
140000
0
0
0
471362
3525000
3490400
948890
1000000
0
0
0
0
0
0
-
494000
UNICEF
5807093
1986444
1674350
0
0
0
0
0
0
0
0
0
0
0
0
0
0
146759
0
0
0
0
0
0
870441
5561917
79772
70833
0
0
120000
0
0
0
1680907
Other
contributions6
Viet Nam
Vanuatu
Solomon Islands
Republic of Korea
Philippines
Malaysia
Country/area
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
Year
6394183
3256001
2322590
22934883
22970152
10970461
4271657
4806916
6932455
4059889
4249171
3777902
Global Fund1
PMI/
USAID2
-
406198
695423
0
0
0
1003840
-2733*
-
1361672
1122915
247375
44424578
39845997
57535038
5842905
388000
377000
39395195
5235686
5861758
681674
519102
556200
269486
270180
260505
8123775
8123775
8123775
4615385
4523810
2666667
Government
3745346
4038937
2475938
0
25311547
695052
7224199
8612874
7395343
0
0
0
1696290
1305840
1362022
2446418
1162890
1310500
3961323
5254143
15263816
Global Fund
The World
Bank
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
271773
120132
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
PMI/
USAID
620000
0
0
0
0
0
0
0
0
1987523
1820735
0
1692091
1064592
0
0
0
Other
bilaterals
20000
20000
113000
0
0
0
315326
0
0
0
0
706000
852472
654985
287615
287615
287615
493802
410000
640700
WHO
UNICEF
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2500
0
43620
0
0
0
0
22220
0
0
0
0
5432362
674896
0
1178215
0
0
0
0
0
Other
contributions6
PMI, United States Presidents Malaria Initiative; UK, Funding from the United Kingdom government; UNICEF, United Nations Childrens Fund; USAID, United States Agency for International Development
1 Source: The Global Fund
2Source: www.foreignassistance.gov
3 Source: OECD Database
4 Source: OECD Database
5 Budget not expenditure
6 Other contributions as reported by countries: NGOs, foundations, etc.
7 South Sudan became an independent State on 9 July 2011 and a Member State of WHO on 27 September 2011. South Sudan and Sudan have distinct epidemiological profiles comprising high transmission and low transmission areas respectively. For this reason data up to
June 2011 from the high transmission areas of Sudan (10 southern states which correspond to South Sudan) and low transmission areas (15 northern states which correspond to contemporary Sudan) are reported separately.
8 Where national totals for the United Republic of Tanzania are unavailable, refer to the sum of Mainland and Zanzibar
* Negative disbursements reflect recovery of funds on behalf of the financing organization.
Western Pacific
WHO Region
209
210
African
WHO region
Gabon
Ethiopia
Eritrea
Equatorial Guinea
Cte d'Ivoire
Congo
Comoros
Chad
Cameroon
Cabo Verde
Burundi
Burkina Faso
Botswana
Benin
Angola
Algeria
Country/area
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
Year
21666
10000
1821267
12627282
18644449
7947747
13918109
4431
8397
10010
83943
86597
0
6260000
11709780
13388552
230043
6321676
666
377252
13576
1203982
14005
180595
30000
150000
555334
264432
9959820
307243
703699
731981
5752583
0
0
0
217600
0
0
0
477044
1182519
2978937
708643
584285
6203924
52500
0
No. of ITN +
LLIN sold or
delivered
0
0
0
477044
1182519
2978937
708643
584285
6203924
52500
0
0
264432
9959820
307243
703699
731981
5752583
0
0
0
217600
0
0
30000
150000
555334
0
230043
6321676
666
377252
13576
1203982
14005
180595
0
1821267
12627282
18644449
7947747
13918109
4431
8397
10010
83943
86597
0
6260000
11709780
13388552
0
21666
10000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
31
26
34
100
100
100
19
8
6
86
100
100
84
74
100
71
68
2
38
7
28
55
52
88
66
93
92
72
71
56
71
83
100
84
96
97
2
4
5
43
42
6
70
62
86
2
3
% ITN coverage
59
65
84
64
58
71
18
20
62
49
36
33
35
62
54
57
69
47
55
80
48
40
28
36
15
54
48
49
48
24
18
31
46
38
38
49
51
58
28
21
15
26
31
41
44
20
46
35
36
Modelled %
of population
with access to
an ITN
0
1
3
2
0
7
7
7
12
12
14
1
0
0
1
0
0
100
100
19
0
0
0
0
0
4
3
0
0
0
0
0
0
19
16
20
6
6
6
25
36
25
0
-
31150
22475
0
0
0
187386
185252
194566
148092
129000
165944
298734
275857
320881
15468785
23150388
16709249
0
-
% IRS coverage
13000
17407
676090
419353
58370
694729
694729
789883
163647
176887
205831
115638
0
0
59300
0
0
282265
298475
25780
0
0
0
0
0
No. of people
protected by
IRS
219793
182911
216195
9000000
9164641
5321471
984423
2358567
11693982
7112841
19008927
40199
40911
814449
1038000
60868
4750
202402
0
0
420000
522270
420000
522270
814449
1038000
60868
4750
202402
6888647
2358567
11693982
14941450
19008927
40199
40911
14577
219793
182911
216195
9000000
12800000
7321471
984423
0
0
92
3747190
2814900
1101154
4606
3953
5720987
5797938
7494498
2183228
3836437
4263178
3960
3144
41
760375
497022
1270172
ACT treatment
courses
delivered
887
603
266
3747190
2814900
1101154
4606
3953
5720987
5797938
7494498
2183228
3836437
4772805
6960
4824
46
762338
1048811
1270172
Any first-line
treatment
courses
delivered
(including ACT)
65
87
87
100
100
100
100
100
96
100
100
100
100
100
100
100
95
37
48
59
58
95
100
100
100
9
25
0
0
100
76
100
100
100
45
38
7
100
100
100
100
100
100
100
% Any
antimalarial
coverage1
0
0
39
100
100
100
100
100
96
100
100
100
100
100
100
100
85
36
23
59
58
95
100
100
100
9
25
0
0
76
100
100
100
45
38
100
100
100
100
100
100
100
% ACT
coverage2
African
WHO region
Sierra Leone
Senegal
Rwanda
Nigeria
Niger
Namibia
Mozambique
Mayotte, France
Mauritania
Mali
Malawi
Madagascar
Liberia
Kenya
Guinea-Bissau
Guinea
Ghana
Gambia
Country/area
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
Year
0
0
3939740
6947498
60091
6742108
636318
1423507
1935348
636465
3790403
13000
105000
178922
40988
39400
5252
2669244
3315727
6112245
93900
104249
163526
541550
409400
2048430
14448634
8559372
23328225
1675233
5249761
1373582
105312
14596
11385
267482
3902145
3785595
139391
441859
3846204
275042
138149
1046510
7874094
1926300
5190887
90188
5268245
73145
73819
116268
1109568
4226261
1641982
5450064
No. of ITN +
LLIN sold or
delivered
275042
138149
1046510
7874094
1926300
5190887
90188
5268245
73145
73819
116268
1109568
4226261
1641982
5450064
0
0
0
3939740
6947498
60091
6742108
636318
1423507
1935348
636465
3790403
13000
105000
178922
40988
39400
5252
2669244
3315727
6112245
93900
104249
163526
541550
409400
2048430
14448634
8559372
23328225
1675233
5249761
1373582
105312
14596
11385
267482
3902145
3785595
139391
441859
3846204
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
100
100
100
92
96
100
3
81
80
33
37
100
61
61
45
74
35
76
89
84
100
94
95
80
73
67
49
12
13
100
100
100
52
63
80
27
28
34
20
15
30
55
43
47
100
100
100
100
100
100
44
84
98
100
18
100
% ITN coverage
81
82
82
62
79
77
27
43
73
69
76
82
78
77
73
44
38
56
52
62
81
49
77
67
63
51
60
9
8
9
49
55
69
70
65
35
27
40
36
38
48
52
57
62
52
53
48
53
76
24
32
60
Modelled %
of population
with access to
an ITN
27
43
18
8
11
8
6
0
0
23
9
0
7
7
12
5
5
5
9
1
1
7
36
21
31
32
25
1
0
0
1
0
0
10
14
11
82
84
67
8
5
5
16
0
0
1873056
758021
826386
836568
4339
381
450
1789110
9647202
5597770
559305
598901
467930
192761
0
0
2415540
132211
316255
1080889
1562411
1243704
146773
153514
124692
1095093
690090
708999
986898
0
0
% IRS coverage
484086
800290
350442
2117240
2936037
2154924
2435836
0
0
960000
367930
0
1597374
1579521
No. of people
protected by
IRS
484901
468767
319182
4170828
8330784
14267045
802110
1402400
644829
171540
12000000
7000000
10614717
5064014
443900
96787
2026100
266000
467854
6956821
7601460
8735160
3842790
3080130
2211118
56015
176192
5106570
13477650
15976059
22313
87520
3500243
6556070
5731036
12877360
32568349
22145889
611482
1204913
1917021
10703
8752
1456
713344
976840
703712
2004308
2201370
1391273
56015
176192
5106570
13477650
15976059
22313
90377
3500243
6556070
5731036
12877360
32568349
22145889
619786
1204913
1917021
10703
8752
1456
713344
976840
703712
2004308
2201370
1391273
ACT treatment
courses
delivered
484901
468767
319182
4170828
8330784
14267045
902516
370771
1312802
171540
12000000
8300000
10839611
6507544
1332055
100535
2026100
266000
467854
6956821
7601460
8735160
3842790
3080130
2211118
Any first-line
treatment
courses
delivered
(including ACT)
83
100
100
90
100
100
28
11
77
59
100
100
100
100
100
14
100
33
95
100
100
100
97
72
51
92
100
100
100
100
67
100
100
100
100
100
100
100
36
92
100
100
100
100
85
82
72
100
100
96
100
100
85
% Any
antimalarial
coverage1
83
100
100
90
100
100
24
43
38
100
100
100
100
100
63
13
100
33
95
100
100
100
97
72
51
92
100
100
100
100
67
100
100
100
100
100
100
100
36
92
100
100
100
100
85
82
72
100
100
96
100
100
85
% ACT
coverage2
211
212
European
Eastern Mediterranean
African
WHO region
Azerbaijan
Yemen
Sudan
Somalia
Saudi Arabia
Pakistan
Djibouti
Afghanistan
Zimbabwe
Zambia
Zanzibar
Mainland
Uganda
Togo
Swaziland
South Sudan3
South Africa
Country/area
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
Year
243728
169084
70360
439181
2238300
1519947
767000
750000
1450000
455000
525000
413000
782901
5803319
4432714
1209215
1405837
375899
10000
0
0
2688575
3362588
6368026
457000
2010000
1743542
37551
359622
4325552
26400
25700
40612
0
5399
329999
468575
4042425
1000747
13219306
10615631
2208293
2547391
510000
1535867
2489536
510000
672426
57855
0
0
0
1036109
3144818
No. of ITN +
LLIN sold or
delivered
0
0
0
1036109
3144818
0
40612
0
5399
329999
468575
4042425
1000747
13219306
10615631
2208293
2547391
510000
1535867
2489536
510000
672426
57855
0
2688575
3362588
6368026
457000
2010000
1743542
37551
359622
4325552
26400
25700
0
243728
169084
70360
439181
2238300
1519947
767000
750000
1450000
455000
525000
413000
782901
5803319
4432714
1209215
1405837
375899
10000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
59
72
63
83
45
23
83
87
100
46
73
100
94
68
16
96
96
90
89
100
100
26
38
63
35
29
36
23
22
21
98
100
100
0
3
4
72
100
100
14
21
24
14
35
50
16
24
26
25
16
8
% ITN coverage
37
43
61
71
75
69
73
72
59
70
38
47
75
65
44
27
65
44
27
77
81
87
39
60
88
29
26
23
15
23
26
34
40
54
-
Modelled %
of population
with access to
an ITN
204224
281203
289249
4584426
1161825
1103480
2210000
1736400
752851
240558
90060
61362
2945746
3902712
3942110
1886500
2204429
2188436
211500
209004
187261
0
0
3971
0
0
0
2543983
2581839
3219122
6518120
3537097
2000000
255930
224900
4250000
1063460
5538574
3106659
3106659
3460871
0
0
0
0
0
5000000
2318129
5650177
170440
332968
No. of people
protected by
IRS
26
36
36
3
1
1
94
72
30
2
1
1
8
10
10
10
11
11
98
96
85
95
43
100
2
3
0
0
1
0
0
0
7
7
9
14
7
4
19
16
29
7
35
27
26
29
0
0
0
0
0
% IRS coverage
11135
21625
8920
11135
21625
8920
3100
3400
8830
596600
590840
162880
1283
974
1155
9268
292000
155450
2462470
2077204
3823175
166500
303847
215486
1
4
2
10175160
10128060
20377410
19937820
47100
5075
4289743
15926301
13000845
1236958
815260
960455
10175160
10128060
20377410
19937820
47100
5075
4289743
15926301
13000845
1236958
815260
960455
5670
6230
8830
2280000
2150000
907200
1283
974
1155
18868
292000
155450
2478038
2630400
3823175
179000
303847
215486
4
4
2
3897
5444
14036
4333150
3125448
197
307
558
914218
802904
1208529
23864320
24375450
ACT treatment
courses
delivered
3897
8272
14036
4333150
3125448
200
356
588
812911
964927
1134604
23864320
24375450
Any first-line
treatment
courses
delivered
(including ACT)
57
61
88
100
100
27
24
79
91
100
62
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
% Any
antimalarial
coverage1
57
40
88
100
100
27
21
75
100
97
66
100
100
100
100
100
100
87
9
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
% ACT
coverage2
European
WHO region
Mexico
Honduras
Haiti
Guyana
Guatemala
El Salvador
Ecuador
Dominican Republic
Costa Rica
Colombia
Brazil
Belize
Argentina
Uzbekistan
Turkey
Tajikistan
Kyrgyzstan
Country/area
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
Year
0
10000
0
13969
2880
2990
618803
282788
49905
16800
27921
152996
2987653
0
0
30630
66920
25118
52766
4500
7500
35000
35000
35000
100000
100000
50000
0
0
0
20000
0
0
3000
2324
2452
24526
20965
23580
361241
147736
229947
313398
146196
169500
3000
7000
0
62095
54139
6733
13502
20337
No. of ITN +
LLIN sold or
delivered
35000
35000
35000
100000
100000
50000
0
0
0
20000
0
0
0
0
0
3000
2324
2452
24526
20965
23580
361241
147736
229947
313398
146196
169500
3000
7000
0
62095
54139
6733
13502
20337
0
0
10000
0
13969
2880
2990
618803
282788
49905
16800
27921
152996
2987653
0
0
30630
66920
25118
52766
4500
7500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
10
12
14
10
13
14
11
15
50
52
52
51
2
4
4
16
2
3
100
100
100
17
21
16
100
100
100
2
4
6
4
3
3
2
2
3
11
12
11
1
2
1
8
7
4
2
1
1
% ITN coverage
Modelled %
of population
with access to
an ITN
1
1
1
3
1
5
1
1
0
1
1
0
1
1
1
1
1
7
7
1
0
0
3
6
4
0
0
0
2
2
2
1
1
1
369103
324477
287150
359100
154000
519333
22000
13560
0
61557
49510
6066
83357
94321
16905
15076
6424
16625
16932
65390
37450
1700
20700
41000
25592
0
0
0
104495
121121
116490
42985
49401
47775
100
100
100
19
16
14
0
12
12
100
100
100
13
12
0
9
9
9
1
1
% IRS coverage
146466
100633
115680
503156
437436
387010
50
2120
2120
375605
328020
372967
26712
24636
300
20052
21413
21413
28000
30280
No. of people
protected by
IRS
905010
452990
334740
171342
68879
86228
50
20
6
947
579
496
4720
378
124753
10865
8
7966
31601
31479
12354
141094
107029
37827
45926
37248
54466
2
2974
4592
3
4
31
1
600
400
350
1
3
1
50
50
37
26
19
7400
7342
Any first-line
treatment
courses
delivered
(including ACT)
1
2
8
2
4
6
141410
122290
59690
50398
48285
32489
0
0
3
5
4
7
548
161
0
0
0
0
20291
13655
12354
0
0
0
0
0
2
1
0
235
350
300
1
3
1
1
0
0
350
959
ACT treatment
courses
delivered
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
65
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
81
100
100
100
65
100
100
100
100
100
100
0
100
100
% Any
antimalarial
coverage1
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
65
100
100
100
100
100
100
0
0
100
1
1
1
100
100
0
100
100
0
87
51
100
0
0
0
0
1
100
100
100
% ACT
coverage2
Annex 4 Intervention coverage estimated from routinely collected data, 20122014 (continued)
213
214
Western Pacific
South-East Asia
WHO region
China
Cambodia
Timor-Leste
Thailand
Sri Lanka
Nepal
Myanmar
Indonesia
India
Bhutan
Bangladesh
Suriname
Peru
Paraguay
Panama
Nicaragua
Country/area
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
Year
4892
0
515
467
2666
85976
717000
786764
10000
93726
80609
332000
0
0
0
0
0
844737
913135
6416947
2964812
2812517
917666
499166
1395865
1064518
637250
0
0
264806
783896
631596
25148
253037
99572
2177808
5418
372789
257935
58874
19899
18350
17100
83279
0
0
0
0
0
0
9900
4600
No. of ITN +
LLIN sold or
delivered
18350
17100
83279
0
0
0
0
0
0
9900
4600
0
0
4892
0
515
467
2666
20052
612000
728773
10000
93726
80609
332000
0
0
0
0
0
844737
913135
6416947
1042244
1508557
904613
499166
1395865
1064518
637250
0
0
139000
670000
528850
25148
253037
99572
2177808
5418
70411
0
0
19899
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
65924
105000
57991
0
0
0
0
0
0
0
0
0
0
0
0
1922568
1303960
13053
0
0
0
0
0
0
125806
113896
102746
0
0
0
0
0
302378
257935
58874
0
17
13
22
22
25
20
26
38
39
31
24
24
4
6
8
39
54
65
63
58
42
0
0
0
3
3
7
0
0
0
32
12
10
0
0
0
23
25
15
39
36
59
11
6
5
1
1
% ITN coverage
Modelled %
of population
with access to
an ITN
3
4
2
12
10
6
17
8
5
1
0
1
0
0
0
65
77
73
0
0
0
26
6
26
15
22
21
4
4
4
0
0
0
0
0
3
3
3
2
1
0
1
0
1
16
0
11
0
0
0
0
0
0
48626
443229
345000
372000
75354
50666
50
451730
106374
362469
159743
0
110707
0
0
0
1096877
447639
504936
% IRS coverage
87446
126403
54834
21071
17055
11422
40126
19425
12809
108629
43617
69155
0
0
0
3637795
4369755
4189850
0
0
0
141322
32824
144669
1835016
2651612
2617120
49942758
45854424
45150612
257915
253815
103285
56414
No. of people
protected by
IRS
27659
32005
71040
42390
58770
35
518
118
0
0
0
3147400
147000
211500
341697
300008
212165
546060
371663
281103
53252
325
195
48
43
23
3348
15069
19314
2923
3131
330
422024
117547
114159
3919
9350
120979
94810
42390
75479
82
518
118
23537
15673
11212
30523925
147000
211500
341697
300008
212346
546060
371663
281103
669152
38113
24500
70
95
49
3348
15069
19314
5211
23667
3432
422024
117547
118483
4127
43150
1
0
0
0
0
0
0
2
7
6504
300
ACT treatment
courses
delivered
218419
49256
68878
920
705
874
15
11
8
42670
800
Any first-line
treatment
courses
delivered
(including ACT)
100
100
100
100
94
86
100
100
100
64
100
100
100
100
100
95
100
100
100
100
100
100
17
19
13
13
11
74
79
100
100
93
17
61
80
100
10
36
51
85
100
100
100
100
100
100
100
% Any
antimalarial
coverage1
0
0
0
0
0
0
18
100
61
74
95
100
100
100
100
98
100
100
100
100
100
32
29
24
24
19
100
100
100
100
7
1
100
100
100
26
83
100
100
100
100
100
100
100
100
100
% ACT
coverage2
Viet Nam
Vanuatu
Solomon Islands
Republic of Korea
Philippines
Malaysia
Country/area
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
2012
2013
2014
Year
54056
439677
276655
220703
317943
622673
1062508
1625831
1613140
783463
715125
996180
0
0
5250
31781
371124
47258
35863
94232
42916
968413
0
526366
No. of ITN +
LLIN sold or
delivered
54056
439677
276655
220703
317943
622673
1062508
1625831
1613140
783463
715125
996180
0
0
5250
31781
371124
47258
35863
94232
42916
0
0
526366
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
968413
0
0
34
22
22
100
100
100
78
94
100
16
14
8
1
1
0
100
100
100
100
100
100
14
9
5
% ITN coverage
Modelled %
of population
with access to
an ITN
ACT, artemisinin-based combination therapy; IRS, indoor residual spraying; ITN, insecticide-treated mosquito net; LLIN, long-lasting insecticidal net
1 Based on presumed and confirmed cases adjusting for reporting completeness and any first-line treatment courses distributed as proxy indicator for treated cases
2 Based on presumed and confirmed cases adjusting for reporting completeness and % of P.falciparum using ACTs distributed as proxy indicator for treated cases
3 In May 2013 South Sudan was reassigned to the WHO African Region (WHA resolution 66.21, http://apps.who.int/gb/ebwha/pdf_files/WHA66/A66_R21-en.pdf)
Western Pacific
WHO region
0
0
0
42
58
51
0
3
2
2
24
18
23
4
1
0
2
2
1
0
1541860
1108220
1175136
131752
98971
128673
9705
3033
0
1364815
1310820
616670
% IRS coverage
1856
13113
4691
489988
682288
615384
No. of people
protected by
IRS
104400
58470
50092
4725
3850
3923
886560
915330
802080
13469
24771
30095
555
443
638
190255
146439
147430
52010
24000
24000
266351
218389
194397
Any first-line
treatment
courses
delivered
(including ACT)
104400
58470
50092
2088
2873
3182
886560
915330
802080
13469
24771
30095
190255
146439
147430
52010
24000
24000
192400
141570
106100
ACT treatment
courses
delivered
100
100
100
100
100
100
89
100
100
100
100
100
65
65
65
100
100
100
100
100
100
100
100
100
% Any
antimalarial
coverage1
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
% ACT
coverage2
Annex 4 Intervention coverage estimated from routinely collected data, 20122014 (continued)
215
216
Benin
Burundi
Comoros
Congo
Cte d'Ivoire
Democratic Republic of the
Congo
African
Sierra Leone
Togo
United Republic of Tanzania
Zambia
Region of the Americas Haiti
Honduras
Eastern Mediterranean Sudan
South-East Asia
Indonesia
Western Pacific
Cambodia
China
Gabon
Gambia
Ghana
Guinea
Liberia
Madagascar
Malawi
Mali
Namibia
Niger
Nigeria
Rwanda
Senegal
Country/area
WHO region
33
67
36
55
91
19
51
-
DHS 2013
DHS 2014
DHS 2012
DHS 2013
DHS 2014
DHS 2012
DHS 2013
DHS 2013
MIS 2012
DHS 2013
DHS 2013
DHS 2012
DHS 2013
DHS 2013
DHS 2013
DHS 2014
DHS 2013
DHS 2014
DHS 2012
DHS 2014
DHS 2012
DHS 2012
DHS 2012
DHS 2012
DHS 2014
DHS 2012
% of HH
that have
at least one
ITN
DHS 2012
DHS 2013
DHS 2012
DHS 2012
DHS 2012
Source
24
14
19
44
9
20
28
18
38
12
22
41
27
34
14
32
52
24
5
30
24
43
23
23
9
30
% of HH
with
enough
ITNs for
individuals
who slept
in the
house the
previous
night
47
27
45
59
25
37
48
37
65
18
36
66
57
58
38
49
74
47
11
31
49
47
64
46
41
23
49
% of
population
with access
to an ITN
in their
household
85
87
77
50
68
71
85
91
90
23
35
75
66
63
93
61
77
65
64
62
49
26
36
35
19
31
54
40
58
4
13
60
39
39
41
33
65
34
7
14
32
49
62
47
37
25
32
89
83
93
90
62
85
% of the
population
who slept
under an
ITN the
previous
night
% of
existing
ITNs in HH
used the
previous
night
39
56
70
12
16
-
31
37
% of the
children <5
years who
slept under
an ITN the
previous
night
59
28
46
43
28
36
61
51
73
4
16
74
43
38
52
40
74
41
8
40
59
74
55
44
26
40
% of
pregnant
women
who slept
under an
ITN the
previous
night
6
32
12
2
13
30
9
6
17
2
12
13
10
5
15
31
2
2
7
6
6
2
20
43
51
11
30
25
42
26
23
41
61
48
7
-
47
28
31
% of HH
% of HH
sprayed by with = 1 ITN
IRS within
for 2 pers.
last 12
and/or
months
sprayed by
IRS within
last 12
months
8
5
12
9
17
4
9
21
3
9
10
5
17
9
6
4
1
3
12
7
4
12
% of
children
aged 659
months
with a
hemoglobin
measurement <8g/
dL
23
1
44
28
53
1
38
4
-
29
17
% of
children
aged 659
months
with a
positive
microscopy blood
smear
59
71
66
80
54
80
59
49
66
64
78
59
61
79
77
49
64
89
-
59
55
67
67
18
37
31
78
5
43
41
91
17
46
79
18
93
18
10
77
48
61
90
27
63
-
19
32
69
14
40
18
% children
% of
<5 years
children
with fever
<5 years
in last 2
with fever
weeks
in last 2
for whom weeks who
advice or received an
treatment ACT among
was sought those who
received
any
antimalarial
19
15
37
34
9
42
13
36
12
22
14
11
30
11
40
24
25
49
12
14
11
19
17
48
29
29
11
% of
children
<5 years
with fever
in the last
2 weeks
who had
a finger or
heel stick
6
2
6
40
12
18
13
13
3
9
7
3
24
5
50
-
11
12
18
8
% of women
who
received
at least 3
doses of
IPT during
ANC visits
during
their last
pregnancy
217
Algeria
Angola
Benin
Botswana
Burkina Faso
Burundi
Cabo Verde
Cameroon
Central
African
Republic
Chad
Comoros
Congo
Cte dIvoire
Democratic
Republic of
the Congo
Equatorial
Guinea
Eritrea
Ethiopia
Gabon
Gambia
Ghana
Guinea
GuineaBissau
Kenya
Liberia
Madagascar
Malawi
Mali
Mauritania
Mayotte,
France
Mozambique
Namibia
Niger
Nigeria
Rwanda
Sao Tome
and Principe
Senegal
Sierra Leone
South Africa
South Sudan1
Swaziland
Togo
Uganda
UN population
72630719
820885
3628415
26372775
1687673
1928201
26786598
12275527
1800513
31491950
4396554
20688516
16695253
15377420
2778737
N/A
27216276
1109185
10130276
135552389
11341544
186342
74877030
820885
5110444
65931937
1687673
1928201
26786598
12275527
1800513
44863583
4396554
23571713
16695253
17086022
3969625
N/A
27216276
1907259
17966904
177475986
11341544
186342
14672557
6315627
5396905
11911184
355351
7115163
37782971
820885
5110444
96958732
1687673
1928201
26786598
12275527
1800513
44863583
4396554
23571713
16695253
17086022
3969625
228070
27216276
2402858
19113728
177475986
11341544
186342
14672557
6315627
53969054
11911184
1269112
7115163
37782971
14085655
6315627
2158762
11911184
0
7115163
37782971
9151544
366364
4504962
22157107
74877030
4804316
4804316
13438336
769991
4504962
22157107
4804316
N/A
24227524
10598482
93513
17589198
10816860
N/A
16168840
At risk
(low + high)
N/A
24227524
10598482
1471781
17589198
10816860
N/A
22773014
At risk
(high)
13587053
769991
4504962
22157107
38934334
24227524
10598482
2219937
17589198
10816860
513906
22773014
Suspected malaria
cases
Number of people
living in active foci
625301
57129
14647380
1737195
103545
290346
6418571
309939
98952
35725
2513863
185996
166229
8453557
1595828
20417
9968983
1513772
2465
248159
4658774
495238
266
3180021
1509221
1485
8280183
4831758
46
1369518
Presumed and
confirmed malaria
cases
15
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
15
1754
5 485 327
15914
3222613
16512127
1610812
1079536
628642
2647375 1898852
543196
13988
711
711
1756700
1130251
19201136 13724345
91445
59136
N/A
N/A
121755
N/A 7457765
N/A
256183
N/A
603424
N/A 10636057
N/A 1595828
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0
8690
N/A 6134471
N/A 1955773
N/A
1485
N/A 9274530
N/A 7622162
482533
6894
N/A 3709906
Malaria
case definition
425151
1137455
103283
108510
5472628
57129
8295749
2231183
909366
5543258
47500
304418
116798
7062717
102087
603424
5598412
116767
P+C
P+C
P+C
P+C
P+C
P+C
P+C
P+C
716518
2122999
540913
1756700
9108730
91445
P+C 12240045
P+C
186972
P+C 5745420
P+C 10870402
P+C 4178206
P+C
P+C
P+C
P+C
P+C
P+C
P+C
P+C
P+C
P+C
P+C
P+C
P+C
P+C
P+C 14647380
P+C
P+C
P+C
P+C
P+C
P+C
8690
P+C 5253429
P+C 1490787
P+C
P+C 6423002
P+C 7375677
P+C
6894
P+C 2340388
13
2808931
864204
2905310
-
23953
1250110
26117
99976
3415912
660207
17452
2203
66323
-
295088
203
1346
46
-
265624
1374476
11705
711
1130251
3631939
1754
265624
1374476
11563
710
1130234
3631939
1754
7117648
7117648
15914
15914
1953309 3906588
7826954
1610812
1623176
15
2808931
864204
365239
2905310
2039853
15835
93431
30768
2118815
31900
166229
3415912
660207
20417
9968983
914032
2203
66323
3712831
295088
266
2298979
1044235
1346
5428655
4585273
46
-
6780
868705
-
50
-
Imported cases /
(introduced cases)
322
-
14
260
20
-
Presumed and
confirmed cases at
community level
110441
454840
0
394088
0
279878
0
71343
109313
17406
1243301
184340
-
19766
0
2027
112445
94681
319536
0
0
-
434110
579112
155630
0
289527
0
57180
109092
17020
13523
181103
-
19766
0
2027
0
67799
319536
0
0
55015
86323
141026
0
12636
18556
4928
104
33546
621737
417
93885
1474
193357
929026
11138
20988
28300
9180
88251
64587
13161
13146
3846
32761
28017
5610
429940
112432
990968
47705
1049
25454
68262
31304
0
238855
90545
152
463774
153468
46
471209
Inpatient malaria
cases
Inpatient malaria
cases
and deaths
500
2848
174
4
1205
5921
3245
61
2691
6082
496
472
2288
551
4490
2309
19
357
15
213
159
170
2200
1067
25502
1720
0
271
2069
635
0
5714
1869
22
5632
2974
2
4398
Malaria attributed
deaths
Method
used
to
calulate3
(1)
(2)
(1)
(1)
(1)
(2)
(2)
(1)
(2)
(1)
(2)
(2)
(1)
(2)
(2)
(1)
(2)
(2)
(1)
(2)
(1)
(1)
(2)
(1)
(2)
(2)
(2)
(2)
(2)
(1)
(2)
(2)
(2)
(1)
(2)
(2)
(1)
(2)
(2)
(1)
(2)
Cases
Population
(2)
(2)
(1a)
(2)
(1b)
(2)
(2)
(1a)
(2)
(1a)
(2)
(2)
(2)
(2)
(2)
(1b)
(2)
(2)
(2)
(2)
(1b)
(1b)
(2)
(2)
(2)
(2)
(2)
(2)
(2)
(1b)
(2)
(2)
(2)
(1b)
(2)
(2)
(1b)
(2)
(2)
(1a)
(2)
Deaths
Country/
area
Lower
1900000
124000
820000
8300000
1500000
3300000
180000
1200000
11000000
2400000
<50
3400000 5100000
3100000 4000000
1000
2100
7100000 10000000
1400000 2000000
<50
5200000 7500000
6500000
1600000
1200000
3500000
7300000
72000
197000
74000
3800000
350000
440000
8300000
4800000
168000
11000000
2100000
2100000
4500000
8800000
120000
370000
120000
7900000
630000
560000
11000000
6000000
290000
1100000
1700000
14000
880000
450
2100000
4400000
12000
25000
1800000 2800000
2500000 3400000
19000
24000
1800000 2900000
620
890
2600000 3100000
8100000 12000000
17000
3800000
1100000
750000
2700000
5900000
40000
70000
42000
790000
110000
330000
5800000
3800000
68000
Lower
650
5700
120
1500
3100
5300
9400
7300
81000
400
2500
1200
87
2500
15000
240
160
10
240
96
120
5900
7400
160
33000
3300
10
300
12000
2700
8900
4400
12000
1700
5200
Estimates, 2013
710000
82000
500000
6400000
870000
2000000
2300000
530
4700000
990000
3400000
Cases
Point
WHO
region
Upper
African
Deaths
12000
2900
7400
11000
25000
1500
990
270
19000
510
930
18000
13000
440
72000
11000
660
2300
20000
4900
20000
8200
32000
5600
14000
Upper
4200
7800
120
2900
<10
4700
12500
<100
6200
11000
120
7200
5900
17000
16500 21000
<50
12000 17000
119000 150000
3000
4600
9900
2200
3200
7800
20000
1100
680
130
6700
370
600
14500
10700
340
50000
7800
310
1600
16000
3800
0
13900
6200
<10
17000
3200
0
9400
Point
218
United
Republic of
Tanzania
Mainland
Zanzibar
Zambia
Zimbabwe
Argentina
Belize
Bolivia
(Plurinational
State of)
Brazil
Colombia
Costa Rica
Dominican
Republic
Ecuador
El Salvador
French
Guiana,
France
Guatemala
Guyana
Haiti
Honduras
Mexico
Nicaragua
Panama
Paraguay
Peru
Suriname
Venezuela
(Bolivarian
Republic of)
Afghanistan
Djibouti
Iran (Islamic
Republic of)
Pakistan
Saudi Arabia
Somalia
Sudan
Yemen
Azerbaijan
Georgia
Kyrgyzstan
Tajikistan
Turkey2
Uzbekistan
8511708
0
N/A
4791623
41833813
10625813
N/A
5013521
N/A
N/A
261466
12288545
710420
10572029
5045601
N/A
3018984
181284
N/A
12165089
84505
5770439
23902611
438087
N/A
181918666
N/A
10517569
39350274
20394487
N/A
N/A
N/A
N/A
N/A
N/A
10561887
206077898
47791393
4757606
10405943
15902916
6107706
261466
16015494
763893
10572029
7961680
125385833
6013913
3867535
6552518
30973148
538248
30693827
31627506
876174
78143644
185044286
30886545
10517569
39350274
26183676
9629779
4034774
5843617
8295840
77523788
29469913
53509117
N/A
5353161
34195388
6561894
N/A
N/A
N/A
N/A
N/A
N/A
798040
3987658
267363
5603175
371191
N/A
78181
170172
N/A
1550406
84505
223553
N/A
N/A
96205
4739792
2154165
N/A
263876
50356338
898603
15721343
4362761
N/A
N/A
50356338
1466283
15721343
12004995
N/A
N/A
UN population
50356338
1466283
15721343
15245855
42980026
351706
At risk
(low + high)
51822621
51254941
At risk
(high)
51822621
Suspected malaria
cases
Number of people
living in active foci
N/A
41404
N/A
N/A
N/A
0
0
0
612596
0
0
606499
N/A
N/A
N/A
N/A
N/A
N/A
N/A
3445972
N/A
N/A
497042
N/A
N/A
N/A
N/A
92717
N/A
N/A
N/A
0
N/A
8514341
79653
1207771
725169
399925
440
35600
200241
189854
812347
743183
-
522617
314294
142843
258817
151420
900578
620977
80701
24832
866047
26964
14651
370825
106915
416729
1670019
403532
4420
124900
N/A 24880179
N/A
309913
N/A 7859740
N/A 1420946
N/A
5691
8589
24122
N/A 25190092
Presumed and
confirmed malaria
cases
3666257
2305
26174
1207771
97089
2
6
0
7
249
1
1243
290079
9439
90708
4931
12354
17696
3380
664
1163
874
8
64676
400
448
241
8
496
143415
40768
6
7401
7399316
4246
5972933
535983
4
19
7403562
Malaria
case definition
P+C
C
P+C
P+C
P+C
C
C
C
C
C
C
P+C
P+C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
5123233
1249752
64480
788281
695593
399925
440
35600
200241
189854
812347
468513
514466
39276
522617
314294
142843
258783
151420
900578
620977
80701
24832
866047
26938
14651
370825
106915
416729
1670019
403532
4420
124900
P+C 18159070
P+C
308267
P+C 5964354
P+C 1420894
C
5691
C
24122
P+C 18467337
1243
61362
9439
90708
4931
12354
17662
3380
664
1163
874
8
64676
374
448
241
8
496
143415
40768
6
7401
678207
2600
4077547
535931
4
19
680807
134
3000
-
27843
92
5140
17662
601
6
163
8
7
10282
216
348
49
-
491
24654
20634
3
341
106609
1274
535931
-
107883
8
8
-
4
0
867 /(7)
Imported cases /
(introduced cases)
232332
1144 2254 /(21)
239
2
6
0
7
5
41
244 /(5)
1
1109
58362
-
62850
4839
7173
2881
658
1000
866
1
54394
158
98
199
8
118724
20129
2
7060
4
19
Presumed and
confirmed cases at
community level
0
0
-
73944
-
0
-
0
0
-
0
36961
-
22558
-
0
-
0
-
0
12345
-
Inpatient malaria
cases
30164
51
1285
135132
495
2
6
0
0
1
77
4971
1171
56
375
0
163
24
1
6
55
169
1756
286
0
212562
292
153009
7689
0
0
212854
56
0
14
823
19
0
0
0
0
1
0
32
28
1
11
9
2
0
0
0
0
4
0
36
17
0
5368
5
3257
406
0
0
5373
Malaria attributed
deaths
Method
used
to
calulate3
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(2)
(1)
(1)
(1)
(2)
Cases
Inpatient malaria
cases
and deaths
(1b)
(1a)
(1b)
(1b)
(1b)
(1a)
(1a)
(1a)
(1a)
(1a)
(1a)
(1a)
(1b)
(1b)
(1b)
(1b)
(1b)
(1b)
(1b)
(1a)
(1b)
(1a)
(1a)
(1a)
(1a)
(1b)
(1a)
(1a)
(1b)
(1a)
(1b)
(1a)
(1b)
(2)
(2)
(2)
(1b)
(1a)
(1a)
(2)
Deaths
Lower
1000000
310000
940000
290000
-
530
180000
1000
86000
6600
45000
62000
8200
500
1900
740
75000
780
940
380
-
650
200000
57000
-
7800
2500000
640000
-
4200000
Cases
1500000
<50
690000
1300000
460000
0
0
0
<10
<50
0
570
250000
5400
132000
10400
63000
109000
11000
540
2400
830
0
95000
1100
1500
400
<10
800
230000
79000
<10
10600
3300000
1000000
0
<50
5700000
Point
Population
Estimates, 2013
2100000
1300000
1800000
710000
-
640
350000
17000
310000
23000
90000
170000
15000
610
3000
890
120000
2000
3400
450
-
980
260000
100000
-
20000
4100000
1600000
-
7300000
Upper
Country/
area
Lower
250
42
120
35
-
46
-
20
10
10
0
-
0
-
1800
71
-
3300
Deaths
1100
0
2000
3300
1100
0
0
0
0
0
0
<10
120
<50
150
<10
100
280
<10
<10
<10
0
0
<10
<10
<10
0
0
<10
<50
<100
0
<10
0
0
6700
2650
0
0
16500
Point
WHO
region
African
2000
4800
6500
2500
-
210
-
350
190
600
-
9200
5700
-
23000
Upper
219
South-East Asia
S
C
C
P+C
C
P+C
4903
638
51649
982
27868
922417
314820
638
233803
35570
2786135
N/A
N/A
6 895 283
N/A
N/A
N/A
6534558
N/A
566449
225034
6282484
60457356
N/A
566449
258883
68114964
7463577
99138690
50074401
572171
258883
92423338
Population
3923
644688
1443958
1 300 150
N/A
7015762
N/A
7463577
29901997
(1)
(1)
(1)
0
23
0
6
994
9
7086
0
332
-
0
332
18 675
579
7845
703
7220
55
10559
279
8532
638
18404
982
15752
200558
35570
2774019
875537
281068
293186
48
561674
130590
2142103
616
27
3121
258
78
3708
7808
4619218
0
73944
0
100791
124 760
4 918 713
1914920
0
22558
0
93 651
75 930
2 107 059
5727373
2894
173346
9
266118
25350
6 195 090
97381
90
972
1
801
297
99542
18000
16000
15000
(1a)
Cases
10000
27000
7900
23000
5800
20000
Estimates, 2013
49000
42000
35000
(1b)
<10
<50
Deaths
<50
470
420
390
(1b)
(1a)
(1b)
(1b)
<50
21000
16000
12000
(1b)
6900
<50
3100
110
3600
2000000
3300
1300000
3000
800000
(1a)
340
180
10
120000
93000
72000
55000
12000
5000
270
220
-
26000
6600
2300
<10
0
<50
130
120
<50
2300
540
120
10
10
-
(1b)
(1b)
(1b)
(1b)
(1a)
(1a)
(1b)
(1b)
(1b)
3200
-
1600
0
69
-
1000000
-
700000
<50
Deaths
500000
-
Method
used
to
calulate3
(1)
(1)
10
525
344
1184
1184
78
834
3995
4903
314820
Inpatient malaria
cases
and deaths
(1)
558911
(1)
9
203
3331
8749
32 850
63 024
766 /(8)
732
78846
409
200215
3923
281182
1443958
(1)
417
11 571
11 552
22625
25445
48071
P+C
294542
48071
294542
N/A
2089861
6194945
6689300
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
561
64
92
0
0
38
1
18
24
252027
10444
47
1533
5
3725
170
0
53 405
3297
64
29993
-
0
53463
64
29993
-
49
2864
379659
107260
41866
1154
28
20513
139
10356
850
722546
142807
110324
315
20
14331
203
14796
1855
1102205
252027
152195
1469
49
37921
342
25152
2921
C 138628331
C 1550296
P+C
890913
P+C
175574
C 1069817
C 1756528
P+C
117107
P+C
141116
P+C 4403633
1102205
252027
152195
122874
49
37921
342
26278
2921
N/A 138628331
N/A 1575907
N/A
890913
N/A
296979
0 1069817
N/A 1756528
N/A
117107
N/A
142242
N/A 4403633
181340816
29945525
8448712
1022742
N/A
5418078
389732
7376802
196 134
12952915410 11787153010
254454778 66484155
53437159
31804541
28174724 13509780
20618991
N/A
67725979 33862990
1157360
1038282
15328136 10839973
13772404510 575 984 744
(1)
10535
10535
38201
P+C
11212
38878
11684511
N/A
N/A
25026772
(1)
(1)
45
0
2062
-
36885
-
47264
-
29
489
31
9727
17
10216
48
Cases
Estimates, 2013
(1b)
(1a)
Method
used
to
calulate3
125201
28716
P+C
P+C
10216
48
125201
28716
N/A
121441
4231462
N/A
16480430
N/A
159077513
765008
Inpatient malaria
cases
and deaths
African
Region of the Americas
Eastern Mediterranean
European
South-East Asia
Western Pacific
Total
Regional summary
Bangladesh
Bhutan
Democratic
Peoples
Republic of
Korea
India
Indonesia
Myanmar
Nepal
Sri Lanka
Thailand
Timor-Leste
Cambodia
China
Lao Peoples
Democratic
Republic
Malaysia
Papua New
Guinea
Philippines
Republic of
Korea
Solomon
Islands
Vanuatu
Viet Nam
Population
Number of people
living in active foci
UN population
UN Population
Suspected malaria
cases
At risk
(low + high)
At risk
(low + high)
At risk
(high)
At risk
(high)
Imported cases /
(introduced cases)
Imported cases /
(Introduced cases)
Country/
area
Presumed and
confirmed malaria
cases
Presumed and
confirmed malaria
cases
Number of people
living in active foci
Presumed and
confirmed cases at
community level
Presumed and
confirmed cases at
community level
Western Pacific
Malaria
case definition
Malaria
case definition
Suspected malaria
cases
Point
WHO
region
Deaths
Point
Inpatient malaria
cases
Inpatient malaria
cases
Deaths
Lower
Upper
Malaria attributed
deaths
Malaria attributed
deaths
Upper
Lower
Lower
Cases
Cases
Lower
Point
Upper
Point
Upper
220
221
222
African
WHO region
Chad
Central
African
Republic
Cameroon
Cabo Verde
Burundi
Burkina Faso
Botswana
Benin
Angola
Algeria
Country/
area
541
27 733
541
506
2 080 348
71 555
3 252 692
484 249
308 095
144
6843
144
89 614
437 041
45 283
40 078
-
2000
435
26 411
435
427
1 249 767
717 290
48 281
352 587
30 006
3 345 881
508 558
312 015
107
7141
107
140 742
451 182
43 180
38 287
-
2001
307
18 803
307
299
1 862 662
782 818
28 907
1 188 870
32 796
2 626 149
530 019
327 138
76
8022
76
43 093
517 004
44 689
43 933
-
2002
427
17 059
427
421
3 246 258
819 256
23 657
1 443 184
31 256
2 243 185
600 369
353 459
68
6001
68
78 094
505 732
54 381
45 195
-
2003
163
16 686
163
160
2 489 170
853 034
22 404
1 546 644
52 874
18 256
1 749 892
608 017
363 395
45
9833
45
129 367
481 122
1525
1360
-
2004
299
18 392
299
297
2 329 316
889 572
803 462
11 242
1 615 695
73 262
21 335
2 334 067
903 942
327 464
68
7902
68
277 413
131 856
501 846
37 439
31 668
-
2005
117
13 869
117
116
2 283 097
1 029 198
106 801
53 200
861 847
23 514
2 060 867
122 047
44 265
2 265 970
1 034 519
649 756
251 925
141 975
80
6979
80
1750
634 507
114 403
251 354
62 895
45 155
-
2006
288
14 745
288
261
2 726 530
1 458 123
1 295 535
506 756
237 950
1 171 522
16 983
14 200
381
113
9
2 487 633
127 120
44 246
2 079 861
1 411 407
860 606
406 738
241 038
18
7402
18
1500
604 153
119 477
518 832
64 884
48 288
-
2007
196
11 964
196
192
3 432 424
2 118 053
1 106 534
541 291
271 458
1 147 005
17 886
23 253
914
941
13
3 790 238
138 414
36 514
1 950 266
1 161 153
690 748
330 915
185 993
35
7033
35
2000
1 650 749
152 260
478 987
64 171
47 757
-
2008
94
15 635
94
90
3 726 606
2 172 036
1 120 410
906 916
453 012
1 256 708
534 590
355 007
14 878
17 553
951
1053
73
4 537 600
137 632
59 420
182 658
123 107
2 588 830
1 537 768
893 314
472 341
292 308
65
65
21 913
1 883 199
175 210
549 048
74 791
-
2009
408
12 224
408
396
3 687 574
1 947 349
1 324 264
639 476
358 606
1 432 095
12 196
1046
5 723 481
177 879
88 540
940 985
715 999
4 255 301
2 825 558
1 599 908
273 324
163 539
47
47
1 845 691
66 484
544 243
89 749
75 342
309 927
125 106
-
2010
191
11 974
191
187
3 501 953
1 765 933
1 147 473
833 753
484 809
1 424 335
88 134
68 745
475 986
354 223
1141
432
5 024 697
400 005
83 857
450 281
344 256
3 298 979
2 859 720
1 485 332
181 489
86 542
36
26 508
36
29
1 829 266
1 110 308
120 466
221 980
528 454
86 348
114 122
94 778
-
2011
887
15 790
887
828
3 031 546
2 245 223
1 056 563
1 069 483
440 271
1 513 212
243 008
825 005
705 839
308
193
6 970 700
223 372
90 089
4 516 273
3 767 957
2 570 754
2 659 372
1 484 676
1 148 965
666 400
36
8715
36
35
1 589 317
1 182 610
93 392
459 999
55 746
46 759
660 575
69 789
-
2012
2013
266
8690
266
260
3 180 021
3 398 029
1 431 313
1 855 400
867 666
1 509 221
155 205
108 714
1 335 582
935 521
1485
1346
8 280 183
198 947
83 259
6 224 055
5 345 396
4 831 758
4 471 998
2 718 391
2 903 679
1 866 882
46
6894
46
20
1 369 518
1 086 095
1 254 293
495 238
55 943
41 436
369 208
253 652
1 513 772
160 260
1 137 455
753 772
-
2014
African
WHO region
Ghana
Gambia
Gabon
Ethiopia
Eritrea
Equatorial
Guinea
Democratic
Republic of
the Congo
Cte dIvoire
Congo
Comoros
Country/
area
801 784
15 751
964 623
3758
897
127 024
50 810
3 349 528
-
2000
879 032
11 981
1 193 288
2 199 247
3244
1531
125 746
22 637
9716
2 555 314
851 942
392 377
132 918
53 167
481 590
3 044 844
-
2001
1 104 310
7677
1 109 751
2 640 168
3704
1735
74 861
52 228
6078
2 929 684
1 115 167
427 795
157 440
62 976
620 767
3 140 893
-
2002
867 398
1633
1 136 810
4 386 638
4820
2438
65 517
52 428
10 346
3 582 097
1 010 925
463 797
166 321
58 212
540 165
3 552 896
-
2003
43 918
12 874
293
1 275 138
4 133 514
5320
2684
27 783
41 361
4119
5 170 614
1 312 422
578 904
200 214
100 107
70 075
395 043
3 416 033
475 441
-
2004
29 554
6086
67
1 280 914
6 334 608
5531
2971
24 192
48 937
9073
3 901 957
1 364 194
538 942
235 479
129 513
70 644
329 426
3 452 969
655 093
0
-
2005
54 830
20 559
157 757
1 253 408
5 008 959
4779
2050
10 148
46 096
6541
3 038 565
785 209
447 780
111 527
136 916
33 458
427 598
3 511 452
472 255
0
-
2006
53 511
149 552
163 924
103 213
1 277 670
3 720 570
1 181 323
740 615
2275
243
20 948
10 752
5842
655
445
19 568
68 905
9528
7520
6037
2 557 152
739 627
451 816
190 749
142 406
45 186
439 798
3 123 147
476 484
-
2007
46 426
157 125
203 869
117 291
1 343 654
19 661
3527
4 933 845
2 613 038
1 618 091
428
127
67 196
11 815
7883
2572
1620
10 572
54 075
4364
6566
4400
2 532 645
986 323
458 561
187 714
151 137
40 701
508 846
39 164
3 200 147
1 100 238
956 359
143 879
138 124
-
2008
57 084
13 387
5982
150 583
203 160
92 855
1 847 366
34 755
7388
7 839 435
2 956 592
1 873 816
12 436
4889
84 532
15 960
11 603
3773
2581
21 298
68 407
6633
5126
3 043 203
2 065 237
927 992
262 877
108 324
113 803
1623
660
479 409
50 378
3 694 671
2 431 048
962 599
468 449
141 771
-
2009
103 670
87 595
35 199
5249
1339
446 656
1 721 461
62 726
9 252 959
3 678 849
2 374 930
54 728
42 850
78 095
42 585
39 636
16 772
14 177
53 750
79 024
13 894
22 088
4 068 764
2 509 543
1 158 197
185 105
54 714
12 816
7887
1120
194 009
290 842
52 245
123 564
64 108
3 849 536
2 031 674
1 029 384
247 278
42 253
-
2010
76 661
63 217
22 278
20 226
2578
277 263
37 744
2 588 004
49 828
29 976
9 442 144
4 226 533
2 700 818
2 912 088
1 861 163
37 267
23 004
20 601
2899
1865
39 567
67 190
15 308
25 570
19 540
3 549 559
3 418 719
1 480 306
178 822
261 967
172 241
71 588
190 379
4 154 261
1 172 838
624 756
781 892
416 504
-
2011
65 139
125 030
45 507
27 714
4333
120 319
120 319
2 795 919
195 546
107 563
1 572 785
1 033 064
9 128 398
4 329 318
2 656 864
3 327 071
2 134 734
20 890
33 245
13 196
6826
1973
42 178
84 861
11 557
33 758
10 258
3 876 745
3 778 479
1 692 578
188 089
66 018
18 694
4129
1059
300 363
156 580
29 325
705 862
271 038
10 676 731
4 219 097
2 971 699
1 438 284
783 467
-
2012
62 565
154 824
46 130
21 546
7026
183 026
69 375
43 232
0
0
4 708 425
395 914
215 104
3 384 765
2 291 849
11 363 817
4 126 129
2 611 478
6 096 993
4 103 745
25 162
27 039
11 235
5489
1894
34 678
81 541
10 890
39 281
10 427
3 316 013
8 573 335
2 645 454
185 196
90 185
26 432
10 132
2550
279 829
236 329
65 666
614 128
175 126
7 200 797
1 394 249
721 898
1 488 822
917 553
-
2013
2465
93 444
1987
9839
216
248 159
88 764
54 523
19 746
11 800
4 658 774
568 562
306 926
4 904 066
3 405 905
9 968 983
3 533 165
2 126 554
11 114 215
7 842 429
20 417
47 322
17 685
9807
2732
35 725
63 766
10 993
53 032
19 775
2 513 863
7 062 717
2 118 815
185 996
90 275
27 687
11 812
4213
166 229
286 111
66 253
317 313
99 976
8 453 557
1 987 959
970 448
3 610 453
2 445 464
-
2014
223
224
Country/
area
WHO region
African
816 539
4800
246 316
4 216 531
1 392 483
31 575
6946
3 646 212
546 634
-
2000
851 877
6238
202 379
3 262 931
1 386 291
33 354
8538
3 823 796
612 896
243 942
-
2001
850 147
16 561
194 976
3 319 399
43 643
20 049
1 598 919
27 752
5272
2 784 001
723 077
224 614
-
2002
731 911
107 925
162 344
5 338 008
96 893
39 383
2 198 297
37 333
6909
3 358 960
809 428
318 120
792
792
-
2003
876 837
103 069
187 910
7 545 541
59 995
28 328
1 458 408
39 174
7638
2 871 098
1 969 214
224 840
743
743
-
2004
850 309
50 452
185 493
33 721
14 659
9 181 224
44 875
8718
5025
57 325
39 850
1 229 385
37 943
6753
3 688 389
962 706
223 472
500
500
-
2005
834 835
41 228
16 554
12 999
148 720
34 862
15 120
8 926 058
1 171 175
165 095
115 677
880 952
645 738
1 087 563
29 318
5689
4 498 949
1 022 592
188 025
31 013
1061
392
392
74
-
2006
888 643
28 646
21 150
15 872
140 205
34 384
14 284
9 610 691
694 428
123 939
80 373
508 987
411 899
736 194
30 921
4823
175 595
43 674
4 786 045
1 291 853
222 476
421
421
129
6 155 082
141 663
-
2007
657 003
33 405
148 542
31 083
11 299
839 903
839 903
726 905
238 752
157 920
635 855
449 032
352 870
30 566
4096
299 000
89 138
5 185 082
1 045 424
201 044
835
268
720
34
346
346
148
4 831 491
120 259
-
2008
812 471
20 932
20 866
14 909
156 633
25 379
11 757
8 123 689
1 035 940
327 392
212 657
676 569
626 924
299 094
23 963
2720
610 035
212 390
6 183 816
1 633 423
174 820
3717
603
4338
337
352
352
250
4 310 086
93 874
-
2009
1 092 554
20 936
140 143
48 799
30 239
56 455
20 152
6 071 583
2 384 402
898 531
2 675 816
335 973
212 927
998 043
709 246
293 910
24 393
2173
604 114
200 277
6 851 108
2 171 542
1 380 178
227 482
244 319
5449
909
2299
1085
396
2023
396
236
3 381 371
1 950 933
644 568
2 287 536
878 009
-
2010
1 189 016
43 549
5450
139 066
90 124
174 986
57 698
21 320
139 531
50 662
11 120 812
3 009 051
1 002 805
2 480 748
728 443
577 641
1 593 676
1 338 121
255 814
34 813
3447
739 572
221 051
5 338 701
119 996
50 526
580 708
253 973
1 961 070
974 558
307 035
154 003
3752
1130
7991
1796
92
1214
92
51
3 344 413
2 504 720
1 093 742
2 966 853
663 132
-
2011
1 220 574
191 421
125 779
129 684
61 048
23 547
97 047
26 834
9 335 951
4 836 617
1 426 719
164 424
26 752
1 800 372
772 362
507 967
1 276 521
899 488
395 149
38 453
3667
906 080
355 753
4 922 596
406 907
283 138
2 763 986
1 281 846
2 171 739
97 995
788 487
169 104
1865
255
3293
1633
72
1463
72
47
3 203 338
2 546 213
886 143
2 234 994
927 841
-
2012
775 341
63 353
147 904
132 176
58 909
17 733
102 079
36 851
9 750 953
6 606 885
2 060 608
655 285
274 678
1 483 676
818 352
496 269
1 144 405
747 951
387 045
41 316
4550
1 029 994
382 495
3 906 838
132 475
44 501
3 029 020
1 236 391
2 327 385
190 337
1 889 286
1 176 881
128 486
5510
957
3576
630
82
82
71
3 924 832
2 058 998
774 891
5 215 893
2 223 983
-
2013
1 595 828
116 767
82 818
577 389
98 952
106 882
35 546
197 536
57 885
9 655 905
7 444 865
2 415 950
850 884
392 981
1 066 107
1 318 801
302 708
912 382
561 496
433 101
35 840
3620
873 526
361 619
5 065 703
198 534
77 635
5 344 724
2 827 675
2 590 643
219 637
1 820 216
156 529
47 500
15 835
15
15
14
5 485 327
2 295 823
1 009 496
9 944 222
6 108 152
-
2014
Country/
area
WHO region
African
2 476 608
32 149
66 076
31 975
1 123 377
56 169
44 959
460 881
64 624
29 374
-
2000
538 512
41 636
1 340 142
2 253 519
1 003 793
748 806
423 493
44 034
83 045
42 086
931 682
55 494
12 920
447 826
4985
2206
26 506
26 506
237 712
12 854
24 123
1395
-
2001
445 803
23 984
888 345
2 605 381
1 073 546
951 797
506 028
50 953
93 882
50 586
960 478
54 257
14 425
507 130
10 605
3702
15 649
15 649
462 056
10 129
13 997
670
-
2002
468 259
20 295
681 783
56 460
2 608 479
1 217 405
1 071 519
553 150
47 830
81 372
42 656
1 414 383
85 246
26 865
524 987
12 298
3945
13 459
13 459
646 673
7203
12 564
342
-
2003
610 799
36 043
760 718
81 814
76 030
3 310 229
1 303 494
1 201 811
589 315
53 991
97 836
46 486
1 195 402
67 750
22 234
355 638
4985
2206
13 399
13 399
515 958
5140
6754
574
-
2004
339 204
23 339
817 707
107 092
46 170
21 230
9873
3 532 108
1 654 246
1 438 603
683 769
22 370
68 819
18 139
1 346 158
105 093
33 160
233 833
10 605
3702
3452
1106
7755
7755
337 582
6066
4587
279
-
2005
265 595
27 690
886 531
87 103
12 567
3956
3 982 372
1 429 072
1 523 892
573 686
7293
58 672
5146
1 555 310
138 254
48 070
160 666
12 298
3945
4675
987
14 456
12 098
116 473
7807
3985
155
-
2006
172 024
4242
1 308 896
1 308 896
55 628
1 308 896
193 399
2 969 950
946 569
1 754 196
382 686
2421
49 298
2421
1 170 234
195 487
78 278
90 161
40 054
653 987
6327
6327
101 008
6338
84
-
2007
132 130
24 361
1092
2 229 812
2 229 812
62 243
530 910
434 615
2 834 174
772 197
1 640 106
316 242
6258
38 583
1647
140 478
4611
737 414
48 324
24 830
487 188
217 096
932 819
235 800
154 459
7796
7796
136 492
116 555
52 011
5881
58
-
2008
87 402
16 059
505
2 358 156
2 358 156
79 066
312 802
230 609
4 295 686
335 201
144 644
1 247 583
2 637 468
698 745
6182
59 228
3798
60 649
2384
584 873
43 026
19 614
485 548
146 319
747 339
770 463
273 149
544 336
373 659
6117
6072
325 634
6624
106
-
2009
25 889
14 522
556
3 643 803
165 514
49 285
7 426 774
570 773
3 873 463
523 513
45 924
27 674
638 669
2 708 973
638 669
3346
48 366
2233
9989
507
707 772
27 793
17 750
651 737
325 920
934 028
718 473
218 473
1 609 455
715 555
8060
3787
276 669
4273
900 283
900 283
1722
87
181
-
2010
14 406
13 262
335
48 599
1525
3 157 482
130 658
68 529
1 130 514
712 347
4 306 945
672 185
242 526
208 858
1 602 271
208 858
8442
83 355
6373
33 924
2069
604 290
18 325
14 142
555 614
263 184
856 332
46 280
25 511
886 994
613 348
9866
178 387
5986
204 047
3880
795 784
112 024
797
130
419
170
2011
3163
7875
194
4 592 519
1 781 505
1 119 929
1 781 505
1 119 929
6 938 519
1 953 399
2 898 052
483 470
2 904 793
422 224
190 593
61 246
12 550
103 773
10 706
23 124
1844
634 106
19 946
15 612
524 971
265 468
1 945 859
194 787
104 533
1 975 972
1 432 789
6846
121 291
1632
30 053
3997
1 125 039
225 371
626
345
217
153
2012
4911
1507
136
32 495
4775
4 288 425
1 799 299
1 176 711
1 799 299
1 176 711
12 830 911
1 633 960
7 194 960
962 618
2 862 877
879 316
201 708
83 302
9243
73 866
6352
34 768
2891
772 222
24 205
20 801
668 562
325 088
1 715 851
185 403
76 077
2 377 254
1 625 881
8851
364 021
2572
239 705
6073
1 855 501
262 520
962
488
474
234
2013
15 914
1894
222
185 078
15 692
3 222 613
2 872 710
0
2 872 710
1 953 309
16 512 127
1 681 469
1 233 654
9 188 933
6 593 300
1 610 812
4 010 202
1 528 825
168 004
81 987
1754
33 355
569
58 090
1185
628 642
19 343
12 636
697 175
252 988
1 898 852
66 277
39 414
2 056 722
1 335 062
13 988
300 291
4101
240 622
7604
711
711
322
2014
225
226
Region of the
Americas
African
WHO region
Belize
Bahamas
Argentina
Zimbabwe
Zambia
Zanzibar
Mainland
United
Republic of
Tanzania
Uganda
Togo
Country/
area
3 552 859
45 643
53 533
17 734
45 643
53 533
17 734
3 337 796
440
7949
440
2
22
2
1486
18 559
1486
-
2000
498 826
5 624 032
369 474
53 804
38 537
324 584
20 152
44 890
53 804
18 385
3 838 402
215
6685
215
4
4
1162
18 173
1162
-
2001
583 872
7 536 748
1 100 374
557 159
413 361
123 352
42 468
369 394
71 384
25 485
43 967
51 968
16 983
3 760 335
125
5043
125
1
1
1134
15 480
1134
-
2002
490 256
9 657 332
1 566 474
801 784
11 418 731
4 350 487
1 976 614
11 379 411
4 296 588
1 960 909
39 320
53 899
15 705
4 346 172
122
3977
122
3
34
3
1084
15 480
1084
-
2003
516 942
10 717 076
1 859 780
879 032
11 930 393
5 579 910
2 502 382
11 898 627
5 528 934
2 490 446
31 766
50 976
11 936
4 078 234
1 815 470
115
3018
115
2
17
2
1066
17 358
1066
-
2004
437 662
9 867 174
2 107 011
1 104 310
11 466 713
8 037 619
2 764 049
11 441 681
7 993 977
2 756 421
25 032
43 642
7628
4 121 356
1 494 518
252
3018
252
1
9
1
1549
25 119
1549
-
2005
566 450
10 168 389
2 238 155
867 398
10 582 608
4 167 063
1 928 296
10 566 201
4 136 387
1 926 711
16 407
30 676
1585
4 731 338
1 313 458
212
6353
212
49
546
49
844
25 755
844
-
2006
715 615
231 860
117 720
188 225
103 390
11 978 636
2 348 373
1 045 378
8 571 839
4 661 982
1 845 917
8 562 200
4 638 471
1 845 624
9639
23 511
293
4 248 295
1 154 519
234 730
116 518
387
6353
387
6
6
845
22 134
845
-
2007
898 112
321 171
152 724
318 895
192 138
11 602 700
2 397 037
979 298
7 739 151
3 887 346
77
173 311
4508
7 643 050
3 830 767
96 101
56 579
77
173 311
4508
3 080 301
1 003 846
59 132
16 394
59 132
16 394
130
5157
130
14
35
14
540
25 550
540
-
2008
961 807
420 053
192 966
314 250
198 372
12 086 399
3 612 418
1 301 337
12 840 249
60 691
211
121 248
3031
12 752 090
88 159
60 691
211
121 248
3031
2 976 395
736 897
122 133
57 014
122 133
57 014
86
1455
86
0
256
26 051
256
-
2009
983 430
478 354
224 087
575 245
393 014
13 208 169
3 705 284
1 581 160
12 893 535
3 637 659
1 277 024
136 123
1974
12 819 192
3 573 710
1 276 660
74 343
63 949
364
136 123
1974
4 229 839
648 965
513 032
249 379
72
2547
72
46
1
27 272
1
150
27 366
150
-
2010
519 450
502 977
237 305
390 611
282 145
12 173 358
385 928
134 726
194 819
97 147
10 164 967
5 656 907
1 813 179
1 628 092
337 582
10 160 478
5 513 619
1 812 704
1 315 662
333 568
4489
143 288
475
312 430
4014
4 607 908
319 935
10 004
470 007
319 935
18
7872
18
18
6
31 013
6
79
22 996
79
7
2011
768 287
579 507
260 535
660 627
436 839
13 591 932
3 466 571
1 413 149
2 449 526
1 249 109
8 477 435
6 931 025
1 772 062
1 091 615
214 893
8 474 278
6 784 639
1 771 388
701 477
212 636
3157
146 386
674
390 138
2257
4 695 400
276 963
727 174
276 963
4
7027
4
4
0
37
20 789
37
4
2012
882 430
560 096
272 855
882 475
609 575
16 541 563
3 718 588
1 502 362
7 387 826
8 585 482
6 804 085
1 481 275
813 103
71 169
8 582 934
6 720 141
1 480 791
369 444
69 459
2548
83 944
484
443 659
1710
5 465 122
422 633
1 115 005
422 633
4
4913
4
4
26
25 351
26
4
2013
1 130 251
621 119
310 207
1 135 581
820 044
13 724 345
2 048 185
578 289
7 060 545
3 053 650
7 403 562
727 130
572 524
17 740 207
108 283
7 399 316
592 320
571 598
17 566 750
106 609
4246
134 810
926
173 457
1674
5 972 933
5 964 354
4 077 547
535 983
1 420 894
535 931
4
5691
4
4
19
24 122
19
0
2014
2000
31 469
143 990
31 469
613 241
2 562 576
613 241
144 432
478 820
144 432
1879
61 261
1879
1233
427 297
1233
104 528
544 646
104 528
753
279 072
753
3708
48 162
3708
53 311
246 642
53 311
24 018
209 197
24 018
-
Country/
area
WHO region
Region of the
Americas
15 765
122 933
15 765
388 303
2 274 610
388 303
231 233
747 079
231 233
1363
43 053
1363
1038
411 431
1038
108 903
538 757
108 903
362
111 830
362
3823
44 718
3823
35 824
198 114
35 824
27 122
211 221
27 122
-
2001
14 276
137 509
14 276
348 259
2 118 491
348 259
204 916
686 635
204 916
1021
17 738
1021
1296
391 216
1296
86 757
403 225
86 757
117
115 378
117
3661
44 718
3661
35 540
197 113
35 540
21 895
175 966
21 895
-
2002
20 343
158 299
20 343
408 886
2 009 414
408 886
180 956
640 453
180 956
718
9622
718
1529
349 717
1529
52 065
433 244
52 065
85
102 053
85
3839
32 402
3839
31 127
156 227
31 127
27 627
185 877
27 627
-
2003
14 910
163 307
14 910
5000
465 004
2 194 780
465 004
142 241
562 681
142 241
1289
9204
1289
2355
322 948
2355
28 730
357 633
28 730
112
94 819
112
3038
32 402
3038
28 955
148 729
28 955
28 866
151 938
28 866
-
2004
21 442
202 021
20 142
6000
1300
606 067
2 660 539
606 067
121 629
493 562
121 629
3541
12 767
3541
3837
397 108
3837
17 050
358 361
17 050
67
102 479
67
3414
32 402
3414
39 571
178 726
39 571
38 984
210 429
38 984
-
2005
19 725
208 616
18 995
6000
730
549 469
2 959 489
549 469
120 096
451 240
120 096
2903
24 498
2903
3525
446 839
3525
9863
318 132
9863
49
113 754
49
4074
32 402
4074
31 093
168 958
31 093
21 064
202 688
21 064
-
2006
14 610
180 316
14 610
1500
458 652
2 986 381
458 652
128 462
564 755
125 262
25 000
3200
1223
22 641
1223
2711
435 649
2711
8464
352 426
8464
40
95 857
40
4828
32 402
2797
2031
15 382
129 410
15 382
3000
11 656
178 005
11 656
-
2007
9748
159 826
9748
5000
315 746
2 726 433
315 746
80 559
470 381
79 230
22 754
1329
966
17 304
966
1840
381 010
1840
4891
384 800
4891
2758
33
97 872
33
3320
11 994
1341
1979
7198
173 678
7198
2000
11 815
137 247
11 815
-
2008
9743
132 633
9234
981
509
309 316
2 620 787
309 316
90 275
79 347
428 004
79 252
8362
95
262
4829
262
1643
353 336
1643
4120
446 740
4120
4992
20
83 031
20
3462
20 065
1433
2029
7080
154 652
7080
2000
13 673
169 309
13 673
-
2009
13 769
133 463
12 252
7394
1517
334 668
2 711 432
334 667
117 650
521 342
117 637
13
114
15 599
114
4
3414
469 052
2482
26 585
932
1888
481 030
1888
7800
24
115 256
24
7
1632
14 373
688
944
7384
235 075
7384
2000
0
22 935
212 863
22 935
-
2010
7143
143 272
6108
7390
1035
267 146
2 476 335
266 713
1486
433
64 436
396 861
60 121
21 171
4188
17
10 690
17
6
1616
421 405
1616
56 150
1233
460 785
1233
14
16
100 883
15
1
1
6
1209
14 429
505
704
6817
195 080
6817
29 506
201 693
29 471
0
35
-
2011
7415
121 944
6293
10 960
1122
242 758
2 325 775
237 978
23 566
4780
60 179
346 599
50 938
70 168
9241
8
7485
8
1
952
415 808
952
90 775
558
459 157
558
14
19
124 885
19
6
900
13 638
401
499
5346
186 645
5346
0
0
31 656
196 622
31 601
55
-
2012
7342
133 260
6272
10 789
1070
178 546
1 873 518
174 048
19 500
3719
51 722
284 332
44 293
42 723
7403
6
16 774
6
4
579
431 683
579
71 000
378
397 628
378
10
7
103 748
7
1
875
22 327
324
551
6214
153 731
6214
0
0
31 479
205 903
31 479
0
-
2013
7401
124 900
7401
143 415
1 658 976
142 031
11 043
1384
40 768
325 713
36 166
77 819
4602
6
4420
6
5
496
362 304
496
54 425
241
370 825
241
8
106 915
8
2
448
14 651
187
261
4931
264 269
4931
50 025
12 354
142 843
12 354
0
-
2014
227
228
Region of the
Americas
WHO region
Venezuela
(Bolivarian
Republic of)
Suriname
Peru
Paraguay
Panama
Nicaragua
Mexico
Jamaica
Honduras
Haiti
Country/
area
16 897
21 190
16 897
35 125
175 577
35 125
7
874
7
7390
2 003 569
7390
23 878
509 443
23 878
1036
149 702
1036
6853
97 026
6853
68 321
1 483 816
68 321
11 361
63 377
11 361
29 736
261 866
29 736
-
2000
9837
51 067
9837
24 149
174 430
24 149
6
596
6
4996
1 857 233
4996
10 482
482 919
10 482
928
156 589
928
2710
71 708
2710
78 544
1 417 423
78 544
16 003
67 369
16 003
20 006
198 000
20 006
-
2001
17 223
178 616
17 223
7
725
7
4624
1 852 553
4624
7695
491 689
7695
2244
165 796
2244
2778
99 338
2778
99 237
1 582 385
99 237
12 837
68 070
12 837
29 491
278 205
29 491
-
2002
14 063
137 891
14 063
9
394
9
3819
1 565 155
3819
6717
448 913
6717
4500
166 807
4500
1392
126 582
1392
88 408
1 485 012
88 408
10 982
43 241
10 982
31 719
344 236
31 719
-
2003
10 802
30 440
10 802
17 134
145 082
17 134
141
3879
141
3406
1 454 575
3406
6897
492 319
6897
5095
171 179
5095
694
97 246
694
93 581
1 438 925
93 581
8378
56 975
8378
46 655
420 165
46 655
-
2004
21 778
3 541 506
21 778
15 943
153 474
15 943
2500
88
2470
88
2967
1 559 076
2967
6642
516 313
6642
3667
208 582
3667
376
85 942
376
87 699
1 438 925
87 699
9131
59 855
9131
45 049
420 165
45 049
-
2005
32 739
87 951
32 739
11 947
125 162
11 947
2500
194
6821
194
2514
1 345 915
2514
3114
464 581
3114
11 563
1663
212 254
1663
823
111 361
823
64 925
1 438 925
64 925
3289
45 722
3289
37 062
479 708
37 062
-
2006
29 825
142 518
29 825
10 512
130 255
10 512
199
199
2361
1 430 717
2361
1356
521 464
1356
16 173
0
1281
204 193
1281
1341
92 339
1341
50 797
1 438 925
50 797
1741
31 768
1104
2224
637
41 749
392 197
41 749
4141
-
2007
36 774
168 950
36 774
8368
119 484
8368
22
30 732
22
2357
1 246 780
2357
762
533 173
762
10 000
0
744
200 574
744
348
94 316
341
1997
7
44 522
796 337
44 522
64 953
2709
28 137
2086
1774
623
32 037
414 137
32 037
-
2008
49 535
270 438
49 535
9313
108 529
9313
4000
0
22
34 149
22
2703
1 240 087
2703
610
544 717
610
9000
0
778
158 481
778
91
64 660
91
42 645
892 990
42 645
2499
33 279
1842
1438
538
35 828
370 258
35 828
-
2009
84 153
270 427
84 153
9685
152 961
9685
4000
12
10 763
12
1226
1 192 081
1226
7
692
535 914
692
18 500
0
418
141 038
418
27
62 178
27
9
31 546
744 627
31 545
23
1
1771
16 533
1574
541
138
45 155
400 495
45 155
-
2010
32 969
184 934
32 969
7618
152 451
7465
4000
45
9
5042
9
1130
1 035 424
1130
6
925
521 904
925
14 201
354
116 588
354
0
0
10
48 611
10
9
25 039
702 894
25 005
58
34
795
15 135
751
1025
20
45 824
382 303
45 824
-
2011
25 423
167 726
25 423
46
6439
155 165
6439
4000
10
5
842
1 025 659
842
9
1235
536 278
1235
16 444
0
844
107 711
844
0
0
15
31 499
15
13
31 570
758 723
31 436
562
569
17 464
306
4008
50
52 803
410 663
52 803
-
2012
26 543
172 624
20 586
5586
5428
144 436
5364
237
64
499
1 017 508
499
4
1194
517 141
1194
19 029
705
93 624
705
0
0
11
24 806
11
11
43 468
863 790
43 139
858
729
13 693
530
6043
199
78 643
476 764
78 643
-
2013
17 696
134 822
10 920
123 961
6742
3380
151 420
3380
1427
102
252
664
900 578
664
8
1163
605 357
1163
15 620
874
80 701
874
0
0
8
24 832
8
8
64 676
864 413
64 676
1634
400
16 559
254
10 379
120
90 708
522 617
90 708
-
2014
Eastern
Mediterranean
WHO region
Somalia
Saudi Arabia
Pakistan
Oman
Morocco2
Iraq
Iran (Islamic
Republic of)
Egypt
Djibouti
Afghanistan
Country/
area
203 911
257 429
94 475
4667
17
1 155 904
17
17
19 716
1 732 778
19 716
7422
1860
1860
59
277 671
59
56
694
494 884
694
688
3 337 054
82 526
6608
6608
1872
10 364
-
2000
4312
11
1 357 223
11
11
19 303
1 867 500
19 303
10 379
1265
997 812
1265
59
335 723
59
59
635
521 552
635
633
3 577 845
3 572 425
125 292
3074
821 860
3074
1471
10 364
-
2001
626 839
5021
10
1 041 767
10
10
15 558
1 416 693
15 558
6436
952
1 072 587
952
107
345 173
107
88
590
495 826
590
584
4 238 778
3 399 524
107 666
2612
825 443
2612
1402
96 922
21 350
15 732
-
2002
585 602
360 940
5036
5036
45
45
45
23 562
1 358 262
23 562
6502
347
681 070
347
3
73
405 800
73
69
740
409 532
740
734
4 210 611
4 577 037
125 152
2592
1724
819 869
1724
1024
23 349
12 578
7571
-
2003
273 377
248 946
242 022
2142
122
43
43
43
13 821
1 326 108
13 821
6219
155
913 400
155
5
56
405 601
56
55
615
326 127
615
615
1 958 350
4 243 108
126 719
1101
1232
780 392
1232
924
36 732
30 127
11 436
-
2004
326 694
338 253
116 444
2469
1913
413
23
23
23
18 966
1 674 895
18 966
4570
47
944 163
47
10 824
0
3
100
100
100
544
258 981
544
544
4 022 823
4 776 274
127 826
290
1059
715 878
1059
855
28 404
47 882
12 516
-
2005
414 407
460 908
86 129
6457
1796
29
29
29
15 909
1 131 261
15 909
2782
24
970 000
24
1
83
83
83
443
242 635
443
443
4 314 637
4 490 577
124 910
1149
1278
804 087
1278
1008
49 092
16 430
-
2006
456 490
504 856
92 202
4694
3461
210
30
23 402
30
30
15 712
1 074 196
15 712
2434
3
844 859
3
1
75
367 705
75
75
705
244 346
705
701
4 553 732
4 905 561
128 570
190
2864
1 015 781
2864
2397
50 444
16 675
-
2007
467 123
549 494
81 574
3528
2896
119
80
34 880
80
80
11 460
966 150
11 460
3111
6
1 105 054
6
4
142
292 826
142
142
965
245 113
965
957
4 658 701
3 775 793
104 454
120
1491
1 114 841
1491
1430
82 980
73 985
36 905
-
2008
390 729
521 817
64 880
2686
2686
94
41 344
94
94
6122
744 586
6122
1645
1
1 493 143
1
1
145
290 566
145
145
898
234 803
898
898
4 242 032
3 655 272
132 688
243 521
34 891
2333
1 078 745
2333
2275
72 362
59 181
25 202
-
2009
392 463
524 523
69 397
1010
1010
85
664 294
85
85
3031
614 817
3031
1184
7
1 849 930
7
7
218
232 598
218
215
1193
226 009
1193
1169
4 281 356
4 281 346
220 870
279 724
19 721
1941
944 723
1941
1912
24 553
20 593
5629
200 105
18 924
-
2010
482 748
531 053
77 549
0
0
230
124
116
116
116
3239
530 470
3239
1529
11
2 097 732
11
0
11
312
171 400
312
312
1531
267 353
1531
1518
4 065 802
4 168 648
287 592
518 709
46 997
2788
1 062 827
2788
2719
41 167
26 351
1627
35 236
1724
-
2011
391 365
511 408
54 840
0
0
27
1410
22
3
206
818 600
206
206
1629
479 655
1629
0
0
842
8
1 963 638
8
0
0
8
364
285 039
364
0
0
364
2051
269 990
2051
0
0
2029
4 285 449
4 497 330
250 526
410 949
40 255
3406
1 186 179
3406
0
0
3324
35 712
37 273
6817
-
2012
319 742
507 145
39 263
0
0
1684
7189
939
262
262
262
1373
385 172
1373
853
8
1 796 587
8
8
314
108 432
314
0
0
314
1451
230 041
1451
0
0
1440
3 472 727
3 933 321
196 078
628 504
85 677
2513
1 309 783
2513
2479
9135
67 464
7407
-
2013
290 079
514 466
61 362
9439
39 284
9439
313
313
291
1243
468 513
1243
867
2
1 595 338
2
2
493
110 858
493
493
1001
184 996
1001
986
3 666 257
4 343 418
193 952
779 815
81 197
2305
1 249 752
2305
2254
26 174
64 480
11 001
-
2014
229
230
European
Eastern
Mediterranean
WHO region
Turkey
Tajikistan
Russian
Federation
Kyrgyzstan
Georgia
Azerbaijan
Armenia2
Yemen
Syrian Arab
Republic3
Sudan
Country/
area
4 332 827
368 557
42
42
36
1 394 495
1 394 495
141
356
141
0
1526
527 688
1526
245
245
0
12
70 500
12
0
795
795
0
233 785
233 785
19 064
11 432
1 597 290
11 432
0
-
2000
3 985 702
203 491
79
79
16
79
174
79
0
1058
536 260
1058
439
3574
438
0
28
72 020
28
0
898
898
0
248 565
248 565
11 387
10 812
1 550 521
10 812
0
-
2001
3 054 400
280 550
27
27
12
187 159
556 143
75 508
52
165
52
0
506
507 252
506
474
6145
474
0
2743
69 807
2743
0
642
642
0
244 632
244 632
6160
10 224
1 320 010
10 224
0
-
2002
3 084 320
933 267
24
24
22
265 032
398 472
50 811
29
126
29
0
482
536 822
482
316
5457
316
0
468
144 070
468
0
533
533
0
296 123
296 123
5428
9222
1 187 814
9222
0
-
2003
2 083 711
537 899
13
13
12
158 561
501 747
48 756
47
220
47
0
386
545 145
386
257
3365
257
0
93
79 895
93
0
382
382
0
272 743
272 743
3588
5302
1 158 673
5302
0
-
2004
2 515 693
628 417
28
28
28
200 560
472 970
44 150
7
209
7
0
242
515 144
242
155
5169
155
0
226
114 316
226
0
205
205
0
216 197
216 197
2309
2084
1 042 509
2084
0
-
2005
2 117 514
721 233
34
34
34
217 270
799 747
55 000
0
230
0
0
0
143
498 697
143
0
60
4400
60
0
1
318
74 729
318
0
1
143
143
0
41
175 894
175 894
1344
28
796
934 839
796
0
29
2006
3 040 181
2 243 981
686 908
37
68 000
37
37
223 299
585 015
67 607
303
70
1
658
1
0
1
110
465 033
110
1
25
3400
25
0
0
96
62 444
96
0
0
122
35 784
122
0
42
159 232
159 232
635
7
358
775 502
358
0
29
2007
3 073 996
2 050 354
569 296
51
51
51
158 608
781 318
43 545
5015
661
1
30 761
1
0
1
73
408 780
73
1
8
4398
8
0
2
18
40 833
18
0
0
96
28 340
96
0
47
158 068
158 068
318
0
215
616 570
215
0
49
2008
2 361 188
2 791 156
711 462
39
25 751
39
39
138 579
797 621
53 445
18 566
2001
0
31 467
0
0
0
80
451 436
80
0
2
7
4120
7
0
6
4
33 983
4
0
0
107
27 382
107
0
107
165
165 266
165
1
84
606 875
84
0
46
2009
1 465 496
625 365
1 653 300
95 192
23
19 151
23
23
198 963
645 463
78 269
97 289
28 428
1
31 026
1
1
52
456 652
52
2
0
2368
0
0
6
30 190
6
3
102
33 024
102
101
112
173 523
112
1
78
507 841
78
69
2010
1 214 004
506 806
2 222 380
48
25 109
48
0
48
142 147
645 093
60 207
108 110
30 203
0
8
449 168
8
4
6
2032
6
5
5
27 850
5
5
85
28 311
85
83
78
173 367
78
13
128
421 295
128
127
2011
964 698
526 931
2 000 700
42
19 136
42
0
0
42
165 678
685 406
68 849
150 218
41 059
4
497 040
4
1
5
1046
5
4
3
18 268
3
3
33
209 239
33
15
376
337 830
376
157
2012
989 946
592 383
1 800 000
22
18 814
22
22
149 451
723 691
63 484
157 457
39 294
4
432 810
4
4
7
192
7
7
4
54 249
4
4
14
213 916
14
7
285
255 125
285
251
2013
1 207 771
579 038
788 281
489 468
21
6803
21
21
97 089
585 826
37 763
109 767
29 750
2
399 925
2
2
6
440
6
6
0
35 600
0
0
7
200 241
7
5
249
189 854
249
244
2014
South-East
Asia
European
WHO region
Sri Lanka
Nepal
Myanmar
Indonesia
India
Democratic
Peoples
Republic of
Korea
Bhutan
Bangladesh
Uzbekistan
Turkmenistan2
Country/
area
Microscopy examined
90 389 019
86 790 375
2 031 790
256993
1880418
256993
581 560
381 610
120 083
48 686
100 063
7981
210 039
1 781 372
210 039
-
8
50 075
8
77
691 500
77
320 010
250 258
54 216
5982
65 974
5982
300 000
143 674
143 674
2 085 484
2001
24
50 105
24
126
735 164
126
437 838
360 300
55 599
5935
76 445
5935
204 428
90 582
2 031 790
2000
1 841 227
273793
1440302
273793
721 739
467 871
173 096
133 431
183 519
12 750
41 411
1 390 850
41 411
-
91 617 725
18
59 834
18
74
735 164
74
313 859
275 987
62 269
6511
74 696
6511
241 192
129 889
16 578
1 841 227
2002
1 869 403
223065
1224224
223065
716 806
481 201
177 530
196 605
196 223
9506
10 510
1 192 259
10 510
-
99 136 143
7
72 643
7
74
812 543
74
489 377
245 258
54 654
3806
61 246
3806
60 559
32 083
16 538
1 869 403
2003
1 915 363
304936
2445538
304936
602 888
432 581
152 070
140 687
158 044
4895
3720
1 198 181
3720
-
97 111 526
3
71 377
3
66
893 187
66
386 555
185 215
58 894
2670
54 892
2670
33 803
27 090
1 915 363
2004
1 816 569
315394
2113265
315394
516 041
437 387
165 737
178 056
188 930
5050
1640
974 672
1640
-
1
56 982
1
102
917 843
102
290 418
220 025
48 121
1825
60 152
1825
11 507
11 315
1 816 569
2005
2007
1
0
58 673
65 666
1
0
0
0
76
89
924 534
858 968
76
89
3
2
164 159
59 866
209 991
266 938
32 857
58 659
3199
1207
1868
793
66 079
51 446
1868
793
12 983
4795
7985
12 983
4795
1 785 109
1 508 927
106 606
86 355 000
703
1 785 109
1 508 927
- 8 500 000
347597
333792
1233334
1223686
347597
333792
538 110
520 887
485 251
512 862
203 071
216 510
499 725
157 448
166 474
135 809
166 476
135 809
4969
5621
591
198
1 076 121
1 047 104
591
198
-
2006
1 532 497
9 000 000
266277
1230495
266277
13314
634 280
499 296
223 174
543 941
223 899
153 331
153 331
3888
670
1 047 104
670
-
86 734 579
1
75 524
1
1
27
883 807
27
20
168 885
336 505
50 004
106 001
34 686
450
47 268
329
16 989
24 299
16 989
378
1 532 497
2008
2010
0
0
94 237
81 784
0
0
0
0
4
5
916 839
921 364
4
5
0
4
2
79 853
91 227
397 148
308 326
25 203
20 519
156 639
152 936
38 670
35 354
1421
487
62 341
54 709
972
436
14 845
13 520
34 818
25 147
14 845
13 520
213
1 563 574
1 599 986
103 396
108 679 429
076
1 563 574
1 599 986
9 100 000 10 600 000
418439
465764
1420795
1335445
418439
465764
20922
21964
591 492
693 124
381 424
275 374
164 965
103 285
599 216
729 878
271 103
317 523
123 903
96 383
150 230
102 977
3335
3115
17 887
779
558
736
909 632
1 001 107
558
736
52
2009
0
1
886 243
1
1
51 773
270 253
20 232
119 849
31 541
207
44 481
194
16 760
26 513
16 760
1 310 656
108 969
660
1 310 656
10 500 384
422447
962090
422447
31535
567 452
312 689
91 752
795 618
373 542
71 752
95 011
1910
25 353
1504
175
985 060
175
51
2011
1
805 761
1
1
29 518
253 887
4016
35 675
5885
82
42 512
82
0
23 537
39 238
21 850
0
0
0
1 067 824
109 033
790
1 067 824
13 125 480
417819
1429139
417819
29278
480 586
265 135
75 220
1 158 831
405 366
70 272
152 780
1659
22 472
433
93
948 250
93
70
2012
1 102 205
14 562 000
252027
1300835
252027
16410
152 195
93 842
11 952
797 071
140 243
122 874
127 130
1469
48 444
49
1 069 817
49
49
1
812 347
1
1
10 216
78 719
3249
46 482
6967
48
33 586
48
29
11 212
38 201
10 535
0
0
0
1 102 205
2014
3
908 301
3
3
3864
74 755
1866
19 171
1998
45
31 632
45
23
15 673
71 453
14 407
0
0
0
881 730
2013
231
232
Western Pacific
South-East
Asia
WHO region
Solomon
Islands
Republic of
Korea
Philippines
Papua New
Guinea
Malaysia
Lao Peoples
Democratic
Republic
China
Cambodia
Timor-Leste
Thailand
Country/
area
78 561
4 403 739
78 561
15 212
15 212
203 164
122 555
51 320
18 167
11 122
279 903
256 273
40 106
874 894
1 832 802
12 705
1 751 883
225 535
79 839
36 596
4183
368 913
300 806
68 107
-
2000
63 528
4 100 778
63 528
83 049
110 161
121 691
42 150
23 928
11 451
26 945
5 391 809
21 237
103 983
226 399
27 076
875 849
1 808 759
12 780
1 643 075
254 266
94 484
34 968
2556
373 838
297 345
76 493
-
2001
44 555
3 819 773
44 555
86 684
60 311
26 651
100 194
108 967
38 048
24 954
8854
172 200
5 641 752
25 520
556
85 192
245 916
21 420
842 683
1 761 721
11 019
1 587 580
227 387
75 748
37 005
1799
353 114
278 178
74 936
-
2002
37 355
3 256 939
37 355
33 411
83 785
33 411
119 712
106 330
42 234
54 024
29 031
169 828
4 635 132
28 491
621
88 657
256 534
18 894
754 540
1 632 024
6338
1 650 662
205 103
72 620
48 441
1171
208 364
300 591
92 227
-
2003
26 690
3 012 710
26 690
202 662
79 459
39 164
91 855
99 593
37 389
51 359
22 356
145 676
4 212 559
27 197
1714
53 808
181 259
16 183
678 952
1 577 387
6154
1 868 413
222 903
91 055
50 850
864
412 251
321 954
90 297
-
2004
29 782
2 524 788
29 782
130 679
97 781
43 093
67 036
88 991
26 914
58 791
22 522
100 106
3 814 715
21 936
2632
30 359
156 954
13 615
573 788
1 425 997
5569
1 788 318
267 132
92 957
46 342
581 871
12 125
1369
393 288
316 898
76 390
-
2005
30 294
2 280 070
30 294
164 413
96 485
37 896
89 109
94 460
33 010
102 590
45 686
116 260
3 995 227
35 383
2097
20 468
113 165
8093
95 676
10 289
590 945
1 388 267
5294
1 676 681
223 464
88 817
10 756
5121
35 405
378 535
18 171
2051
403 892
328 555
75 337
-
2006
33 178
2 041 733
33 178
121 905
114 283
46 869
32 027
5944
59 848
135 731
22 081
46 989
20 437
133 699
3 958 190
29 304
1192
20 364
159 002
6371
113 694
11 087
551 586
1 565 033
5456
1 618 699
239 956
82 979
7643
3976
36 235
403 415
36 235
4839
2227
2227
150 126
311 447
65 404
-
2007
28 569
1 910 982
26 150
20 786
2419
143 594
92 870
45 973
30 134
5287
58 887
130 995
20 347
51 036
21 777
135 467
4 316 976
16 650
780
19 347
168 027
4965
143 368
14 382
588 489
1 562 148
7390
873
1 606 843
240 686
81 657
5955
2795
23 655
278 652
23 655
1052
1052
102 140
276 639
40 535
-
2008
29 462
1 816 383
23 327
68 437
6135
108 434
96 828
41 824
41 132
5703
83 777
96 886
24 999
94 788
39 596
14 598
4 637 168
9287
22 800
173 459
5508
84 511
9166
7010
1 565 982
7010
584
1 431 395
128 335
62 845
25 150
14 913
19 316
352 006
19 316
1345
1345
36
84 078
231 221
33 002
-
2009
32 480
1 695 980
22 969
81 997
9511
119 072
109 806
40 250
85 643
7887
49 356
90 175
14 277
103 035
35 079
7855
7 115 784
4990
23 047
150 512
4524
127 790
16 276
6650
1 619 074
6650
831
1 379 787
198 742
75 985
20 820
17 971
19 106
301 031
18 560
1772
1772
56
95 006
212 329
35 373
17 300
4331
-
2010
24 897
1 354 215
14 478
96 670
10 419
36 064
82 175
19 739
127 272
57 423
86 526
13 792
130 186
43 631
4498
9 189 270
3367
17 904
213 578
6226
7743
11 609
5306
1 600 439
5306
1142
1 151 343
184 466
70 603
27 391
13 457
9617
327 060
9552
838
838
64
80 859
182 847
23 202
17 457
3455
-
2011
32 569
1 130 757
32 569
6148
64 318
5211
117 599
45 553
80 212
10 124
108 974
30 352
2678
6 918 657
2603
2399
46 819
223 934
13 232
145 425
32 970
4725
1 566 872
4725
924
878 371
156 495
67 202
228 857
82 993
8154
332 063
7133
555
555
47
57 296
202 620
21 904
13 987
2479
-
2012
41 362
1 830 090
33 302
1042
56 192
1025
121 991
24 130
54 716
4598
94 600
16 711
4121
5 554 960
4086
4007
41 385
202 422
10 036
133 337
28 095
3850
1 576 012
3850
865
1 125 808
139 972
70 658
468 380
209 336
7720
317 360
5826
1523
688
443
443
50
53 270
191 137
21 540
26 216
4069
-
2013
37 921
1 756 528
37 921
342
30 515
342
86 592
0
26 278
48 591
5288
92 525
19 864
2921
4 403 633
2921
2864
48 071
133 916
8018
160 626
40 053
3923
1 443 958
3923
766
644 688
83 257
68 114
475 654
213 068
4903
286 222
3618
28 598
1285
638
638
78
51 649
173 900
13 865
26 658
4539
-
2014
Country/
area
2001
33 779
19 493
31 668
36 576
6768
7647
274 910
188 122
2 682 862
2 821 440
74 316
68 699
10 000
2000
2001
33178671 44481658
9312314
7602649
248086
261964
1181104
982778
3871042
3999981
3828225
3378990
51619442 60708020
2000
35 151
54 234
14 339
151 961
2 856 539
47 807
94 000
2002
47844356
8228975
259365
895134
3704402
3366879
64299111
2002
43 386
54 524
15 240
135 989
2 738 600
38 790
2003
69120148
8200465
307254
889993
3640897
3220750
85379507
2003
42 008
53 524
14 653
108 350
2 694 854
24 909
2004
74251865
4528808
279279
909466
3619974
3453027
87042419
2004
34 912
61 092
9834
84 473
2 728 481
19 496
2005
75645235
7117410
219219
1050744
3291911
3119991
90444510
2005
30 067
40 625
8055
74 766
2 842 429
22 637
130 000
2006
75736127
7137177
177431
921236
3211598
3039644
90223213
2006
Western Pacific
WHO region
20 215
38 214
5471
59 601
3 634 060
16 389
78 294
2007
79810658
8348266
160033
788428
2720150
2652600
94480135
2007
2009
2010
2011
2012
2013
2014
24 279
22 271
16 831
5764
3435
2381
982
30 267
24 813
29 180
19 183
16 981
15 219
18 135
3473
3615
4013
2077
733
767
190
1639
2065
10 246
12 529
16 292
13 724
17 435
292
574
4156
2743
2702
1614
792
51 668
49 186
54 297
45 588
43 717
35 406
27 868
1 297 365
2 829 516
2 760 119
2 791 917
2 897 730
2 684 996
2 357 536
11 355
16 130
17 515
16 612
19 638
17 128
15 752
72 087
44 647
7017
491 373
514 725
412 530
416 483
2008
2009
2010
2011
2012
2013
2014
71715909 94061289 103145240 100205022 110913398 124458213 126256273
8459131
7217208
6370339
5954143
5850635
4948628
5302187
158507
451
356
311
422
317
265
565443
573032
678386
493915
469577
434398
389660
2945542
2931981
3112779
2502183
2128448
1640960
1689089
2611827
1735776
1653707
1379140
1091303
1298514
811921
86456359 106519737 114960807 110534714 120453783 132781030 134449395
2008
233
234
Country/area
Suspected
No Pf
Algeria
No Pv
No Other
Suspected
No Pf
Angola
No Pv
No Other
Suspected
No Pf
Benin
No Pv
No Other
Suspected
No Pf
Botswana
No Pv
No Other
Suspected
No Pf
Burkina Faso
No Pv
No Other
Suspected
No Pf
Burundi
No Pv
No Other
Suspected
No Pf
Cabo Verde
No Pv
No Other
Suspected
No Pf
Cameroon
No Pv
No Other
Suspected
No Pf
Central African Republic
No Pv
No Other
Suspected
No Pf
Chad
No Pv
No Other
Suspected
No Pf
Comoros
No Pv
No Other
Suspected
No Pf
Congo
No Pv
No Other
Suspected
No Pf
Cte dIvoire
No Pv
No Other
Suspected
No Pf
Democratic Republic of the Congo
No Pv
No Other
Suspected
No Pf
Equatorial Guinea
No Pv
No Other
WHO region
African
27 733
261
277
2 080 348
71 555
3 428 846
6843
144
0
89 614
442 246
20 977
19 101
967 484
889
-
2000
26 411
247
181
1 249 767
717 290
48 281
382 593
0
3 542 424
7141
107
0
140 742
456 075
19 520
18 767
1 193 288
2 200 960
1517
-
2001
18 803
188
116
1 862 662
782 818
28 907
1 221 666
0
2 829 030
8022
76
0
517 760
21 959
21 974
1 109 751
2 642 137
1727
-
2002
17 059
313
111
3 246 258
819 256
23 657
1 474 440
0
2 490 095
6001
68
0
78 094
514 918
21 532
23 663
1 136 810
4 389 020
2418
6
-
2003
16 686
71
92
2 489 170
853 034
22 404
1 581 262
0
1 994 514
9833
45
0
129 367
481 287
665
695
43 918
1 275 138
4 136 150
2659
7
-
2004
18 392
242
57
2 329 316
803 462
11 242
1 667 622
0
2 910 545
7902
68
0
277 413
131 856
507 617
14 770
16 898
29 554
1 280 914
6 337 168
2844
110
-
2005
13 869
91
24
2 283 097
106 400
861 847
23 514
2 138 649
0
2 760 683
283 950
8729
160
0
634 507
114 403
269 094
21 354
23 801
54 830
157 757
1 253 408
5 011 688
2043
3
-
2006
14 745
261
24
3 157 924
475 900
1 171 522
30 906
381
2 570 507
0
2 796 362
482 060
8902
36
0
0
604 153
119 477
535 428
24 282
24 006
53 511
210 263
103 213
0
0
1 277 670
4 163 310
1885
7
26 068
5842
-
2007
11 964
186
10
0
4 713 776
542 916
1 147 005
41 153
914
3 892 138
0
2 565 593
371 986
9033
70
0
0
1 650 749
152 260
495 401
24 015
23 742
46 426
243 703
117 291
0
0
1 359 788
5 929 093
1254
27
72 080
7883
-
2008
2009
2010
2011
15 635
12 224
11 974
88
401
179
6
4
12
0
3
0
5 232 136 4 591 529 4 469 357
1 256 708 1 432 095 1 565 487
534 590
68 745
0
0
0
0
32 460
12 196
1141
951
1046
432
4 675 363 6 037 806 5 446 870
3 413 317 5 590 736 4 768 314
21 913
47
26 508
65
47
36
0
0
0
0
0
0
1 883 199
1 845 691 3 060 040
175 210
66 484
221 980
623 839
743 471
528 454
64 489
159 976
135 248
5771
33 791
21 387
79
528
334
132
880
557
260 888
446 656
277 263
92 855
37 744
0
0
0
1 874 733
1 721 461 2 607 856
8 929 758 10 568 756 12 018 784
0
0
0
0
0
0
90 081
83 639
40 704
11 603
53 813
22 466
-
2012
12 762
550
30
23
5 273 305
2 041 444
506
912
7 857 296
7 384 501
10 621
46
0
3 652 609
491 074
1 272 841
185 779
46 032
72
363
209 169
43 232
0
0
5 982 151
14 871 716
4 103 745
0
0
44 561
13 129
-
2013
8690
203
50
13
6 134 471
1 955 773
1485
1346
9 274 530
7 622 162
6894
46
0
3 709 906
625 301
295 088
0
0
1 737 195
103 545
2203
0
0
290 346
66 323
0
0
6 418 571
14 647 380
57 129
17 452
-
2014
African
WHO region
Mozambique
Mayotte, France
Mauritania
Mali
Malawi
Madagascar
Liberia
Kenya
Guinea-Bissau
Guinea
Ghana
Gambia
Gabon
Ethiopia
Eritrea
Country/area
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
127 024
50 810
3 349 528
816 539
4800
246 316
4 216 531
1 417 112
3 646 212
546 634
-
2000
138 667
8994
722
3 014 879
233 218
157 625
132 918
53 167
481 590
3 044 844
851 877
6238
202 379
3 262 931
1 411 107
3 823 796
612 896
243 942
-
2001
121 011
5335
743
3 617 056
262 623
164 772
157 440
62 976
620 767
3 140 893
850 147
16 561
194 976
3 342 993
1 621 399
2 784 001
723 077
224 614
-
2002
107 599
8998
1348
4 129 225
291 402
171 387
166 321
58 212
540 165
3 552 896
731 911
4378
162 344
5 395 518
39 383
2 228 721
3 358 960
809 428
318 120
792
-
2003
65 025
3480
639
5 904 132
396 621
178 676
230 246
70 075
395 043
3 416 033
876 837
103 069
187 910
7 577 208
28 328
1 489 944
2 871 098
1 969 214
224 840
743
-
2004
64 056
7506
1567
4 727 209
374 335
158 658
294 348
70 644
329 426
3 452 969
850 309
50 452
204 555
9 181 224
66 043
44 875
1 260 575
3 688 389
962 706
223 472
500
-
2005
49 703
5750
791
3 375 994
293 326
149 020
214 985
33 458
427 598
3 511 452
834 835
41 228
168 462
8 926 058
1 455 807
761 095
1 111 192
4 498 949
1 022 592
217 977
392
375
3
2
-
2006
80 428
9057
6508
0
2 844 963
280 106
171 710
287 969
45 186
439 798
3 123 147
457 424
0
19 060
888 643
28 646
160 305
12 855
9 610 691
835 082
80 373
0
0
894 213
4 786 045
1 291 853
222 476
421
414
0
1
6 155 082
-
2007
62 449
5932
2832
0
3 060 407
285 261
173 300
298 150
40 701
508 846
3 349 781
918 105
0
38 254
657 003
33 405
168 326
839 903
839 903
994 560
157 920
0
0
589 202
5 185 082
1 045 424
202 297
346
335
4
7
4 831 491
-
2008
77 946
3389
3244
0
4 335 001
640 878
287 114
0
114 766
187
23
0
479 409
5 489 798
924 095
0
38 504
812 471
20 932
170 255
8 123 689
1 200 320
212 657
0
0
717 982
6 183 816
1 633 423
181 935
352
326
8
20
4 310 086
-
2009
96 792
9848
3989
57
5 420 110
806 577
390 252
0
233 770
2212
720
2015
492 062
64 108
5 056 851
926 447
0
102 937
1 092 554
20 936
195 006
7 557 454
898 531
3 087 659
212 927
0
0
719 967
6 851 108
3 324 238
250 073
2023
386
10
31
6 097 263
878 009
-
2010
2012
2013
97 479
138 982
134 183
10 357
12 467
13 873
4932
9204
7361
19
83
5 487 972 5 962 646 9 243 894
814 547
946 595
1 687 163
958 291
665 813
745 983
178 822
238 483
256 531
26 432
0
0
261 967
862 442
889 494
190 379
271 038
175 126
5 067 731 12 578 946 8 444 417
593 518 3 755 166
1 629 198
0
0
0
31 238
0
0
1 276 057 1 220 574
775 341
5450
191 421
63 353
0
0
300 233
237 398
238 580
13 127 058 12 883 521 14 677 837
1 002 805
1 453 471 2 335 286
2 887 105 2 441 800 2 202 213
577 641 1 407 455 1 244 220
0
0
805 701
980 262
1 071 310
5 734 906 6 528 505 5 787 441
- 1 564 984 1 280 892
2 628 593
2 171 739 2 849 453
162 820
172 374
135 985
1214
1463
82
86
70
77
1
5
2
0
4
7 059 112
6 170 561 8 200 849
663 132
927 841 2 998 874
-
2011
121 755
23 953
6780
35
7 457 765
1 250 110
868 705
256 183
26 117
0
1570
603 424
99 976
10 636 057
3 415 912
0
0
1 595 828
660 207
309 939
15 142 723
2 808 931
2 433 086
864 204
0
0
977 228
7 703 651
2 905 310
2 590 643
188 194
15
13
1
1
12 626 716
7 117 648
-
2014
235
236
African
WHO region
Zanzibar
Mainland
Uganda
Togo
Swaziland
South Sudan1
South Africa
Sierra Leone
Senegal
Rwanda
Nigeria
Niger
Namibia
Country/area
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
2 476 608
66 250
1 134 587
44 959
460 881
64 624
29 374
0
3 552 859
81442
17734
81 442
17 734
-
2000
538 512
1 340 142
2 253 519
1 329 106
84 993
974 256
14 261
450 605
2206
0
26 506
237 712
35 582
1395
0
498 826
5 624 032
404893
18385
324 584
80 309
18 385
-
2001
2002
2003
445 803
468 259
888 345
681 783
2 605 381 2 608 479
1 519 315
1 735 774
94 249
86 546
1 000 310 1 472 764
15 261
28 272
514 033
533 340
3702
3945
0
0
15 649
13 459
462 056
646 673
23 456
19 425
670
342
0
0
583 872
490 256
8 079 963 10 422 022
546 015
785 748
494245 13792604
16983
15705
415 293 13 715 090
78 952
77 514
16 983
15 705
-
610 799
766 502
53 637
3 310 229
1 915 990
105 341
1 240 918
23 171
358 417
2206
0
13 399
515 958
11 320
574
0
516 942
11 697 824
861 451
15007921
11936
14 937 115
70 806
11 936
-
2004
2005
339 204
889 986
74 129
3 532 108
2 409 080
73 050
1 418 091
38 746
243 082
3702
0
7755
337 582
10 374
279
0
437 662
10 869 875
1 082 223
16740283
7628
16 679 237
61 046
7628
-
2006
265 595
982 245
44 612
3 982 372
2 379 278
60 819
1 645 494
49 366
172 707
3945
0
14 456
116 473
11 637
155
0
566 450
11 539 146
850 050
12821375
1585
12 775 877
45 498
1585
-
2008
2009
2010
2011
2012
2013
172 024
155 399
102 956
39 855
74 407
10 844
34 002
1092
505
556
335
194
136
0
0
0
0
0
0
0
0
0
0
0
0
3 677 661 4 493 676 4 719 439 10 616 033 3 637 778
5 915 671 5 533 601
54 515
60 998
77 484
618 578
778 819 2 207 459 2 352 422
0
0
0
0
1113
1245
1581
5102
2 969 950 2 834 174 4 295 686 3 873 463 5 221 656 11 789 970 21 659 831
523 513
2 318 079 2 096 061 3 186 306 2 708 973
1 602 271 3 095 386 3 064 585
316 242
698 745
638 669
208 858
483 470
962 618
0
0
0
0
49 298
179 061
119 877
58 961
117 279
126 897
108 634
2219
6363
10 700
9242
14
4
1
1
0
6
0
1 337 550 1 031 000
947 514 1 043 632
900 903
897 943
1 119 100
118 332
194 234
19 614
343 670
277 326
281 080
345 889
0
0
0
0
653 987
1 014 160 1 415 330 2 327 928
1 150 747 2 579 296 2 576 550
273 149
218 473
25 511 1 537 322
1 701 958
6327
7796
6117
276 669
382 434
152 561
603 932
2193
6906
4565
8645
0
0
14
5
5
15
0
101 008
201 036
325 634
900 283
795 784
1 125 039 1 855 501
112 024
6338
5881
6624
1722
797
626
669
84
58
106
87
130
345
487
0
0
0
0
0
0
0
0
0
0
0
0
0
1
914 590
1 193 316 1 304 772
1 419 928
893 588
1 311 047
1 442 571
220 521
344 098
191 357
224 080
237 282
260 526
272 855
0
0
0
0
0
0
0
0
0
195
7
23
8
13 281 631 13 020 439 14 397 480 15 332 293 12 522 232 16 845 771 26 145 615
1 045 378
979 298
1 301 337
1 612 783
231 873 2 662 258 5 518 853
0
0
15 812
0
0
0
0
0
11387904 11795223 13018946 15388319 15299205 14513120 14650226
293
77
211
2338
4489
215567
71705
0
0
0
0
0
0
0
0
0
0
0
0
11 355 047 11 473 817 12 752 090 15 116 242 14 843 487 13 976 370 14 122 269
212 636
69 459
32 857
321 406
266 856
272 077
455 718
536 750
527 957
293
77
211
2338
4489
2931
2246
0
0
0
0
0
0
0
0
0
0
0
0
2007
186 972
15 914
0
0
7 014 724
3 906 588
0
19 555 575
4 178 206
1 623 176
0
0
91 445
1754
0
0
1 079 536
265 624
0
0
2 647 375
1 374 476
0
0
543 196
11 563
0
0
711
710
1
1 756 700
1 130 234
0
17
19 201 136
3 631 939
0
0
25190092
107883
0
0
24 880 179
106 609
309 913
1274
0
0
2014
Region of the
Americas
African
WHO region
Guyana
Guatemala
El Salvador
Ecuador
Dominican Republic
Costa Rica
Colombia
Brazil
Belize
Bahamas3
Argentina
Zimbabwe
Zambia
Country/area
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
2000
3 337 796
7949
1
439
22
18 559
20
1466
143 990
2536
28 932
1
2 562 576
131 616
478 212
932
478 820
51 730
92 702
61 261
12
1867
427 297
1226
7
544 646
48 974
55 624
279 072
9
744
48 162
3265
657
214
246 642
1474
50 171
36
209 197
12 324
11 694
-
2001
3 838 402
6685
0
215
4
18 173
6
1156
122 933
808
14 957
2 274 610
81 907
306 396
574
747 079
100 242
130 991
43 053
1
1362
411 431
1034
4
538 757
37 491
71 412
111 830
2
360
44 718
3166
657
198 114
1044
34 772
211 221
12 831
14 291
-
2002
3 760 335
5043
0
125
1
15 480
0
1134
137 509
727
13 549
2 118 491
81 014
267 245
826
686 635
88 972
115 944
35
17 738
2
1008
391 216
1292
4
403 225
20 015
66 742
115 378
0
117
44 718
2707
954
160
197 113
1841
33 695
175 966
10 599
11 296
-
2003
4 346 172
3977
0
122
34
15 480
0
1084
158 299
793
17 319
2231
2 009 414
88 174
320 378
298
640 453
75 730
105 226
9622
14
704
349 717
1528
1
433 244
10 724
41 341
102 053
2
83
32 402
3080
759
156 227
1310
29 817
185 877
12 970
14 654
3
2004
4 078 234
1 815 470
3018
0
115
17
2
0
0
17 358
6
1060
2
168 307
695
14 215
2 194 780
110 422
354 366
216
562 681
55 158
87 083
11
9204
5
1284
322 948
2353
2
357 633
5891
22 839
94 819
1
111
32 402
2437
600
148 729
852
28 103
151 938
12 226
16 141
446
2005
4 121 356
1 494 518
3018
1
251
9
1
0
0
25 119
32
1517
208 021
1080
19 062
2 660 539
155 169
450 687
211
493 562
43 472
78 157
17
12 767
3
3538
397 108
3829
8
358 361
2212
14 836
102 479
2
65
32 402
1777
1637
71
178 726
1062
38 641
48
210 429
16 438
21 255
1291
2006
4 731 338
1 313 458
6353
1
211
546
25 755
10
834
214 616
1785
17 210
2 959 489
145 858
403 383
228
451 240
46 147
73 949
24 498
32
2667
446 839
3519
6
318 132
1596
8267
113 754
1
48
32 402
1847
2227
27
168 958
804
30 289
202 688
9818
10 560
686
2007
4 248 295
1 272 731
6353
2
385
6
22 134
0
845
0
181 816
1622
12 988
2 986 381
93 591
364 912
149
589 755
54 509
70 753
19
22 641
11
1212
435 649
2708
3
352 426
1158
7306
95 857
2
38
0
32 402
845
1804
23
132 410
196
15 182
178 005
4677
6712
267
2008
3 080 301
1 089 322
5157
0
130
35
14
0
1
25 550
0
540
0
164 826
836
8912
0
2 726 433
49 358
266 300
80
493 135
22 392
56 838
917
17 304
0
966
0
381 010
1839
1
0
387 558
396
4495
97 872
1
32
0
11 994
406
925
10
175 678
50
7148
10
137 247
5741
5927
147
2009
2 976 395
867 135
86
0
86
0
0
26 051
1
255
0
133 614
574
8660
0
2 711 062
50 933
258 271
112
436 366
22 141
57 111
0
4829
1
261
0
353 336
1643
0
0
451 732
551
3569
0
83 031
1
19
0
20 065
424
789
6
156 652
56
7024
169 309
7542
6029
102
2010
4 229 839
912 618
249 379
2547
72
0
27 272
27 366
1
149
0
140 857
1592
13 694
0
2 711 433
51 048
283 435
183
521 342
34 334
83 255
48
15 599
2
112
0
495 637
2480
2
0
488 830
258
1630
0
115 256
2
22
0
14 373
1548
476
5
237 075
35
7163
212 863
14 401
8402
132
2011
2012
2013
5 465 122
1 115 005
422 633
4913
0
4
0
10 605
25 351
0
26
0
144 049
1014
7398
0
1 893 797
35 201
143 050
32
327 081
21 060
37 862
11
16 774
1
4
1
502 683
576
3
0
397 628
161
217
0
103 748
0
7
0
22 327
1092
337
153 731
152
6062
0
205 903
17 425
13 953
101
7 859 740
1 420 946
535 931
5691
0
4
24 122
0
19
124 900
341
7060
0
1 670 019
24 654
118 724
37
403 532
20 634
20 129
5
4420
3
2
1
416 729
491
5
0
370 825
49
199
106 915
0
8
14 651
348
98
2
314 294
92
4839
0
142 843
5140
7173
41
2014
237
238
Eastern
Mediterranean
Region of the
Americas
WHO region
21 190
16 897
0
175 577
1446
33 679
874
2 003 569
131
7259
509 443
1369
22 645
149 702
45
991
97 026
0
6853
1 483 816
20 631
47 690
13
63 377
10 648
1673
811
261 866
5491
24 829
1
366 865
5115
89 240
17
0
0
2546
-
No Pf
No Pv
No Other
Suspected
No Pf
Honduras
No Pv
No Other
Suspected
No Pf
Jamaica3
No Pv
No Other
Suspected
No Pf
Mexico
No Pv
No Other
Suspected
No Pf
Nicaragua
No Pv
No Other
Suspected
No Pf
Panama
No Pv
No Other
Suspected
No Pf
Paraguay
No Pv
No Other
Suspected
No Pf
Peru
No Pv
No Other
Suspected
No Pf
Suriname
No Pv
No Other
Suspected
No Pf
Venezuela (Bolivarian Republic of)
No Pv
No Other
Suspected
No Pf
Afghanistan
No Pv
No Other
Suspected
No Pf
Djibouti
No Pv
No Other
Suspected
No Pf
Egypt3
No Pv
No Other
Suspected
No Pf
Iran (Islamic Republic of)
No Pv
No Other
Suspected
No Pf
Iraq3
No Pv
No Other
2000
Suspected
Haiti
Country/area
9837
0
174 430
938
23 211
596
4
2
1
1 857 233
69
4927
482 919
1194
9304
156 589
39
889
71 708
4
2706
1 417 423
17 698
61 680
11
67 369
13 217
1229
1549
198 000
2705
17 224
8
9
2158
17 145
0
-
51 067
2001
0
178 616
606
16 617
725
1 852 553
19
4605
491 689
995
6700
165 796
337
1907
99 338
1
2777
1
1 582 385
21 184
78 000
10
68 070
11 140
1648
1388
278 205
2533
26 907
12
84 528
330 083
0
8
2
0
2382
13 176
0
-
2002
0
137 891
540
13 583
394
1 565 155
44
3775
448 913
1213
5525
166 807
627
3873
126 582
4
1388
1 485 012
19 167
66 588
13
43 241
8782
1047
1153
344 236
5394
26 111
46
44 243
316 697
0
44
1
0
4475
19 087
0
1
346
0
2003
10 802
0
145 082
834
16 425
3879
1 454 575
49
3357
492 319
1200
5699
171 179
882
4213
97 246
1
693
1 438 925
20 905
72 676
10
56 975
6738
915
726
420 165
4230
41 972
63
280 301
12 789
229 233
0
39
4
0
1380
12 441
0
1
154
0
30 440
2004
2005
21 778
0
153 474
998
15 011
2470
1 559 076
22
2945
516 313
1114
5498
208 582
766
2901
85 942
0
376
1 438 925
15 058
72 611
59 855
6931
1611
589
420 165
5725
38 985
38
548 503
5917
110 527
0
3969
413
0
0
23
0
0
2219
16 747
0
0
47
0
3 541 506
32 739
0
125 162
767
11 156
6821
1 345 915
16
2498
476 144
336
2784
212 254
62
1601
111 361
2
821
1 438 925
8437
56 488
45 722
2331
733
225
479 708
6576
30 111
23
789 186
6216
79 913
0
1796
0
0
27
2
0
1199
14 710
0
0
24
0
87 951
2006
29 824
1
130 255
813
9700
199
1 430 717
4
2357
537 637
106
1250
0
204 193
48
1233
92 339
2
1337
1 438 925
7766
43 031
33 992
547
509
14
396 338
7724
33 621
51
869 144
6283
85 919
0
7945
210
0
0
28
2
0
1390
14 322
0
0
3
0
142 518
2007
36 768
6
119 484
610
7758
30 732
21
1
1 246 780
0
2357
543 173
61
701
0
200 574
4
740
96 313
7
333
861 290
4768
33 895
7
29 911
838
639
17
414 137
5127
26 437
60
935 043
4355
77 219
0
6305
119
0
0
76
4
0
1123
10 337
0
1
5
0
168 950
2008
2009
49 535
0
0
108 529
1382
7939
0
34 149
18
4
1
1 240 087
1
2702
0
553 717
93
517
0
158 481
3
775
0
64 660
10
81
0
892 990
4044
32 976
2
34 836
929
895
18
370 258
7944
27 002
50
847 666
4026
60 854
0
81
13
0
637
5485
0
0
1
0
270 438
2010
84 153
0
0
152 961
986
8759
0
10 763
1 192 081
7
1226
0
554 414
154
538
0
141 038
20
398
0
62 178
5
22
0
744 650
2374
29 169
3
17 133
721
817
36
400 495
10 915
32 710
60
847 589
6142
63 255
0
1010
0
0
82
3
0
421
2610
0
3
4
0
270 427
2011
32 969
0
0
152 604
619
7044
0
5042
1 035 424
6
1124
0
536 105
150
775
0
116 588
1
353
0
48 611
7
3
0
702 952
3018
22 018
3
16 184
331
382
17
382 303
10 633
34 651
6
936 252
5581
71 968
0
354
107
9
0
571
2668
0
4
7
0
184 934
25 423
0
0
155 165
584
5865
0
3687
1 025 659
9
833
0
552 722
236
999
0
107 711
1
843
0
31 499
11
4
0
759 285
3501
28 164
7
21 685
126
167
2
410 663
13 302
39 478
23
847 933
1231
53 609
0
1412
20
0
0
180
26
0
144
1418
0
0
8
0
167 772
2012
20 378
0
0
144 673
1199
4293
0
1 017 508
4
495
0
536 170
220
974
0
93 624
6
699
0
24 806
9
2
1
864 648
6843
36 285
11
19 736
569
359
0
476 764
27 659
50 938
46
787 624
1877
43 369
0
0
0
0
243
19
0
299
1073
1
1
7
0
20 586
2013
17 662
0
0
151 420
601
2881
0
900 578
6
658
620 977
163
1000
0
80 701
8
866
0
24 832
7
1
866 047
10 282
54 394
26 964
216
158
0
522 617
27 843
62 850
15
743 183
3000
58 362
39 284
259
54
134
1109
0
2
-
258 817
2014
European
Eastern
Mediterranean
WHO region
Turkmenistan4
Turkey
Tajikistan
Russian Federation3
Kyrgyzstan3
Georgia3
Azerbaijan
Armenia4
Yemen
Sudan
Somalia
Saudi Arabia
Pakistan
Oman
Country/area
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
328
366
12
571
1
140
0
527 688
0
1526
0
173
0
245
0
70 500
0
12
0
795
60
233 785
831
18 233
0
1 597 290
7
11 424
50 105
0
24
0
2000
299
336
16
7 024 978
41 771
83 504
0
2360
678
14
269
0
79
0
536 260
1
1056
0
3575
0
438
0
72 020
0
28
0
898
248 565
826
10 561
0
1 550 521
11
10 799
50 075
0
8
0
2001
275
315
9
7 530 636
32 591
75 046
0
1999
567
102 540
15 732
0
0
6
667 794
73 667
1659
278
0
52
0
507 252
0
506
0
6145
1
473
0
69 807
1
2742
0
642
48
244 632
509
5651
0
1 320 010
12
10 209
59 834
0
18
0
2002
312
428
13
8 662 496
39 944
85 176
1234
462
28 356
7571
0
0
8
612 693
47 782
1474
223
4
25
0
536 822
0
482
0
5457
2
314
0
144 070
0
468
0
533
51
296 123
252
5176
0
1 187 814
12
9209
72 643
0
7
0
2003
166
449
8
6 074 739
32 761
93 385
0
55 423
11 436
0
0
9
611 552
47 306
1297
393
2
45
0
545 145
0
386
0
3365
1
255
0
79 895
0
93
0
382
43
272 743
151
3437
0
1 158 673
13
5289
0
71 377
0
3
0
2004
159
385
6
8 671 271
42 056
85 748
0
63 770
12 516
0
0
17
629 380
42 627
1442
411
0
7
0
515 144
0
242
0
5169
0
155
0
114 316
0
226
0
205
31
216 197
81
2228
0
1 042 509
32
2052
0
56 982
0
1
0
2005
102
341
2
8 680 304
37 837
86 999
984
280
16 430
0
0
27
962 017
53 887
1019
460
0
0
0
498 697
0
143
0
4400
1
59
0
74 729
1
318
0
143
41
175 894
28
1316
0
934 839
29
767
0
58 673
0
1
0
2006
2008
95
95
602
870
2
1
9 330 723 8 330 040
39 871
24 586
88 699
79 868
15
36
2349
833
515
658
0
0
120 060
16 058
36 167
617
738
0
0
35
46
740 940
900 735
65 268
42 796
2339
745
0
4
1315
31 231
1
1
0
0
0
0
465 033
408 780
2
1
109
72
0
0
3400
4398
0
1
7
24
1
0
62 444
40 833
0
0
96
18
0
0
35 784
28 340
43
47
76
46
4
3
159 232
158 068
7
2
628
316
0
0
775 502
616 570
29
23
329
191
0
1
65 666
75 524
0
0
0
1
0
0
2007
162
718
2
7 973 246
37 084
95 604
0
1649
672
12
106 341
24 698
504
0
38
1
0
899 320
52 853
589
3
31 467
0
0
0
451 436
0
80
0
4120
5
1
1
33 983
0
4
0
27 382
62
40
5
165 266
1
164
0
606 875
16
65
3
94 237
0
0
0
2009
143
1039
3
8 601 835
73 857
143 136
0
894
1023
24
220 698
5629
0
0
22
0
3
835 018
77 301
966
2
31 026
1
0
0
456 652
2
50
0
2368
0
0
0
30 190
0
6
0
33 024
63
34
5
173 523
1
111
0
507 841
50
28
0
81 784
0
0
0
2010
101
1422
0
8 418 570
73 925
205 879
0
1050
1719
19
99 403
37
9
0
804 940
59 696
478
33
449 168
2
6
0
2032
3
3
0
27 850
1
4
0
28 311
39
40
6
173 367
5
73
0
421 295
97
30
1
-
2011
87
1963
1
8 902 947
97 996
228 215
0
1279
2088
70 459
40
1
1
891 394
109 504
398
497 040
1
3
0
1046
3
2
0
18 268
1
2
0
209 239
2
31
0
337 830
131
243
-
2012
85
1366
0
7 752 797
56 573
283 661
0
974
1527
6
85 174
21
1
0
927 821
102 369
408
0
432 810
4
0
192
6
1
54 249
1
3
213 916
1
13
255 125
191
94
-
2013
134
865
2
8 514 341
42 817
232 332
0
1155
1144
6
79 653
1 207 771
21
0
725 169
67 274
239
0
399 925
2
0
440
6
0
35 600
0
0
200 241
0
7
189 854
204
41
4
-
2014
239
240
Western Pacific
South-East Asia
European
WHO region
Malaysia
China
Cambodia
Timor-Leste
Thailand
Sri Lanka
Nepal
Myanmar
Indonesia
India
Bhutan
Bangladesh
Uzbekistan3
Country/area
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
735 164
1
125
0
742 539
39 475
16 124
76 445
2738
3197
204 428
86 790
375
1 047 218
984 572
3178212
100 716
156 277
843 087
95 499
21 802
140 768
560
7056
1 781 372
59 650
150 389
4 403 739
43 717
37 975
15 212
281 444
46 150
4505
496 070
38 271
1689
2 694 991
6000
5953
-
2000
2001
691 500
0
77
0
516 052
39 274
14 942
65 974
2915
2805
300 000
0
115 615
90 389
019
1 005 236
1 080 248
2737927
82 927
184 665
954 155
130 029
35 783
266 917
428
6216
1 353 386
10 600
55 922
4 100 778
29 061
34 467
83 049
202 179
37 105
4408
5 397 517
3732
17 295
303 306
25 851
1204
2 671 828
5643
6315
857 101
1 012 302
2482906
74 968
148 097
1 020 477
138 178
35 151
383 322
1195
8200
1 192 259
1273
9237
3 256 939
19 024
18 331
83 785
33 411
15 392
208 801
36 338
5179
4 776 469
3497
24 852
326 297
18 307
574
2 380 226
2756
3127
-
99 136 143
91 617 725
897 446
943 781
2660674
93 419
180 374
1 016 514
133 187
35 030
304 200
2165
10 621
1 390 850
4848
36 563
3 819 773
20 389
24 166
120 344
26 651
11 148
187 213
33 010
4386
5 788 432
5753
19 581
309 688
20 696
712
2 593 385
5486
4921
-
812 543
0
74
0
679 981
41 356
13 298
61 246
1518
2126
76 104
0
16 538
-
2003
735 164
1
72
527 577
46 418
15 851
74 696
3207
3015
354 503
0
98 852
-
2002
890 152
1 025 211
2445538
123 962
180 974
883 399
114 523
34 045
293 836
743
3892
1 198 181
549
3171
3 012 710
13 371
13 319
242 957
39 164
16 158
183 062
31 129
5709
4 331 038
3879
23 138
218 884
15 648
491
2 250 185
2496
3167
-
97 111 526
893 187
0
66
0
512 876
46 402
12 492
54 892
966
1580
33 803
0
15 827
-
2004
917 843
0
102
0
462 322
37 679
10 442
60 152
853
871
11 507
0
6728
104 120
792
805 077
1 011 492
2113265
146 353
169 041
787 691
124 644
37 014
361 936
1181
5691
974 672
134
1506
2 524 788
14 670
14 921
185 367
43 093
15 523
165 382
17 482
9004
3 892 885
3588
18 187
173 698
13 106
473
1 994 216
2222
2729
-
2005
2006
924 534
3
73
0
341 293
24 828
8029
66 079
772
963
9353
0
6913
106 606
703
840 360
944 769
1320581
165 108
182 489
820 290
149 399
50 667
327 981
1358
3932
1 076 121
27
564
2 280 070
14 124
15 991
223 002
37 896
13 477
207 463
24 779
7551
4 076 104
2808
32 345
210 927
28 347
316
1 973 918
1790
2774
-
2007
858 968
2
87
0
270 137
46 803
13 063
51 446
379
414
0
7985
0
4795
0
94 855
000
744 049
767 851
2142747
158 135
175 657
1 159 516
152 027
53 351
433
265 997
1391
3870
1 047 104
8
191
2 041 733
16 667
16 495
16
215 402
34 325
12 544
0
200 050
17 094
4987
4 062 585
1754
27 550
141
275 602
17 178
193
7
2 111 163
1979
2862
615
2008
883 807
0
27
0
526 701
70 281
14 409
47 389
181
148
0
24 299
0
16 989
0
95 734
579
779 163
750 687
2106957
141 127
125 150
1 230 444
170 630
52 256
288
302 774
792
3096
1 047 104
47
623
1 931 768
12 254
13 886
10
215 338
34 678
11 295
0
198 794
37 014
4625
4 435 793
1327
15 323
105
311 395
18 938
247
21
2 143 247
2559
3820
1011
916 839
1
3
0
569 767
18 350
6853
62 790
644
413
0
34 818
0
14 845
0
112 496
076
842 705
723 697
221 270
196 666
503
1 136 064
124 251
40 167
319
270 798
762
2760
909 632
29
529
1 884 820
9688
13 616
23
198 867
29 664
12 160
0
210 856
18 637
6362
0
4 642 479
948
8214
125
266 096
5332
176
0
1 565 982
2129
3379
1502
2009
921 364
0
5
0
496 616
52 049
3824
0
54 760
175
261
0
25 147
0
13 520
0
119 279
429
834 364
765 622
2205293
242 041
221 176
2547
1 277 568
72 995
29 944
346
213 353
766
2349
0
1 001 107
28
702
1 777 977
9548
13 401
20
266 384
28 818
11 432
0
193 210
9483
4794
0
7 118 649
1295
3675
20
280 549
4401
122
1
1 619 074
1854
3812
984
2010
2011
886 243
1
0
0
390 102
49 194
2579
0
44 494
102
92
0
26 513
0
16 760
0
119 470
044
665 004
645 652
2092187
232 197
187 989
2261
1 210 465
62 624
28 966
162
188 702
249
1631
0
985 060
17
158
1 450 885
5857
8608
13
225 772
15 981
3758
0
216 712
8637
5155
0
9 190 401
1410
1907
50
221 390
5770
442
14
1 600 439
1126
2422
1758
2013
805 761
908 301
1
2
0
1
0
309 179
93 926
9464
3602
396
262
0
0
42 512
31 632
33
14
47
31
0
40 925
72 719
0
0
21 850
14 407
0
0
122 159
127 891 198
270
524 370
463 846
534 129
417 884
2051425 1833256
229 255
191 200
187 583
150 985
981
1342
1 423 966 1 364 792
342 593
234 986
135 388
98 860
25
243 432
169 464
612
295
1480
1659
0
0
948 250 1 236 580
41
42
45
52
1
1 130 757
1 838 150
11 553
14 645
17 506
15 573
3084
182 854
178 200
1962
373
2288
512
0
0
194 263
152 137
19 867
9510
19 575
11 267
0
6 918 732 5 554 995
1419
3091
1080
930
184
369 976
339 013
38 461
25 494
7634
12 537
1
1 566 872
1 576 012
894
663
1461
969
2218
2012
722 546
379 659
1575907
142 807
107 260
1960
890 913
110 324
41 866
5
296 979
315
1154
1 069 817
20
28
1
1 756 528
14 331
20 513
3077
117 107
203
139
0
142 242
14 796
10 356
0
4 403 633
1855
850
216
294 542
25 445
22 625
1
1 443 958
409
732
2782
812 347
1
0
125 201
9727
489
0
28 716
17
31
38 878
0
10 535
0
2014
Viet Nam
Vanuatu
Solomon Islands
Republic of Korea
Philippines
Country/area
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
Suspected
No Pf
No Pv
No Other
2000
1 897 579
63 591
14 721
36 596
25 912
4183
601 612
46 703
21 322
58 679
3226
2972
2 883 456
58 377
15 935
-
2001
1 802 857
74 117
18 113
34 968
18 006
2556
594 690
50 806
25 649
48 422
3402
4236
2 950 863
52 801
15 898
-
2002
1 739 219
58 403
14 187
37 005
22 831
1799
556 356
50 090
24 822
75 046
7016
7210
3 054 693
36 961
10 846
-
2003
1 783 145
54 653
14 055
48 441
32 948
1171
416 728
64 910
27 399
82 670
8406
6582
2 835 799
29 786
9004
-
2004
2 000 261
63 053
18 730
50 850
29 018
864
643 908
64 449
25 927
80 879
6999
6350
2 778 295
19 228
5681
-
2005
1 962 493
62 926
22 833
593 996
20 033
6482
1369
633 796
54 001
22 515
86 170
3817
4453
2 793 458
14 394
5102
-
2006
1 816 963
62 038
22 744
432 111
24 515
8839
2051
657 110
54 441
20 971
62 637
3522
4405
3 024 558
18 140
4497
-
Western Pacific
WHO region
2007
1 779 343
67 929
16 239
2787
408 254
9016
3622
17
2227
2227
396 169
48 751
16 653
139
52 958
2484
2987
0
3 755 566
11 470
4737
0
2008
1 769 032
66 202
16 806
1444
278 652
12 039
4806
197
1052
11
1052
338 244
29 576
11 173
84
52 420
1623
1850
0
1 409 765
8901
2348
0
2009
1 507 122
50 349
11 472
1024
352 006
14 074
4951
262
1345
26
1319
282 297
19 813
8544
44 960
1979
1632
4
2 907 219
12 719
3206
0
2010
1 505 393
60 824
13 171
1990
301 577
12 038
2885
175
1772
51
1721
0
284 931
23 092
12 281
48 088
1738
2265
10
2 803 918
12 763
4466
0
2011
1 279 140
60 317
9654
632
327 125
7043
2380
127
838
56
782
0
254 506
14 537
8665
0
32 656
851
1224
2
3 312 266
10 101
5602
0
2012
1 113 528
58 747
7108
333 084
4774
2189
555
54
501
0
249 520
14 980
9339
33 273
1727
1680
0
3 436 534
11 448
7220
0
2013
1 454 166
120 748
7579
1279
320 089
5051
1357
67
443
33
397
3
245 014
13 640
11 628
0
28 943
1039
1342
0
3 115 804
9532
6901
0
922 417
200 215
78 846
2125
314 820
3995
834
74
638
55
579
1
233 803
10 559
7845
0
35 570
279
703
0
2 786 135
8532
7220
0
2014
241
242
Country/area
Algeria
Angola
Benin
Botswana
Burkina Faso
Burundi
Cabo Verde
Cameroon
Central African Republic
Chad
Comoros
Congo
Cte dIvoire
Democratic Republic of the Congo
Equatorial Guinea
Eritrea
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Kenya
Liberia
Madagascar
Malawi
Mali
Mauritania
Mayotte, France
Mozambique
Namibia
Niger
Nigeria
Rwanda
Sao Tome and Principe
Senegal
Sierra Leone
South Africa
South Sudan1
Swaziland
Togo
Uganda
United Republic of Tanzania2
Mainland
Zanzibar
Zambia
Zimbabwe
Region of the Americas Argentina
Bahamas
Belize
Bolivia (Plurinational State of)
Brazil
Colombia
Costa Rica
Dominican Republic
Ecuador
El Salvador
French Guiana, France
Guatemala
African
WHO region
2
9510
691
439
712
3856
2016
6108
626
48 767
591
748
1244
254
1275
424
379
379
0
0
0
11
245
124
0
6
66
0
0
0
2000
1
9473
468
29
4233
417
0
535
957
416
133
1681
1693
275
1717
517
635
48 286
742
3355
562
1728
2366
4317
4275
248
1515
328
81
62
1394
1228
838
390
9369
0
0
0
0
142
168
0
17
84
0
3
0
2001
14 434
707
23
4032
483
2
98
2152
86
1607
1141
259
2376
440
780
47 697
575
5775
826
1504
2769
4092
3167
321
1226
461
96
46
1661
815
441
374
9021
1844
0
0
0
4
95
162
0
11
64
0
2
0
2002
38 598
560
18
4860
425
4
417
1021
989
79
2138
692
192
2103
586
1137
51 842
817
4767
1309
1106
2248
5343
2679
193
1602
157
142
30
1130
15251
14 943
308
9178
1044
1
0
1
104
118
0
12
46
0
5
0
2003
12 459
944
19
4205
689
4
859
13
28
13 613
24
3327
466
153
1575
528
565
25 403
715
3457
1012
1185
1333
6032
2362
169
1524
126
88
28
1183
19859
19 547
312
8289
1809
0
0
1
3
102
126
0
16
37
0
1
2
2004
13 768
322
11
5224
776
2
836
668
558
92
15 322
49
1086
353
426
2037
490
565
44 328
41
699
5070
1285
1325
2060
6494
2581
85
1587
50
63
17
1024
18322
18 075
247
7737
1916
0
0
0
0
123
87
0
16
22
0
2
4
2005
10 220
1226
40
8083
434
8
930
865
837
56
12 970
47
1357
238
150
3125
507
40 079
877
441
6464
1914
67
571
1150
6586
2486
26
1678
90
87
27
819
4252
20962
20 825
137
6484
802
0
0
1
0
110
77
0
10
9
0
5
2
2006
2007
0
9465
918
12
7834
595
2
7673
456
1018
47
143
1249
17 940
4
19
1169
156
403
3889
441
487
345
355
8048
1227
4424
152
2461
8677
566
16
741
871
43
263
10
2663
2372
12497
12 405
92
3781
232
0
0
0
0
68
54
0
11
5
0
2
0
2008
1
10 530
1375
6
7982
1183
2
4943
667
221
116
18 156
21 168
23
23
1121
197
240
3378
586
369
1706
348
8915
2331
91
3747
68
2159
7522
809
23
574
1734
45
254
13
1556
6296
16776
16 696
80
3862
108
0
0
0
0
85
28
1
14
6
0
1
0
2009
5
8114
964
8
9024
2677
1
4536
526
886
53
1023
23 476
30
27
1581
182
151
3859
735
296
26 017
1422
427
8206
3006
211
0
3354
63
3929
4238
670
14
553
8188
83
1053
8
1507
8431
15867
15 819
48
4834
255
0
0
0
0
76
42
0
15
4
0
1
0
2010
1
6909
1753
8
7001
2233
1
3808
858
1220
19
892
1389
23 748
52
12
936
74
440
3259
743
472
713
398
6674
2128
77
0
3086
36
2802
3353
380
19
472
3573
54
406
1
1314
5958
11806
11 799
7
4540
451
0
0
0
0
70
23
0
10
2
0
2
0
2011
0
5736
2261
3
7963
2263
1
3209
1442
1359
17
623
1534
21 601
77
30
1621
134
289
2855
979
370
785
1725
552
5516
1894
106
0
2818
4
2825
7734
459
7
649
3611
72
1321
3
1197
6585
7820
7812
8
3705
351
0
0
0
0
60
24
0
8
1
0
2
0
2012
3
7300
2288
7
6294
3411
0
4349
1026
1881
15
2870
3261
30 918
66
6
358
273
262
2506
108
418
360
1191
641
3723
1680
25
0
2941
21
2209
7878
409
11
815
4326
105
1311
4
1361
7277
8528
8526
2
3548
352
0
0
0
0
41
10
0
5
4
0
3
1
2013
0
5714
1869
22
5632
2974
2
4398
635
1720
0
271
2069
25 502
15
213
159
170
2200
1067
357
472
2288
551
4490
2309
19
0
3245
61
2691
6082
496
0
500
2848
174
4
1205
5921
5373
5368
5
3257
406
0
0
1
36
17
0
4
0
0
1
2014
WHO region
Country/area
973
2634
3
30
361
457
42
195
38
647
71
0
61
13
50
110 516
503
2135
2
4610
1574
119340
1015
2814
1
52
424
476
27
242
46
562
439
0
55
4
91
103 036
593
2254
3
4790
1942
112618
892
833
2556
77
625
608
31
350
35
617
536
0
38
3
142
77 642
570
2166
2
5482
2360
88222
2002
28
77
0
0
0
8
2
0
12
15
23
2
0
8
2125
0
0
0
0
2
0
0
0
0
598
11
2001
30
70
0
0
0
2
1
0
25
23
28
2
0
2252
0
0
0
0
3
0
0
0
0
470
14
29
16
0
0
0
4
1
0
20
24
24
4
2162
0
0
0
2
0
0
0
484
15
2000
1006
2476
5
4
204
492
52
187
21
537
162
0
71
14
50
152 657
518
2538
4
4283
1586
161586
44
109
0
0
0
7
4
0
9
18
40
5
0
54
2479
0
0
0
0
4
0
0
0
0
574
14
2003
949
508
1982
7
1
230
65
382
31
105
35
619
167
0
51
3
34
114 045
401
1894
5
4254
1427
122026
38
24
0
0
0
1
2
0
6
7
35
1
0
79
1814
0
0
0
0
5
0
0
0
0
505
7
2004
963
88
1707
10
0
161
71
296
48
77
33
725
145
0
38
5
18
137 269
346
1860
3
3506
1385
144369
33
29
1
0
0
6
1
0
4
1
17
0
1
0
1
0
52
0
15
1789
2
0
0
0
0
3
0
0
0
0
501
5
2005
1708
494
1647
42
1
113
68
396
37
21
21
668
124
0
12
1
41
136 955
286
1367
4
4588
1321
144521
20
32
0
0
0
1
1
0
6
1
11
29
0
1
0
2
0
9
0
58
1193
2
73
0
0
0
0
4
0
0
0
0
508
7
2006
Deaths reported before 2000 can be presumed and confirmed or only confirmed deaths depending on the country.
1 In May 2013 South Sudan was reassigned to the WHO African Region (WHA resolution 66.21, http://apps.who.int/gb/ebwha/pdf_files/WHA66/A66_R21-en.pdf)
2 Where national totals for the United Republic of Tanzania are unavailable, refer to the sum of Mainland and Zanzibar
3 There is no local malaria transmission
4 Armenia, Morocco and Turkmenistan are certified malaria free countries, but are included in this listing for historical purposes
28
0
0
0
1
0
2
1
16
25
1
0
3
0
2
0
24
2
45
1254
1
0
0
0
0
3
0
1
0
1
228
2
2007
1055
669
1087
0
101
33
209
23
11
30
628
56
0
21
4
25
103 664
182
1229
5
3101
1007
109188
11
17
2
0
0
0
1
0
2
0
9
46
2
3
0
1
2
0
49
1125
1
0
0
0
0
2
0
3
0
0
154
2
2008
1144
900
972
8
1
70
53
279
10
5
26
604
24
1
53
2
26
131 224
176
1263
2
3199
1030
136894
20
7
1
0
0
0
0
0
2
0
11
32
0
2
0
1
2
0
45
1142
1
38
0
0
0
0
1
0
1
0
0
47
4
2009
1018
432
788
6
0
80
58
151
19
24
33
616
30
2
34
1
21
150 490
194
1149
1
2421
931
155186
24
8
3
0
0
1
1
0
0
1
18
22
0
2
2
0
2
0
0
6
1023
0
92
0
0
0
0
1
0
0
0
0
37
2
2010
36
5
2
0
0
1
0
1
1
16
40
0
4
0
0
0
4
2
5
612
0
75
0
0
1
1
0
4
0
36
1
754
388
581
2
0
43
16
94
33
17
18
523
12
2
19
1
14
104 069
169
742
6
1821
733
107540
2011
519
252
403
0
0
37
3
45
14
44
16
381
16
0
18
0
8
104 106
157
1001
0
1226
542
107032
35
6
1
0
2
1
0
7
0
10
36
0
0
4
0
260
0
10
618
1
72
0
0
0
0
0
0
11
1
2012
440
45
236
0
0
47
3
12
23
28
14
307
12
2
18
0
6
116 336
100
1054
3
786
422
118701
14
10
1
0
0
0
0
4
1
6
24
17
3
2
0
0
244
0
23
685
1
55
0
0
0
0
3
0
15
0
2013
561
64
92
0
0
38
1
18
24
4
9
203
10
0
23
0
6
97 381
90
959
1
801
297
99529
11
9
2
0
0
0
0
4
0
5
32
28
2
0
0
9
0
56
0
14
823
4
19
0
0
0
0
1
0
45
0
2014
243
World Malaria
Report 2015
a t l a s
p r o j e c t
m a l a r i a